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Inevitably, clinical practice first aroused my interest in arteriovenous malformations
(AVMs) of the brain. As a senior house officer in neurology, I strove to control a flurry
of seizures — which were followed by hemiplegia — in a man of my own age, already
wheelchair-bound by a prior haemorrhage from his brain AVM. I tried to determine
whether he had suffered a recurrent haemorrhage, and if I suspected so, whether I
should transfer him across London for urgent CT of the brain. I wondered what his
prognosis might be. Should he be treated if this was a bleed, and if so, with which of the
many available treatments?
At this time during my training, I was also developing a keen interest in clinical
epidemiology, not only through my reading, but also by attending the Edinburgh
Clinical Trials Course in 1996 and meetings about the new religion of evidence-based
medicine. I was left believing that to address the most important unanswered clinical
questions about the most common diseases was the priority, and that this could only be
done using appropriate, robust research methods.
The next logical step seemed to be to combine my clinical and research interests. My
attendance at the Edinburgh Clinical Trials Course and knowledge of the work of
Charles Warlow's stroke research group led me to approach him about setting up a
research project. Correspondence and a trip to Edinburgh left me with a one-page hand¬
written guide to grant proposals and the idea for the research projects that constitute
this thesis! Whilst Charles Warlow gathered a multidisciplinary Steering Committee to
facilitate these projects, I wrote grant applications with his help.
I was fortunate to be awarded a Medical Research Council Clinical Training Fellowship
(which funded me through this thesis) as well as a project grant from the Chief Scientist
Office of the Scottish Executive Health Department (which funded secretarial and
programming support, as well as equipment and consumables).
This enabled me to start postgraduate study on 1 September 1998 and to continue until
April 2002. Therefore, excluding a 3-month period when I undertook a clinical
neurology locum, I was a member of staff at the University of Edinburgh for 3 years
and 3 months. During this time my involvement was part-time in view of a weekly
general neurology outpatient clinic, a regular out-of-hours on-call commitment, and
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other distractions such as gaining ethical approval for the projects (Chapter 16),
defending their conduct in the light of developments in data protection law and
confidentiality guidance (Chapter 17), and applying for two further project grants to
continue the research.
This thesis is organised into seven sections. The first comprises background information
about brain AVMs and the systematic literature review that underlies the need for a
prospective, population-based study of their frequency and prognosis. Such a project —
the Scottish Intracranial Vascular Malformation Study (SIVMS) — forms the bulk of this
thesis; its design, methods and definitions (both clinical and radiological) are described
in the second section. Section 3 is devoted to an evaluation of these methods, and also
includes a separate study of observer agreement in the radiological assessment of brain
AVMs, because it is pertinent to the methods of SIVMS. The fourth section describes
the main results of SIVMS (the incidence and presenting features of adults with brain
AVMs in the first two years of the study), and a separate, but complementary study of
the point prevalence of brain AVMs in just one part of Scotland. Following my
conclusions in the fifth section, as a postscript I reflect on how difficult it was to gain
ethical approval for these projects. Each chapter is organised in a standard format, with
its main findings followed by a summary, followed by a discussion, followed by its tables
and then its figures. The summaries of each chapter are collated in a summary of
summaries (15.1, page 286) followed by my conclusions, and references are compiled in
a single bibliography (Chapter 18, page 325).
This thesis was achieved by working as part of a team. I was responsible for searching
and appraising the literature for the systematic review, with supervision from Charles
Warlow. For the set-up and conduct of all the other research projects, I had
administrative assistance from a part-time secretary and various sources of computing
support (primarily a Napier University computing studies BSc student, but also
Edinburgh University computing services and our departmental programmers). Whilst I
was largely responsible for data modelling, structure, and fundamental table, query and
report design for the research projects' databases, the complexities of turning the
databases into tailor-made applications using programming languages were all
attributable to computer programmers. Two Special Study Module medical students at
the University of Edinburgh helped with the prevalence and observer agreement studies.
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I supervised the work of the secretary, programmers and medical students, and
collectively we were supervised on a weekly basis by Charles Warlow. Nationwide
ongoing collaboration with SIVMS was facilitated by the Steering Committee, who met
every 6 months to monitor the study's progress. The two neuroradiologists on the
Steering Committee reviewed all the diagnostic imaging with me. I analysed the results,
with some help from the departmental statistician with the prevalence and observer
agreement studies. Although this thesis depended on teamwork, the responsibility for




I now realise that a collaborative medical research project is not successful when its
execution is easy, but simply when it works. Were it not for the involvement of several
people, acknowledged below, my research might well have failed. I am also tempted to
acknowledge those who hindered the progress of my research, for the intellectual
stimulation they sometimes caused, which ultimately spurred me on to learn, study and
publish more than I would otherwise have done.
My first debt is to the participants themselves, for their altruism in being willing to
further knowledge about their condition. I am also grateful to the study's steering
committee and collaborators (listed in the appendix) for their willingness to contribute
participants and/or co-operate with data collection. Equal thanks are due to many
general practitioners who helped in the same way. Without Rosemary Anderson's
cheerful attitude and dependable administrative abilities, the study would almost
certainly have failed. David Watson came to my rescue with his unique programming
abilities and methods, by harnessing the power ofMicrosoft Access to automate almost
every aspect of the study, thereby simplifying Rosemary's job and mine. There are many
others who deserve thanks, including James Boyd and Lena Henderson at the
Information and Statistics Division, Jason Fang and Nandita Pal (University of
Edinburgh Special Study Module students), Estela Dukan (assistant at the library of
Royal College of Physicians of Edinburgh), Tricia Gwynne-Jones (Chelsea and
Westminster Hospital library), and Claire Leach and her colleagues at the Western
General Hospital medical library. The observer variability study would have been
impossible were it not for the candid participation of five busy interventional
neuroradiologists: Andy Clifton, Andy Molyneux, Anil Gholkar, Shawn Halpin and John
Millar. The whole of this thesis has benefited from the enthusiastic scrutiny of the
Stroke Research Group and other contemporaries of mine in 'D block' at the
Department of Clinical Neurosciences.
I never anticipated that postgraduate study would teach me as much about myself as
about brain AVMs. My supervisor, Charles Warlow, helped me with both. Above all, he
taught me to distinguish what's important from what's not. He was constantly
supportive, retained a calming presence at the helm when the study entered stormy seas,
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and frequently reminded me that, "good research is never easy to do." I was grateful
that his supervision was permissive, because it allowed me to follow my own reasoning,
as well as make my own mistakes. He avidly corrected and enhanced my punctuation —
especially teaching me the value of hyphenated asides mid-sentence — and he improved
my writing style. Both of us being keen collectors of the "grocer's apostrophe", I was
relieved that he never found any of mine to be misplaced. For all of this, and the time
he has invested in me, I shall always be grateful.
Above all, for tolerating my protracted efforts to complete this thesis (and sometimes
curtailing them), for their love, support and encouragement, I thank my parents and




I declare that this thesis is of my own composition, and that the research contained
herein is my own original work. None of this work has been submitted in support of an
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Arteriovenous malformations (AVMs) of the brain are part of the spectrum of
intracranial vascular malformations (IVMs). They are the leading cause of intracerebral
haemorrhage in young adults, they account for ~10% of non-traumatic subarachnoid
haemorrhage, and they also cause epilepsy. Not only are affected individuals subject to
the initial consequences of these events, but there are substantial risks of recurrent
haemorrhage and epilepsy, and long-term disability.
For a disorder discovered as long ago as the mid-nineteenth century, surprisingly little is
known about it. In this thesis, I begin by systematically reviewing the sizeable medical
literature about brain AVM frequency, presentation, clinical course and prognosis. I did
not find a single prospective, truly population-based study, which is why I set up the
Scottish Intracranial Vascular Malformation Study (SIVMS) with the multidisciplinary
collaboration of the four clinical neuroscience centres in Scotland.
SIVMS aspires to meet the standards of the ideal study of frequency and prognosis, by
using multiple, overlapping sources of case ascertainment to prospectively recruit a
population based inception cohort of adults, with explicit diagnostic criteria and
outcome definitions for events which are validated by independent review. During
1999-2000, 96 adults (of whom 92 were definite) were detected with a first-in-a-Hfetime
diagnosis of a brain AVM in Scotland. Quality of baseline demographic, clinical and
basic morphological data was excellent, although detailed variables about
angioarchitecture were less complete, partly because only three-quarters of patients
underwent catheter angiography. The cohort was distributed in proportion to the
dispersion of the Scottish population, and standardised incidence ratios were not
significantly different between healthboards. The sensitivity of ICD-10 coding of brain
AVMs in hospital discharge data was 72% (95%CI 61% to 80%), and its positive
predictive value was 46% (95%CI 38% to 55%). Reliance on hospital discharge data for
case ascertainment or a requirement for catheter angiography to make the diagnosis
would have biased the cohort. Furthermore, I found that expert neuroradiologists'
assessment of AVM angioarchitecture on catheter angiography was characterised by
greater intra-observer than inter-observer agreement (which ranged from less than
chance for e.g. 'angiogenesis' to almost perfect for e.g. nidus size).
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In a survey with multiple, overlapping sources of ascertainment confined to the Lothian
healthboard region of Scodand, using capture-recapture analysis, I found the point
prevalence of brain AVMs to be 18 (95%CI 16 to 24) per 100,000 adults. In SIVMS, the
crude incidence of brain AVMs in Scodand in 1999 and 2000 was 1.1 (95%CI 0.9 to 1.4)
per 100,000 adults per year. Of the incident adults, 53% were male and their median age
at presentation was 45 years (range 16 to 81); one fifth were incidental discoveries and
four fifths were symptomatic (presentation was with intracranial haemorrhage in 59%,
one or more seizure(s) in 34%, and focal neurological deficits in 7%). 9% of cases were
pure arteriovenous fistulae, 75% were lobar in location, 53% were superficial, and 22%
had associated aneurysms. There appeared to be significant differences between SIVMS
and well-established hospital-based cohorts.
Having established brain AVM prevalence, incidence and the characteristics of
presenting adults, the next stage for this work is to describe prognosis for this enlarging
population-based cohort. The data are being collected, the hurdles of ethical approval
have been negotiated, although the direction in which privacy legislation and
confidentiality guidance are heading will make this a challenging task.
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1.1 Early descriptions of brain arteriovenous malformations
The first description of arteriovenous malformations (AVMs) may be attributable to the
ancient Egyptians, in the lengthy Papyrus Ebers, dating to the ninth year of the reign of
Amenhotep I (~1534 BC) [Ivrayenbiihl and Yasargil 1958], although a scholarly
Egyptologist disputes this (John F Nunn, personal communication). Antyllus probably
made the first mention of AVMs by distinguishing what he thought were two forms of
aneurysm, one ofwhich had an audible bruit [Osier 1915]:
There are two different kinds of aneurysms. The one kind occurs
when there is a local dilatation of an artery (this was the origin of the
name aneurysm or dilatation). The other kind arises from the rupture
of an artery and the discharge of the blood into the flesh beneath it.
Aneurysms due to the dilatation of an artery are longer than others;
those due to a rupture are rounder. In the former there is a thicker
layer of tissue; in the latter you can hear a certain crepitation if you
press them with your finger; while in aneurysms due to dilatation
there is no sound.
Following the death in the West of the science of the Greeks — a period when illness
was thought to be due to an imbalance in the four humours of the body, and scholars
pursued knowledge of god, not man — AVMs escaped medical attendon for almost two
millennia. The first case report of an extracranial AVM in a medical journal was made by
William Hunter in the mid-eighteenth century [Hunter 1757], with subsequent
elaboration [Hunter 1761].
Does it ever happen in surgery, when an artery is opened through a
vein, that a communication, or anastomosis, is afterwards kept up
between these two vessels? It is easy to conceive this case; and it is
not long since I was consulted about one, which had all the symptoms
that might be expected, supposing such a thing to have actually
happened, and such symptoms as otherwise must be allowed to be
very unaccountable. It arose from bleeding; and was of some years
standing, when I saw it about two years ago; and I understand very
little alteration has happened to it since that time. The veins at the
bending of the arm, and especially the basilic, which was the vein that
had been opened, were there prodigiously enlarged, and came
gradually to their natural size, at about two inches above, and as much
below the elbow. When emptied by pressure, they filled again almost
instantaneously; and this happened even when a ligature was applied
tight around the fore-arm, immediately below the affected part. Both
when the ligature was made tight, and when it was removed, they
shrunk, and remained of a small size, while the finger was kept tight
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upon the artery, at the part where the vein had been open in bleeding.
There was a general swelling in the place, and in the direction of the
artery, which seemed larger, and beat stronger, than what is natural;
and there was a tremulous jarring motion in the vein, which was
strongest at the part that had been punctured, and became insensible
at some distance both upwards and downwards.
[Hunter 1757]
It was not until the mid-nineteenth century that Luschka [Luschka 1854], and later
others [Virchow 1863; D'Arcy Power 1888; Steinheil 1895], described intracranial AVMs.
Rendu's first description of the syndrome now recognised as hereditary haemorrhagic
telangiectasia (HHT) followed not long afterwards [Rendu 1896].
The spirit of medical enquiry in the nineteenth century, an era rich in diarists and
scholars, often led to a close examination of not only their works, but also their brains
(after their demise), to gain insight into both their brilliance and their illnesses. Thus we
know that Gustave Flaubert [Gastaut and Gastaut 1982] and Paul Broca [Huard et al.
1982] may have had a brain AVM, Thomas Stamford Raffles had a dural AVM [Khoo et
al. 1998], and Robert Louis Stevenson may have died due to a haemorrhage from a brain
AVM secondary to HHT [Guttmacher and Callahan 2000] (Figure 1, page 49).
1.2 The classification of brain arteriovenous malformations
within the spectrum of intracranial vascular malformations
1.2.1 Early classification schemes
Virchow made the first attempt to classify what are now referred to as intracranial
vascular malformations (IVMs); he distinguished IVMs — which he assumed to be
congenital — from tumours [Virchow 1863]. The nomenclature of the whole spectrum
of IVMs first entered the medical lexicon when Virchow divided them into 'angioma
cavernosum' and 'angioma racemosum' (the latter was subdivided into capillary, venous,
arterial and arteriovenous types).
Following Virchow's classification, an array of synonyms was used to describe the
category of arteriovenous shunting malformations, reflecting developments over time in
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understanding their nature (see Appendix A of [Jellinger 1986]). Taxonomy has
combined terms referring to their location (brain, cerebral, pial), vessel type (vascular,
cerebrovascular, cerebral vascular, cirsoid, arteriovenous, arterial venous,
arteriolovenous, angiomatous), and the abnormality itself (neoplasm, angioma,
aneurysm, anomaly, and malformation).
1.2.2 Contemporary classification
Advances in diagnostic radiology in the second half of the twentieth century have
helped understand the anatomy and haemodynamics of IVMs, and have led to their
increasing detection — and so an appreciation of their importance as a cause of death
and long-term morbidity, mostly due to ICrH and epilepsy. The advent of cerebral
catheter angiography [Moniz 1927], and brain imaging has popularised a morphological
approach to the classification of IVMs. This has been reinforced by the apparent
differences in prognosis and response to treatment between morphological subtypes.
The contemporary integrated classification shown in Table 1 (page 48) best reflects the
main morphological groupings of IVMs, and fundamentally distinguishes
'malformations' (which have normal endothelial cell turnover and, if they grow at all, do
so by hypertrophy) from 'haemangiomas', which grow by endothelial hyperplasia
[Mulliken and Glowacki 1982].
1.3 Brain arteriovenous malformations
1.3.1 Morphology
A brain AVM is an anastomosis of mature arteries and veins — completely lacking
intervening capillaries — within the brain parenchyma (Figure 2, page 50 and Figure 3,
page 51). Arteriovenous shunting occurs through fistulae in a nidus (from the Latin
nidus, meaning nest), which is the area towards which usually multiple feeding arteries
converge, and from which one or more tortuous, dilated veins drain [Doppman 1971].
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A brain arteriovenous fistula (AVF) is a type of brain AVM, but is distinguished by
being a direct fistula between a single artery and one or more veins.
Aneurysms may exist on vessels within or feeding the nidus. Aneurysms are associated
with brain AVMs in approximately 10% of patients in many series [Crawford et al.
1986a; Brown, Jr. et al. 1990; Westphal and Grzyska 2000; Al-Shahi et al. 2002a],
although they are identified in up to 50% of patients in series with greater use of super-
selective angiography and an endovascular treatment interest [Meisel et al. 2000].
1.3.2 Nomenclature
Some unity of terminology is required to overcome the historical variation in taxonomy,
so I have chosen to use 'brain arteriovenous malformation.' The abnormality is a
'malformation' (it is not neoplastic, and therefore not an 'angioma'). The constituent
vessels may be anywhere on the morphological spectrum between arteries and veins (the
safest generalisation being 'arteriovenous'). Brain AVMs' location almost anywhere
within the brain parenchyma makes 'pial' (with its connotations of the superficial
cortical grey matter) and 'cerebral' (implying the telencephalon of the forebrain, and not
more caudal structures) inappropriate terms.
This classification based on morphology, and location of the nidus or fistula, is less
arbitrary than one based on the sources of afferent and efferent vessels, which are
endlessly diverse [Morcos and Spetzler 1995]. Angiographic and pathological studies of
the vascular anatomy ('angioarchitecture') and haemodynamics of AVMs have
reinforced these simple morphological descriptions, but also illustrated the complexity
of their anatomy [Houdart et al. 1993]. This has tempted some 'splitters' to reflect the
complexity in brain AVMs' nomenclature, with subdivision using other terms referring
to their radiological features (e.g. microangioma, micromalformation, cryptic vascular
malformation, angiographically occult vascular malformation). By simply calling all of
them, "brain AVMs", I have chosen to be a 'lumper' until such a time as these
subgroups are found to reflect more than mere morphological variation.
The accurate distinction of brain AVMs from the other IVMs usually depends on





1.3.3.1 Differentiating a brain AVM from normal brain and other
pathologies
The widespread availability and immediacy of computed tomography (CT) pragmatically
make it the first test an individual with a brain AVM might have at their initial
presentation. Unenhanced CT may only show an asymmetry in tissue density to suggest
a brain AVM (Figure 4A, page 52), and smaller brain AVMs can be missed altogether.
Enhanced CT is probably a more sensitive investigation, because it may reveal the
dilated vasculature of an AVM (Figure 4B, page 52) with a serpiginous pattern of
contrast enhancement [Kumar et al. 1984]. On the other hand, the specificity of CT,
either with or without enhancement, is affected by the occasional difficulty in
distinguishing an AVM from a low-grade glioma, especially when the AVM is
thrombosed [Wharen, Jr. et al. 1982], The particular strengths of magnetic resonance
imaging (MRI) He in its evaluation of AVM nidus size [Noorbehesht et al 1987] and its
anatomical relationships (Figure 4C&D, page 52). Modern intra-arterial digital
subtraction angiography (IADSA) is regarded by most as the diagnostic reference
standard [Joint Writing Group 2001], and demonstrates rapid contrast opacification of
the nidus in the early capillary/venous phase (Figure 5, page 53). The specificity of both
MRI and IADSA is affected by the occasional similarity of neoplasms to AVMs.
Occasionally CT or MRI appearances suggest an IVM that is not demonstrated on
complete IADSA at all. These 'cryptic' or 'angiographically occult' vascular
malformations (AOVMs), when subjected to pathological examination, are
morphologically heterogeneous, but cavernous malformations (CMs) and small brain
AVMs are the main contributors [Lobato et al. 1988; Robinson, Jr. et al 1993;
Tomhnson et al. 1994; Hallam and Russell 1998].
There is, therefore, no single definitive investigation for brain AVMs, which means that
existing evaluations of the diagnostic accuracy of any imaging modahties do not have a
reference standard, but rely on pathological confirmation or direct comparisons of
different techniques [Pott et al. 1992]. Despite the recognition of these sources of error,
there are no adequate studies (because they have been small, retrospective and
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radiologists were usually not blinded to clinical features) evaluating the sensitivity and
specificity of MRI or IADSA against any reference standard for the detection of brain
AVMs.
1.3.3.2 Detecting a brain AVM underlying intracranial haemorrhage
The investigation of intracerebral haemorrhage (ICeH) with unenhanced CT has a
sensitivity for identifying an underlying brain AVM of between 50% and 77% and a
specificity between 84% and 99%, when compared against a reference standard of
IADSA, with or without pathological confirmation [Halpin et al. 1994; Hayward and
O'Reilly 1976; Laissy et al. 1991]. However, some of these studies have been limited by
being retrospective and unblinded, with selected patient groups, varying CT matrix sizes,
and inconsistent use of intravenous contrast.
Although there are, as yet, no adequate studies ofMRI as a diagnostic test in identifying
an underlying cause for an ICeH, it is a helpful investigation in its follow-up [Meyer and
Gorey 1998], especially in the context of recurrent ICeH [Heier et al. 1986].
The usefulness of IADSA in the investigation of ICeH has been studied in terms of its
diagnostic yield. Some of these studies have been retrospective and reported on the
same series of patients [Toffol et al 1986; Loes el al 1987]. But even when prospective,
other studies have been conducted on highly selected groups of patients [Zhu et al
1997], so unsurprisingly the authors of these studies have drawn varying conclusions.
On the basis of the available evidence, for the further investigation of a suspected brain
AVM (or other underlying condition) as a cause of ICeH demonstrated on CT, a
minimum standard is IADSA in everyone apart from those over 45 years of age with
both pre-existing hypertension and haemorrhage in deep locations [Zhu et al 1997].
Early IADSA may not reveal some brain AVMs underlying ICeH, presumably because
of their compression by haematoma, so a normal IADSA close to the onset of an ICeH
should be supplemented by delayed IADSA or MRI, although which should be used,
and when, is debatable [Lemme-Plaghos et al. 1986; Halpin et al. 1994; Sigal et al. 1990;
Willinsky et al. 1993]. Of course, these algorithms may be superseded by the need for
surgical intervention, and their appropriateness may depend on the clinical condition
and age of the patient. The investigation of subarachnoid haemorrhage (SAH) with CT
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and adequate IADSA is widely accepted, but the value of repeat IADSA is questionable,
and MRI might be helpful if an underlying brain AVM is strongly suspected, although
this strategy has not been formally evaluated. A second IADSA tends to be
recommended only if the patient suffers a recurrent haemorrhage, or if the initial
examination was technically inadequate, affected by vasospasm or did not cover both
carotid and both vertebral arteries [du Mesnil de Rochemont et al 1997; Forster et al
1978; Gilbert et al 1990; von Hoist et al 1988].
1.3.3.3 Brain AVM angioarchitecture
There is a growing literature on angioarchitecture [Valavanis 1996; Houdart et al 1993],
haemodynamics [Kader and Young 1996], and an interest in creating artificial models of
brain AVMs to better understand their haemodynamic complexity [Gao et al 1998],
including unusual outcomes such as spontaneous regression without treatment [Nehls
and Pittman 1982], Whilst IADSA may only be necessary to establish diagnostic
certainty in some cases, the interest in how angioarchitecture and haemodynamics might
determine prognosis has made it a requisite, and often an entry criterion, for some
studies of the clinical course of brain AVMs.
The principal angioarchitectural features of interest are illustrated in a schematic
diagram in Figure 6, page 54. However, objective definitions of the variations in
angioarchitecture have been unclear and inconsistent until recently [Joint Writing Group
2001], and experts disagree about their existence and prognostic value. Furthermore, the
accuracy of detailed angioarchitectural information may depend not only on inter- and
intra-observer variation, but also on the use of super-selective IADSA, which involves
the coaxial catheterisation of individual arterial branches with flow-guided or wire-
guided microcatheters. By avoiding the superimposition of other arterial vessels, this
technique may better determine the type of feeding artery and the detailed
angioarchitecture of the nidus. In some radiologists' hands, super-selective IADSA is
used for measurement of arterial pressures if coupled to a pressure transducer, and also





Prior to systematically reviewing the literature (Chapter 2), I was aware of only one truly
population-based (albeit retrospective) study of the incidence of brain AVMs. This study
was based on the population of Olmsted County, Minnesota, USA (~ 124,000) over 27
years, used the comprehensive Mayo Clinic Medical Records Linkage system, and found
a brain AVM incidence of ~1 per 100,000 person-years [Brown, Jr. et al. 1996b]. I knew
of no reliable estimates of brain AVM prevalence.
At least half the adults newly diagnosed with a brain AVM present with ICrH, thereby
accounting for approximately one third of all non-traumatic ICrH in young adults [Rufz-
Sandoval et al. 1999].
1.3.4.2 Prognosis
Based on the population-based data available so far, the risk of death is greatest in the
month following a first-ever haemorrhage from a brain AVM, with a 30-day case fatality
of ~18% [Brown, Jr. et al. 1996a]. This relatively low early case fatality and a subsequent
annual case fatality of ~1% is likely to leave a sizeable prevalent burden of adults with
long-term disability, potentially exposed to the risks of recurrent haemorrhage and/or
epilepsy, due to the disease itself or its treatment.
1.3.5 Treatment
Until the end of the nineteenth century brain AVMs were not treated because there
were no known therapies. 'Conservative management' continues to be appropriate for
some people with brain AVMs, although the development of neurosurgical,
endovascular and radiation treatment has led to their use alone or in combination for
selected individuals.
Neurosurgical exposure of brain AVMs was first reported around the turn of the
twentieth century [Giordano 1890; Krause 1908]. In 1928 Cushtng and Bailey wrote, "to
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extirpate one of these aneurysmal angiomas in its active state would be unthinkable..
[Cushing and Bailey 1928], but whilst their book was in press Walter Dandy published a
case series of 8 patients of his own treated surgically, and 22 similar cases from the
literature [Dandy 1928]. Subsequent developments in catheter angiography, bipolar
coagulation, the operating microscope and stereotactic surgery have encouraged surgical
intervention and probably improved the completeness and safety of resection [French
1977],
Endovascular embolisation of brain AVMs, by injecting artificial agents in the afferent
blood supply, was first reported in 1960 [Luessenhop and Spence I960]. The technique
has been refined ever since [Luessenhop et al. 1965], initially as an adjunct to
neurosurgical excision [Wolpert and Stein 1975], but more recently — with the
development of liquid polymer glues — as a potentially curative procedure.
Stereotactic radiotherapy came into use a decade later [Steiner et al. 1972], initially
advocated for small brain AVMs, and later in conjunction with other therapies for larger
brain AVMs, using both the Leksell gamma knife and linear accelerator techniques.
The pace of development of endovascular, surgical and radiation therapies during the
late twentieth century, combined with considerable conviction amongst interventionists
about their clinical- and cost-effectiveness in the absence of randomised controlled
trials, must have led to an increasing burden on health service budgets [Sellar 2000; Al-
Shahi and Warlow 2003].
1.3.6 Aetiology
The aetiology of a condition is conventionally discussed ahead of morphology,
classification and treatment, but in the case of brain AVMs I leave it until last because
even less is known about their cause.
Most theories about the cause(s) of brain AVMs have been postulations about
persistence or redevelopment of an embryonic arteriovenous connection [Mullan et al.
1996; Truwit 1994; Jelhnger 1986], A congenital origin is thought to be supported by the
absence of features of neoplasia and the co-existence of brain AVMs with aneurysms, as
well as with other types of IVM, congenital anomaly and dysplasia [Warkany and Lemire
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1984; Jellinger 1986]. The evidence that brain AVMs detected in adults are always
present from birth was thought to be incomplete [Lasjaunias 1997], but there are reports
of their prenatal detection using foetal ultrasound [Auyeung et al. 2003]. It is likely that
brain AVMs are usually too small to be detected by this means, unless they are
associated with grossly distorted angioarchitecture such as venous varices, or colour
Doppler is used [Dan et al. 1992], The diversity of brain AVMs' biological behaviour
(such as de novo appearance, spontaneous regression and evolution with time) has led to
scepticism about their assumed congenital origin, although their postnatal growth could
simply be stimulated by some trigger (e.g. haemodynamic, vascular remodelling,
hormonal, or traumatic etc.) [Nussbaum et al. 1998; Lasjaunias 1997].
Whether the development of a brain AVM occurs in utero or not, an underlying genetic
mechanism — at least in some cases — is suggested by their occurrence in two or more
members of some families and in families with the autosomal dominant condition HHT
[McAllister et al. 1994; Herzig et al. 2000]. There are no twin studies of apparently
sporadic brain AVMs. How much any putative genetic mechanism accounts for
sporadic brain AVMs is speculative.
1.4 Aims of this thesis
Now that brain AVMs can be distinguished clearly from other IVMs on morphological
grounds, using imaging techniques that are in increasingly widespread use, at a time
when too little is known about their prognosis yet there is rapid development in
expensive and sometimes risky interventions, there seems a pressing need to re-examine
the epidemiology of brain AVMs. Their burden of disability, death, economic hardship
and loss of quality of life is likely to be considerable (1.3.4, page 44), and I will show that
the quality of existing research is poor (Chapter 2).
Information about the proportions of any population newly diagnosed with a brain
AVM over a period of time (incidence), or living with the diagnosis at a single point in
time (prevalence), are sparse. These measures would help to provide fundamental
information on disease burden for healthcare planning and comparison with other
populations. The clinical course of brain AVMs in general and, more so, the prognosis
for individuals are uncertain, as are the risks and benefits of the available treatments,
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perpetuating inevitable variation in treatment practice and disagreement about the need
for randomised trials.
To help address these uncertainties, in 1998 I set up a prospective, inception cohort
study of adults newly diagnosed with any type(s) of IVM in the Scottish population —
the Scottish Intracranial Vascular Malformation Study (SIVMS). Intriguingly, during the
time span of my thesis, research interest in the population-based frequency and clinical
course of brain AVMs appeared to grow [Berman et al. 2000]. I visited the Columbia
AVM research group at the Neurological Institute of New York, USA to find that they
were in the process of setting up a similar incidence study, due to start a year after
SIVMS, in the New York Islands (http://cpmcnet.columbia.edu/dept/avm).
This thesis is based on every adult with a brain AVM during the first two years (1999-
2000) of SIVMS, and aims to address the following questions:
• What is the quality of existing studies of brain AVM frequency and prognosis, and
what are their findings (Chapter 2)?
• What is the design of SIVMS, and what clinical and morphological variables does it
collect (Chapter 3 to Chapter 6)?
• How complete is case ascertainment in SIVMS, is it truly population-based, and
what is the quality of its data (Chapter 7 to Chapter 9)?
• How well do experienced observers agree in their interpretation of morphological
variables of brain AVMs observed on IADSA (Chapter 10)?
• What is the prevalence of brain AVMs among adults in Scotland (Chapter 11)?
• What is the incidence of brain AVMs in adults in Scotland (Chapter 12)?
• How do incident brain AVMs present, and what are their morphological
characteristics when first diagnosed (Chapter 13 and Chapter 14)?
• What are the future directions for SIVMS (Chapter 15)?
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Table 1 An integrated classification scheme for vascular malformations
of the brain
From [Chaloupka and Huddle 1998]




Venous malformation (developmental venous anomaly)
Cavernous malformation (cavernoma)









Figure 1 Notable sufferers from brain arteriovenous malformations
A: Paul Broca (1824-1880), French neurologist renowned for his localisation
of the motor speech area to the inferior frontal gyrus, died from a brain
haemorrhage, thought to be due to rupture of a brain AVM [Huard et at. 1982]
B: Gustave Flaubert (1821-1880), French novelist of the realist school
famous for Madame Bovary, suffered intractable epilepsy and died from a
brain haemorrhage, both thought to be due to a brain AVM [Gastaut and
Gastaut 1982]
C: Robert Louis Stevenson (1850-1894), Bohemian Scottish author famed for
works such as Treasure Island, may have died due to a haemorrhage from a
brain AVM secondary to hereditary haemorrhagic telangiectasia (HHT)
[Guttmacher and Callahan 2000]
D: Sir Thomas Stamford Raffles (1781-1826), founder of Singapore, had a
right frontal dural AVM that caused hyperostosis of the skull - which he tried
to mask with his distinctive hairstyle - and which led to his death from a brain
haemorrhage [Khoo etal. 1998]
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Figure 2 Schematic diagram of a brain AVM, with an aneurysm on a
feeding artery, in the right frontal lobe (sagittal view)
F = two arterial feeding vessels; A = feeding artery aneurysm; N = nidus;
V = three draining veins
50
Chapter 1
Figure 3 Illustrations of brain AVM macroscopic pathology
A: Autopsy specimen of a brain AVM lying superficially in the cortex of the
right temporal lobe
B: Surgically resected brain AVM illustrating vessels of varying calibre
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Figure 4 Computed tomography (CT) and magnetic resonance imaging
(MRI) of brain AVMs
CT of the brain in the axial plane without (A) and with (B) intravenous
contrast demonstrates a brain AVM in the right temporal lobe. Coronal,
unenhanced, T1-weighted MRI demonstrates a brain AVM in the left parietal
lobe (C). Axial proton density MRI demonstrates a brain AVM in the midbrain
and right thalamus (D)
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Figure 5 Lateral projections of intra-arterial digital subtraction
angiograms (IADSA) of the normal cerebral vasculature (left) and a
brain AVM (right, arrowed)
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Although there have been narrative reviews of the frequency and clinical course of brain
AVMs [The Arteriovenous Malformation Study Group 1999; Stapf and Mohr 2000],
there have been no systematic reviews. I have redressed this deficit by gathering all the
available research on brain AVMs in adults using thorough search methods, critically
evaluating the literature against objective methodological criteria, and summarising the
best studies according to modern standards in observational epidemiology [Stroup et al.
2000; Al-Shahi and Warlow 2001]. I have tried to straddle the objective statistical
technique of meta-analysis and the subjective art of a traditional narrative review, largely
because the heterogeneity of the included studies in their design and reporting has
precluded a quantitative synthesis [Slavin 1995; Centre for Reviews and Dissemination
Using strict criteria to judge the quality of methods and reporting, I have selected the
highest quality studies from an exhaustive systematic electronic and hand search of the
medical literature.
I sought any publication about brain AVMs in Medline (Index Medicus online, American
Library of Medicine, from 1966) and Embase (Excerpta Medica online, Bath Information
Data Services, from 1980) to the end of February 2001, and in the Cochrane Library
2001, Issue 1, using a 14-line search strategy (Table 2, page 83). This strategy had 94%
sensitivity when evaluated against a hand search of the two journals in which the largest
number of studies of brain AVMs have been published {Journal ofNeurosurgery and the
American Journal ofNeuroradiology) (Table 3, page 84) [Dickersin et al 1994],
I also searched other databases, registries of clinical trials and research in progress (the
MRC Clinical Trials Directory, the National Research Register (NRR) and Cochrane






search, were sought by scanning the bibliographies of retrieved articles, and by
surveillance of paper and electronic journals.
Nearly ten thousand publications were found by this combination of search methods
(Figure 7, page 91). By scanning their abstracts, I found approximately 3000 to be
germane to the scope of the systematic review. Because of the difficulty in reliably
limiting a literature search about a condition using a search strategy for studies of its
prognosis [Altman 2001b], the titles and available abstracts of all 3000 papers were
scrutinised using a bibliographic software package (Reference Manager® Version 9.ON,
Research Information Systems), and those of apparent relevance were read in full [Pitkin
et al 1999],
I did not seek unpublished data (it is uncertain whether bias is reduced or increased by
including such data), nor did I try to obtain individual patient data. I was alert to
publication bias in its many forms: English language bias, database bias, citation bias,
multiple publications from single studies, republication of existing series following
accrual of additional cases, and speciality bias [Easterbrook et al. 1991]. These sources of
bias are likely to be masked by the other biases of a predominantly observational
literature.
2.2.2 Critical appraisal
I used methodological quality filters based on explicit criteria, with corresponding data
collection forms, to guide my assessment of studies' validity [Sackett et al. 1991;
Laupacis et al 1994; Dixon et al 1997]. I was aware that any assessment of a study's
quality is a subjective process (largely because the reporting of methods is often
inadequate for this purpose), so where there was doubt about a particular study, my
supervisor independently appraised it [Egger and Smith 1998].
I have chosen to cite only those studies whose results are least likely to be affected by
systematic bias, confounding, and chance in their design and conduct. The criteria for
including studies in my analysis are specified below; because the studies did not remotely
resembl an ideal study of prognosis, these criteria were used for guidance, and an




2.2.2.1 Incidence and prevalence studies
I sought large, unselected, prospective, population-based studies, whose internal and
external validities were enhanced by a standard definition of what actually constitutes a
brain AVM, and adequate brain imaging to detect it. If there were no population-based
data meeting these criteria, I chose to resort to the best available hospital-based studies
of brain AVM frequency, recognising that these are likely to be unrepresentative of the
population (because of selection bias and under-ascertainment of particularly severe or
particularly mild cases). If no prospective studies were available, I resorted to the
existing retrospective data.
2.2.2.2 Studies of clinical presentation
A representative assessment of the way brain AVMs manifest themselves should also be
undertaken in population-based samples. But, because of the paucity of population-
based data on brain AVMs, I have had to include hospital-based studies without an
explicit treatment selection bias. I have selected those with more than one hundred —
preferably consecutive — patients and, for each and every individual, an explicit
allocation to a single dominant mode of presentation at diagnosis. In view of the re¬
publication of some eligible studies following the accrual of additional people, and
occasional duplicate publication, I have restricted my analysis to the largest single series
from each hospital meeting these criteria.
2.2.2.3 Studies of prognosis
To explore the recognised heterogeneity of brain AVM prognosis and establish the
behaviour of the 'average patient', the clinical course of large, representative samples of
people with brain AVMs needs to be investigated. Insights into the factors that predict
and explain future risk can be gleaned from such studies to help estimate the prognosis
for any individual person. With this knowledge, stratification of individuals according to
their subsequent risk of death (due to ICrH, for example), or their risk of the future
occurrence of ICrH, epilepsy, focal neurological deficit (FND) and cognitive
impairment, might help decide whether they should be considered for treatment or not.
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However, the findings of studies of prognosis are extremely susceptible to imperfections
in study design, which makes a careful appraisal of study methods essential.
The criteria that have guided my selection of the best available studies of the clinical
course and prognosis of brain AVMs are based on published guides [Sackett et al 1991;
Laupacis et al 1994]; given the paucity of these guides, I supplemented them with expert
opinions of members of my department. These criteria subsume many of the
aforementioned requirements of studies of brain AVM frequency and clinical
presentation (Table 4, page 85).
Adequate radiological or pathological investigation should have been used to reliably
diagnose a brain AVM according to a clear, explicit definition, so that the study sample
was not contaminated by dural AVMs or other types of IVM. The sample should be
followed prospectively from an early and uniform ('inception') point in the clinical
course of the disease. The most meaningful and practical point to standardise as 'zero
time' is the time of first-ever brain AVM diagnosis, bearing in mind that diagnosis may
well be occurring earlier nowadays, perhaps making prognosis seem better than before
because of lead-time bias. The alternative of choosing the first-ever symptom as the
inception point would often involve retrospective data collection, whilst the other
alternative of choosing the first presentation to a particular hospital is not uniform
because it could occur at any time after the onset of someone's symptoms.
The individuals being studied should be a representative sample, preferably from a well-
defined population including people diagnosed at smaller hospitals and those who died
in the community. Studies at tertiary referral centres are likely to represent people who
have survived their initial presentation with more aggressive disease, and this sort of
sampling bias affects prognostic sub-groups unequally [Hofmeister et al. 2000].
Again, my choice of sample size has been set arbitrarily at a minimum of 100 people, to
maximise the precision of the studies' results, and to increase the power to detect, at
best, large effects. The number of outcome events is the main determinant of the power
of a study of prognosis, but because outcome events for brain AVMs are relatively
infrequent, and by being treated many people will be censored from an actuarial analysis
before the occurrence of an outcome, a large sample size is all the more important. This
size cut-off was also chosen because the methodological quality of studies of fewer than
100 people was so poor, with only 2 exceptions (Table 7 to Table 9).
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The outcomes studied should be clinically important (such as death and morbidity from
ICrH and epilepsy), and their objectivity should be enhanced by clear definitions or the
use of generic outcome measures. The assessment of morbidity should preferably be
blinded to the prognostic factors under investigation (to minimise the effect of
measurement bias due to clinicians' prior expectations), and it should be as accurate and
consistent as possible with, for example, radiological evidence of ICrH. Moreover, in
view of the current tendency to treat brain AVMs once they are discovered, the
assessment of outcome should be stratified according to any therapeutic intervention
during follow-up. When outcome measures are used to evaluate impairment, disability,
handicap or health-related quality of life, their validity, reliability and responsiveness for
people with brain AVMs should have been demonstrated.
Follow-up should be prospective and as complete (>90%) as possible, starting at the
inception point in all cases. Incomplete follow-up jeopardises study results, as the
reasons for it are often linked to important prognostic outcomes. Follow-up needs to be
lengthy, especially because the average interval between ICrH from brain AVMs may be
~8 years [Ondra et al. 1990; Hartmann et al. 1998]. Although an analysis of prognostic
outcome as an annual rate, averaged over the period of the study, has the virtues of
simplicity and ease of comparison across studies, it obscures variation between patient
subgroups and over time. For example, the prognosis for a dichotomous variable such
as dead versus alive can be evaluated at a specific time (e.g. at one year after diagnosis)
or as a proportion of people affected (e.g. case fatality). On the other hand, using an
actuarial analysis (e.g. time to death) and plotting a survival curve, provides far more
enlightening information about the pattern over time, which would otherwise be lost in
an annualised survival rate.
Studies of the average clinical course for people with brain AVMs can be used to
identify factors that may help predict the prognosis of a particular event for a specific
individual. Continuous predictor variables should be kept as such, avoiding arbitrary
cut-offs [Altaian 2001b], The evaluation of prognostic factors should include not only
their statistical significance, but also their clinical significance in terms of an odds ratio
or relative risk, with 95% confidence intervals. Disentangling true determinants of
prognosis from those merely associated with particular outcomes in a univariate analysis is
difficult. Insights into clinically useful predictors of outcome, which may be either
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associated with particular outcomes or actual determinants of them, can be gleaned
from a multiple regression analysis, although stratification may be useful in simpler
situations. For outcomes that are binary or time to a specific event, logistic or Cox
proportional hazards regression models respectively are appropriate for examining the
influence of several prognostic factors simultaneously [Altman 2001b]. These models
are not accurate unless there are adequate numbers of subjects and outcome events per
variable studied [Sackett et al. 1991; Peduzzi et al. 1996], nor are they generaliseable
unless their robustness has been externally validated in other brain AVM populations.
Systematic reviews of such studies are particularly difficult because the outcome of
interest is often the time to an event, the variable of interest is often one of many
putative prognostic factors, and many of these are continuous variables for which there
are a variety ofmethods of analysis [Altman 2001a; Altman 2001b].
2.3 Results
2.3.1 Frequency
I have summarised the best studies of the incidence and prevalence of brain AVMs in
unselected populations. Data about brain AVM prevalence in selected disease groups
were easier to find, so I applied the same selection criteria to samples of people with
stroke, ICeH, SAH, epilepsy, headache and HHT (Figure 8, page 92).
2.3.1.1 Incidence in unselected populations
In the published literature, there is only one population-based study of brain AVM
incidence, although it was retrospective [Brown, Jr. et al. 1996b], and there are other
studies which purport to measure incidence, but are not truly population-based
[Jessurun et al. 1993]. The earliest study was based in the only hospital serving a
population of 155,000 living on the islands of Curacao and Bonaire in the Dutch
Antilles, between the years of 1980 and 1990 [Jessurun et al. 1993]. The crude incidence
of people of any age affected by an AVM over the ten-year period was 1.1 (95%CI 0.6
to 1.8) per 100,000 person-years. However, this study is only approximate because there
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was just one source of case ascertainment, sudden deaths in the community due to as
yet undiagnosed AVMs were unaccounted for, information about the means of brain
AVM identification was scanty, all cases were symptomatic, and there was an unusually
high frequency of multiple AVMs (probably attributable to the large proportion of
people with HHT). The later study used the comprehensive Mayo Clinic Medical
Records Linkage system to identify 26 brain AVMs over a period of 27 years in Olmsted
County, Minnesota [Brown, Jr. et al. 1996b]. The age- and sex-adjusted incident brain
AVM detection rate was 1.1 (95%CI 0.7 to 1.5) per 100,000 person-years between 1965
and 1992. However, the brain AVM detection rate increased over time due to the
escalating use of progressively more advanced brain imaging during the study period.
2.3.1.2 Prevalence
2.3.1.2.1 Unselected populations
Until now, there have been no studies of the prevalence of brain AVMs in unselected
populations, although large post mortem series have been used to attempt to estimate
the prevalence of both symptomatic and clinically silent brain AVMs. Hospital-based
post mortem series have reported brain AVM prevalences up to 600 per 100,000
[Sarwar and McCormick 1978; Courville 1950; Jellinger 1986]. However, the method of
cohort selection and the thoroughness of lesion ascertainment during pathological
examination are potential and often insuperable biases.
2.3.1.2.2 Stroke
There have been several population-based studies of the frequency of stroke, but their
primary aim was not to describe the frequency of brain AVMs as a cause of stroke. It
was therefore unsurprising that, of eight comparable stroke incidence studies performed
in the modern era of brain imaging meeting strict methodological criteria and providing
data about pathological subtypes, none commented on brain AVMs as a cause of stroke
[Sudlow and Warlow 1997], For example, the Oxfordshire Community Stroke Project
found that 10% of first-ever-m-a-lifetime strokes were due to primary ICeH, but no
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underlying brain AVMs were found because the use of MRI was infrequent, and only
two people with primary ICeH ever had IADSA [Bamford et al. 1988; Bamford et al.
1990; Boonyakarnkul et al. 1993].
I therefore sought prospective, hospital-based studies with adequate rates of CT (>90%)
and the appropriate use of IADSA, at least, to give a rough estimate of the frequency of
brain AVMs as a cause of first-ever-in-a-lifetime stroke. Even then, only two stroke
registries provided any information about brain AVMs. The Lausanne Stroke Registry is
a prospective study of people with first-ever-in-a-lifetime stroke, excluding SAH
[Bogousslavsky et al. 1988]. By imaging every patient with CT, and almost a third of all
strokes with IADSA, brain AVMs were detected in 1.4% (95%CI 0.8% to 2.3%). I
excluded the Harvard Co-operative Stroke Registry from my analysis because CT was
not widely used, and brain AVMs were lumped with aneurysms as a cause of stroke.
I applied similar selection criteria to eight studies giving information about brain AVMs
as a cause of first-ever-in-a-lifetime stroke in young people, whose ages generally ranged
from a minimum of 15 years to a maximum of 44 years. The only truly prospective,
population-based study found that brain AVMs account for roughly 3% (95%CI 1% to
11%), of first-ever-in-a-lifetime strokes in young adults [Nencini et al. 1988;
Radhakrishnan et al. 1986]. Several retrospective hospital-based series were excluded
because they were not explicit about studying first-ever-in-a-lifetime strokes, did not
specify the extent of brain imaging, or combined brain AVMs and aneurysms in one
aetiological category.
2.3.1.2.3 Intracerebral haemorrhage
Overall, approximately 10% of first-ever-in-a-lifetime strokes in Whites are caused by
primary ICeH [Bamford et al. 1990; Thrift et al. 1995]. The importance of primary ICeH,
and of brain AVMs as a cause, has been recognised since the increasingly widespread
use of CT in the early investigation of stroke [Broderick et al. 1989]. Many studies have
varied in the extent of their further investigation of an underlying cause, and their
inclusion criteria by aetiology or location of haemorrhage.
There is a paucity of satisfactory population-based data on the frequency of brain AVMs
as a cause of first-ever-in-a-lifetime primary ICeH. The only truly population-based
63
Chapter 2
study was retrospective, and was performed before the CT era, although it did use the
comprehensive Mayo Clinic Medical Records Linkage system to study cases of first-ever
primary ICeH in Rochester, Minnesota, of which 4% (95%CI 2% to 8%) were
attributable to brain AVMs [Furlan et al 1979]. Four other studies were hospital-based,
of which two did not explicitly study first-ever-in-a-lifetime primary ICeH, and the two
others combined brain AVMs with the other IVMs in one aetiological group. Two
retrospective autopsy studies of fatal spontaneous primary ICeH found an underlying
brain AVM in 15% to 16% of cases, probably an over-estimate due to case selection
bias [McCormick and Rosenfield 1973; Jellinger 1977].
There are no population-based studies, either prospective or retrospective, of the
frequency of brain AVMs as a cause of first-ever-in-a-lifetime primary ICeH in young
people. The best available estimate comes from a retrospective, hospital-based study of
people under 40 years of age with primary ICeH, that confirmed brain AVMs with MRI
or IADSA in all cases [Rufz-Sandoval et al 1999]. In this study, brain AVMs were the
leading cause of primary ICeH in the young, affecting 33% (95%CI 27 to 40%) of
people. Four other similar, retrospective hospital-based studies did not specifically study
first-ever-in-a-lifetime primary ICeH, and their IADSA rates ranged from 40% to 85%.
2.3.1.2.4 Subarachnoid haemorrhage
In Western populations, the most frequent cause of spontaneous SAH is rupture of a
saccular aneurysm on or near the Circle of Willis. One recent prospective, population-
based study in Norway, that studied every person with CT and 76% with IADSA, found
brain AVMs caused 9% (95%CI 5% to 18%) of SAH [Kloster 1997]. All the other
studies of SAH that mention brain AVMs as a cause have been hospital-based, and
mostly retrospective. There seems to be variation between geographical regions and
ethnic groups [Becker 1998]; it is debated whether brain AVMs are more common than
aneurysms as a cause of SAH in Asian populations, on the basis of studies which do not




Despite the frequency of epileptic seizures, there have been few prospective,
community-based studies of people with newly diagnosed epilepsy in the general
population [Sander et al. 1990]. The estimation of the true frequency of epilepsy is
complicated by the difficulty of achieving comprehensive case ascertainment and the
heterogeneity of different diseases causing epilepsy. The contribution made by brain
AVMs is often hidden by the investigators' classification of aetiologies into broad
categories. Furthermore, the extent and frequency of investigation with neuroimaging
have been variable between studies, so structural causes — such as brain AVMs — have
not always been identified reliably. The use of neuroimaging, ideally MRI, is indicated
for patients whose epilepsy cannot be controlled with first-line anti-epileptic drugs, and
those with focal epilepsies or fixed/progressive neurological deficits [Duncan 1997],
particularly for the identification of brain AVMs. The best information about brain
AVMs as a cause of epilepsy in the general adult population comes from a Swedish
prospective, population-based incidence study of first presentations with seizures. Using
either CT or MRI in all patients, the study found 0.9% (95%CI 0.2 to 5.1) of apparendy
unprovoked seizures to be attributable to a brain AVM [Forsgren 1990].
2.3.1.2.6 Headache
In the general population, brain AVMs are an extremely infrequent cause of headache.
Largely because of neurologists' reasonable aversion to unnecessary investigation,
studies have not attempted to ascertain the frequency of structural causes of headache
syndromes, defined according to the International Headache Society (IHS) criteria, in
unselected populations of people with headache and normal neurological examination.
Rather, the majority of existing studies have described small, retrospective, selected
series of people at tertiary referral centres, mostly using first-generation CT scanners
without intravenous contrast, thereby decreasing the chance of detecting an underlying
brain AVM. A pooled synthesis of these imaging studies of the frequency of detection
of structural brain abnormalities in samples of over 18 people with unspecified headache
and no abnormal neurological signs up to 1991 found 0.3% of them (95%CI 0.1 to 0.7)
to harbour a brain AVM [Frishberg 1994], Only 0.07% (95%CI 0.006 to 0.4) of
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migraineurs were found to have a brain AVM in similar studies, several of which used
MRI [Frishberg 1997],
2.3.1.2.7 HHT and other neurocutaneous disorders
HHT is a generalised vascular dysplasia that manifests itself in the mucocutaneous
membranes, lungs, and gastrointestinal tract as well as in the brain where capillary,
venous and arteriovenous malformations are found. The prevalence of brain AVMs in
people with HHT has been estimated to lie between 4% and 13% [Roman et al. 1978;
Porteous et al 1992]. However, brain AVMs tend to be small in the context of HHT,
often involving a direct fistula between a single afferent and efferent vessel, and their
detection is particularly dependent on the use of IADSA [Putman et al. 1996; Fulbright
et al. 1998; Willemse et al. 2000]. Due to the limited uptake of IADSA in many of the
existing studies of HHT, the frequency of brain AVMs is likely to have been
underestimated. Interestingly, at least one third of people with HHT may have multiple
brain AVMs [Willemse et al. 2000], far in excess of the infrequent multiplicity observed
in people with sporadic brain AVMs [Willinsky et al. 1990]. Despite the higher
prevalence of brain AVMs amongst people with HHT, they seem to be asymptomatic
more often than sporadic brain AVMs, which may be an artefact because they are
deliberately screened for. In fact, two thirds of any neurological complications are
attributable to pulmonary AVMs and not brain AVMs [Guttmacher et al. 1995]. There is
a relatively higher prevalence of migrainous aura amongst people with HHT, which
suggests over-ascertainment by repeated questioning, embolic phenomena from
pulmonary AVMs, or perhaps a real association with brain AVMs [Steele et al 1993].
Occasionally, single or multiple brain AVMs occur in the context of two other rare
neurocutaneous disorders, usually diagnosed in childhood. In Wyburn-Mason syndrome
AVMs affect not only the brain, but also the orbit and face, and in the blue rubber bleb





Most studies describing the clinical presentation of brain AVMs share many of the
methodological failings of studies of their frequency; their small, retrospective nature
often leaves uncertainty about the presentation of every person, either because of the
lack of radiological investigation, or incomplete data collection. In addition,
'presentation' has been variously interpreted as the clinical event that led to the
diagnosis of a brain AVM, or the first symptom in someone's lifetime that was
attributable to the brain AVM. Probably in an attempt to estimate the frequency of
particular symptoms amongst people with brain AVMs, more than one mode of
presentation has tended to be allocated to each individual; for example, the occurrence
of seizures and headache with acute ICrH. Furthermore, the roles that brain AVMs play
in the aetiology of headache, dizziness and cognitive dysfunction are subject to varying
interpretation, resulting in some clinicians attributing the symptoms to the brain AVM,
and others declaring the brain AVM asymptomatic, and so incidental.
2.3.2.1 How do brain AVMs present clinically?
Despite these limitations, some general comments can be made about three studies
(Figure 9, page 93). Although the sample size was small and the data were collected
retrospectively, I have included the population-based study from Olmsted County
[Brown, Jr. et al. 1996a], but not the study from the Dutch Antilles because of the
limitations of its sources of case ascertainment. The only large, multidisciplinary
hospital-based studies that allocated a single mode of presentation to each individual
and did not have a treatment selection bias (which was either declared in the text, or was
implicit in the focus of the paper and the interests of the authors), originate from
England [Crawford et al. 1986a] and the USA [Mast et al 1997].
The study in Olmsted County provides the most reliable population-based data on the
clinical events that led to the diagnosis of a brain AVM, although the small sample size
resulted in large confidence intervals around every estimate, and headache, FND and
rarer modes of presentation were not mentioned [Brown, Jr. et al. 1996a]. Whilst 15% of
people harbouring brain AVMs were asymptomatic, and seizures affected 20%, ICrH
was the predominant mode of presentation in 65% of the sample.
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The two hospital-based series portray different patterns from the population-based
study, especially in the proportion of people who are declared asymptomatic (Figure 9,
page 93). Many of the differences are likely to have arisen from some of the biases
inherent in hospital-based studies. For example, some people may never reach tertiary
referral centres, either because they have died or because their symptoms are not
thought to merit referral, and others may be referred only because of the availability of a
particular treatment. Not only are there differences between population-based and
hospital-based series, but large differences have also been demonstrated between three
hospital-based series in the relative frequencies of different modes of presentation, age
at presentation and brain AVM angioarchitecture [Hofmeister et al. 2000]. In general,
however, the ratio of males to females appears equal, and the mean age at presentation
is approximately 35 years, with a standard deviation of approximately 15 years.
2.3.2.2 Which characteristics of brain AVMs are associated with the
different modes of presentation?
Because characteristic manners of clinical presentation might help to raise the suspicion
of an underlying brain AVM, leading to appropriate investigations, there has been more
interest in potential distinguishing features of each mode of presentation than in an
accurate appreciation of their relative frequencies. Furthermore, in an effort to gain a
quick understanding of why brain AVMs express themselves differently, some of the
hospital-based studies have also sought angioarchitectural features that are associated with
a particular mode of presentation, sometimes making the further inference that these
factors are causative. Almost all studies of this nature have involved a retrospective
correlation of angioarchitecture described after diagnosis, with prior presentation with
ICrH or epilepsy. Although many of these studies have used umvariate and multivariate
analysis, no amount of statistical sophistication can overcome tenuous cause and effect
assumptions.
There are many potential flaws in this attempt to elucidate why some brain AVMs
present with haemorrhage, some present with epilepsy and others never cause any
symptoms at all. There is not only speculation about how repeated modification of
angioarchitecture through life eventually determines clinical presentation, but also good
evidence that the angioarchitecture of a brain AVM changes in both the short- and
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long-term after ve.ssel rupture [Stein and Wolpert 1980; Brown, Jr. et al 1988; London
and Enzmann 1981]. The mere occurrence of ICrH may distort angioarchitecture so
that any factors found in association with ICrH could be a consequence rather than a
cause of it. For example, the interpretation of whether a brain AVM or an associated
aneurysm is the cause of haemorrhage can be difficult, with pure SAH around the
aneurysm being the principal argument in favour of the aneurysm being responsible
[Barraclough 1982; Redekop et al 1998], The occurrence of pseudoaneurysms (an
artefact of haemorrhage) on distal feeding arteries and within the nidus in the presence
of SAH may lead to their over-interpretation as the cause, but the only way to know for
sure is pathological examination or comparison with any prior IADSA [Garcia-Monaco
et al. 1993; Redekop et al. 1998].
Factors associated with the first occurrence of ICrH or epilepsy might be spurious for not
only these reasons, but also they could be very different from those conferring a higher
risk of recurrence. This latter risk is what is really of interest to someone with a brain
AVM that has bled, and in any discussion of treatment. A particular feature of brain
AVMs may be so prevalent in those with one type of presentation, such as ICrH, that it
is useless for predicting future events if hospital-based series of mainly ruptured brain
AVMs are studied. For example, a study of the first occurrence of seizures found
presentation with haemorrhage to be a predictive factor, yet 86% of the cohort had
presented in this fashion [Crawford et al. 1986b]. This perception may also lead to bias
due to the expectation of finding the feature in those with a first occurrence, or
recurrence, of haemorrhage. For example, brain AVMs that present with haemorrhage
on the whole are smaller and have fewer draining veins than those with other clinical
features. These features may be difficult to disentangle as predictors of recurrent
haemorrhage, all the more so when cohorts subject to treatment selection bias (usually
favouring small brain AVMs) are used to study prognosis.
Where appropriate, I have summarised the findings of studies involving at least 100
people using this flawed retrospective approach as they are useful for identifying





Before the advent of non-invasive imaging of the brain, ICrH from brain AVMs was
underestimated because the only possible means for its detection in life was examination
of the cerebrospinal fluid (and lumbar puncture would understandably have been
avoided in many such cases). Therefore, when ICrH was detected, it was excessively
attributed to SAH, so the site of rupture was thought to be predominantly into the
subarachnoid space. With or without subarachnoid or intraventricular extension,
primary ICeH is now known to be the principal type of haemorrhagic presentation. In
the Olmsted County study, primary ICeH accounted for 41%, SAH for 24%,
intraventricular haemorrhage for 12% and a combination of these types accounted for
23% of all haemorrhages [Brown, Jr. et al. 1996a].
Hospital-based studies retrospectively comparing the angioarchitecture of bram AVMs
with a prior haemorrhagic presentation to those with other initial manifestations have
identified several factors that seem to be consistently associated with haemorrhage
(Table 5, page 86): deep venous drainage, a single draining vein, and venous stenosis.
Studies have been more inconsistent about intranidal aneurysms, small nidus size, deep
location of the nidus and venous reflux being associated with haemorrhagic
presentation. Some studies have identified systemic hypertension and vertebrobasilar or
perforating artery supply in association with haemorrhagic presentation [Langer et al.
1998; Turjman et al 1995b], but these remain unconfirmed by others. Increasing age at
presentation [Langer et al 1998] and smoking [Langer et al. 1998; Taha et al. 1982] have
not been confirmed as associated factors. Potential protective factors that have been
investigated are arterial stenosis and ectasia [Mansmann et al. 2000], dural arterial supply
[Langer et al. 1998], venous recruitment [Nataf et al. 1998], and angiogenesis [Mansmann
et al. 2000].
Of course, many of these factors may confound each other; for example, small brain
AVMs tend to have only one draining vein and higher feeding mean arterial pressure
(FMAP) [Shi et al. 1993; Albert et al. 1990], Furthermore, small brain AVMs may present
with haemorrhage because they rarely present with epilepsy or other neurological
symptoms before diagnosis [Crawford et al. 1986a; Brown, Jr. et al. 1988], and deeply
located brain AVMs tend to be supplied by perforating arteries or the vertebrobasilar
system [Turjman et al. 1995b].
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The consistent findings of a single draining vein, deep venous drainage, venous stenosis
and high FMAP being associated with a haemorrhagic presentation may reflect the
haemodynamics of these brain AVMs, and suggest that high intranidal pressure may be
the major determinant of brain AVM rupture [Hademenos and Massoud 1996].
However, just because these factors are associated with a haemorrhagic presentation does
not necessarily mean they are also predictors of either the occurrence or recurrence
haemorrhage. This has to be tested in large, prospective studies.
2.3.2.2.2 Epilepsy
Although their relative frequencies are not described in potentially unbiased samples,
epileptogenic brain AVMs clearly can express themselves as apparently generalised
seizures, as well as by simple or complex partial seizures with or without secondary
generalisation [Miserocchi et al. 1984; Osipov et al. 1997]. A few studies have examined
factors that are retrospectively associated with a presentation with epilepsy.
Unsurprisingly, they have found the brain AVMs to have statistically significant
associations with a larger (>6cm) nidus diameter [Crawford et al 1986b], and that
several other factors (which may well confound each other) seem to be associated
including supratentorial cortical location, feeders from the middle cerebral artery,
cortical feeders, venous varix, the absence of intranidal aneurysms [Turjman et al
1995a], and location in an arterial borderzone [Stapf et al 2000b]. These factors too
should be tested for their prognostic value for the occurrence or recurrence of seizures
in long-term, prospective studies.
2.3.2.2.3 Headache
There has been more curiosity and controversy about the semeiology of headache,
especially migraine and cluster headache, amongst patients known to have brain AVMs
than there has been about how often brain AVMs are a cause of headache in the general
population. Again, the absence of prospective, population-based studies with a
validation of headache diagnosis has generated conflicting opinions about whether the
relationship between headache and brain AVMs is no more than coincidental [Ozer et al
1964; Mohr 1984], in which case the brain AVMs may be dubbed asymptomatic, or
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whether there is a greater than chance association [Bruyn 1984; Pereira Monteiro et al.
1993].
Publication bias is most likely to explain the reporting of atypical migraine and cluster
headache in brain AVM patients, as unusual cases are more likely to be reported in the
literature. The migraines reported to accompany brain AVMs are usually characterised
by atypical features, although these are not specific for identifying an underlying brain
AVM in a person with migraine [Troost and Newton 1975]. The reported headaches
tend always to be on the same side, ipsilateral to the brain AVM, with disruption of the
classical migraine tempo and sequence [Troost et al. 1979; Pereira Monteiro et al. 1993;
Bruyn 1984; Lees 1962; Frishberg 1994].
A large, prospective cohort study using semi-structured interviews and/or validated
questionnaires based on the IHS criteria would be required to determine the true
prevalence of different types of headache amongst people with brain AVMs. Studying
the converse, the prevalence of brain AVMs amongst patients with various headache
syndromes, would be a huge undertaking.
2.3.2.2.4 Focal neurological deficit
Rarely, brain AVMs may cause focal symptoms and signs in the absence of prior or
concomitant ICrH. These deficits often have an insidious onset, and their subsequent
course may be transient, persistent or infrequently progressive. Occasionally they give
rise to fluctuations and slow progression suggesting the diagnosis of multiple sclerosis
[Stahl et al. 1980]. Their exact frequency in the population is unknown, but they account
for up to 10% of presentations in hospital-based series [Crawford et al. 1986a; Mast et al.
1995; Mast et al. 1997]. Whilst these deficits have traditionally been attributed to reduced
perfusion pressure (steal) due to high flow in the feeding arteries of the brain AVM, the
actual measurement of feeding artery pressures and flow velocities in selected patients
has not supported this [Mast et al. 1995].
2.3.2.2.5 Cognitive dysfunction
Despite early suggestions that cognitive disorders affect up to 50% of people with brain
AVMs [Olivecrona and Riives 1948], there are few data on their frequency amongst
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people harbouring brain AVMs; rather, case reports of unusual syndromes and studies
of the neuropsychological outcome following treatment populate the literature. Existing
research does, however, shed some light on the time of onset of cognitive dysfunction,
and the areas of the brain implicated.
Although adults diagnosed with brain AVMs seem to have met their developmental
milestones during childhood, a single, retrospective case-control study found that 44
patients affected by brain AVMs were more likely to have had a disorder of learning or
behaviour during their school years [Lazar et al. 1999]. Subsequent psychological
impairments that develop in relation to unruptured brain AVMs do not appear to be
equivalent to those from other focal lesions of similar size, nor do they appear to be
related just to the area or side of the brain in which the AVM resides [Waltimo and
Putkonen 1974; Lazar et al. 1997; Brown et al 1989]. Controversial explanations for
cognitive deficits related to areas of the brain distant from an AVM are steal — although
this is as yet unproven — and venous hypertension [Mahalick et al 1991; Mast et al 1995],
2.3.2.2.6 Other complications
Although pulsatile tinnitus is a celebrated feature of brain AVMs, in particular those
within the dura mater, it is in fact unusual [Sabra 1959]. On the limited evidence
available, it is a symptom with poor specificity, but which certainly merits at least
auscultation over the orbit and cranium, and probably non-invasive investigation [Dietz
et al 1994; Waldvogel et al 1998]. Raised intracranial pressure is another infrequent
manifestation of brain AVMs, resulting from cerebrospinal fluid outflow obstruction by
an enlarged draining vein, or the haemodynamic effect of venous hypertension leading
to poor cerebrospinal fluid resorption [U and Kerber 1983; Chimowitz et al. 1990]. Of
course, other deficits depend on the location and size of a brain AVM, so those in the
occipital lobes may cause atypical visual disturbance [Maleki and Kirkham 1983], those
in the posterior fossa can cause cranial nerve palsies [Hatori et al. 1991], trigeminal
neuralgia [Johnson and Salmon 1968] and hemifacial spasm [Kim et al. 1991], whilst




2.3.2.2.7 Health-related quality of life
Whilst only one published study of untreated brain AVMs has used validated self-
reported measures of disability [Hartmann et al. 1998], there has also been only one
study of people affected by brain AVMs to explore their perceptions of health and risks
for the future. A small study, using the standard gamble technique to compare patients'
different health states by the utility values they assigned to them, demonstrated
considerable variation in individuals' perceptions of their quality of life [Shin et al. 1997],
This clearly suggests that patients should be involved in decision-making about their
own management, as their future quality of life is affected not only by their prognosis,
but also by their interpretation of it. Larger studies are needed to evaluate the factors
associated with patients' different perceptions of their health, especially in the context of
their treatment and the design of clinical trials.
2.3.3 Prognosis
2.3.3.1 Methodological problems with studies of brain AVM prognosis
Once again, ideal study design (Table 4, page 85) has been approached by very few of
the existing observational cohort studies, leading to varying degrees of bias. I have
therefore chosen the studies that best meet my requirements, explicitly mentioning their
failings in particular areas (Table 6, page 87).
Definitions of the diagnostic criteria for a brain AVM or its angioarchitectural features
and information about the extent of investigation to achieve adequate diagnostic
certainty are provided so infrequently that I have not rejected any studies on these
criteria alone. Some studies have used restrictive entry criteria (including only those
patients with 'adequate' imaging and complete data collection) to produce a more
homogeneous cohort, although this inevitably results in a more selective cohort.
Furthermore, many of the older studies enrolled patients before the modern era of brain
imaging [Graf et al. 1983; Crawford et al. 1986a]. Because there is only one truly
population-based study, I have not rejected any study solely on the grounds of being
hospital-based, but the fact that they are all likely to suffer selection bias should not be
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ignored. Retrospective survival cohorts far outweigh studies with a prospective design,
mainly because large amounts of data are available immediately, but the data are, by their
nature, incomplete and inaccurate.
The inception point has been unclear in many studies. The uncertainty about exactly
when a brain AVM develops, and its evolution during the latent period of 'maturation'
before clinical presentation, surely make a 'lifetime' period of risk with inception at birth
an invalid assumption, involving by its nature a retrospective assessment of the clinical
course [Martin et al. 1995]. The inclusion of this latent period in the denominator of the
calculation of time at risk attenuates the apparent annual risk of an outcome. Moreover,
the prognosis from the point of diagnosis onwards is what concerns patients and
clinicians alike, especially from the point of view of treatment.
Follow-up has been variable both in duration and completeness. Scarcely any studies
have achieved more than 10 years of follow-up. In retrospective studies, completeness
has been quoted as near 100%, but 'I have already discussed the vagaries of this method
of data collection. In prospective studies, the completeness of follow-up has been more
variable, having potentially dramatic effects on less frequent outcomes in particular. The
assessment of outcome has never been blinded to features of the people under study
that are hypothesised to determine prognosis, and has often lacked standardisation with
authors frequently adopting their own arbitrary outcome scales. Outcome has usually
been assessed at varying time intervals, often without actuarial analysis, and without
stratification by differences in treatment after inception, making comparison of different
cohorts virtually impossible.
Again, I have been careful to include only the largest series from each research group,
because existing series have been republished, either when they have enlarged, or after
further follow-up [Ondra et al. 1990; Troupp 1965; Troupp et al. 1970].
A meta-analysis of the included studies has not been possible because comparable
outcomes cannot be derived from them, they have poor generalisability due to
variations in confounding effect modifiers, and there are likely to be different selection
biases operating at specialist treatment centres [Egger et al. 1998]. In any attempted
quantitative synthesis, the heterogeneous biases of these studies would be combined
rather than diluted in a pooled estimate and I would be, "simply producing tight
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confidence intervals around spurious results" [Egger et al 1998; Egger et al 2001].
Instead, I have tabulated the best available evidence (Table 7 to Table 9, pages 88-90).
2.3.3.2 What is the risk of death?
Detailed information about the early and long-term risk of death for people with a brain
AVM is sparse (Table 7, page 88). Because there are no long-term population-based data
on the risk of death following the diagnosis of a brain AVM, the brain AVM 'mortality
rate' (number of deaths per 1000 per unit time) is unknown. Studies only yield
information about the proportion of people with a brain AVM who die (the 'case
fatality').
People with a haemorrhagic presentation do appear to have a lower case fatality
compared to other causes of primary ICeH and aneurysm rupture [Perret and Nishioka
1966; Rosenow et al 1997]. In the Olmsted County study [Brown, Jr. et al. 1996a], the 30
day case fatality following a first ICrH from a brain AVM was 18% (95%CI 4% to
43%). Presumably because of selection bias, in hospital-based survival cohorts case
fatality following ICrH has ranged from 0% over approximately one year in recent
studies [Hartmann et al 1998; Mast et al 1997], to 17% over at least one year following
an initial or recurrent ICrH in another [Porter et al 1998]. Interestingly this does not
seem to translate into a long-term difference in survival between patients presenting
with and without ICrH. Long-term crude annual case fatality rates appear to he between
1% and 1.5% per annum, with no factors apparentiy conferring a greater risk of death,
although 50% to 70% of all deaths are due to ICrH [Crawford et al 1986a; Ondra et al
1990].
2.3.3.3 What is the risk of developing intracranial haemorrhage?
Because ICrH is the most feared outcome of a brain AVM, there has been an
overwhelming curiosity about the frequency and risk of its occurrence and recurrence,
and a tendency to treat brain AVMs early in an attempt to avoid it. The crude annual
rate of ICrH from brain AVMs is widely quoted to be approximately 2% in the existing
hospital-based studies of prognosis (Table 8, page 89), although this must mask




From the few studies of the clinical course of unruptured brain AVMs, the crude annual
risk of a first-ever ICrH appears to be approximately 2% [Brown, Jr. et al. 1988; Mast et
al. 1997]. Whilst one study found no factors that predicted the occurrence of ICrH
[Brown, Jr. et al. 1988], a sub-study of the same patient group with complete IADSA
examinations found the co-existence of aneurysms at baseline conferred a higher annual
rate of first-ever ICrH for people with unruptured brain AVMs [Brown, Jr. et al 1990].
2.3.3.3.2 Recurrent haemorrhage
Because the majority of brain AVMs present with ICrH, their risk of recurrent ICrH has
been studied more often than the risk of its first-ever occurrence. Early treatment
following ICrH may, of course, preclude the study of the real natural history of its
recurrence. People who have already experienced ICrH are thought to carry a risk of
recurrence greater than the 2% annual risk of first-ever occurrence, possibly up to 18%
in the first year [Mast et al 1997]. Some studies have found the risk of recurrent ICrH
after a haemorrhagic presentation to be greater than the risk of first-ever ICrH after any
other type of presentation [Crawford et al. 1986a; Mast et al. 1997], whilst other
methodologically less sound studies have not [Graf et al. 1983; Ondra et al. 1990]. These
studies have found other features to predict recurrence of ICrH, including exclusively
deep venous drainage and male sex [Mast et al. 1997], increasing age [Crawford et al.
1986a], and small nidus size [Graf et al. 1983], although the studies are not all in
agreement (Table 8, page 89). None of these factors predictive of recurrence were
identified by a celebrated long-term prospective study that found a 4% crude annual risk
of ICrH [Ondra et al. 1990]. This study was, however, flawed in some respects. It
enrolled patients before the modern era of neuro-imaging, making the diagnosis of
ICrH potentially inaccurate; by being based at a specialist centre, although serving most
of its country, it was only more-or-less population-based; and it calculated bleeding rates




2.3.3.3.3 Morbidity caused by haemorrhage
The recognition of a lower case fatality in comparison to other causes of ICrH has
generated further interest in the morbidity attributable to haemorrhage caused by brain
AVMs (Table 8, page 89). Theoretically, the morbidity of brain AVM rupture may be
ameliorated by patients being younger than their counterparts with primary ICeH, by
haemorrhage occurring from vessels at a lower pressure than aneurysmal SAH or
spontaneous primary ICeH, by there being less vasospasm than after aneurysmal SAH
[Sasaki et al. 1981], and by the limitation of haemorrhage to the nidus of the brain AVM.
Furthermore, the morbidity of ICrH may be less than previously thought, perhaps
because the improved resolution and availability of non-invasive imaging have
augmented the detection of small primary ICeH. In a recent study, up to 84% of
patients with a first occurrence of haemorrhage made a full recovery or scored only 1 on
the Rankin scale [Hartmann et al. 1998], whilst in another only 45% made a recovery
without a permanent deficit [Porter et al 1998]. These findings were, however, based on
hospital-based survival cohorts, and are probably subject to their inherent biases, in
particular that people who were more disabled at presentation may not have been
ascertained. Whether recurrent ICrH carries a similar morbidity is even less certain
[Hartmann et al. 1998; Porter et al. 1998].
2.3.3.3.4 Prediction models
Prognostic models are useful for helping to make informed decisions in routine clinical
practice, in particular for deciding who may be at greatest risk with conservative
management. However, in the absence of a relatively uniform consensus on the
important prognostic factors for patients with brain AVMs, the generalisability of the
conflicting results of the existing multivariate analyses is poor. In an effort to simplify
the issue of risk prediction, a general 2-4% annual risk of (first or recurrent) ICrH has
been used to determine the likelihood of survival free of ICrH using the multiplicative
law of probability [Kondziolka et al. 1995; Brown, Jr. and Kondziolka 2000]. However,
these calculations assume population homogeneity and a uniform risk of ICrH over
time, both ofwhich are very unlikely to be the case.
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2.3.3.4 What is the risk of developing seizures?
Little attention has been given to the risk of epilepsy from brain AVMs (Table 9, page
90), especially by authors who thought that seizure disorders, although common, were
too difficult to quantify [Ondra et al. 1990]! From the data that are available, it appears
that people with brain AVMs carry an annual risk of developing de novo seizures of 1%,
and they may be at a greater risk following presentation with haemorrhage, or if they are
older [Crawford et al. 1986b]. However, when they do occur, at least three quarters of
patients' seizures come under good control on first line anti-epileptic drugs [Osipov et
al 1997].
2.3.3.5 Pregnancy
Controversy has dogged the influence that pregnancy, labour, different modes of
delivery and the puerperium may have on bleeding rates from brain AVMs. Some
women with brain AVMs are advised against pregnancy, others are sterilised, and those
who do become pregnant may or may not be encouraged to have a Caesarean section or
a termination [Horton et al. 1990; Velut et al 2000]. One retrospective study of women
of childbearing age in an untreated survival cohort being considered for stereotactic
radiosurgery, without information on the completeness of follow-up or a statistical
analysis, compared their crude rates of first or recurrent haemorrhage outwith and
during pregnancy [Forster et al. 1993]. Compared to the bleeding rate of 4.5% per
annum when they were not pregnant, there was a higher rate of haemorrhage during the
second trimester (17% per annum), but not in the other stages of gestation. A second
similar study found no influence of pregnancy on haemorrhage rates, although its
conclusions are invalidated in a sensitivity analysis by changing the arbitrary duration of
pregnancy that they chose [Horton et al. 1990].
Of course, there are several biases inherent in these studies; in particular, the occurrence
of haemorrhage may have a fatal outcome so preventing future pregnancy, or discourage
some women from becoming pregnant if the haemorrhage is not fatal. Although it is
logistically difficult to resolve this dilemma, only a population-based, prospective cohort
study could examine pregnancy as a risk factor for the development of haemorrhage.
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2.3.3.6 Hereditary haemorrhagic telangiectasia
Despite the prevalence of brain AVMs in people with HHT, there is a paucity of
information about their prognosis, and whether it is any different from sporadic brain
AVMs. AVMs of the brain were an infrequent cause of death in a population-based
study of people with HHT [Kjeldsen et al. 1999]. A small study in which a large
proportion of people were asymptomatic, with a short prospective follow-up period in
which no haemorrhages were observed, suggested that the risk of ICrH from a brain
AVM in the context of HHT may be lower than for people with sporadic brain AVMs,
based on an annual bleeding rate of 0.4% (95%CI 0.1% to 1.2%) derived from a
lifetime-risk assumption. Clearly, here too large prospective, population-based studies
are needed.
2.4 Summary
There is a serious shortage of high quality studies of the frequency,
presentation, clinical course and prognosis of brain AVMs
Whilst very little can be reliably concluded about the likely prevalence of
brain AVMs, their incidence in unselected populations is of the order of
1 per 100,000 per year
Long-term crude annual case fatality due to a brain AVM is 1-1.5%
The crude annual risk for the first occurrence of a haemorrhage from an
unruptured brain AVM is approximately 2%, and this may be increased
by co-existent aneurysm(s)
The risk of haemorrhage recurrence may be as high as 18% in the first
year, although consistent risk factors for haemorrhage recurrence have
not yet been observed
Brain AVMs seem to carry an annual risk of developing de novo seizures
of 1%, with a good prospect of control on anti-epileptic drugs





Many of the existing studies of their frequency have not met my selection criteria, or the
studies are no longer appropriate because of the radical improvements in imaging of the
brain's vasculature over the last two decades. A clear brain AVM definition was lacking
in so many of the studies I have selected that if I had excluded any of them on this
criterion alone, there would have been hardly any left. Clearly, there is still a need for
some large, prospective studies of the incidence and prevalence of brain AVMs in well-
defined, stable populations across the world, with widespread availability and uptake of
CT, MRI and IADSA.
Despite the large number of studies of the clinical course of brain AVMs, very few meet
rudimentary standards for an ideal design, and fewer still provide consistent results that
can be extrapolated to the generality of people with brain AVMs. It is, of course,
difficult to assess the clinical course of brain AVMs because of their heterogeneity and
because they are often treated when discovered.
Because of the inconclusive and uncertain nature of existing research about the clinical
course of brain AVMs, clinicians are frequently faced with various management
dilemmas: what is the clinical course of brain AVMs in general, what is the prognosis
for a particular person, and which treatment(s) — if any — should be used?
There is therefore a pressing need for prospective, population-based observational
cohort studies of people with brain AVMs, both ruptured and unruptured. These
studies should share core methods (Table 4, page 85) in order to minimise both bias and
confounding to an acceptable level, to make studies comparable, and to speed the
evaluation of prognosis with the greatest world-wide economy of research effort by
cautiously synthesising their results [Sudlow and Warlow 1996; Sackett et al. 1991; Al-
Shahi and Warlow 2001]. They may help to elucidate the untreated clinical course for
large groups of people with brain AVMs (mortality rate, case fatality, and prognosis for
first or recurrent haemorrhage or seizures), and the factors that determine prognosis for
particular individuals. The widespread availability and uptake of brain imaging now




Even with thorough, targeted investigation of their presenting symptoms, the number
of patients will still be comparatively small. Therefore, multicentre studies, possibly with
international collaboration, will be required to collect sufficient people with untreated
brain AVMs to prospectively establish their clinical course over several decades.
Whilst these people may be subject to treatment selection bias, current variation in
practice — reflecting uncertainty about whether and how to treat brain AVMs - will
eventually mean that a representative sample is collected. In the interim, these studies
will generate useful observational data about both beneficial and adverse effects of
treatment, which may lead to appropriate randomised trials. Although these trials will be
difficult to do, and will clearly require multicentre collaboration, they are particularly
necessary in the context of a condition where the prognosis is uncertain for groups of
people, let alone for any particular individual.
But it is likely that the true natural history of brain AVMs — be it identical to or different
from existing knowledge — will be the last uncertainty to be resolved. In the next section
I describe and evaluate the design of a prospective, population-based cohort study of
newly diagnosed brain AVMs in adults — the Scottish Intracranial Vascular
Malformation Study (SIVMS) — which I set up in 1998 to address this uncertainty.
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Table 2 Electronic literature search strategies
Ovid Medline on Biomedical Data Services from 1966 to February 2001
Line number Search term
1 exp cerebral arteries/
2 exp cerebral arterial diseases/ or intracranial arterial diseases/
3 cerebral veins/
4 exp cerebral ventricles/
5 (cranial or cerebral or cerebell$ or brain$ or dural or supratentorial or
intracerebral).tw
6 1 or 2 or 3 or 4 or 5
7 arteriovenous malformations/ or arteriovenous fistula/
8 angiomas, tw
9 ((arteriovenous or vascular) adj10 malformation$).tw
10 7 or 8 or 9
11 6 and 10
12 cerebrovascular malformation$.tw
13 intracranial arteriovenous malformations/
14 11 or 12 or 13
15 limit 14 to human
EMBASE from Bath Information Data Services from 1980 to February 2001
Line number Search term
1 exp brain artery/
2 cerebrovascular disease/
3 brain vein/
4 exp brain ventricle/
5 (cranial or cerebral or cerebellS or brainS or dural or supratentorial or
intracerebral).tw
6 1 or 2 or 3 or 4 or 5
7 arteriovenous malformation/
8 angiomas.tw
9 ((arteriovenous or vascular) adj10 malformation$).tw
10 7 or 8 or 9
11 6 and 10
12 cerebrovascular malformationS.tw
13 brain arteriovenous malformation/ or cerebrovascular malformation/
14 11 or 12 or 13
15 limit 14 to human
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Table 3 Literature search sensitivity and precision
Sensitivity = (articles identified by literature search / articles identified by
hand search)
Precision = (relevant articles identified by literature search / all articles




Hand search Sensitivity (%) 95%CI
AJNR 1986 3 5 60 17-100
1996 6 7 86 60-100
J Neurosurgery 1986 8 8 100 -
1996 16 16 100 -
Overall 34 36 94 87-100
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Table 4 Characteristics of the ideal study of brain AVM prognosis




Sample size > 100
Objective, pre-defined outcome events and validated measures of functional status
Assessment of outcome blinded to baseline factors of interest
Stratification of outcome by differences in treatment
Follow-up > 90% complete
> 5 year follow-up
5 year survival rate and an actuarial analysis of the chosen outcomes
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Table 5 Angioarchitectural features of brain AVMs associated with a




Deep venous drainage Duong et at. 1998
Langer et at. 1998
Nataf et at. 1998
Turjman et at. 1995b
Kader et at. 1994
Miyasaka et at. 1992
Single draining vein Shi etal. 1993
Miyasaka et at. 1992
Albert etal. 1990
Venous stenosis Nataf et at. 1998
Mansmann et at. 2000
Miyasaka et at. 1992
High feeding mean
arterial pressure
Duong et at. 1998
Intranidal aneurysm Redekop et at. 1998 Meisei et at. 2000
Nataf et at. 1998 Duong et at. 1998
Turjman et at. 1995b Langer et at. 1998
Mansmann etal. 2000
Small nidus size Langer et at. 1998
Kader et at. 1994
Shi etal. 1993
Albert et at. 1990
Crawford et at. 1986a
Mansmann et at. 2000
Duong et al. 1998
Deep location Mansmann et at. 2000 Duong et al. 1998
Turjman et at. 1995b Langer et al. 1998



























































































































































































































































































Table 7 Studies of brain AVM clinical course after first presentation with
information about case fatality
Where no overall average period of follow-up is given in the original studies,
the range of average follow-up for the subgroups is given
Study
details












































































symptoms (n=78) parietal lobe
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Table 8 Studies of brain AVM clinical course after first presentation with
information about the prognosis for intracranial haemorrhage
Where no overall average period of follow-up is given in the original studies,
the range of average follow-up for the subgroups is given
Study
details




















































































Unruptured AVMs 91 Coexisting aneurysm s.
Annual bleed 7% per
rate at 5 years annum
No aneurysm








































Table 9 Studies of brain AVM clinical course after first presentation with
information about the prognosis for seizures
Study Patient
details group






Mixed prospective and retrospective studies









































Figure 7 Literature search results
Medline search = 6287
Embase search = 3500
Duplicates = 1694 ■ AVM Bibliography = 8093
Total Embase and Medline References = 9787
Chapter 2
Figure 8 Frequency of brain AVMs in different patient and age groups,
with point estimates and 95% confidence intervals










Intracerebral haemorrhage (any age)
Furlan etai, Retrospective 7/180(3.9%)
1979 Population
Intracerebral haemorrhage (age <40 years)
Ruiz-Sandoval Retrospective 67/200 (33.5%)
etal., 1999 Hospital
Spontaneous subarachnoid haemorrhage
Kloster, 1997 Prospective 7/76 (9.2%)
Population
Newly diagnosed unprovoked seizures
Forsgren, 1990 Prospective 1/107(0.9%)
Population
Headache with a normal examination
Frishberg, 1994 Pooled synthesis 6/1825(0.3%)
Migraine
Frishberg, 1997 Pooled synthesis 1/1432 (0.07%)
0 5 10 15 20 25 30 35 40 45
Percentage attributable to brain AVMs
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Figure 9 The relative frequencies of clinical events at diagnosis, with
point estimates and 95% confidence intervals
Headache, focal neurological deficit and other modes of presentation were
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Section 2: The Scottish Intracranial Vascular Malformation Study
(SIVMS) - methods and design
Chapter 3 Methods of a population-based disease register for adults
with intracranial vascular malformations
Chapter 4 Database design for a population-based disease register
for adults with intracranial vascular malformations
Chapter 5 Variables relating to patients with brain arteriovenous
malformations and their clinical features
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3.4.4 Comparison with other studies
Chapter 3
3.1 Introduction
Because of the inconclusive nature of most of the existing literature about all IVMs —
and not just the deficiencies I exposed in the brain AVM literature in Chapter 2 - I set
up the Scottish IVM Study (SIVMS) in the autumn of 1998. The study team included
myself, an administrator (Rosemary Anderson), my supervisor (Professor Charles
Warlow), and a multidisciplinary, collaborative steering committee representative of the
four neuroscience centres in Scotland (Chapter 19). Data collection started on lbt
January 1999 and will continue uninterrupted until, at the earliest, January 2005. This
chapter describes study design, and descriptions of the database and variables follow.
3.2 Study design and process
3.2.1 SIVMS inclusion criteria
Patients are provisionally included in SIVMS if they meet the following criteria
(according to their data supplied by the source(s) of notification):
• Any of the principal sub-types of IVM1:
a) Brain AVM (including brain arteriovenous fistulae)
b) Dural AVM (including carotid-cavernous fistulae)
c) Cavernous malformation (CM)
d) Venous malformation (VM)
• Date of first-in-a-lifetime diagnosis (by imaging or histology) > 1st January 1999
• Age >16 years at the time of this diagnosis
• Permanendy resident in Scodand at the time of this diagnosis
1 Although SIVMS recruits adults with any type of IVM, this thesis only relates to brain AVMs
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After notification, a patient's provisional inclusion is confirmed or refuted following
review of case notes, pathology reports and diagnostic brain imaging when they
eventually become available (see 3.2.9, page 106). Only adults are included because of
die different consent procedures required for children and the different clinical
behaviour of brain AVMs in the paediatric population.
Diagnostic criteria for brain AVMs are described below (3.2.3, page 98). Occasionally an
included patient may harbour more than one brain AVM (for example, in people with
HHT). Intermediate types of IVM arise, with radiological and/or pathological
characteristics overlapping different IVM types; the greatest difficulty arises in telling
CMs and VMs apart. Whilst these rare, intermediate forms of IVM are 'included', they
are never regarded as 'definite' (3.2.3.4, page 99) and form a separate subgroup for
analysis.
3.2.2 SIVMS exclusion criteria
• Incorrect diagnosis of an IVM
• Other types of intracranial vascular malformation
a) Vein of Galen malformation
b) Dural AVMs with exclusively spinal medullary venous drainage
c) Capillary malformation/telangiectasis
• Spinal vascular malformation
3.2.3 Diagnostic criteria specifically for brain A VMs in SIVMS
For the purpose of a generaliseable population-based study, the working definition used
by SIVMS to diagnose a brain AVM reflects routine clinical practice by being dependent




A brain AVM is an anastomosis of non-nutritive blood vessels in the brain parenchyma,
in which arteriovenous shunting occurs in a nidus (the area towards which usually
multiple feeding arteries converge, and from which one or more veins drain). This
working definition includes a brain AVF (which involves a single direct fistula between
one feeding artery and one draining vein), but excludes pure vein of Galen
malformations and dural AVMs.
3.2.3.2 Pathological definition
Macroscopically, a brain AVM is an abnormal tangle in the brain parenchyma composed
of tortuous vessels of varying calibre, occasionally calcification, and often thickened and
opacified overlying leptomeninges (Figure 3, page 51). Microscopically, a brain AVM is
composed of vessels which have a mature phenotype, but which are morphologically
between arteries and veins (due to the haemodynamic stresses placed upon them) and
intervening capillaries are missing [McCormick 1966].
3.2.3.3 Radiological diagnostic criteria
Brain AVMs may be suggested (but not regarded as definite) by calcification on CT, but
they are only definite if the tangle of vessels enhances with contrast [Kumar et al. 1984].
Brain AVMs are seen as a serpiginous cluster of flow voids on standard spin-echo MRI
(Tj and K), representing multiple dilated vascular channels with relatively rapid blood
flow, which usually enhance with contrast (although this is usually not necessary for a
definite diagnosis) [Wallace and Bourekas 1998]. Four-vessel IADSA demonstrates the
collection of abnormal vessels within the brain parenchyma, associated with early
visualisation of veins during the late arterial or capillary phase on rapid sequence
angiography.
3.2.3.4 Certainty
It is not always the case that investigations establish a brain AVM diagnosis beyond all
doubt. Therefore, a measure of certainty (definite/probable/possible) is attached to the
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diagnosis of each brain AVM on every investigation to reflect routine practice. Whilst
'definite' diagnoses meet the diagnostic criteria above, the distinction between 'probable'
and 'possible' is more subjective, being based on the clinical instincts of the notifying
radiologist/pathologist and the SIVMS neuroradiologists (see Table 10, page 114).
Brain AVM diagnosis may be uncertain on imaging because extensive radiological
investigation has not been performed. This may have been because it was thought to be
clinically inappropriate, because the patient declined it, or because it was not available
(for examples see section 13.3.1, page 257). Even when thorough investigation is
undertaken, only a small remnant of AVM may be visualised preventing a definite
diagnosis from being made. This usually occurs in two situations following ICrH from a
brain AVM. Firsdy, a brain AVM may be 'angiographically-occult' due to compression
by haematoma, especially in the acute phase of ICeH. Secondly, an IADSA might only
demonstrate an early draining vein that would implicate a brain AVM — now with its
nidus obliterated by the haemorrhage — as the 'probable' cause; haemodynamic changes
or recanalisation might lead to the subsequent appearance of the AVM, whereas
spontaneous obliteration/thrombosis might result in its disappearance.
Inevitably, certainty of radiological diagnosis is also affected by variation between
observers reflecting their experience and professional perceptions about the
interpretation of diagnostic studies of brain AVMs. This will be explored further in
Chapter 10.
For these reasons, the final decision about radiological certainty of diagnosis and the
collection of detailed angiographic data is taken collectively after review of all diagnostic
imaging. Certainty is arbitrated at consensus meetings between the SIVMS research
fellow (myself 1999-2001) and the two consultant interventional neuroradiologists (Dr
Robin J Sellar, Western General Hospital, Edinburgh and Dr Jo J Bhattacharya,
Southern General Hospital, Glasgow). If any participant is found to have received an
incorrect diagnosis of a brain AVM after review of their CT/MRI/IADSA by the study
neuroradiologists, they are excluded.
Certainty of pathological diagnosis is determined from pathologists' reports of autopsies
and specimens from surgical excision, and is not subject to independent review.
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A patient is not excluded if a brain AVM diagnosis is possible, but its certainty is less
than 'definite'. In routine clinical practice, management sometimes proceeds with a
'possible' or 'probable' working diagnosis of a brain AVM, as if the diagnosis was
'definite'. Further investigation may not be undertaken, and these people will be an
interesting subgroup for future analysis. Subsequent events (such as ICrH or epilepsy)
may lead to investigations that confirm the 'definite' existence of a brain AVM, which
militates against the exclusion of these individuals.
Therefore, in any analysis, the level of certainty of the included patients' diagnoses will
be specified.
3.2.3.5 Date of diagnosis
Some time after a patient presents, their IVM is diagnosed on the basis of radiological or
pathological examination, according to the study's inclusion criteria (3.2.3, page 98). The
earliest date of definite radiological/pathological diagnosis constitutes the 'date of
diagnosis' of the IVM, when it is deemed to be 'incident' or 'detected'. Exceptionally, a
person may harbour multiple definite IVMs, in which case each attracts a separate date
of diagnosis [Chaloupka and Huddle 1998]. A patient's date of diagnosis, on the other
hand, refers to the earliest date that any of their definite IVMs were diagnosed.
3.2.4 Study setting
3.2.4.1 Demographics of Scotland
The most recent decennial census in Scotland was conducted on 29th April 2001. At that
time, the total population was 5,062,011 of whom 51.95% were female, 4,089,946
(80.8%) were aged >16 years, and 87% were born in Scotland. Scotland's population
denominator is a manageable size for surveys of a condition like brain AVMs with an
estimated incidence of 1-2 per 100,000 per year.
The size and age structure of the Scottish population at the time of this study were
derived from annual between-census estimates. The General Register Office (GRO)
produces these estimates using registration of births and deaths as well as data on
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immigration and emigration (www.gro-seotland.gov.uk). The mid-2000 estimate of the
population of Scotland was 5,114,600, of whom 4,114,052 were adults aged over 16
years. There was only a small (0.3%) annual flux in the population (immigration of 6,400
and emigration of 6,600 people) in the 12 months prior to 30 June 2000.
3.2.4.2 The Scottish health service
Few patients receive health care outside the National Health Service (NHS), almost
every patient is registered with a general practitioner (GP), and there is negligible
overseas and cross-border flow to England of the population for health care. The
Information and Statistics Division (ISD) (www.show.scot.nhs.uk/isd) centrally registers
and codes every death certificate and every hospital inpatient admission in the NHS in
Scotland. There are four Neuroscience centres in separate health boards (Glasgow,
Greater Glasgow; Edinburgh, Lothian; Dundee, Tayside; Aberdeen, Grampian) staffed
by — amongst others — 32 consultant neurologists, 19 consultant neurosurgeons, and 71
consultant radiologists based at a Neuroscience centre or affiliated to another hospital
providing CT, MR or IADSA. Patterns of investigation of ICrH probably vary
depending on each clinical scenario and the facilities available. Compared to previous
estimates, autopsy rates are declining [Cameron et al. 1977]; in the years 1999 and 2000
ISD data show that there were 118,080 adult deaths in Scotland, of whom 14,630 (12%)
had a post mortem examination.
3.2.5 Ethical approval
At the time of this project, in Britain multicentre research was defined as taking place
over five or more local research ethics committee (LREC) geographical boundaries,
each LREC usually corresponding to a part or the whole of a healthboard. A multicentre
application for ethical approval had to be submitted to a single multicentre research
ethics committee (MREC) for an independent opinion on all the ethical and scientific
aspects of the research proposal, and once approved, it had then to be distributed to
every LREC in the geographical location of the study. Each LREC's executive
subcommittee then judged the suitability of the local site, researcher(s) and facilities
before the research could start in their area.
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The MREC for Scotland (MREC/98/0/48) and every LREC in Scotland approved the
following study methods, following a laborious application process, described in
Chapter 16.
3.2.6 Sources of case ascertainment
SIVMS uses multiple overlapping sources of case ascertainment (Figure 10, page 116) to
identify all adults meeting its inclusion criteria (see 3.2.1, page 97):
3.2.6.1 Collaborative neuroscience network
The primary source of ascertainment is an all-inclusive, collaborative network of
clinicians, radiologists and pathologists working m the clinical neurosciences and stroke
medicine (Chapter 19). Collaborators are not only based at the four neuroscience
centres serving the population of Scotland, but also at the other hospitals in the country
- and at neighbouring hospitals in the North of England — where brain imaging facilities
are available. SIVMS steering committee members in Edinburgh and Glasgow also
actively survey (and retrospectively check) the records of the two Scottish specialist
brain AVM clinics for new cases. Although the vast majority of patients in Scotland
receive healthcare through the state-funded NHS, I have ensured that the network also
covers the few private facilities offering brain imaging and clinical consultations from
relevant specialists. Collaborators receive monthly newsletters, reminders about the
study by email, and use materials available on the study website (www,shuns .com) to
notify the study of incident cases as they arise. Up-to-date information about any
potential new collaborators in each hospital is obtained quarterly from the Steering
Committee.
3.2.6.2 General practitioners
I estimated that each general practice in Scotland would have, on average, at least one
adult with an IVM. I supposed that GPs would find these people memorable, so I
contacted all 3,700 GPs in Scotland in January 2000, asking if any of their patients, who
SIVMS did not already know about, were eligible for inclusion in the study. This
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method of ascertainment was only used once, for the first year of the study, in view of
its low yield (see 8.2, page 188).
3.2.6.3 Centralised coding of hospital discharge data and death
certificates
In Scodand, every episode of hospital care is coded with details of a patient's main
diagnosis, comorbidity (up to five subsidiary diagnoses), and any operations or
procedures conducted. Diagnostic data from hospital discharges as well as death
certificates are coded using the tenth revision of the International Classification of
Diseases (ICD-10). In Scodand, all hospital inpatient stays (known as Scottish Morbidity
Records, SMR01) have been collated since 1980, and are linked with death records from
the GRO by ISD. Several mechanisms for ensuring data quality are in place at ISD,
including validation, accreditation, quality assurance and monitoring, and national
coding advice and training programmes [Harley and Jones 1996].
Every six months SIVMS requests records of adults (age > 16 years) dying or discharged
from hospital for the first time ever according to ISD's records with an ICD-10 code
for a brain AVM in any diagnostic position (Table 11, page 115). The data upon which
this thesis is based were provided by ISD in August 2001 for the complete years 1999
and 2000.
3.2.7 Notification
SIVMS receives notifications of potentially eligible patients on posted, faxed, or emailed
notification forms from the collaborative neuroscience network or GPs (see appendix of
study materials — 1 and 2), and from ISD in biennial delimited ASCII electronic files
which are imported into the study database. SIVMS later thanks collaborators and GPs
for their notifications, and informs them if the patients are excluded (see appendix of




Following notification of a newly diagnosed patient from one of the sources of case
ascertainment, SIVMS approaches a patient's GP and their main hospital consultant by
post. An interval of four weeks is left to allow a discharge summary and/or brain
imaging report to reach the clinicians before SIVMS approaches them. A structured
letter seeks confirmation of die accuracy of the information supplied by the notifier,
permission to access the patient's case notes, and questions about whether the patient is
suitable for SIVMS to approach by post with a consent pack. These letters are
customised according to whether the patient is alive, the patient's gender, whether the
patient was identified by ISD, and whether the main consultant is a
neurologist/neurosurgeon and whether they were responsible for notification (see
appendix of study materials — 9 to 14 and 16 to 19). Whether SIVMS subsequendy
contacts the patient depends on how the GP and main hospital consultant respond.
SIVMS approaches the consultant caring for the patient at any other hospital(s) the
patient has attended four weeks after the main consultant's response and as and when
other hospital attendances come to light (see appendix of study materials — 15).
Non-responders are pursued by a three-week reminder letter, and further pursued by
letter or telephone if necessary.
Disagreements about whether a patient is aware of their diagnosis, caused by the lag in
information passing from hospital consultant to GP, are resolved by correspondence. If
access to case notes is denied on the grounds of cost by a GP, SIVMS negotiates
reimbursement and/or agrees to go to the practice to copy the notes. If access to case
notes is conditional upon patient consent and the patient has not been deemed to be
aware of their diagnosis, SIVMS attempts to gain access to the notes by reassurance that
explicit patient consent is not required for this by the MREC for Scotland.
Disagreements between GP and consultant about whether SIVMS should approach a
patient with a postal consent pack are ofmost concern because SIVMS strives to obtain
consent and questionnaire data from every living patient. SIVMS has little choice but to
refrain from approaching a patient when a clinician's opinion is that they had been
reassured about their prognosis and would be worried by an approach from a research
study, or that the patient is too anxious or cognitively impaired for postal contact.
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However, annual GP follow-up (see 3.2.10.1, page 108) is used as an opportunity to
review the appropriateness of these decisions, should contact from SIVMS become
appropriate at a later date (see appendix of study materials — 22).
For a patient to be approached with a consent pack, they must be alive, aware of their
diagnosis and deemed appropriate for postal contact. Ethics committees regard a direct
first communication from a research study to a patient to be unethical (so-called 'cold
calling'). For this reason SIVMS sends a patient consent pack to the patient's GP, asking
the GP to sign a pre-formatted letter introducing SIVMS and then to forward this letter
with the consent pack in a pre-paid envelope addressed to the patient. The consent pack
contains a letter from SIVMS to the patient, a consent form, an information leaflet
about SIVMS, and a questionnaire requesting simple demographic details (see appendix
of study materials — 21). On the consent form, patients are asked whether they permit
access to their medical records and whether they are willing to complete annual
questionnaires. If necessary, up to two reminders are sent to the GP at three-week
intervals. If there is still no response from the patient after a further six weeks, attempts
to gain their consent and completion of a questionnaire are abandoned until the annual
follow-up procedure starts (see 3.2.10, page 108).
Following the conclusion of the recruitment process, each patient's GP and main
hospital consultant are sent a letter summarising whether SIVMS has access to notes
and whether the patient has agreed to complete annual questionnaires (see appendix of
study materials — 23 to 25).
3.2.9 Collection of study materials during recruitment
3.2.9.1 Medical records
SIVMS allows at least 8 weeks to pass following a patient's diagnosis before requesting
copies ofmedical records from every hospital where they have been seen as an inpatient
or outpatient and from their GP (see appendix of study materials — 26 to 29). An
interval of at least 3 weeks following a patient's death is left before requesting the GP
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case notes to allow for their passage to one of the three Practitioner Services2 regional
medical offices where they are usually kept for 3 years and then destroyed.
Deferring these requests is intended to allow completion of secretarial and
administrative tasks relating to the patient's diagnosis/death. Additional delays may be
incurred if clinicians do not return the recruitment forms, or if there is a dispute about
patient consent, cost or access to case notes. SIVMS requests notes from the
neuroscience centre as well as any referring hospital(s) to ensure that information is
obtained about the mode of a patient's presentation, which may well have occurred
elsewhere.
A reminder is sent if case notes have not been received within 3 weeks, and non-
responders are contacted by telephone.
3.2.9.2 Diagnostic brain imaging
At least four weeks after diagnosis, SIVMS enquires about the extent of brain imaging at
the hospital where the diagnosis was made (and the referring hospital, if appropriate).
The relevant CT, MRI and IADSA studies are requested by telephone, and if they are
not received within 3 weeks, non-responders are contacted by telephone. Once received,
1 review the brain imaging. Apart from the IADSA sequences that demonstrate vascular
territories not involving the brain AVM, hard copies of each complete imaging study are
made and transported to the image library filing cabinet at the Institute of Neurological
Sciences in Glasgow to await review by the study neuroradiologists at their consensus
meetings.
3.2.9.3 Patient questionnaire
If SIVMS is permitted to approach a patient by their GP and main hospital consultant,
the postal consent pack contains a questionnaire that cross checks demographic details
2 These Practitioner Services teams are divisions of the Common Services Agency, NHSScotland, and
register patients with family doctors on the population database (the Community Health Index — CHI),




including ethnicity, and enquires about handedness, number of children, medical history,
current medications, and family history (see appendix of study materials — 21).
3.2.10 Collection of study materials during follow-up
Patients are followed-up on an annual basis during their lifetime using several
overlapping methods.
3.2.10.1 GP questionnaire
Every patient's GP is contacted six weeks before the anniversary of the patient's
diagnosis (see appendix of study materials — 30 and 31). A single-page GP questionnaire
seeks confirmation of the patient's address and enquires about whether they are still
suitable for postal contact, or whether it is now appropriate to send a postal consent
pack if it had not been before. The questionnaire also validates survival and asks about
hospital visits/admissions in the preceding year, the occurrence of brain haemorrhage
and epilepsy, and asks the GP to assess the patient's current disability on the Rankin
scale [Rankin 1957]. A reminder letter is sent after 3 weeks, and GPs are telephoned
after a further 3 weeks if they still do not reply.
3.2.10.2 Patient questionnaire
Participants are contacted directiy if they have already consented to complete annual
questionnaires and if their GP — in their annual questionnaire (above) — has confirmed
that the patient is both alive and still suitable for a questionnaire. For example, it might
be inappropriate to send a questionnaire in the event of a recent ICrFI resulting in
hospitalisation.
The patient questionnaire includes postal versions of the Barthel Index, Short-Form 36,
and Hospital Anxiety & Depression Scale [Mahoney and Barthel 1965; Zigmond and
Snaith 1983; Ware 1993], questions about epistaxis and telangiectasia (screening for
HHT), and two questions screening for the occurrence of headaches and epilepsy (see
appendix of study materials — 34-36). If a participant claims to be, 'significantly bothered
by recurrent headaches' they are sent a further questionnaire screening for migraine
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[Tom et al. 1994], If they claim to have, 'epilepsy (seizures or fits)' then they are sent a
further questionnaire attempting to define seizure type (which although not validated,
has been used in a community postal survey by the Walton Centre, Liverpool [Jacoby et
al. 1996]).
If the patient does not respond to the main questionnaire, postal reminders are sent
after 3 weeks and if necessary after a further 3 weeks, but attempts are abandoned if a
reply has still not been received 3 months after the second reminder. Patients are
reminded about returning their headache and epilepsy supplementary questionnaires
once only, 3 weeks after they were first sent.
3.2.10.3 Medical records
Each year SIVMS requests copies of case notes held by the GP and every hospital the
patient has visited (see appendix of study materials - 32 and 33). In order to minimise
contact with GPs, SIVMS makes this request at the same time as the annual GP
questionnaire is sent (see 3.2.10.1, page 108). Hospital case notes are requested one year
after the last request was made, provided the patient has not been discharged from the
consultant's care. The letters sent merely request correspondence subsequent to the date
of the most recent letter in the SIVMS notes obtained from the GP/hospital records.
Postal reminders are sent after 3 weeks.
3.2.11 Collection of materials when a patient dies
Whether a patient has died during recruitment or follow-up, SIVMS still obtains the
entire set of GP case notes from Practitioner Services (to ensure that all potentially
relevant correspondence has been copied), copies of hospital case notes, and copies of
diagnostic brain imaging (if the IVM was diagnosed during life). An electronic copy of
the patient's death certificate is obtained from the GRO, and autopsy and




There are various measures taken to prevent poor data quality, detect imperfect data and
their causes, and institute necessary corrective action during case ascertainment,
recruitment, collection of medical records and brain imaging, and patient consent. As
data are entered, reminders appear to prevent duplicating a patient's inclusion in the
study and there are basic compulsory data entry requirements to ensure the collection of
a minimum dataset. The study database runs several routine procedures invisible to the
user (using 'queries' — see Chapter 4), to ensure data are appropriately updated and cross
checked and events (such as triggering annual questionnaires) are initiated at the
appropriate time. Occasionally, exceptions to the usual process of the study mean that
further safeguards are required to maintain data quality and accuracy. For example,
ascertainment of a patient three years after their first diagnosis might normally result in
three annual questionnaires being sent because the process is triggered by the time
interval that elapses since diagnosis, were it not for compensatory processes to modify
the data when this occurs.
Progress is reviewed at weekly meetings with my supervisor. This provides an
opportunity to check the effectiveness of SIVMS's procedures and troubleshoot
individual doctors' or patients' objections to the study. Year-on-year recruitment, quality
and completeness of data, and interim analyses are presented at biennial steering
committee meetings. Reports are produced on the basis of these data at the request of
SIVMS's sponsors. These data will be presented in a later chapter on data quality
(Chapter 7).
3.4 Summary
• SIVMS aspires to meet the standards of an ideal study of prognosis, as
defined in Chapter 2 (Table 4, page 85)
• SIVMS includes adults who were aged >16 years at the time of a first-in-




• This thesis, however, only pertains to the adults with brain AVMs,
diagnosed between 1 January 1999 and 31 December 2000
• The SIVMS neuroradiologists divide brain AVM diagnoses into definite,
probable and possible on the basis of diagnostic criteria
• Whilst the point of inception is the presentation that led to the brain
AVM diagnosis being made, the incidence date is the year in which the
definite diagnosis was first made
• Cases are recruited using multiple overlapping sources of case
ascertainment (a collaborative neuroscience network, central coding of
hospital discharge data and death certificates, and a mailshot to every GP
in Scodand, used in the first year of SIVMS only)
• Recruitment and data collection are controlled by a Microsoft Access
database, with in-built audit processes
3.5 Discussion
In this chapter, I have provided a description of the stages of the study through which a
patient may (or may not) pass. As SIVMS evolved, complexity increased because of
unforeseen problems, which sometimes resulted in a modification of the study's
methods. This description is correct at the time of writing (2002-2003).
3.5.1 Inclusion
I have tried to retain inclusion and exclusion criteria that are robust and externally valid.
Because of its population-based design, SIVMS has tended to be over-inclusive, with a
brain AVM working definition that does not rely on IADSA, which is likely to be
available only at tertiary referral centres. A definition reliant on IADSA would miss
diagnoses made on CT, MRI or pathological examination alone, and ignores the
existence of AOVMs [Joint Writing Group 2001]. Although such a definition might
foster complete collection of variations of vascular anatomy (angioarchitecture) that are
of interest as prognostic factors, it would be likely to bias studies towards patients
having extensive investigation, under-estimate the true frequency of brain AVMs, and
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under-estimate their importance as a cause of sudden death by missing post mortem
diagnoses. Furthermore, the flexibility of including anyone with a definite, probable or
possible brain AVM, enables the prospective follow-up of uncertain diagnoses that may
subsequently change, the description of the clinical course of such lesions, and a post hoc
ability to stratify analysis by certainty of diagnosis (and/or its verification by IADSA).
3.5.2 Recruitment
The sources of case ascertainment used by SIVMS were based upon the successful
collaboration used by the Scottish Motor Neurone Disease Register [Chancellor et al.
1993], albeit with the addition of other relevant specialities (e.g. neurosurgery and
radiology). I considered other potential sources of case ascertainment, but none was
suitable at the time of setting up the study, although this may change. The British
Neurological Surveillance Unit (BNSU) is run by the Association of British Neurologists
(ABN) and functions as a postal means of detection of specified neurological diseases. I
found it unnecessary to use the BNSU because I already contacted every neurologist in
Scotland (and they are not all members of the ABN), so the use of the BNSU would
entail needless cost and use of a 'middleman'. A more attractive source of case
ascertainment would have been an electronic search of free text and/or diagnostic
coding amongst radiology reporting systems across Scotland. I surveyed all the radiology
departments with CT, MRI and IADSA facilities across Scotland at the start of SFVMS,
and found that the technological limitations of the reporting systems in use at the time
made electronic searching for diagnoses impossible.
The timing of SIVMS's recruitment efforts was derived from the anticipated duration of
standard processes in the NHS, such as relaying diagnostic information from secondary
care to GPs. In the first year of SIVMS, the timing of study letters and reminders was
refined to allow more time for information to filter to GPs and consultants, given the
unpredictable variation in process I observed in the NHS. The recruitment process, with
its in-built pauses, would take several months, let alone the delays incurred by non-
respondents, disagreements between GP/consultant, objections to the study, and time




I considered other means of using technology to the study's advantage, apart from
electronic searching of radiology reporting systems. Early on, case ascertainment and
notification by post/fax/telephone seemed convenient and time-effective for SIVMS
collaborators, without the need for web-based data collection systems. Concerns about
the safety of data transmission via the Internet as well as the ease of use and efficacy of
digital encryption technologies meant that some of our collaborators would have been
unhappy to employ this, which precluded its further development. Digitising brain
imaging would provide an invaluable electronic archive, thereby protecting vital study
data (sometimes not permanently archived by radiology departments on optical disc)
and potentially making it available for studies of observer variability and multimedia
teaching tools. Sadly, this has not met with unanimous approval from the steering
committee.
3.5.4 Comparison with other studies
SIVMS surpasses the existing literature about IVM frequency and prognosis (Chapter 2),
by providing clear diagnostic definitions, aiming to attain comprehensive and
representative recruitment from a whole population using multiple overlapping sources
of case ascertainment, and specifying a uniform inception point from which patients are
prospectively followed. The mechanism of follow-up is designed to make an annual
record of a patient's survival at the very least, and for the vast majority a record ofmajor
outcomes (death, haemorrhage, epilepsy and disability on the Rankin scale) by several
means. Although the chosen measures of functional status have not been validated in
groups of people with IVMs, they have been well used in adults with stroke and
epilepsy.
The variable and sometimes complex processes that lead to recruitment and data
collection at baseline and during follow-up are all managed by a database, the
architecture ofwhich I will describe in the next chapter.
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Table 10 Broad definitions of the different levels of radiological
certainty of brain AVM diagnosis
CT = computed tomography; MRI = magnetic resonance imaging; IADSA =
intra-arterial digital subtraction angiography
Certainty CT MRI IADSA Pathology
Definite Anastomosis of
non-nutritive blood














of flow voids on
standard spin-echo
MRI (Ti and T2).
Anastomosis of
non-nutritive blood
vessels in the brain
parenchyma, with
arteriovenous
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Table 11 Diagnostic codes pertinent to brain AVMs in the tenth revision
of the International Classification of Diseases (ICD-10)
D In situ neoplasms
D18 Haemangioma and lymphangioma, any site
D18.0 Haemangioma, any site
I Diseases of the circulatory system
I60 Subarachnoid haemorrhage
I60.8 Other subarachnoid haemorrhage
160.80 Rupture of specified arteriovenous malformation
I67 Other cerebrovascular diseases
167.1 Cerebral aneurysm, nonruptured (including acquired cerebral
arteriovenous fistula)
I77 Other disorders of arteries and arterioles
I77.0 Acquired arteriovenous fistula (aneurysmal varix, acquired
arteriovenous aneurysm; excluding cerebral (167.1))
Q Congenital malformations, deformations and chromosomal abnormalities
Q27 Other congenital malformations of peripheral vascular system
Q27.3 Peripheral arteriovenous malformation
Q28 Other congenital malformations of the circulatory system
Q28.2 Arteriovenous malformation of cerebral vessels
Q28.3 Other malformations of cerebral vessels
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Figure 10 Scottish Intracranial Vascular Malformation Study flowchart
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Chapter 4. Database design for a population-based disease register





4.2.2 Added advantages of Access








The subject matter and methods of this research project present various degrees of
complexity and unpredictability; these are ideally managed by a database, yet present
challenges for its design.
For example, although IVMs usually exist as solitary lesions in patients' brains they may
be multiple, they may be diagnosed with certainty at different times, and some may
develop de novo over time. Furthermore, IVM structure ranges from the simplicity of a
single transcortical venous malformation to a large, complex brain AVM with various
numbers of draining vein(s), arterial feeder(s) and associated aneurysm(s). Although
each patient's ideal flow through the study is clearly defined (Figure 10, page 116), there
is considerable heterogeneity in their clinical state and subsequent clinical course, as well
as heterogeneity in their own preferences and those of their GP and hospital
consultant(s).
A manual paper-based system might have sufficed with careful management by the
SIVMS secretary and myself. Flowever, the availability and the capability of database
software compelled me to use Microsoft Access 97 (hereafter referred to as Access) to
manage study recruitment, follow-up and data collection.
4.2 Design
Before embarking upon the study, I modelled the data I intended to collect and the
processes I would use to manipulate it. These models were then mapped to the ideal
'relational' database structure offered by Access. This data-centred discipline
undoubtedly avoided several preventable errors, although subsequent restructuring and
reorganisation of the data were inevitable.
On the grounds of flexibility, I had been encouraged to adopt a database design that
corresponded to the natural structure of the information I wished to store. If I had not
done this, over-simplification of data could have led to inflexible analysis, preventing the
exploration of real-world association/causation. Flowever, I later came to appreciate
how reflecting the complexity of the natural structure of IVM and patient data would
make data analysis more versatile but the programming more difficult.
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Although the database is the principal means of managing patients' progress through
SIVMS and analysing data, the most comprehensive dataset is stored on paper in
individual sets of case notes bearing each patient's study number. Copies are kept of the
notification form(s), as well as all correspondence about study enrolment with patients
and their GPs and hospital consultants, complete copies of case notes, and GP and
patient follow-up questionnaires. However, a large number of these data are abstracted
by the relevant member of the study team and manually entered in the database to
enable automated processing of patients through the study and systematised data
analysis. The paper record remains a source of reference for future clarification, or
exploration of other hypotheses using information not specified in this thesis.
4.2.1 Relational databases
Access is a relational database. Such databases store sets of data in 'tables' (composed of
columns and rows). These data are related to each other, and the related tables are
linked using variables ('fields') common to both tables. The designer can specify the
types of relationships between separate tables of information.
For example, one patient may be cared for at several hospitals, in which case the
relationship between the patient and hospital tables is described as 'one-to-many'. This
enables the details at each separate hospital to be linked to the same patient, simply
using the patient's study number in the hospital table. In the diagram overleaf, the
patient table ('davesPatientDetails') is linked to the hospital table
('davesPatientRegistration') by a one-to-many relationship between the common fields
containing each patient's study number. This is represented by a line with a figure 1 and
an infinity symbol at each end, indicating the direction of the relationship. There is a
similar relationship between the hospital table ('davesPatientRegistration') and a 'look¬







































The other types of relationship are one-to-one and many-to-many. The latter is usually
best decomposed by using an intermediate 'junction table' with a one-to-many
relationship to each of the tables it links (as above).
Relational databases have many strengths. Subdivision of data into separate tables of
variables avoids unnecessary repetition of data (for example, every time a hospital is
referred to, only its code number in the look-up table above is used). Several small
tables are easier to manage (and subsequently modify) than one large table of variables.
A relational database can also reflect the natural structure of the information being
stored (for example, each patient usually harbours one IVM, but may harbour many
IVMs, best reflected by a one-to-many relationship between the patient and IVM
tables).
4.2.2 Added advantages ofAccess
Access is a fully featured 'rapid application development' environment for creating
database applications on both single-user and networked personal computers. Access
offers more than just a flexible means of storing data in tables. 'Queries' extract,
manipulate and summarise data stored in tables. Access executes these queries using
structured query language (SQL), and its distinct advantage is its graphical query
development tool that requires no knowledge of SQL from the user. The data — held by
tables and derived using queries — are visually presented on the computer screen using
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custom-designed 'forms', and are printed as customised 'reports'. Complex procedures
involved in query design, navigation between forms, and executing automated
procedures (such as running audit and reminder queries when a particular user opens
the database) are handled by user-defined 'macros' and programming in Visual Basic
and SQL statements. These are beyond the scope of this thesis.
Access has the added advantage of being able to both link to and/or import other
collections of data, via Open Database Connectivity (ODBC) drivers. For example,
routine hospital discharge and death certificate data supplied by ISD in dBase and
Microsoft Excel are imported into Access in a standardised format so that they may be
appended to core tables, and further processed according to SIVMS's standard
procedures. The SIVMS database also links to other collections of data on the DCN
network which — although static in their structure and location — are regularly updated
(for example, databases of Scottish GPs and their practices).
Furthermore, Access interacts with Microsoft Word by using the Mail Merge function in
Word. Standardised letters (see appendix of study materials) are reproduced only for
patients meeting certain criteria, specified in queries in Access. By running these queries
every time the SIVMS secretary opens the database, Mail Merged letters and reminder
reports ensure that patients' progress in the study is regularly addressed.
The SIVMS database is divided into two separate components. The data file ('SIVMS-
data.mdb') contains the tables of data, and the application file ('SIVMS.mdb') contains
the queries, forms, reports, macros and 'modules' (the latter collate various procedures).
The tables are linked to the application file. One advantage of this structure is that the
application file can be updated without disrupting the data file, and vice-versa. In
SIVMS's multi-user environment, the data file is shared on a networked server, which
enables all its users to update the same copy of the database simultaneously. The
application component is also networked, but once its development is complete each
user will ultimately have their own copy of the application file (which will reduce
network traffic, and so speed up database use).
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4.3 Data protection and confidentiality
Of central importance to medical research is the protection of data by restricting access
to them, and the maintenance of patients' confidentiality by the removal of associated
information that could identify them. These are related: confidentiality is enhanced by
data protection when information that identifies a patient is used.
Several conflicting pressures face medical researchers when deciding whether and how
to use identifiable data about patients; these are discussed in Chapter 17. Because of the
design of SIVMS — which relies upon other agencies to provide copies of medical
records, brain imaging, and follow-up information — referring to patients by name and
using other identifiable information about them is an absolute necessity. SIVMS's use of
such data is sanctioned by the MREC for Scotland, and covered by the University of
Edinburgh's registration with the Data Protection Act (1998).
The data held by SIVMS which are deemed — either alone or in combination — to be
patient-identifiable information are: name, date of birth, Community Health Index
(CHI) number (a composite of date of birth and another number), address, telephone
number, email address, next of kin details, and hospital identification numbers (for case
notes, imaging, and pathological examinations).
Were it not essential to identify patients, various strategies are available to protect access
to patient-identifiable data. Ultimate protection is offered by irreversible anonymisation, in
which data are stripped of identifiable details either at source or after receipt, with no
means of re-establishing a patient's identity. Data may be reversibly anonymised ipseudo-
anonymised or pseudonymised) by de-identifying them and attaching a unique code (which is
mapped to each patient's details in a separate file).
SIVMS employs pseudonymisation when exporting data for reference or analysis
(whether this is done in-house or by collaborators at another institution), using patient
study number as the only identifier. Confidentiality of stored data is not safeguarded in





Within the University of Edinburgh's local area network (LAN) the DCN has its own
dedicated servers, which are physically located in the DCN and are protected from
external threats by a firewall. One of these servers (DCN-skull) contains a networked
drive (G drive), within which there are a variety of directories and subdirectories. The
SIVMS database resides in the 'SIVMS' subdirectory of the 'Data' directory of the G
drive (G/Data/SIVMS/).
Not only does access to the DCN's network require an individual username and
password, but the network administrator restricts access privileges to G/Data/SIVMS/
to members of the study team currendy working on SIVMS. Furthermore, to be able to
open the Access database, users require another username and case-sensitive password,
co-ordinated by an Access electronic workgroup file (which is encrypted). The
permission assignments granted to each user are also managed by this workgroup,
preventing some users from modifying design and data by granting them read-only
access rights. Accountability is achieved by automatically updating each entry in each
table with the identity of the user who last modified it. One further case-sensitive
password is required to open the separate data file of the database allowing modification
of the data architecture. Overall, between three and four layers of security protect
SIVMS data.
4.5 Backup
The contents of the Data/SIVMS subdirectory of the networked G drive are backed up
onto tape on a daily basis. These tapes are held centrally by the University of Edinburgh,
and files (such as the SIVMS database) can be restored from a particular time and date.
Another mechanism of data recovery is from Access backup files if users create them as
they exit the database. The data, application and security workgroup information files of





• SIVMS stores paper records of study materials and identifiable data
collected for every individual in the study, the fundamentals of which are
stored in an electronic relational database
• A customised database application has been created using Microsoft
Access, which effectively runs the study, imports data (e.g. information
from secondary data sources) and exports data (e.g. for Mail Merge using
MicrosoftWord)
• The database is password-protected, resides on a secure network, allows
multiple users to update it simultaneously, and it is regularly backed up
4.7 Discussion
Seldom does database design warrant a chapter of a thesis, but it is in this case because
of the extent of data modelling and development of automated processes for managing
recruitment and follow-up. The database has become more than simply a vehicle for
data storage and subsequent extraction (this being all that is required of most
observational datasets), but more like a randomised trial's software which checks and
acts upon the data according to certain criteria — in essence, it is a customised
application.
The design of the database evolved alongside modifications to study methods. For
example, in the first year of the study, having gained the unanimous approval of both
GP and main hospital consultant to approach a potential recruit, SIVMS would mail the
patient a recruitment pack directly. But the MREC later revised their opinion, because
this method involved 'cold calling' the patient (i.e. the approach to join the study came
from an organisation potentially alien to them). Instead SIVMS now has to ask the GP
to sign a covering letter and forward it with the recruitment pack to the patient. Such an
apparently simple modification required the creation of new fields in the database,
transposition of existing data about when recruitment letters were last sent, re-design of
queries, the formation of new mail merges with the new GP letters, and reconfiguration
of reminder forms and reports for the SIVMS secretary.
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So far, data have been exported from the SIVMS database on only one occasion. The
radiological data collected by reviewing diagnostic brain imaging have been exported to
a separate database for the use of the custodian of the SIVMS imaging library in
Glasgow (Dr Jo J Bhattacharya). The data were reversibly anonymised (i.e. patient study
numbers were the only identifiers), but the data were not encrypted. The database was
transferred in person, but if it had been posted I would have used registered/recorded
delivery.
Password protection and restricted network access are the mainstay of SIVMS database
security. The study does not routinely use encryption, except for encouraging its use in
emailed patient notifications. Nor does SIVMS encourage regular changes of password,
and a SIVMS security clause has not been added to staff contracts. These are all
potential future security developments.
Based on the premise that high quality clinical databases will benefit from sharing
knowledge and data, and that centralising them will promote this aim [Black 1999],
SIVMS has become part of the UK Directory of Clinical Databases (DocDat)
(www.lshtm.ac.uk/docdat/). Apart from simply indexing databases, DocDat also lists
the data they collect and judges them according to the quality of their data, all of which I
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The foregoing chapters about the methods of SIVMS and the principles of its database
design apply equally to all IVMs. However, the morphological and clinical differences
between the various IVM subtypes require that this and subsequent chapters refer only
to the main focus of this thesis, brain AVMs.
This chapter defines the demographic and clinical data that are stored about each patient
with a brain AVM. Whilst some of these data are routinely collected and factual, others
rely on medical concepts that may be perceived differently by different doctors (for
example, what type of epilepsy a patient has). Systematically reviewing the brain AVM
literature (Chapter 2) has revealed how few studies used clearly defined variables. To
give SIVMS internal validity by standardising the assessment of each patient, I intended
to clearly define the variables that would be collected before the study started.
A challenge to maintain external validity emerged in the third year of SIVMS with the
publication of reporting terminology for brain AVM radiographic and clinical features
by a multidisciplinary North American JointWriting Group [Joint Writing Group 2001],
and latterly with the publication of the design of a similar study to SIVMS, the New
York Islands AVM Study (NYIAVMS) [Stapf et al. 2003]. I have highlighted any areas
where SIVMS differs, but fortunately similarities in definitions have meant that there
has been littie need for modification, so internal validity has not been jeopardised.
5.2 Types of variable
The majority of variables in SIVMS are either known entities (for example, dates of
responses to patient or GP questionnaires) or radiological/clinical concepts (for
example, the nature of a patient's epilepsy, or variants of angioarchitecture). Fewer
variables are derived (for example, a patient's duration of follow-up is determined by the
comparison of several dates).
Wherever possible, variable contents are one of a limited list of categories, a number or
a date, rather than being free text character strings (which are much more difficult to
summarise and analyse). Date entries are stored in a standard format (dd/mm/yyyy); the
15th of the month is used for an event when its exact day is not known but the month
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and the year are, and the 1st July is used when the day and month are not known but the
year is. Variables with yes/no properties avoid check boxes and tend to use drop-down
lists with the opdons 'yes', 'no' and 'unknown'; otherwise a blank field would be
ambiguous, potentially indicating that the data were either not collected or were
unknown.
5.3 Demographic variables
Basic demographic variables (such as name, sex and date of birth) are initially derived
from study notifications. The research fellow (myself 1999-2001) subsequently cross¬
checks them against clinical records when they become available, although the ultimate
arbiter of their accuracy is the patient themselves if they are approached with an
enrolment form.
Ethnicity is solely determined by the patient, and uses the Office of Population
Censuses and Surveys (OPCS) criteria because of their widespread use (White, Black-
Caribbean, Black-African, Black-other, Indian, Pakistani, Bangladeshi, Chinese, Other,
Unknown). Handedness is categorised as right, left, ambidextrous or unknown. Marital
status is categorised as single, married, divorced, widowed, cohabiting, or estranged.
CHI numbers are obtained either when making enquiries about a patient with the
Health Board, or in periodic batches from ISD.
5.4 Clinical features
SIVMS records all clinical events that affect patients, whether before, at, or after the
time of presentation (5.4.3.1, page 135). The concept of a 'clinical event' can only be
loosely defined, but is best regarded as new symptom(s) (with or without signs) that
represent a significant change from the patient's clinical state immediately preceding the
'event'. These data are derived from case note review, GP annual questionnaires, and
patient annual questionnaires; the source of the information is specified for every event.
Clinical events possibly related to a patient's brain AVM(s)/aneurysm(s) are recorded as
being of a particular type and occurring on a particular date. Each event is attributed to
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both the patient in question and to the relevant brain AVM/aneurysm (with an
indication of how certain I was that the brain AVM/aneurysm was the cause).
Clinical events that are completely unrelated to a brain AVM or aneurysm are stored
separately. A patient's other/past medical history is subdivided into neurological and
systemic comorbidities, and stored in two free text fields in the database. Patient
enrolment forms and/or review of case notes provide information about a potential
family history of brain AVMs, and its nature. An attempt is made to record the drugs a
patient is taking and their start and end dates, although this information is likely to be
moderately accurate, at best. A rudimentary obstetric history is also stored, with start
and end dates for each pregnancy abstracted from case notes, and the number of
children at the time of recruitment is requested on the patient's enrolment form.
The remainder of this chapter is an attempt to define different types of clinical events,
to decide what caused them, and to be clear about their timing.
5.4.1 Types of clinical events
Depending on the individual case, brain AVMs can usually be confidently said to cause
ICrH and epilepsy. They are probably the cause of FNDs referable to the anatomic
location of the AVM nidus (in the absence of haemorrhage or infarction, usually on
brain imaging), and are likely to cause subjective vascular bruits. But brain AVMs' role
in causing headache, brain infarction and cognitive impairment is less clear.
5.4.1.1 Intracranial haemorrhage
A clinical event is classified as a haemorrhage if there are clinical features of ICrH with
radiological, pathological, surgical, or — rarely — only cerebrospinal fluid (CSF) evidence
of recent haemorrhage. The clinical features of haemorrhage may be sudden/subacute
onset headache ± seizures + global neurological deficit + focal neurological deficit
referable to the anatomic location of the brain AVM nidus. Radiological evidence of
acute haemorrhage is defined as fresh blood of high density on CT, or high density
methaemoglobin on Tj.-weighted MRI (6.5.1, page 156). If the haemorrhage is classified
as 'radiographically proven', the imaging study number is also stored. Very occasionally,
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there is no supplementary evidence to support a strong clinical suspicion of
haemorrhage, and these haemorrhages are classified as 'clinically probable'. Only the
following types of haemorrhage are specified:







Intraparenchymal, intraventricular & subarachnoid
Subdural
Unknown
This classification of haemorrhage complements the definitions used by the NYIAVMS
and JointWriting Group.
5.4.1.2 Epilepsy
Any occurrence of an epileptic seizure is classified according to the 1989 International
League Against Epilepsy (ILAE) classification [Commission on Classification and
Terminology of the International League Against Epilepsy 1989]. The recent update of
the ILAE classification post-dates the set-up of this study. Seizure type is categorised as
one of the categories overleaf, within the limits of the data available in the patient's case




Simple partial ± secondary generalisation




At each mention of epilepsy in case notes or questionnaires the following additional
data are stored, where available: epilepsy activity [inactive (<l/year), active (<l/month),
active (>1/month), unknown], whether the patient is treated (on anti-epileptic drugs, off
anti-epileptic drugs, unknown), and the timing of the secures (day, night, either,
unknown).
5.4.1.3 Focal neurological deficit
FNDs are clinical impairments referable to the anatomical location of the brain AVM
nidus, that are neither migrainous, nor post-ictal, nor found to be due to haemorrhage
or infarction after radiological investigation [Mast et al. 1995]. They are further classified
as transient (lasting <24 hours), persistent (lasting >24 hours), or progressive (lasting
>24 hours with further deterioration). Figure 11 (page 140) illustrates the decision¬
making process in categorising focal neurological symptoms ± signs.
Considerable controversy surrounds the pathophysiology of these FNDs. Some argue
that vascular 'steal' explains them, while others disagree and feel it is venous
hypertension. Distinguishing this type of event from a clinically probable haemorrhage
(for which no radiological investigation was performed) may be difficult; because it is a
matter of subjective judgement it would need to be independently evaluated by another
SIVMS investigator. It is possible that transient deficits might be due to feeding arterial
stenosis or transient ischaemic attacks, and that persistent deficits might be due to
haemorrhage/infarction that was not investigated at the right time or with the




Determination of headache type is attempted from case note review and patient postal
questionnaires, according to the first International Headache Society (IHS) classification
[Headache Classification Committee of the International Headache Society 1988]. The
recent second IHS classification post-dates the set-up of this study.
Subtypes of headache
Associated with head trauma
Associated with metabolic disorder
Associated with non-cephalic infection
Associated with non-vascular intracranial disorders
Associated with substances or their withdrawal
Associated with vascular disorders
Cluster and chronic paroxysmal hemicrania
Cranial neuralgias
Nerve trunk pain and deafferentation pain
Headache or facial pain associated with facial or cranial structures
Migraine
Miscellaneous




At each mention of headache in case notes or questionnaires, an estimate of its




This category is only used for presentations (5.4.3.1, page 135), when the investigation(s)
that led to the brain AVM diagnosis being made were prompted by symptoms/signs
that may possibly — but not definitely — be due to the brain AVM or symptoms/signs
attributable to something else. For example, headache, brain infarction and cognitive
impairment might only possibly be due to a brain AVM; asymmetrical sensorineural
hearing loss, chronic sinusitis, and head trauma might also lead to brain imaging and
incidental detection of a truly 'asymptomatic' brain AVM. Long before diagnosis, these
patients may have experienced symptoms that were likely to have been — in retrospect —
due to the brain AVM (see 5.4.3.2, page 136), but their presentation is nevertheless
'incidental'.
Infarctions are classified according to the Oxfordshire Community Stroke Project
(OCSP) classification as involving the total/partial anterior circulation, lacunar or
posterior circulation [Bamford et al. 1991]. These events are classified as being
supported by radiological and/or pathological evidence, or the diagnosis may be made
on clinical acumen only.
5.4.1.7 Cognitive impairment
Cognitive impairment is recorded without a degree of severity, and is simply recorded to
give an idea of its burden on patients with brain AVMs, rather than as a meaningful
outcome that can be quantified by SIVMS's methods of follow-up.
This category encompasses a variety of symptoms and signs that may be attributable to
a brain AVM but have no category of their own (e.g. an abnormally dilated vein on the
forehead leading to the diagnosis of a brain AVM with external carotid artery supply).





event 'other' is entered coinciding with the date of presentation, to provide further
information about what led to AVM detection.
5.4.1.9 Tinnitus/bruit
This is a category that subsumes the variety of patients' subjective experiences of noises
heard in their head. Whilst tinnitus is typically non-vascular, the vascular noises
perceived by patients are bruits or pulsatile tinnitus.
5.4.2 Cause of clinical event
Every clinical event recorded is attributed to a patient. Each is also attributed to, where
appropriate, a single brain AVM, a single aneurysm, a procedure complication, some
other mechanism, or declared of an unknown aetiology.
Usually there is no doubt that a brain AVM caused a clinical event, for example a
radiographically demonstrated ICrH in the same area of the brain in the absence of any
other cause. In other cases, the radiological appearances of the ICrH and the
morphology of aneurysms associated with the brain AVM are sufficient to attribute the
haemorrhage to an associated aneurysm, rather than to the brain AVM nidus. This may
be difficult with distal and nidal aneurysms (6.2.3, page 145), but may be easier with
locations more distant from the nidus. The closer an aneurysm is to the nidus, the less
clear this distinction becomes. If there is any doubt, the clinical and radiological details
are independendy reviewed by the SIVMS principal investigator, and if doubt remains
the bleed is attributed to the brain AVM.
When there is uncertainty about whether a brain AVM or aneurysm caused an event or
not, the attribution is 'unknown'. Headache is probably the most problematic of the
clinical events in terms of determining its nature from case notes and interpreting
whether it is attributable to a brain AVM or not. Without exception, the attribution of
the headache — no matter what type — is unknown, pending satisfactory case-control
studies demonstrating a clear association between brain AVMs and headache. The
aetiology of cognitive impairment is similarly labelled 'unknown'. If brain infarction or
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any type of FND is referable to the anatomic location of the nidus, its aetiology is
attributed to the AVM, but if not it is labelled 'unknown'.
Occasionally, clinical events occur that could be construed as being due to a brain AVM,
but they are probably not. For example, a patient has focal motor seizures, but the
motor activity is ipsilateral to the brain AVM, which is very unlikely to be the cause;
equally, a patient has an ICrH but it occurs contralateral to the AVM. In these
circumstances, the event is recorded, independently reviewed by another SIVMS
investigator and — depending on the clinical probability — either attributed to the AVM,
'unknown' causes, or 'other' causes if they clearly exist (which may be described in a free
text box).
Clinical events that are clearly related to an intervention (e.g. haemorrhage during
embolisation or surgical excision, or hair loss following embolisation/coiling) and occur
within 30 days of it are attributed to a 'procedure complication'.
5.4.3 Timing of clinical events
5.4.3.1 Presentation (inception)
The date of the symptom onset that directly lead to a medical evaluation that in turn
prompted investigation and a subsequent brain AVM diagnosis — known as the date of
presentation — is the point of 'inception' in SIVMS, from which prospective follow-up
starts. I supposed that little time would elapse between this date of 'presentation' and
the date of 'diagnosis' (3.2.3.5, page 101) (when investigations either diagnose or raise
the suspicion of a brain AVM). I also supposed that the diagnosis first coming to light
would prompt notification of the patient to SIVMS, so that data collection from case
notes would occur close to the date of first presentation, and so inception would truly
mark the point from which prospective follow-up starts in the study.
Even if the event that prompted the investigation leading to brain AVM diagnosis was
not symptomatic of the brain AVM, the date of this clinical presentation — albeit leading
to an incidental discovery of the brain AVM — is the point of inception in the study.
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Where the date of symptom onset is unknown, the date of the medical evaluation that
led to diagnosis is regarded as the date of presentation.
Whereas the Joint Writing Group suggests the documentation of all symptoms
occurring at presentation, SIVMS differs from it by allocating only one type of clinical
event to presentation. For example, the co-occurrence of ICrH, an epileptic seizure and
headache would simply be recorded as ICrH by SIVMS, because all else is symptomatic
of it.
5.4.3.2 Symptoms prior to inception
The identification of symptoms occurring long before inception is usually made
retrospectively from the past history of previous clinical encounters documented m the
case notes, or the patient describes these symptoms at the time of presentation when a
history is taken. Because I did not interview every person in SIVMS, the occurrence of
these events is likely to have been underestimated. Nevertheless, SIVMS records these
events because they provide an indication of the burden a brain AVM may have inflicted
during the patient's lifetime.
5.4.3.3 Symptoms during follow-up/outcomes
Follow-up starts at inception and ends when a patient dies. Before death, the period of
follow-up is derived from a variety of different fields in the database. The duration of
follow-up is calculated from the most recent of the following dates: the date of the most
recent clinic letter or discharge summary that SIVMS has managed to obtain from a
patient's case notes, the date of completion of the most recent GP annual questionnaire,
or the date of the most recently returned patient questionnaire.
During follow-up, various clinical events may occur either due to the brain AVM,
associated aneurysm(s), or their treatment. An exact date is attributed to the onset of each
clinical event (to enable time-dependent analyses), but an approximation (to the nearest
day or month) is sometimes necessary when the three sources of follow-up information
are imprecise. Information about these events is collated by the research fellow (myself
1999-2001) from the GP and hospital case notes, and GP and patient annual
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questionnaires. As such, the assessment of outcome is independent of the clinicians
directly involved in each patient's care in as much as the case notes give an independent
account. However, the assessment is blinded to the morphological features of interest
but not to the interventions a patient has received.
5.4.3.4 Death
Death marks the end of follow-up for every patient in SIVMS; in any other case follow-
up is regarded as still underway. Death is either attributed to the brain AVM, associated
aneurysm, a procedure complication, another cause, or unknown (and the source of this
information is stored as one of the post mortem report, death certificate, or the case
notes). In addition to the cause of death, information about its date and place, and
whether a post mortem and/or neuropathology examination were performed are also
recorded.
5.5 Summary
Data about clinical events that affect study participants are derived from
their hospital and GP case notes, follow-up GP questionnaires, hospital
case notes surveillance, as well as questionnaires completed by the
participants
All clinical events that could possibly be related to a brain AVM are
stored, whether they occurred at presentation (inception), prior to it
(retrospective events), or during follow-up
Clinical events are attributed to the brain AVM, an associated aneurysm,
a procedure complication, another cause altogether, or unknown (when
the brain AVM might have been responsible)
The definitions used by SIVMS have external validity in the light of




My approach to the categorisation and attribution of data has been reductionist. There
are few certainties in clinical medicine, and especially not in the relatively unexplored
area of brain AVMs. Whilst some events are certain (e.g. occurrence of ICeH in the
same location as a brain AVM), others are less certain (e.g. whether rupture within the
brain AVM nidus or an associated aneurysm caused the haemorrhage), and some are
completely unknown (e.g. whether headaches are caused by brain AVMs). Other
examples include the dilemma of whether a FND with perhaps mild headache and
depressed consciousness for 24 hours without brain imaging is declared a 'FND' or a
clinically probable 'haemorrhage'. By reflecting any (uncertainty in the way data are
coded, I have made provision for ambiguities to be explored in sensitivity analyses.
The biases inherent in the way patients come to medical attention could be explored in a
similar way, given the way data are stored. For example, in the interval between the date
of presentation/inception (5.4.3.1, page 135) and the date of first definite brain AVM
diagnosis by imaging or pathological examination (3.2.3.5, page 101), other clinical
events may occur. The dilemma is whether the mode of presentation and these other
events should be regarded as part of a patient's clinical course during prospective
follow-up, or whether they are disregarded because the brain AVM diagnosis is not yet
certain. Counting such events will tend to overestimate the aggressiveness of brain
AVMs, yet reflect the character of those that do come to medical attention. Patients
with less aggressive presentations may tend not to be investigated as thoroughly, or not
investigated at all; this is evident amongst those who have apparently incidental brain
AVMs, but examination of their medical history reveals retrospective events that — if
investigated — might have led to brain AVM discovery. It is my personal opinion that
the events between presentation and the time of definite diagnosis should be counted,
because they do influence the way patients are managed, which is likely to affect
prognosis. It will be of considerable academic interest, though, to describe clinical
course both with and without these early events.
In Chapter 3 it was clear that my ascertainment of study participants is prospective, but
that the retrieval of prior information about them is retrospective, occurring some time
after the events in question. This is probably of little consequence, because the
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fundamental distinction between these two methods of data collection rests upon how
likely an event is to be missed. Any events occurring prior to inception are best regarded
as retrospective, because they depend on recall, the completeness of the GP record (and
whether SIVMS has access to it), and their perceived importance (e.g. episodic migraine
versus an isolated, unprovoked seizure, both without further investigation).
Whilst the accurate documentation of outcome events in clinical records is dependent
on clinical acumen, adequate investigation, clear discharge summaries and bureaucratic
efficiency, so too is it dependent on my judgement. My interpretation is most difficult
when any of these attributes of adequate clinical records are missing, but my experience
and education also influence it, and so too may my lack of blinding to certain features of
interest. SIVMS has subsequently set up an outcome audit, whereby the study's principal
investigator (Charles Warlow) categorises clinical outcomes, blinded to the research
fellow's opinions as well as morphological features of interest and interventions
received. Arguably, this should also be applied to clinical events at presentation.
Thereby, a consensus of two opinions will hopefully result in a more accurate future
analysis of prognosis.
Many of the fundamental clinical concepts are shared with the few other studies that
have chosen to define them (e.g. NYIAVMS). However, SIVMS differs from other
studies by striving to represent certain ambiguities, thereby being able to combine
comparable data in any individual patient data meta-analyses, whilst also being able to
explore the unknown biases of brain AVM clinical course using sensitivity analyses.
In the next chapter, I will describe the morphological attributes of brain AVMs
themselves — whether identified by imaging or pathology — that have provoked so much
interest as predictors of outcome.
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Figure 11 Categorisation of focal deficits - including their duration (A)
and their cause (B) - affecting patients with brain AVMs
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6.3.4.1 Pattern of venous drainage




6.5 Complications viewed on CT and MRI
6.5.1 Acute/new haemorrhage
6.5.2 Prior/old haemorrhage






Compared to the clinical characteristics covered in the preceding chapter, the
morphological features of brain AVMs are likely to be the subject of as much — if not
more — debate, and so observer variation (quantified in Chapter 10). The morphological
variables of the majority of brain AVMs in SIVMS are collected whilst reviewing
diagnostic imaging studies (performed prior to any treatment), although for some the
only source of this information may be pathological examination. Although I clearly
defined radiological variables that would be collected before SIVMS started,
modifications were inevitable as my knowledge of brain AVMs grew and as concepts
developed at brain imaging review meetings with the two study neuroradiologists. I have
attempted to illustrate each radiological variable. As in the preceding chapter, I have
highlighted areas where SIVMS's definitions deviate from those laid down by the Joint
Writing Group and the NYIAVMS [Joint Writing Group 2001; Stapf et al. 2003].
6.2 General morphological variables
These variables describe attributes of brain AVMs that can be derived from radiological
or pathological examinations. For exclusively radiological variables, see 6.3 (page 146).
The side of a brain AVM refers to the laterality of its nidus. If the nidus involves a
midline structure, yet it does not predominate on the left or the right, then it is deemed
to be in the midline. For example, Figure 12 (page 160) illustrates a lateralised nidus (A),
and another that involves midline structures, but predominates on one side (C).
Brain AVM topographical location relates to the single anatomical structure in the brain
that the majority of the brain AVM nidus occupies. Where two or more structures are





Existing terminology for the huge variety of brain locations is almost insufficient to
classify nidi that often cross both anatomical and vascular boundaries, or have a diffuse
margin (6.3.2, page 147). On the other hand, any attempt at simplification of the
classification of location — to make grouping of lesions easier — could be seen as
reductionist.
MRI and/or pathological examination are preferable to CT for the determination of
brain AVM location; IADSA is the least desirable determinant of location, but it is rare
for this to be the only diagnostic investigation.


























Furthermore, the configuration of the brain AVM nidus in relation to the surface of its
predominant brain area is specified, using information from MRI and/or IADSA
and/or pathological examination (Figure 12, page 160). Where a detailed description of
this configuration is not possible, the terms superficial or deep are used.











SIVMS allocates a single brain location to each AVM, as others have done [Marks et al.
1990], but this differs from the Joint Writing Group's suggestion of specifying every
location occupied by a brain AVM's nidus. My brain area categories are also more
diverse than those used by the Joint Writing Group (cortical, basal ganglia, subcortical,
internal capsule, ventricular, intraventricular, corpus callosum, cerebellar hemisphere,
frontal, vermian (paramedian), temporal, deep cerebellar nuclei, parietal, brain stem,
occipital), and the NYIAVMS (lobar: frontal, parietal, temporal, and/or occipital lobe;
deep: basal ganglia, thalamus, internal capsule, corpus callosum; and/or infratentorial:
midbrain,pons, medulla, cerebellum).
For each brain AVM, a determination of the 'eloquence' of its location is made, based
on the Spetzler-Martin surgical grading scheme (6.4.1, page 155) [Spetzler and Martin
1986]. This anatomical scheme defined eloquent areas as: the sensorimotor (Figure 12A,
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page 160; Figure 25B, page 173; Figure 26A, page 174), language and visual cortex
(Figure 12D, page 160; Figure 25D, page 173); the hypothalamus and thalamus (Figure
12C, page 160; Figure 25C, page 173); the internal capsule; the brainstem (Figure 12C,
page 160); the cerebellar peduncles and the deep cerebellar nuclei.
Naturally, the Spetzler-Martin determination of eloquence employed by both SIVMS
and NYIAVMS is somewhat arbitrary; in contrast, the Joint Writing Group suggested
that the basal ganglia should also be regarded as eloquent, in addition to 'other' sites (for
example, non-dominant parietal lobe).
6.2.3 Associated aneurysms
An aneurysm is a focal luminal dilatation of a parent artery with a narrow neck or broad-
based opening, visible on selective/non-selective IADSA and/or pathological
examination, usually visible on CTA/MRA, and sometimes visible on plain CT and
MRI. SIVMS does not classify large infundibula (>3mm) as aneurysms, although some
research groups have done [Lasjaunias et al. 1988; Meisel et al. 2000], because they may
be associated with brain AVMs [Miyasaka et al. 1982], The NYIAVMS restricts its
definition of aneurysms to those dilatations that are >2 fold larger than the diameter of
their parent vessel.
Regardless of each aneurysm's mode of detection, SIVMS records its arterial territory
(anterior cerebral, anterior communicating, middle cerebral, posterior cerebral, posterior
communicating, vertebrobasilar, internal carotid), side (left/right/midline) and location
in relation to the brain AVM nidus. 'Nidal' aneurysms originate from the vasculature of
the nidus (although they may protrude beyond it), and should be visualised before the
venous phase of IADSA (Figure 13C, page 161 and Figure 14A,B,D,E, page 162).
'Feeding artery' aneurysms are said to be 'proximal' if they reside on the supraclinoid
internal carotid artery, on the circle of Willis, anywhere up to the middle cerebral artery
bifurcation, anywhere on the anterior cerebral artery up to and including the anterior
communicating artery, or on the vertebrobasilar trunk [Redekop et al. 1998]. Feeding
artery aneurysms are 'distal' if they occur anywhere closer to the brain AVM nidus than
the proximal locations (Figure 13A,B,D, page 161 and Figure 14C, page 162).
Aneurysms are 'remote' if they are not associated with feeding or nidal vessels, but
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occur in locations elsewhere, typical of sporadic aneurysms (Figure 13E, page 161 and
Figure 14F, page 162).
If detected by IADSA, aneurysm morphology (saccular, fusiform, or ruptured), and
aneurysm luminal diameter (in millimetres) are recorded. If any observed aneurysms are
false aneurysms or pseudoaneurysms, this is recorded in free text boxes.
The Joint Writing Group differs from SIVMS by also stating whether aneurysms
associated with brain AVMs are 'flow-related' or not. Furthermore, the Joint Writing
Group suggests documenting whether and when an associated aneurysm has bled, but
SIVMS records this separately from radiographic data, by attributing either aneurysm or
brain AVM to a particular clinical event (5.4.2, page 134).
6.3 Exclusively radiological variables
Some features are reported for the brain AVM(s) demonstrated by every diagnostic
imaging study performed on each patient. Brain AVM nidus side and location are stored
only once and they are determined by the patient's imaging study that is best suited to
the task (6.2.1, page 142 and 6.2.2, page 142).
However, the following variables (sections 6.3.1, page 146 to 6.3.5, page 154) are
recorded for every diagnostic imaging study (prior to treatment) that visualises the brain
AVM. The final determination of what characteristic an individual brain AVM has for
each of these variables is made by comparing the results of all the patient's imaging
studies, with some being preferred because they are the ideal modality for that
characteristic and others rejected because they do not provide adequate information.
6.3.1 Nidus size
Nidus size has been the subject of great interest in many studies of brain AVM
prognosis and treatment, although its accurate and consistent measurement is plagued
by several difficulties. The definition of a nidus as the area towards which multiple
feeding arteries converge and from which enlarged veins drain is somewhat arbitrary.
Measurement of the entire nidus' maximum linear diameter in each of three dimensions
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is complicated by diffuse nidus types (6.3.2, page 147 and Figure 17, page 165).
Furthermore, brain AVMs are commonly supplied by more than one vascular territory,
which can prevent complete visualisation of the entire nidus when injecting a single
vascular territory during IADSA. Neither consistent magnification factors nor calibrated
markers are in frequent use [Pott et al. 1992]. Moreover, there are different methods of
calculating size, including the maximum linear diameter in any dimension (when
authors' interpretations of 'small' may be anything less then between 2cm and 3.5cm),
and various volume calculations dependent on assumptions about the approximate
shape of the nidus [Pasqualin et al. 1991; Soderman et al. 2000].
In SIVMS, brain AVM nidus size is measured as its maximum linear diameter in each of
three dimensions (vertical, anteroposterior and transverse) which are measured in
millimetres using any type of imaging. For measurement, MRI is preferable to CT,
which in turn is preferable to IADSA. Ideally transverse, coronal and sagittal views
should be available on MRI/CT, although some vertical dimensions are roughly
estimated from the slice thickness on axial imaging when sagittal and/or coronal views
are unavailable (Figure 15, page 163 and Figure 16, page 164). When nidus size is
estimated from IADSA, the study radiologists used the diameter of the genu of the
petrous portion of the internal carotid artery (5mm) as a reference [Paullus et al. 1977]
6.3.2 Nidus morphology
The nidus itself is usually compact - the arteriovenous tangle adopts a tightly packed
spherical/elliptical configuration with a clear demarcation between nidus and
neighbouring brain parenchyma (Figure 17, page 165 and Figure 12B,D, page 160).
Occasionally the nidus border is diffuse, with a more irregular boundary interspersed
with, or engulfing, islands of brain parenchyma (Figure 18A-C, page 166) [Chin et al.
1992], Superselective IADSA has revealed the diversity of arteriovenous shunts within
the nidus, from a simple fistula to a complex plexus [Houdart et al. 1993].
Pure arteriovenous fistulae do not have a nidus as such, but it is usually possible to
visualise the fistula on IADSA. Sometimes a fistula is also discernible within a nidus as
rapid shunting through a direct arteriovenous communication early in the angiographic
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study (Figure 18D, page 166) [Marks et al. 1990], although its visualisation can be
dependent on the use of superselective IADSA (Figure 18E, page 166).
6.3.3 Arterial feeders
There are usually several tortuous, branching, high flow arterial vessels of varying calibre
and wall thickness that supply the central nidus where arteriovenous shunting occurs
through one or more fistulae. These afferent vessels are typically recruited from more
than one intracranial branch of the internal carotid and/or vertebrobasilar systems, and
occasionally from branches of the external carotid or vertebral arteries through
transdural anastomoses [Miyachi et al. 1993].
IADSA alone determines which vessels are seen to enter and feed (contribute flow to)
the nidus. Feeding vessels are subdivided according to their side of the brain
(left/right/midline), their arterial territory of origin (see overleaf), and the number of
feeders supplied by each territory (Figure 18D,E, page 166 and Figure 19, page 167); >9
feeders implies multiple, uncountable branches (Figure 24A, page 172). Because arterial
feeders may terminate in the nidus, continue to supply brain beyond the nidus (giving
'transit' — also known as 'en passage' supply) (Figure 18E, page 166 and Figure 21B,
page 169), or arise indirecdy from an artery in close proximity to the nidus, each is














The Joint Writing Group suggests using a more detailed array of arteries (external
carotid branches, internal carotid penetrators, other internal carotid branches, anterior
choroidal, posterior choroidal, anterior cerebral cortical branches, anterior cerebral
penetrators, middle cerebral cortical branches, middle cerebral penetrators, posterior
cerebral cortical branches, posterior cerebral penetrators, basilar penetrators, vertebral
branches, vertebral penetrators, superior cerebellar, anterior inferior cerebellar, posterior
inferior cerebellar, other).
6.3.3.1 Arterial tortuosity
Arterial tortuosity of feeding arteries is subjectively graded (none, mild, moderate,
severe) by comparing the vessel in question with the comparable contralateral vessel




Chronic high blood flow in the feeding arteries is thought, by some, to cause stenotic
(Figure 21A, page 169) and/or dilated (Figure 21A, page 169; Figure 25B, page 173;
Figure 26B, page 174) arterial 'angiopathy' due to endothelial thickening and intimal
hyperplasia [Pile-Spellman et al. 1986]. Arterial angiopathy is subjectively graded (none,
dilated, stenosed, dilated & stenosed) by comparing the feeding artery in question with
the comparable contralateral vessel. Both the Joint Writing Group and NYIAVMS
record the presence/absence of moyamoya-type changes in feeding arteries, by which
they mean any pattern of collateral small-vessel recruitment resulting from proximal
feeding artery occlusion or near-complete stenosis [Montanera et al 1990], This pattern
includes recruitment of collateral supply to compensate for the occluded or stenotic
arterial segment. Although SIVMS does not explicitly record this characteristic, it would
be possible to detect brain AVMs that might have it by reviewing those with both
arterial angiopathy and collateral supply.
6.3.3.3 Collateral supply
Collateral supply refers to arterial inflow supplying the high flow, low resistance nidus
and/or brain distal to the AVM. This supply originates from anastomoses with dural
(Figure 20C&D, page 168 and Figure 26B, page 174) or leptomeningeal (Figure 20B,
page 168 and Figure 22, page 170) arteries supplying adjacent vascular territories, or
between pedicles within the same vascular territory. This is also known as 'non-
sprouting angiogenesis'. It is recorded as being present (dural, leptomeningeal, unclear),
absent, or uncertain.
6.3.3.4 Angiogenesis
Sprouting angiogenesis (Figure 21C&D, page 169) on IADSA represents anomalous
arterial vessels feeding the nidus from arteries that are not usually expected to supply the
territory occupied by the AVM nidus [Marks et al. 1990], This is subjectively graded
(yes/no/uncertain) by comparing the vessel(s) in question with the comparable
contralateral vessel(s), although it can be hard to distinguish diffuse nidus morphology
from sprouting angiogenesis (Figure 21D, page 169). Its correlate on MRI is perinidal
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contrast enhancement. Neither the Joint Writing Group nor NYIAVMS record the
existence of sprouting angiogenesis.
6.3.4 Draining veins
One or more dilated veins originate deep within the brain AVM nidus, and reach its
surface acquiring tributaries along the way to drain, direcdy or via collateral pathways,
into the superficial and/or deep venous systems (Figure 23, page 171). Through the loss
of the normal resistance to flow in the capillary bed, the arteriovenous shunt transmits
arterial pressure to the compliant venous system, causing venous hypertension. The
draining veins are often anomalous, due to haemodynamic stresses causing stenosis,
ectasia and varix formation [Vihuela et al. 1985].
From IADSA alone, SIVMS attempts to describe the complex anatomy of the venous
drainage from a nidus by recording the total number of draining veins exiting the nidus
and the side (left, right, midline) and ultimate destination of each, whether deep
(subependymal) or superficial (see table overleaf). This is derived from the concept that
the nidus is divided into compartments, each with its own draining vein. However, the
JointWriting Group has an additional method of simplifying the complexities of venous
anatomy, by also quantifying the total number of veins reaching a venous sinus.
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Draining vein destinations Depth
Superior cerebral veins Superficial
Middle cerebral vein Superficial
Inferior cerebral vein Superficial
Cortical vein Superficial
Vein of Labbe Superficial
Vein of Trolard Superficial






Superior petrosal sinus Superficial
Inferior petrosal sinus Superficial
Internal jugular vein Superficial
Marginal sinus Superficial
Spinal veins Superficial
Great cerebral vein of Galen Deep (periventricular)
Internal cerebral vein Deep (periventricular)
Basal vein of Rosenthal Deep (periventricular)
Straight sinus Deep
Inferior sagittal sinus Deep
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Amongst all these separate draining veins, sometimes there is, or is not (Figure 24B,
page 172), a dominant draining trunk.
6.3.4.1 Pattern of venous drainage
The overall pattern of venous drainage is deemed to be superficial (Figure 23C, page
171 and Figure 24C, page 172), deep (to the periventricular system) (Figure 23B, page
171 and Figure 24B, page 172), deep (but not to the periventricular system) (Figure 24A,
page 172), or both deep and superficial (Figure 23A, page 171 and Figure 24B, page
172). Superficial drainage is defined as being exclusively through the cortical venous
system, or to cerebellar hemispheric veins that drain directly into the straight sinus,
torcula or transverse sinus. Deep drainage occurs through the deep cerebral veins, such
as the internal cerebral veins, basal veins or precentral cerebral vein (above). This
classification is also derived from the Spetzler-Martin grading scheme [Spetzler and
Martin 1986] (6.4.1, page 155), with the additional subdivision of deep drainage
according to whether it is subependymal/periventricular or not.
6.3.4.2 Other venous characteristics
SIVMS also records other attributes of venous angioarchitecture of the brain AVM as a
whole, rather than of each individual draining vein. If there is any evidence of venous
stenosis (narrowing of a draining vein in comparison to the vein proximal to it) then its
degree is recorded (percentage reduction in the maximum proximal diameter at the
narrowest portion) as is its location (at a dural sinus, or elsewhere) (Figure 23D&E, page
171 and Figure 24C, page 172). The degree of stenosis is at best an approximation
because the measurements are close to the limit of resolution of IADSA films. The Joint
Writing Group requires that venous stenosis be visualised in two different angiographic
views, although these have rarely been available in SIVMS, so I have not used this
criterion. One research group has recorded the existence of venous stenosis without a
degree [Mansmann et al. 2000], whilst others have required a >50% reduction in calibre
to qualify as stenosis [Marks et al. 1990; Nataf et al. 1998]. Venous ectasia is defined as
dilatation of a whole draining vein, when compared with surrounding veins (being
distinct from focal stenosis) (Figure 23D, page 171 and Figure 24A, page 172). Whilst
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SIVMS records venous ectasia as yes/no/uncertain and does not quantify it, the Joint
Writing Group and NYIAVMS require a >2-fold calibre increase, although another
group has stipulated that it only relates to segmental dilatations [Nataf et al 1998].
SIVMS also records the presence of venous varices (yes, no, uncertain), which are
aneurysmal dilatations or pouches on draining veins [Wallace and Bourekas 1998;
Willinsky et al. 1988] (Figure 24D, page 172), whilst NYIAVMS and the Joint Writing
Group do not, presumably - like others [Vinuela et al. 1987; Turjman et al. 1995a] —
regarding them as part of the same phenomenon as venous ectasia.
If the brain AVM is anatomically close to a dural venous sinus, then the side and sinus
on IADSA are recorded, as is whether it is occluded by anything other than arachnoid
granulations (narrowed, patent, or occluded). Dilation or thrombosis of a sinus adjacent
to the nidus are also recorded on CT or MRI.
The Joint Writing Group records the existence of venous reflux (the reversal of flow in
any venous outflow pathway, in a direction away from the closest venous sinus), a
subject of other research groups' interest too [Nataf et al. 1998; Mansmann et al. 2000],
but SIVMS does not record it (Figure 23E, page 171).
6.3.5 Other information
Other information of interest is stored in a free text field, to identify whether extra
angioarchitectural information was gleaned from super-selective angiography and assist
retrospective identification of interesting cases.
Because endovascular catheters with pressure-monitoring devices are not in routine (or
research) use in Scotland, intravascular pressure measurements are not recorded,
although they are recommended by the Joint Writing Group (but not intended to be





This grading system was designed for the prediction of the risk of morbidity and death
from operative treatment, according to particular characteristics of a brain AVM
[Spetzler and Martin 1986]. A brain AVM is graded based on the maximum diameter of
its nidus (6.3.1, page 146), pattern of venous drainage on IADSA (6.3.4.1, page 153),





Eloquence of adjacent brain*
not eloquent 0
eloquent 1
Pattern of venous drainage'
superficial only 0
deep 1
Grade — Total of scores
* Eloquent — sensorimotor, language and visual cortex; hypothalamus and thalamus;
internal capsule; brainstem; cerebellar peduncles; and deep cerebellar nuclei
* Superficial = cortical venous system & cerebellar hemispheric veins (that drain directly
into the straight or transverse sinuses)
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6.5 Complications viewed on CT and MRI
6.5.1 Acute/new haemorrhage
Acute haemorrhage is defined as fresh blood of high density on CT, or high signal
methaemoglobin on Tj-weighted MRI. Diagnostic CT/MRI at or close to the time of
presentation may reveal acute haemorrhage, in which case its type (5.4.1.1, page 129),
side (6.2.1, page 142) and predominant intracranial location (6.2.2, page 142) are
specified. These data provide radiological support for the clinical data about
haemorrhage at presentation or during follow-up, and the radiological data are
associated with these clinical events in the database.
The Joint Writing Group also suggests recording the estimated age and size of such
haemorrhages, but SIVMS does not do this.
6.5.2 Prior/old haemorrhage
The occurrence of prior haemorrhage from a brain AVM is inferred on CT by
calcification in the surrounding brain parenchyma (unrelated to the vasculature of the
brain AVM), and on MRI by the presence of haemosiderin (and perhaps
methaemoglobin). This is simply recorded, and may correspond with knowledge about
clinically evident haemorrhages prior to inception in SIVMS, in which case these
retrospective events are associated with the diagnostic imaging study.
The JointWriting Group also infers prior haemorrhage from encephalomalacia adjacent
to the nidus and/or the incidental discovery of haemosiderin at the time of surgical
resection, but SIVMS does not. They also attempt to age prior haemorrhage, which
SIVMS does not.
6.5.3 Other features and potential complications
The existence of the radiological appearances of brain infarction — 'low density without
mass effect' on CT or 'infarction' on MRI — as well as its side (6.2.1, page 142) and
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location (6.2.2, page 142) are recorded. On either imaging modality, the appearances of
mass effect and hydrocephalus are recorded — whether due to the brain AVM or not —
as are oedema related to the AVM nidus, vessel calcification on CT, and gliosis on MRI.
These features are not mentioned in the Joint Writing Group or NYIAVMS variable
lists. SIVMS records radiological and/or clinical (5.4.1.6, page 133) evidence of
infarction because of the uncertain relationship between brain AVMs and infarction.
SIVMS records mass effect and hydrocephalus as an indication of haemorrhage severity,
and oedema and gliosis because they may reflect other ways in which brain AVMs cause
symptoms.
6.6 Summary
• SIVMS has a minimum morphological dataset for brain AVMs,
specifying the location and side of the brain the nidus resides m, as well
as the presence of any associated aneurysms (identified by radiological or
pathological examination)
• Other attributes of the arterial feeders, nidus and draining veins are only
described if brain/vascular imaging is adequate to characterise them
• Composite variables, such as the Spetzler-Martin surgical grade, may be
derived if adequate data are available from pathological and/or
radiological investigation
• The definitions used by SIVMS have reasonable external validity in the
light of recent definitions proposed by the Joint Writing Group, the
latter being more specific
• The retention of hard copies of every participant's imaging in the SIVMS
library will enable post hoc exploration/re-categorisation of
angioarchitecture
6.7 Discussion
Great interest has been shown in the morphology of brain AVMs, perhaps because this
has been the fundamental basis for their distinction from other IVMs, but also because
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morphology is the most tangible — and therefore easiest — way to attempt to explain the
heterogeneity of brain AVMs. It is telling that from my systematic review (Chapter 2)
there are far more studies exploring the retrospective association of morphological
variations with modes of presentation than there are good prospective studies of
prognosis.
The core morphological dataset in SIVMS comprises those features likely to be available
in the majority of cases, whether diagnosed by brain and vascular imaging or
pathological examination. All of these features — side and location within the brain, and
associated aneurysms — sadly, are arbitrary to varying extents. The nidus of a bram AVM
may be irregular, vary in size, and involve several lobes of the brain thereby
complicating the allocation of a single side and location. I may have over-simplified the
determination of location by choosing one area only, but this will make data analysis
easier. In my choice of a single area, I have chosen the most 'eloquent' area colonised by
the AVM nidus. Eloquence itself is a rather arbitrary concept, defined by Spetzler and
Martin (6.4.1, page 155) according to anatomical locations whose damage would cause
disabling and obvious post-operative deficits (since functional MRI is not in routine
use). The presence of aneurysms associated with brain AVMs may be identified by
pathological examination, or any form of brain imaging from CT to IADSA, although
IADSA is essential for their characterisation.
Many of the other detailed features of angioarchitecture are also dependent on the use
of IADSA, but they are also susceptible to the technical limitations of the procedure,
often incomplete recording of every view on hard copy, and observer variation in
IADSA interpretation. For example, in routine clinical practice it seems that sizing
markers are used infrequently during IADSA for the measurement of nidus size, and
magnification errors are often not calculated (although a coin applied to the patient's
head is occasionally used as a surrogate marker). The volume of irregular nidi is difficult
to determine, but can be derived from the maximum diameters recorded in three
orthogonal planes, using a simple formula with assumptions about nidus shape
[Pasqualin et al. 1991].
In the same way that SIVMS has stored complete paper copies of all case notes and
extracted data currently thought to be relevant, copies of all available diagnostic imaging
have been archived and morphological attributes currently thought to be relevant are
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extracted. Just as for clinical data, the strength of this approach lies in the ability to refer
back to the source data to validate abstracted variables, reclassify features when/if
definitions change, and later collect other variables not originally thought to be
pertinent. I imagine this approach is just as vital for morphological data, which are just
as likely to be susceptible to observer variation, reclassification and post hoc collection
as hypotheses develop.
Whilst a film-based archive of diagnostic radiological data is most convenient and
familiar to radiologists, the source data are susceptible to degradation by manual
handling and vulnerable to loss. Therefore, a digital archive would be an ideal storage
medium for these valuable data, and furthermore it could enable more accurate
measurement of, for example, nidus size and it could be easily and cheaply duplicated
for distribution in observer variability studies (Chapter 10).
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Figure 12 Laterality and location of brain AVMs
A: coronal T1-weighted MRI demonstrates a corticoventricular brain AVM
clearly lateralised to the left parietal lobe.
B: sagittal T1 -weighted MRI shows a superficial, frontoparietal piocortical
(gyral) brain AVM.
C: axial proton density MRI reveals a brain AVM deep in the midbrain,
predominating in the right thalamus.
D: sagittal T1-weighted MRI demonstrates a superficial, parieto-occipital
piocortical (sulcal) brain AVM.
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Figure 13 Classification of aneurysms, illustration from [Joint Writing
Group 2001]
A and B: distal flow-related aneurysms
C: nidal aneurysms




Figure 14 Aneurysms associated with brain AVMs, from SIVMS
A: a nidus with an unruptured nidal aneurysm. B: a nidus with an unruptured
nidal aneurysm but multiple feeding artery aneurysms one of which had
ruptured (C). D and E: a nidus with an unruptured 15mm nidal aneurysm on
routine (D) and superselective angiography (E). F: an aneurysm remote from
a brain AVM in the right temporo-parietal area
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Figure 15 Size of brain AVM nidus on MRI, illustration from [Joint
Writing Group 2001]
Each dimension can be measured on two views: transverse dimension from
both axial and coronal views, anteroposterior dimension from axial and
sagittal views, and vertical dimension from sagittal and coronal views (or by





Figure 16 Size of brain AVM nidus on IADSA, illustration from [Joint
Writing Group 2001]
Measurement of transverse (x), vertical (z) and anteroposterior (y)




Figure 17 Nidus morphology, illustration from [Joint Writing Group
2001]
A: Compact nidus border









Figure 18 Nidus morphology, illustrations from SIVMS
A-C: Diffuse nidus. D and E: Arteriovenous fistula (solid arrow) with a single
terminal feeder (dashed arrow) (D), but a second feeder giving en passage /
transit supply (long dashed arrow) revealed by superselective IADSA (E).
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Figure 20 Variants of arterial angioarchitecture, from SIVMS
A and B: a right occipital brain AVM nidus, with moderate arterial tortuosity of
5 feeders from the posterior cerebral artery (arrows) visible on a lateral view
of a right vertebral injection (A), with 3 middle cerebral artery leptomeningeal
collateral feeders (arrows) revealed by an internal carotid artery injection (B).
C and D: a left temporal brain AVM nidus fed by terminal branches (arrow) of
the left middle cerebral artery seen on a lateral view of a left internal carotid
artery injection (C), with dural collateral supply from the middle meningeal
branch of the left external carotid artery seen on a lateral view of a left




Figure 21 Variants of arterial angioarchitecture, from SIVMS
A: an anteroposterior view of a right internal carotid artery injection,
demonstrating a right frontal brain AVM nidus, with arterial supply from the
anterior and middle cerebral arteries, and evidence of both dilated (arrow)
and stenosed (dashed arrow) arterial angiopathy.
B: a right occipital brain AVM nidus fed by terminal (arrow) and transit
(dashed arrow) branches of the right posterior cerebral artery.
C: a right basal ganglionic brain AVM compact nidus (arrow), with dilated
feeding artery angiopathy and sprouting angiogenesis (dashed arrows).
D: a right frontal brain AVM diffuse nidus, also with angiogenesis (arrows).
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Figure 23 Venous drainage, illustration from [Joint Writing Group 2001]
A: superficial and deep venous drainage.
B: periventricular deep venous drainage.
C: multiple superficial draining veins (3 vessels leave the nidus and 3 reach a
sinus).
D: venous ectasia and stenosis.





Figure 24 Venous drainage of brain AVMs
A: lateral IADSA of the vertebrobasilar system supplying the same brain AVM
in Figure 12C (page 160) reveals multiple feeders, deep venous drainage to
the Basal vein of Rosenthal (solid arrow), and venous ectasia (dashed
arrow).
B: venous phase of a right internal carotid angiogram, demonstrating
superficial venous drainage to the superior sagittal sinus (arrows) and deep
periventricular drainage to the internal cerebral vein (dashed arrow), without
a dominant draining trunk, from a compact right parietal nidus.
C: right parieto-occipital brain AVM nidus, with superficial venous drainage to
the superior sagittal sinus, and 90% venous stenosis at the sinus (arrow).
D: left parieto-occipital brain AVM nidus, with venous drainage to the superior
sagittal and transverse sinuses, and venous varices (arrow).
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Figure 25 Spetzler-Martin grading scheme for brain AVMs
A: grade 1 small (7mm3) brain AVM nidus (arrow) in the non-eloquent right
temporal lobe with superficial drainage to a cortical vein.
B: grade 2 small brain AVF (large arrow) in the eloquent dominant
frontoparietal cortex (motor strip), fed by the anterior cerebral artery (smali
arrow) and draining to the superior sagittal sinus.
C: grade 3 small (7mm3) brain AVM nidus (arrow) in the eloquent right
thalamus, which had venous drainage to both the right transverse
(superficial) and straight (deep) sinuses (not shown).
D: grade 4 medium (30 mm3) brain AVM nidus (arrow) in the eloquent right
occipital lobe (visual cortex) with venous drainage to both the right transverse
and superior sagittal sinuses (superficial), as well as the deep straight sinus.
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Figure 26 Spetzler-Martin grading scheme for brain AVMs
A and B: Grade 5 large (50 mm3) brain AVM nidus (arrow) in a
corticoventricular distribution in the eloquent left parieto-occipital area, with
venous drainage to both the left transverse and superior sagittal sinuses
(superficial), as well as the deep straight sinus.
B: dilated feeding artery angiopathy (solid arrows) and dural collateral supply
(dashed arrows) are also evident on catheter angiography.
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Chapter 7. The Scottish Intracranial Vascular Malformation Study
(SIVMS) - data quality
Chapter contents
7.1 Introduction
7.2 Evaluation of completeness and progress with study recruitment
7.3 Quality of baseline clinical data






Even if SIVMS realises the aspirations of section 2, its value will still depend on the
quality of its data.
Sources of error causing poor quality data may be systematic or random. They can be
categorised into data collection problems, data errors, and lack of quality improvement
devices [Arts et al. 2002]. Various errors intrinsic to the data may occur due to
ambiguous definitions, unclear guidelines for those inputting data, confusing data entry
design, database programming errors, and incompleteness/unsuitability of the data
source. Errors arising in data collection are attributable to non-adherence to definitions,
typing/transcription errors, and insufficient data checks. Quality improvement schemes
designed to minimise these errors include both quality assurance and quality control,
occurring before and after data collection respectively.
Various database procedures were implemented as SIVMS started in order to prevent
insufficient data quality (e.g. a minimum acceptable dataset for notification), detect
imperfect data and their causes (e.g. queries checking appropriateness, completeness and
inconsistencies in the data), and institute necessary corrective action (3.3, page 110).
Furthermore, other checks occur after data collection to highlight problematic or
inconclusive cases at the time of data analysis and these will be mentioned in Chapter
12.
I have taken a pragmatic view of the meaning of quality, viewing it as the characteristics
of a data set that bear on its ability to satisfy the intended uses of the data. In this
chapter I have described the quality of baseline variables in terms of:
• completeness, or the extent to which data are recorded for each variable, with <5%
the acceptable level for missing data
• range (upper and lower variable limits)
This process of evaluating important study variables (Chapter 19) is essential, prior to
investigating in the next two chapters whether the study has achieved its desired aim of




7.2 Evaluation of completeness and progress with study
recruitment
During 1999 and 2000 in Scodand — following independent review of case notes, brain
imaging and pathological records — 96 adults were diagnosed with a definite, probable or
possible brain AVM, and were therefore regarded as being 'included' in SIVMS. 45
adults were incident in 1999, and 51 were incident in 2000. Of these 96 adults, 92
harboured a definite brain AVM. Adults with a probable or possible brain AVM, which
may subsequendy become definite, are of equal interest to SIVMS and so worthy of
active recruitment and participation in the study (described further in Chapter 13).
Therefore, my interest in, and evaluation of, study recruitment applies to all 96 included
adults (Table 12, page 182).
The progress of patients through SIVMS and the quality of their recruitment data are
testament to the automated database processes that relentlessly press for data
completeness, and the tireless efforts of the study secretary. All 96 patients' GP and
main hospital consultant are known. They tended to disagree more about whether
SIVMS could contact patients by post (13%) than they did about whether the patient
was aware of their diagnosis (2%). This was largely because of the contrasting
perspectives of primary and secondary care: particular consultants felt certain patients
should not be bothered and GPs generally felt every patient should be approached
about their inclusion in a research study.
Of all 96 included patients, 85 (89%) were alive at the time of recruitment. Of these
living patients, 73 (86%) were approached to join the study, of whom 69 (95%) returned
their forms and consented (3% of whom declined to complete annual questionnaires).
No one specifically declined to join the study, or denied access to their case notes.
GPs tended to express concern about SIVMS accessing notes when explicit consent had
not been obtained from the patient, despite ethical approval having been given for this
when consent was impossible/impractical. Ultimately 96% of GPs granted access to
case notes, but because some required us to attend the practice to copy the notes (which
I have not yet done), only 91% of them have been received. In contrast, access to case
notes was granted by 99% of consultants at every hospital the patient had visited and
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which held notes about them, and 99% of these notes have been received. 98% of
diagnostic scans performed at these hospitals have also been received.
7.3 Quality of baseline clinical data
The patient group of interest for detailed description and analysis of baseline clinical and
morphological data are those with a 'definite' brain AVM, so this and the following
section on the quality of these data refer to the 92 such adults in the first 2 years of
SIVMS.
Basic demographic data such as name, date of birth and gender are available for every
patient (Table 13, page 183). Many other demographic details (for example, telephone
number and next of kin), mainly useful for contacting and tracing the patient, are
dependent on the study having obtained a baseline questionnaire, and therefore reflect
the proportion who consented (72%). The study's high quality data for variables such as
maiden name (also obtained by questionnaire) and CHI number (obtained from
Practitioner Services) assist accurate record linkage by ISD. The comprehensive data
about mode of presentation reflect the study's success in obtaining case notes.
Information about family history primarily is drawn from the patient's baseline
questionnaire, but exceeds its completion rate because the notes are sometimes
enlightening too. The completeness of death certificate data reflects the ease of
acquiring contemporary data from the GRO. However, the completeness of autopsy
data disguises how difficult it was to obtain these reports (especially when the
Procurator Fiscal had been involved) at a time when pathologists were guarded about
releasing data because of the Alder Hey scandal.
7.4 Quality of baseline diagnostic morphological data
These data are obtained about brain AVMs and associated aneurysms from brain
imaging, and occasionally only autopsy/biopsy (Table 14, page 184 and Table 15, page
185). Of all 92 adults with a definite brain AVM, 80 (87%) had >1 CT, 41 (45%) had >1
MRI, 68 (74%) had >1 IADSA, and 10 (11%) had a pathological examination of some
sort (excision biopsy or autopsy). Amongst the imaging studies performed, a brain AVM
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was visualised on only 61% of CTs, 77% of MRIs, and on all 68 IADSAs. I have
evaluated data completeness for all investigations performed, rather than per modality
per patient, or per investigation on which a brain AVM was visualised.
From these investigations, complete data were available for the location of each brain
AVM (Table 14, page 184). Although size measurements were available on 84% of all
CTs, 94% of all MRIs and 93% of IADSAs, overall size in three dimensions was only
available for 76 (83%) of the whole cohort.
Data quality was excellent (100%) for important attributes such as whether imaging
revealed ICrH, but was poor for attributes perceived as less important, such as the state
of adjacent venous sinuses (50% on CT and <34% on IADSA) and venous stenosis
(53% on IADSA).
7.5 Summary
• Baseline data quality in SIVMS is a reflection of study definitions,
process and database procedures
• SIVMS maximises data quality by using clear definitions of clinical and
radiographic variables, automatically checking minimum data provision
and consistency at data entry, deliberately analysing for errors, and
spotting outliers
• 89% of patients were alive at the time of recruitment, of whom 86%
were approached to join the study, of whom 69 (95%) returned their
forms and consented to join SIVMS (72% of the whole cohort)
• 96% of GPs granted access to case notes, but only 91% of them have
been received; 99% of consultants granted access to case notes, and 99%
of these notes have been received; 98% of diagnostic scans performed at
these hospitals have been received
• Basic demographic data were present for every patient, and more
detailed information were available if they consented
• Complete data were available for the location of each brain AVM, but




The existing data quality reflects the passage of time between the recruitment of the
cohort and completing this thesis 5 years after the start of SIVMS. Disagreements (e.g.
between GP and hospital consultant) early on in recruitment — although they usually
result in the most conservative outcome — have been largely resolved, and variable
completeness has been improved over time. Some data cannot be evaluated and are still
dependent on thorough study process (e.g. ensuring SIVMS has recorded every hospital
a patient visits and so retrieved every imaging study).
Data accuracy (the extent to which the data conform to the truth) comprises validity,
consistency and reliability. The main approaches to this are:
• range checks (to ensure that data outside a permitted range are not allowed)
• consistency checks (to ensure that the data make sense)
• external validation using an alternative source (for example, by auditing a random
sample of study patients to ensure their baseline attributes and outcomes recorded
in the database match the paper clinical record and questionnaires)
Whilst the first two approaches have been used, SIVMS has not yet been subject to the
latter. This could be performed not only to validate existing paper records, but also by
other researchers to assess inter- and intra-rater variation in the interpretation of case
notes or imaging (Chapter 10). Prior to writing this thesis, I had produced draft
guidelines for subsequent researchers to use for the interpretation of radiological data,
but sadly these never benefited from peer review by the study neuroradiologists, so they
are yet to be introduced. If any such innovations were to be used to improve data
quality (perhaps not only of baseline variables, but also of outcomes), I would intend to
conduct pre- and post- assessments of quality to quantify their impact.
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Table 12 Study recruitment: completeness of variables and progress
Data on completeness and/or measures of study progress (where applicable)
from 96 included adults with a definite (92), probable (1), or possible (3) brain
AVM, first diagnosed 1999-2000
N/A = not applicable
Completeness (%) Progress, n (%)
Patient's GP's identifier 96 (100) N/A
Patient's main consultant's identifier 96(100) N/A
Does the GP think the patient is aware of their diagnosis? 96(100) N/A
Does the main consultant think the patient is aware of their
diagnosis?
96 (100) N/A
GP and main consultant disagree about awareness N/A 2 (2) disagree; 94 (98) agree
Overall decision about patient's awareness of diagnosis 96 (100) 77 (80) aware
Does the GP think SIVMS can contact the patient by post? 96 (100) 75 (78) yes, 8 (8) unknown,
13(14) no
Does the main consultant think SIVMS can contact the
patient by post?
96 (100) 78 (81) yes, 4 (4) unknown,
14 (15) no
GP and main consultant disagree about postal contact - 12 (13) disagree
Overall decision about postal contact with the patient 96 (100) 73 of 85 (86) living patients
to be contacted
Patients replied to recruitment forms - 69 (95) did, 4 (4) did not
Patients declined to join study 69 (95) 0 actively declined
Patient consented to SIVMS copying their notes? 68 (99) 68 (99)
Patient consented to receive questionnaires? 69(100) 67 (97) consented, 2 (3%)
declined
Does the GP grant access to the patient's notes? 96(100) 92 (96) agree
GP case notes received? 92 (100) 84 (91) received, 7 (8) fetch
Hospital's identifier 190 (100) N/A
Consultant's identifier 190 (100) N/A
When case notes exist at a hospital, does the consultant
grant access to them?
178 (100) 2 (1) decline
Where there's access, notes identification number 144 (81) N/A
Notes received from each hospital? 178(100) 176 (99) received
Scanned at this hospital? 190 (100) 158 (83) yes, 2 (1) unknown
If scanned, imaging identification number 92 (58) N/A
Diagnostic scans received from each hospital? 216 (100) 211 (98) received
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Table 13 Completeness of baseline clinical variables
Data on completeness and range of baseline demographic and clinical
variables from 92 adults with a definite brain AVM, first diagnosed 1999-2000
N/A = not applicable
Completeness, n (%) Range
All patients (n=92)
Title 92 (100) N/A
Forename 92 (100) N/A
Surname 92 (100) N/A
Date of birth 92 (100) 31/01/1917 to 07/04/1984
Gender 92 (100) See Chapter 13
Marital status 62 (67) N/A
Maiden name (of 23 known to have been married) 21(91) N/A
Handedness 65 (71) N/A
Ethnic code 65 (71) See Chapter 13
CHI number 92 (100) N/A
City 92 (100) N/A
Post code 91 (99) N/A
Telephone number 61 (66) N/A
Email 4(4) N/A
Next of kin 64 (70) N/A
Next of kin telephone number 59 (64) N/A
Is there a family history of IVMs, or similar? 78 (85) 6 (7) may have FHx
First presentation date 92 (100) 23/11/1998 to 07/11/2000
First presentation type 92 (100) See Chapter 13
Baseline Rankin score at presentation 92 (100) See Chapter 13
Dead patients (n=13)
Place of death 12(92) N/A
Cause of death 13 (100) See Chapter 13
Source of information about cause of death 13 (100) N/A
Death certificate obtained? 13 (100) 13 (100)
Post mortem examination performed (n=4)
Where the examination was performed 4 (100) N/A
Date of post mortem 4(100) N/A
Post mortem report received?
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Table 14 Completeness of baseline morphological features of brain
AVMs and their CT/MRI characteristics
Data from 92 adults with a definite brain AVM, first diagnosed 1999-2000
Completeness (%) Range
General AVM morphological attributes (n=92)
Side of the brain 92 (100) See Chapter 14
Brain area 92 (100) See Chapter 14
Location within brain area 92 (100) See Chapter 14
Eloquence of brain area 92 (100) See Chapter 14
Spetzler Martin grade 71 (77) See Chapter 14
CT attributes (n=112; 80 diagnostic, 32 follow-up)
Intravenous contrast given? 86 (77) 30 yes, 56 no
Does the AVM enhance (of all given contrast)? 30 (100) 30 yes
AVM dimensions (AVM visible on 68 CTs) 57 (84) See Chapter 14
Mass effect exerted by AVM? 112 (100) 50 yes, 59 no, 3 uncertain
Hydrocephalus? 112 (100) 28 yes, 81 no, 3 uncertain
Oedema around AVM? 70 (63) 9 yes, 59 no, 2 uncertain
Vessel calcification? 100 (89) 28 yes, 69 no, 3 uncertain
Calcification from old haemorrhage? 100 (89) 5 yes, 87 no, 8 uncertain
Acute haemorrhage? 112 (100) 62 yes, 50 no
Type of acute haemorrhage 62 (100) See Chapter 13
Area of acute haemorrhage 55 (89) See Chapter 13
Side of acute haemorrhage 51 (82) See Chapter 13
Infarction? 100 (89) 8 yes, 92 no
Aneurysms visible? 86 (77) 4 yes, 82 no
Dilatation/thrombosis of adjacent venous sinus 56 (50) 1 yes, 44 no, 11 uncertain
MRI attributes (n=47; 41 diagnostic, 6 follow-up)
Intravenous contrast given? 43 (91) 12 yes, 31 no
Does the AVM enhance? 11 (92) 8 yes, 2 no, 1 uncertain
AVM dimensions (AVM visible on 36 MRIs) 34 (94) See Chapter 14
Mass effect exerted by AVM? 47 (100) 17 yes, 29 no, 1 uncertain
Hydrocephalus? 47 (100) 4 yes, 41 no, 2 uncertain
Oedema around AVM? 39 (83) 2 yes, 35 no, 2 uncertain
Gliosis around AVM? 35 (74) 9 yes, 25 no, 1 uncertain
Perinidal contrast enhancement? 10 (83) 1 yes, 6 no, 3 uncertain
Evidence of old haemorrhage 36 (77) 34 none, 2 some
Acute haemorrhage? 47 (100) 15 yes, 32 no
Type of acute haemorrhage 15 (100) See Chapter 13
Area of acute haemorrhage 15 (100) See Chapter 13
Side of acute haemorrhage 12 (80) See Chapter 13
Evidence of infarction? 36 (77) 1 yes, 35 no
Aneurysms visible? 43 (91) 2 yes, 41 no
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Table 15 Completeness of baseline angiographic features of brain
AVMs and associated aneurysms








Side of arterial feeder
Type of arterial feeder
Quantity of branches from the feeder
Collaterals
Source of collaterals
Related to a dural sinus?
Side of this dural sinus
State of sinus
Nidus border
Discernible fistula in nidus?















































ACA 26, dural 2, ICA 2,
MCA 41, PCA 23, Pcom 1,
vertebrobasilar 9
49 left, 2 midline, 57 right
72 terminal, 12 transit, 5






2 left, 2 right, 13 midline












17 yes, 49 no
See Chapter 14
Limited categories





Chapter 8. The Scottish Intracranial Vascular Malformation Study
(SIVMS) - evaluation of population-based design
Chapter contents
8.1 Introduction
8.2 Completeness of case ascertainment






Whether or not the dataset for each patient is complete, SIVMS's exhaustive search for
eligible adults would only be worthwhile if it resulted in a reasonably complete
population-based sample. The more complete the sample, the more accurate the
measured incidence will be. The more the sample is representative of the population as
a whole, the more the results from SIVMS will be generaliseable and have external
validity.
8.2 Completeness of case ascertainment
Figure 27 (page 191) illustrates the overlap between the sources of ascertainment of
brain AVMs. In the first year of the study, GPs only contributed cases already known to
SIVMS, so this labour-intensive and ineffective exercise was abandoned in the second
year. The widespread collaborative network identified the vast majority of adults, and
there was ~50% overlap between the two major sources. Routine coding of hospital
discharge and death certificate data (using 160.8 and Q28.2; see Table 11, page 115)
identified the majority of adults who had died or been admitted to hospital. Coding
failed to identify several adults who had only been seen as outpatients, but it did yield 4
adults (4% of the total) who were unidentified by the collaborative network.
8.3 Representativeness of the population
The adults incident in 1999 and 2000 were domiciled in proportion to the dispersion of
the whole mid-2000 population estimate by health board (Figure 28, page 192),
suggesting even ascertainment. Based on this dispersion of the cohort, there appeared to
be mild over-ascertainment in the two Scottish health boards where specialist brain
AVM clinics operate (Lothian and Greater Glasgow). However, the 95% confidence
intervals of the age-standardised incidence ratios for each health board all overlapped 1
(Figure 29, page 193 and Figure 30, page 194), indicating that there were no detectable
differences in ascertainment when the spread of the cohort was adjusted for the




• The optimal sources of case ascertainment were notifications from a
multidisciplinary network of collaborators in the clinical neurosciences,
supplemented by routine coding of hospital discharge and death
certificate data
• There was ~50% overlap between these two sources
• The cohort was domiciled in proportion to the dispersion of the Scottish
population
• Age-standardised incidence ratios did not suggest significant differences
in ascertainment between health board areas
8.5 Discussion
In attempting to identify a complete sample representative of the population, SIVMS
used several sources of case ascertainment. My pragmatic approach to assess the
completeness of ascertainment was to observe the degree of overlap between the
sources used (Figure 27, page 191). Whilst prospective identification of every adult by
the two main sources — although impossible — would be extremely reassuring, the ~50%
overlap is adequate. In the context of a country which — as yet — does not have routine
coding of brain imaging and outpatient attendances, the study has achieved as thorough
case ascertainment as is possible. Coding would never detect people diagnosed only as
outpatients, although some may still be retrospectively ascertained in future years if they
are admitted to hospital with epilepsy or ICrH, or for investigations or treatment, so the
degree of overlap will increase over time.
Regional healthcare systems dictate which sources are most appropriate. I contemplated
searching additional potential secondary data sources, including diagnostic radiology and
pathology reporting systems in the geographical area of interest [Singh et al. 2000]. But
when I surveyed these departments across Scotiand I found that few had electronic
reporting systems, and fewer still were searchable. There are few existing surveillance
systems that might have provided a ready-made infrastructure for incident brain AVM
detection. The British Neurological Surveillance Unit (BNSU) co-ordinated by the
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Association of British Neurologists (www.theabn.org/acadeniic/bnsu.litrnh is one such
system. However, the disadvantage for SIVMS was that the BNSU only targets
consultant neurologists, rather than all the specialists (and training grades) in the clinical
neurosciences who might encounter patients with brain AVMs. I simply ensured that
the study's collaborative network encompassed all consultant neurologists in Scotland
known to the BNSU.
By using as broad a collaborative network as possible and aiming to recruit every
incident adult with a brain AVM in the population, SIVMS has recruited what seems to
be a population-based cohort. Of course, this may simply represent even under-
recruitment across the country, but the similarity of the total number included in the
first two years suggests not.
By being population-based, hopefully SIVMS will have quantified incidence accurately
and so in its future analysis of prognosis it will avoid many of the disadvantages of
hospital-based studies.
Hospital-based cohorts tend to represent local referral practices and the beliefs and
treatment preferences of research groups with a special interest in brain AVMs, rather
than describe the behaviour of a more representative population-based sample.
Hospital-based studies are more likely to detect people with a disabling (yet non-fatal)
mode of presentation, and if SIVMS had simply relied upon specialists it would
probably have been biased towards people with more extensive investigation and
treatment (Chapter 9). This hospital-based sampling bias also affects prognostic
subgroups unequally, it makes the comparison of separate hospital-based cohorts
inappropriate, and it militates against their meta-analysis. This has been confirmed by an
analysis of five single centre brain AVM cohorts, which were found to have significant
differences in both demographic and clinical characteristics as well as in brain AVM
angioarchitecture [Hofmeister et al. 2000]. Comparison of such cohorts with SIVMS will
be made later in this thesis (Chapter 13 and Chapter 14).
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Figure 27 Sources of ascertainment of brain AVMs in the population of
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Figure 28 The percentage distribution (with 95%Cls) of adults with a
brain AVM recruited to SIVMS in 1999-2000 by their health board of
residence (white), compared with Scottish population density (black)
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Figure 29 Age-standardised brain AVM incidence ratios for each of the
15 health boards in Scotland with 95%Cls.
The area of each point estimate is proportional to the age-standardised
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Figure 30 Age-standardised brain AVM incidence ratios for each of the
15 health boards in Scotland (bold if ratio >4)
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Chapter 9. The Scottish Intracranial Vascular Malformation Study




9.2 Utility of ICD-10 coding
9.2.1 Sensitivity
9.2.2 Positive predictive value
9.3 Evaluation of potential biases
9.3.1 Simplified case ascertainment
9.3.2 Pattern of diagnostic investigation
9.4 Summary
9.5 Discussion
9.5.1 Utility of coding




In the previous chapter, I showed how routine coding of hospital discharge data and
death certificates is an important source of ascertainment in SIVMS for the detection of
cases occasionally missed by the collaborative network. Coding could, theoretically, be a
single source of ascertainment in order to minimise the administrative and financial
burden of maintaining the collaborative network. However, this would only be
appropriate if coding were proven to be comprehensive and reliable. With this in mind,
another research group has evaluated ICD-9 coding of brain AVMs at one hospital in
New York, and found its specificity to be unacceptably poor [Berman et al. 2002]. This
was unsurprising, since ICD-9 had only one code pertinent to IVMs (747.8,
cerebrovascular anomaly). There has been no evaluation of the utility of ICD-10 coding
of brain AVMs, which is likely to result in fewer false positives than ICD-9 because of
its clear codes for brain AVMs (but sadly not other IVMs).
In this chapter I evaluate ICD-10 coding in order to provide data on the effectiveness of
hospital coding departments in Scodand and collation of their output by ISD. To
inform SIVMS's future methods of case ascertainment, I also evaluate a simulation of
some potential biases. I pre-supposed that these could be introduced if inclusion in
SIVMS were restricted to: routine coding as the sole means of case ascertainment,
collaborators based at neuroscience centres as the sole means of case ascertainment, and
using IADSA as the diagnostic standard for brain AVMs.
9.2 Utility of ICD-10 coding
I have evaluated the sensitivity and positive predictive value of the combination of the
two ICD-10 codes for brain AVMs (Q28.2 and 160.8), by comparing the yield from
coding in Scotland with overall case ascertainment to SIVMS, the latter regarded as the




The search of coding identified 58 (63%) of the 92 incident adults (Figure 27, page 191
and Figure 31, page 203). Of these 58 adults, coding contributed only four who were
unknown to SIVMS because collaborators failed to notify us of them (Figure 31, page
203). To evaluate sensitivity, ISD used probability matching record linkage to detect
records of any hospital admissions and/or death certificates of all 92 adults. Of the 34
adults missed by the search of coding, 11 would never have been detected because they
had not died and were never hospital inpatients. This makes the 'true positive'
denominator for the calculation of coding sensitivity 81 ([A-D] in Figure 31, page 203),
resulting in a sensitivity of 72% (95%CI 61% to 80%). Coding missed the 'false
negatives' [E] because of the incorrect allocation of Q27.3 to 8 adults and 167.1 to 3
adults (see Table 11, page 115); the remainder were due to brain AVM diagnoses not
appearing on the discharge summary or death certificate, or missing records in the ISD
dataset.
9.2.2 Positive predictive value
The search of coding for first-ever hospital admissions yielded 47 correctly coded but
prevalent brain AVMs (because the adults had never been admitted to hospital in
Scotland prior to the study period). Of the 67 adults with incorrectly allocated codes
('false positives'), intracranial aneurysms and perimesencephalic SAH accounted for the
attribution of code 160.8, other IVM types were occasionally allocated the code Q28.2,
and the diagnosis of a brain AVM was uncertain in 2 adults ([F] in Figure 31, page 203).
The positive predictive value of an apparently incident code was 46% (95%CI 38% to




9.3 Evaluation of potential biases
9.3.1 Simplified case ascertainment
Only 58 (63%) of 92 adults would have been detected by coding alone, thereby
underestimating the overall detection rate if coding was used as a single source of case
ascertainment. Moreover, such a cohort would be biased towards younger people, with
more haemorrhagic and fewer incidental presentations, greater investigation with
IADSA and a strong tendency towards treatment (Table 16, page 202).
Furthermore, if SIVMS were to base its recruitment purely on collaborators at the four
tertiary referral centres in Scotland (simulating a hospital-based cohort), it would have
missed 8 (9%) of the 92 adults with a definite brain AVM. Comparing these eight adults
with the other 84, fewer had had an IADSA (38% versus 77%, 7^1=1=C p—0.014) and
fewer had been treated (13% versus 66%, %2df=1=8.6, p=0.003). The numbers were too
small to detect any other disparities, but these differences reflect how specialist hospital
cohorts are generally unrepresentative of the population at baseline, and are likely to
remain so during follow-up.
Considering the reliance of other research groups on IADSA as the diagnostic reference
standard, I was also interested in whether so doing would bias the SIVMS cohort.
In this population-based study, 68 (74%) of 92 adults with brain AVMs were
investigated with IADSA, which led to definite diagnoses in 66 (72%) of them (Figure
32, page 204). The other 28% were diagnosed by CT, MRI or pathological examination.
These investigation patterns resulted in a median time between clinical presentation and
diagnosis for the 92 adults of 14 days (range 0 to 259 days), with delays reflecting the
mode of presentation and occasional need for extensive and/or repeated investigation.
Using IADSA as the diagnostic reference standard would have biased the cohort
towards younger people (mean age 42 versus 56, two sample t-test p=0.002), more likely
9.3.2 Pattern of diagnostic investigation
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to have presented with haemorrhage (52% versus 29%, Fisher's exact test, p=0.011),
and to have been subsequendy treated (77% versus 17%, x2df=i=26.6, p=0.0000002).
9.4 Summary
• Coding missed 37% of adults with brain AVMs, although it benefited
SIVMS by being the sole source of 4% of the whole cohort of brain
AVMs
• The sensitivity of ICD-10 coding of brain AVMs was 72% (95%CI 61%
to 80%); false negatives were mainly due to incorrect coding, brain AVM
diagnoses not appearing on the discharge summary or death certificate,
or missing records in the coding dataset
• The positive predictive value of an apparentiy incident ICD-10 code for
a brain AVM was 46% (95%CI 38% to 55%); false positives were mainly
due to intracranial aneurysms and perimesencephalic subarachnoid
haemorrhage (160.8) and other IVM types (Q28.2)
• Even with as small a cohort as 92 adults, I have also been able to
demonstrate that both simplified methods of case ascertamment and
reliance on IADSA for diagnosis all would have biased the cohort,
sometimes very seriously
9.5 Discussion
9.5.1 Utility of coding
The NFIS has a long established coding infrastructure and the median accuracy of a
wide variety of ICD codes in the UK has been found to be 84% [Campbell et al. 2001].
However, I knew from previous experience in Scotland that coding inaccuracies did
make a large impact on the detection and mortality rates of motor neurone disease, a
disease with a similar incidence to brain AVMs [Chancellor et al 1993]. Regrettably, I
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found the sensitivity and positive predictive value of ICD-10 coding of brain AVMs to
be moderate in practice.
The utility of routinely collected data depends on the precision of diagnosis at death or
at discharge from hospital. This is affected by the variable nomenclature used by
clinicians, inadequate completion of the discharge summary and SMR01 form, as well as
inaccuracies in transcription to ISD and its record linkage. 12% of adults with brain
AVMs in SIVMS were not admitted to hospital in the year of their diagnosis. Coding
might only identify these people some time after inception, depending on whether they
die and whether they are admitted for further investigation or treatment.
Moreover, the adequacy of ICD coding depends on the existence of relevant codes.
ICD-9 used a single code (747.8) for 'cerebrovascular anomalies' — encompassing a
heterogeneous spectrum of IVMs and other lesions — which has been shown to have a
94% (95%CI 91% to 96%) sensitivity but poor specificity in one New York hospital
[Berman et al. 2002], The transition to ICD-10 has merely created an explicit code for
brain AVMs, but not for the other IVMs. In doing so, ICD-10 appears to have
diminished the sensitivity of coding for brain AVMs (although direct comparison with
the New York study is not possible, because they evaluated all IVMs, and not just brain
AVMs). This is unsurprising, because coders need time and training to become familiar
with a new coding scheme; furthermore, the continued existence of categories bearing
descriptions such as, 'other...' and, 'not otherwise specified...' will result in those less
familiar with the dedicated codes allocating non-specific catch-all codes to brain AVMs.
9.5.2 Bias in simplification of ascertainment
The administrative burden ofmaintaining a collaborative network and following people
prospectively through their medical records questions whether coding alone would be a
satisfactory means of ascertaining and following-up incident adults. Sadly, I have found
that adults who are coded are a biased group. Using coding for follow-up would also
subject this group to the accuracy of record linkage and coding of death certificates, and
it would miss any important outcomes (such as epilepsy) not resulting in hospital
admission. Furthermore, restricting the collaborative network to those based at
neuroscience centres (implying a special interest in brain diseases) would further bias the
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cohort towards patients identified by the investigation practices of specialists, missing
patients detected at district hospitals who are not referred onwards. This may be due to
the still scarce provision of neurologists in the UK or perhaps due to characteristics of
the patients themselves.
This exploration of ICD-10 coding, and the potential biases introduced by an otherwise
attractive simplification of SIVMS's methods of ascertainment, reinforces the need for
SIVMS to continue using its current design. Furthermore, inclusion criteria
encompassing diagnoses that can be made using non-invasive imaging alone do result in
a less biased cohort. Because IADSA is available for 74% of the cohort, SIVMS will
only be able to explore variants of angioarchitecture as prognostic factors in this
proportion. But before describing angioarchitecture and exploring its influence on
prognosis, it is important to quantify the degree of observer variation in its
determination, which I do in the next chapter.
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Figure 31 Comparison of ascertainment by the disease register with
coding of hospital discharge and death certificate data
Utility of ICD-10 codes Q28.2 and I60.8 for identifying adults with a definite
brain AVM:
Sensitivity = [B + C]/[A-D]
Positive predictive value = [B + C]/[B + C + F]
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Figure 32 Investigations that led to a definite diagnosis of a brain AVM
for the 92 incident participants
Pathological examination = autopsy or specimen from surgical excision
CT / MR imaging ^
16
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The angioarchitecture of brain AVMs demonstrated on IADSA is thought to influence
their prognosis [Al-Shahi and Warlow 2001], and is therefore often used to decide
whether and how to treat a brain AVM [Nataf et al. 1998; Mansmann et al. 2000].
However, accurate description of angioarchitecture is inevitably affected by the inherent
complexity of AVMs, the extent and quality of their imaging, neuroradiologists' personal
interpretations of it, and human error. These sources of observer variation are likely to
have been compounded by inconsistencies in angioarchitecture terminology used in the
literature, varying perceptions of what is abnormal, and — until very recently - the lack
of structured definitions intended for widespread use [JointWriting Group 2001].
Previously, there has been just an abstract reporting agreement about AVM size and
morphology using World Wide Web based joint photographic expert group (JPEG)
format magnetic resonance and angiographic images [Stapf et al. 2000a]. This study's
response rate was 63%, only 2 of 19 participants were neuroradiologists, and JPEG
images rather than hard copies of IADSAs were used.
Because I anticipated that inter-observer variation could complicate the data collection
process for SIVMS, the two study neuroradiologists have reviewed every diagnostic
IADSA together. In the meantime, I took the opportunity to use the IADSA studies
collected by SIVMS to evaluate inter- and intra-observer variation, necessarily having to
involve observers outside Scotland because of their unfamiliarity with the study patients.
10.2 Methods
10.2.1 Angiograms
In order to be representative of everyday practice, I used the IADSA studies of 40
patients — obtained at the time of first-ever brain AVM diagnosis — from the first year of
SIVMS. I used identical copies of the entire run of the four-vessel IADSA that made the
first-ever brain AVM diagnosis. The IADSAs were performed at the four neuroscience
centres in Scotland; they included all the antero-posterior, lateral and oblique views and
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vascular territories necessary to visualise the brain AVM, and only omitted normal
vascular territories and frames from superselective vascular catheterisation performed
prior to embolisation. Because of the different facilities for angiography, the spectrum
of experience of the radiologists in Scodand, and the variable resolution of copy films,
the 40 IADSAs inevitably varied in quality. In order to explore the influence of film
quality, the two non-participating SIVMS neuroradiologists rated the quality of the films
prior to starting the study (12 were 'excellent', 18 were 'good', 8 were 'average', 2 were
'poor' but none was 'terrible'). Axial CT or MRI from the presentation that led to
diagnosis was included to aid localisation. Size markers on CT and MRI were obscured
to force observers to estimate nidus dimensions from the IADSA.
10.2.2 Observers
The 5 observers were practising consultant interventional neuroradiologists in the UK
(Table 17, page 218). They worked in separate cities and had never been involved in the
management of any of the patients in SIVMS. They interpreted IADSAs without
knowledge of clinical details, the original imaging findings or each other's results. The
observers were not presented with definitions of any of the angioarchitectural features
under investigation, and — as often occurs in everyday practice — they used the diameter
of the genu of the petrous portion of the internal carotid artery (5mm) as a reference for
sizing a nidus, either using callipers or a customised scale on paper [Paullus et al. 1977].
10.2.3 Angiogram distribution
The 40 IADSAs were distributed and reviewed in two batches between January and May
2001. Every IADSA was reviewed by 2 of the 5 observers for the inter-observer study,
and 38 of the 40 IADSAs were reviewed by the same observer on two separate
occasions for the intra-observer study. The IADSAs were divided amongst the
observers so that each neuroradiologist was allocated a similar spectrum of brain AVMs
according to crude indicators of their nidus diameter (2 large (>6cm), 14 medium, 24
small (<3cm)) and vascular complexity (18 simple (<2 feeders or draining veins) and 22




A standard data collection form was distributed with each IADSA to collect the
following data:
Data collected (forced categories are described in brackets)
• Depth (deep, superficial)
• Nidus diameter (mm) in 3 dimensions (antero-posterior, transverse and vertical)
• Number of feeding arteries
• Feeding artery angiopathy (yes, no), and if present whether abnormally dilated,
stenosed, or both dilated and stenosed [Pile-Spellman et al. 1986]
• Angiogenesis (yes, no) [Mansmann et al. 2000]
• Collateral supply (yes, no), and if present whether dural, pial/leptomeningeal, or
both dural and leptomeningeal [Russell and Berenstein 1981]
• Nidus border (compact/diffuse) [Chin et al. 1992]
• Discernible fistula in the nidus (yes, no) [Houdart et al. 1993]
• Number of draining veins/nidus compartments [Albert et al. 1990]
• Spetzler-Martin surgical grade
calculated by an observer summing scores from the scale provided for AVM
nidus size, pattern of venous drainage and eloquence of adjacent brain (although
constituent scores on each of these 3 items were not collected) [Spetzler and
Martin 1986]
• Venous varices (yes, no) [Lasjaunias et al. 1986]
• Venous ectasia (yes, no) [Lasjaunias et al. 1986]
• Venous stenosis (yes, no) [Vinuela et al. 1985]
• Aneurysm(s) (yes, no), and aneurysm type if identified (feeding artery, nidal,




All data were double-punched to ensure accuracy of data entry. Because the same
observer reviewed some IADSAs on two separate occasions for the intra-observer
agreement study, only data from the earliest date that an observer reviewed a particular
IADSA were used to evaluate inter-observer agreement.
10.2.6 Statistical analysis
The primary outcomes in this study were observer variation quantified by the kappa
statistic (k) for nominal data (e.g. dichotomous yes/no answers) [Cohen 1960], the
weighted k statistic for ranked ordinal data (e.g. Spetzler-Martin grade) and discrete
interval data (e.g. number of feeders) [Cohen 1968], and Bland & Altman analysis for
continuous data (e.g. nidus dimensions in millimetres) [Bland and Altman 1986;
Rothwell 2000]. Percentage agreement between observers is not a good measure,
because — unlike k (Figure 33, page 220) — it does not discriminate between actual
agreement and agreement which arises due to chance.
The raw data were re-coded for some variables to enable a simple assessment of
observer agreement using the k statistic, although I did also examine cross tabulations
of the raw data and Bland & Altman plots for these variables where appropriate (e.g.
nidus dimensions, Figure 35, page 222). For example, nidus size in each of the three
dimensions was re-coded into a dichotomous variable according to whether an observer
found them to be >30mm or <30mm (the size threshold for stereotactic radiosurgery).
The numbers of feeding arteries and draining veins were re-coded as 1,2, or >3 because
different radiologists had different thresholds for deeming there to be 'multiple' vessels
when they were too numerous to count, which made Bland & Altman analysis of these
variables impossible.
All analyses were performed in Statistical Product for the Social Sciences (SPSS) version
10.0.5 except confidence intervals for k, which were calculated using Confidence
Interval Analysis software [Altman et al. 2000], and weighted k tests and their
confidence intervals, which were calculated in Statistical Analysis Software (SAS) version
8.
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The study was designed with 87% power to detect a greater than fair agreement (k—0.4)
at the p=0.05 level of significance, assuming the level of agreement for the
characteristics would be substantial (k=0.7) [Walter et al. 1998].
10.3 Results
Complete responses were received from all 5 observers, and the median time between
an observer reporting the two batches of IADSAs for the intra-observer study was 5
(range 4 to 6) months. The interpretation of inter-observer agreement requires a prior
appreciation of intra-observer agreement because between-observer variation is
inevitably affected by the extent ofwithin-observer variation.
Figure 34 (page 221) demonstrates that for every characteristic intra-observer agreement
was greater than inter-observer agreement. Intra-observer agreement was mosdy
moderate to substantial with 95% confidence intervals ranging from fair to almost
perfect. Inter-observer agreement was mosdy slight to moderate, with 95% confidence
intervals ranging from less than chance to almost perfect.
Intra-observer agreement about whether the diameter of an AVM nidus was >30mm or
<30mm ranged from substantial to almost perfect, whereas inter-observer agreement
was somewhat worse. Plotting the raw, continuous nidus size data on Bland & Altman
plots reveals a tendency for both intra- and inter-observer variation to increase as nidus
size increases, especially above 20mm. Using the transverse nidus dimension as an
example (Figure 35, page 222), the greater scatter about the mean for inter-observer as
opposed to intra-observer comparisons of raw continuous data explains why k=0.36 for
inter-observer comparisons as opposed to k=0.78 for intra-observer comparisons using
categorical data with a 30mm size threshold (Figure 34, page 221).
Inter-observer agreement was greatest for characteristics such as determining whether
nidus diameter was >30mm or <30mm (e.g. vertical dimension k = 0.62 (95%CI 0.37 to
0.88)), and whether there were venous varices or not (k = 0.56 (95%CI 0.31 to 0.81)). In
general there was the greatest overall agreement between observers for AVMs with
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simple angioarchitecture lacking many of the features of interest (Figure 36, page 223).
Inter-observer agreement was worst for characteristics such as venous stenosis (k =
0.14 (95%CI -0.33 to 0.60)), angiogenesis (k = 0.18 (95%CI -0.13 to 0.49)), and the type
of nidus border (k = 0.22 (95%CI -0.20 to 0.64)) — in other words, AVMs with more
complex angioarchitecture (Figure 36, page 223). Alarmingly, inter-observer agreement
was only moderate for the variables with the greatest importance in routine practice:
Spetzler-Martin grade, which influences predictions of morbidity from surgery
(weighted k = 0.47 (95%CI 0.30 to 0.64)), and the presence of aneurysms, which are
thought to confer a greater risk of subsequent haemorrhage and may also influence
management decisions (k = 0.40 (95%CI 0.11 to 0.68)).
I asked observers to assess IADSA quality with the intention of exploring whether it
influenced observer agreement. Flowever, intra-observer agreement about IADSA
quality was k = 0.43 (95%CI 0.20 to 0.67), and inter-observer agreement was k = 0.19
(95%CI -0.04 to 0.42), making stratification of kappas by quality for each
angioarchitectural feature susceptible to observer variation in the determination of
quality. Moreover, the small number of observations in each quality category resulted in
even wider confidence intervals around the kappa estimates, and I found no consistent
trend towards a better level of agreement for higher quality films.
10.4 Summary
This study of 5 neuroradiologists' interpretations of 40 IADSA studies
was a pragmatic effort to understand both intra- and inter-observer
agreement in day-to-day assessment ofAVM angioarchitecture
The IADSAs were of adequate quality, although it will always be difficult
to reflect the dynamic nature of angiography in hard copy format
Unsurprisingly, there was greater intra-observer than inter-observer
agreement
Inter-observer agreement was greatest for characteristics such as nidus
size (although there was a tendency for variation to increase as nidus size
increases), moderate for Spetzler-Martin grade and the presence of
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aneurysms, and worst for the presence of venous stenosis and type of
nidus border
10.5 Discussion
The findings of this study should be regarded as a baseline measure of observer
agreement for future studies, the results should be considered in the light of important
statistical caveats common to all studies using k, and they have some implications for
routine practice.
10.5.1 Statistical considerations
10.5.1.1 Bias, confounding and chance
I avoided bias by using IADSAs that the study neuroradiologists had never seen before,
by anonymizing films, and by leaving a median of 5 months between an observer re-
reviewing the same IADSA (to lessen recognition effects). By distributing IADSAs
evenly according to image quality and AVM complexity, I sought to minimise
confounding. Chance effects were minimised by ensuring the study was adequately
powered to detect a difference from only fair agreement (k = 0.4), assuming agreement
would be substantial (k = 0.7) for any characteristic. Indeed I confirmed my suspicion
that intra-observer agreement was of this order for most angioarchitectural features
(Figure 34, page 221).
10.5.1.2 Precision
To establish the extent of observer agreement with greater precision, a larger study will
be required. This could be achieved by increasing the number of observers and/or
IADSAs, which would also enable an analysis of the bias of any individual observer
(10.5.3, page 216). A greater number of IADSAs for which there are two observer
comparisons would certainly narrow the 95% confidence intervals around estimates of k
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(Figure 34, page 221), but having more than two observers per IADSA would
complicate the statistical analysis.
10.5.1.3 Kappa caveats
Although there are several well-rehearsed caveats to the use of K [Brennan and Silman
1992], and experts debate whether or not the intraclass correlation coefficient is a better
measure [Maclure and Willett 1987], K is nevertheless the most frequently used index of
agreement. K relies on both the subjects under study and the observers being
independent, and that the categories in the scale are independent, mutually exclusive and
exhaustive [Cohen I960]. These assumptions held for this study, although varying
beliefs about angioarchitecture between research groups (a form of global observer
variation) will affect whether readers perceive overlap between categories for some
characteristics.
The greater the number of scale categories, the lower K will inevitably be, so agreement
will tend to appear better with a dichotomous scale [Brennan and Silman 1992]. For
example, K for inter-observer agreement falls from 0.29 to 0.19 when subdividing
angiopathy into more than yes/no categories and it falls from 0.41 to 0.30 when
subdividing collateral supply into more than yes/no categories). Conversely, using only
3 categories for the numbers of feeding and draining vessels masked variation; I would
have used Bland & Altman analysis were it not for different thresholds between
observers for declaring vessels "multiple".
An artefact of K is that it is affected in complex ways by both the prevalence of
abnormality amongst the subjects used and also by observer bias [Brennan and Silman
1992; Byrt et al. 1993], Firstly, most characteristics in this study were unevenly
distributed between their different sub-categories (the most extreme being venous
stenosis and nidus border), although the distribution of some features such as
aneurysms was more even (Table 18, page 219). The nature of my sample means this
probably reflects the population distribution of these abnormalities. But when marginal
totals are unbalanced, or expected levels of agreement are high because of a high
underlying prevalence, K is fragile and examination of the influences of prevalence
effects will be essential when comparing studies [Byrt et al. 1993]. Secondly, agreement is
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only one aspect of variation between observers, the other being biases between them
(e.g. a tendency for one observer to systematically overestimate nidus size) [Brennan and
Silman 1992], I avoided this sort of bias by ensuring each neuroradiologist was observer
1 or observer 2 a comparable number of times in the inter-observer study, and each
neuroradiologist was equally represented in the intra-observer study.
When there are several ordinal scale categories (e.g. Spetzler-Martin grade), between
which large disagreements are more serious but would be treated as equally serious by K,
the weighted K can be used when the relative seriousness of disagreements is specified
[Cohen 1968]. In this study I allocated weights evenly (e.g. weights of 1, 0.75, 0.5, 0.25
and 0 for Spetzler-Martin grades 1 to 5), but whether and how uneven weighting should
be used to reflect clinically important thresholds (such as <2 and >3 on the Spetzler-
Martin scale) is debatable.
10.5.2 Implications for routine practice
The high level of intra-observer agreement shows that experienced interventional
neuroradiologists are consistent, but poor inter-observer agreement shows that
assessment and interpretation differ between them. This argues for caution in
interpreting prognosis and basing treatment decisions on angioarchitectural features
with less than adequate inter-observer agreement.
10.5.2.1 Evaluate nidus size with standardised calibration markers
There are several barriers to accurately sizing an AVM on an IADSA, which are
reflected by the scatter of size estimates in Figure 35 (page 222). The definition of a
nidus as the area towards which multiple feeding arteries converge and from which
enlarged veins drain is somewhat arbitrary [Doppman 1971]. This is especially
problematic when nidus morphology is diffuse (Figure 18A-C, page 166) [Chin et al.
1992], and when the AVM is a simple fistula (Figure 36, page 223, which elicited nidus
dimensions of 0-20mm in this study). The nidus is often not imaged in its entirety when
catheterising single vascular territories during IADSA, making the maximum linear
diameter in any dimension difficult to gauge [Soderman et al. 2000]. It is therefore hard
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to imagine how proposed nidus volume calculations [Pasqualin et al. 1991; Soderman et
al. 2000J, dependent on further assumptions about the shape of the nidus, can be
accurate. Moreover, magnification or minification by both film projection and digital
subtraction imaging distorts the abnormal vessels. Without reference markers, the
widespread use of the diameter of the genu of the petrous portion of the internal carotid
artery — as in this study — can be inaccurate; for example, it is larger than 5mm if feeding
ipsilateral, large, high-flow brain AVMs. Potential solutions to these sources of
measurement error include consistent angiographic magnification factors, widespread
use of simple calibration markers such as rulers, washers and coins (which were not in
frequent use a decade ago [Soderman et al. 2000], and do not seem to be now), and
magnification/minification rulers [Forbes et al. 1996]. The routine use of standardised
calibration markers on IADSAs is therefore essential to reduce variation in which
patients are considered — and then further evaluated with stereotactic sizing [Elisevich et
al. 1995] — for stereotactic radiosurgery. Given the many sources of error in assessing
nidus size on IADSA, perhaps MRI should be used in preference, as has been SIVMS's
policy. I will compare measurements of nidus size using different types of imaging later
(14.3.2, page 275).
10.5.2.2 Perform angiography which is adequate to characterise subtle
angioarchitecture
The reliable characterisation of angioarchitectural features of interest usually requires
imaging of suspected abnormalities in at least two planes (e.g. identification of
aneurysms and venous stenosis) [Joint Writing Group 2001]. This should be the
required standard of routine clinical practice. Super-selective angiography further assists
expert neuroradiologists in their interpretation of arterial supply (e.g. the number of
feeders) and the nidus (e.g. whether there is a single fistula within it). But the balance
between the risks and benefits of the routine use of super-selective angiography has not





The results of this study argue that the further development of acceptable radiological
definitions and future studies of observer agreement should be prioritised in certain
areas.
Agreement about nidus size should be re-evaluated on MRI and when standardised
angiographic calibration markers are in widespread use, because of the importance of
size in determining who is eligible for stereotactic radiosurgery.
The Spetzler-Martin grading system is in widespread use to predict morbidity from
surgical excision, but the observed levels of intra-observer (weighted k = 0.63 (95%CI
0.48 to 0.79)) and inter-observer (weighted k = 0.47 (95%CI 0.30 to 0.64)) agreement
are cause for some concern. In addition to nidus size, the other two components of the
Spetzler-Martin grading system (eloquence of adjacent brain and pattern of venous
drainage) should be explored. It will be interesting to discover which of the three
components is most responsible for less than perfect observer agreement in the use of
this scale. In this study, observers assumed left hemisphere dominance for the
determination of eloquence. To assist with determination of eloquence, future studies
might benefit from a brief clinical history accompanying each LADSA. However, this
benefit might be offset by indirectly encouraging over-interpretation of some
angioarchitectural features in cases with a more severe presentation, thereby introducing
bias.
Since a worse prognosis for the first occurrence of haemorrhage seems to be conferred
by the identification of aneurysms in conjunction with unruptured AVMs [Al-Shahi and
Warlow 2001] (especially those in the nidus, not thought to be pseudoaneurysms
[Elisevich et al. 1995]), efforts should be made to understand why inter-observer
agreement about the very presence of aneurysms was only k=0.40 (95%CI 0.11 to 0.68).
This is likely to be only partly explained by neuroradiologists in this study reviewing
hard copies of the IADSAs, rather than performing them, and superselective studies not
being available. It will be important to further evaluate agreement about the presence of
aneurysms (distinct from infundibula), their number, their locations and whether or not
they should be treated.
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In this study individual observers' thresholds for declaring feeding or draining vessels
multiple appeared to differ. Clearly, the ability to correctly define feeding vessel anatomy
is to some extent dependent on the use of superselective angiography -
neuroradiologists do occasionally discover unsuspected feeders only at the time of
embolisation. Therefore, the only way for me to interpret agreement about feeding and
draining vessel anatomy was to group the raw, continuous data about numbers of
vessels into three simple ordinal categories (1, 2, or >3 vessels), although some authors
have reservations about this statistical approach [Maclure and Willett 1987]. Whilst there
are no clear data about the absolute number of feeding or draining vessels carrying
particular prognostic importance, future studies might profit from assessing the
agreement about the original vascular territories of feeding vessels, because this too may
determine outcome [Stapf et al. 2000b].
Particular emphasis should be placed on developing internationally agreed definitions
for the characteristics above [Joint Writing Group 2001], and for those features which
had the greatest inter-observer variation in this study (angiopathy, angiogenesis,
collateral supply, nidus border, discernible fistula and venous stenosis). Thereafter, using
this study as a baseline measure of observer agreement prior to publication of the Jomt
Writing Group's definitions [Joint Writing Group 2001], it will be important to reassess
observer agreement in larger studies, amongst neuroradiologists from different
countries, and using emerging techniques (such as MR and digital angiography, image
manipulation and reconstruction).
From the point of view of SIVMS, the data in this study are of interest in as much as
they refer to observer agreement amongst interventional neuroradiologists of
comparable experience to the two study neuroradiologists. In future, I would like to
explore the observer variation between the two SIVMS neuroradiologists, but this will
require an IADSA set from another research group.
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Table 17 Characteristics of the 5 observers (all consultant
interventional neuroradiologists)







A 10 Yes 15-30
B 12 Yes 40
C 8 Yes 6
D 7 Yes 15
E 21 Yes 30
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Table 18 Percentage agreement about the different variables in the
intra-observer and inter-observer agreement studies
% disagreement = 100 - ^(prevalence of agreement in each category)
Variable % prevalence of agreement % prevalence of agreement
(intra-observer study) (inter-observer study)
AVM depth
■ Deep 24 23
■ Superficial 58 53
Anteroposterior diameter
■ >3cm 34 23
■ <3cm 55 58
Transverse diameter
■ >3cm 34 23
■ <3cm 55 48
Vertical diameter
• >3cm 37 28






■ Yes 50 40
■ No 26 15
Angiogenesis
■ Yes 32 18
■ No 58 43
Collateral supply
■ Yes 29 23
• No 58 50
Nidus border
■ Compact 68 68
■ Diffuse 18 8
Discernible fistula
■ Yes 29 20
■ No 58 48
Number of veins










■ Yes 37 30
■ No 55 48
Venous ectasia
■ Yes 55 55
■ No 24 18
Venous stenosis
■ Yes 13 5
■ No 74 70
Aneurysms
■ Yes 29 30
No 58 40
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Agreement expected on the basis of Actual agreement






Actual agreement beyond chance (x)
Kappa (k) =
Potential agreement beyond chance (y)
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Figure 34 The extent of intra-observer (open boxes) and inter-observer
(filled boxes) agreement, measured by the un-weighted or weighted
(asterisked) k, shown as point estimates with 95% confidence intervals
Qualitative ranges for the extent of agreement measured by k are marked
with dotted lines (0.8-1 almost perfect; 0.6-0.8 substantial; 0.4-0.6 moderate;

































Intra-observer kappa Inter-observer kappa
(95%Q)(95%Q)
0.59 (0.32 to 0.87)
0.78 (0.58 to 0.98)
0.78 (0.58 to 0.98)
0.78 (0.58 to 0.98)
0.70 (0.54 to 0.86)
0.70 (0.46 to 0.95)
0.77 (0.57 to 0.98)
0.72 (0.49 to 0.95)
0.68 (0.38 to 0.94)
0.71 (0.48 to 0.95)
0.75 (0.61 to 0.90)
0.63 (0.48 to 0.79)
0.46 (0.17 to 0.75)
0.55 (0.27 to 0.83)
0.36 (0.06 to 0.66)
0.62 (0.37 to 0.88)
0.49 (0.32 to 0.66)
0.29 (-0.05 to 0.63)
0.18 (-0.13 to 0.49)
0.41 (0.11 to 0.71)
0.22 (-0.20 to 0.64)
0.30 (-0.02 to 0.61)
0.53 (0.34 to 0.73)
0.47 (0.30 to 0.64)
0.84 (0.66 to 1.00) 0.56 (0.31 to 0.81)
0.55 (0.27 to 0.83) 0.36 (0.04 to 0.68)
0.59 (0.25 to 0.93) 0.14 (-0.33 to 0.60)
0.72 (0.48 to 0.95) 0.40 (0.11 to 0.68)
I 1 1 1 1 1




Figure 35 Bland & Altman plots of the difference between paired
observations of nidus size in the transverse dimension (mm) against
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Figure 36 Anteroposterior (top) and lateral (below) projections of a right
carotid intra-arterial digital subtraction angiogram which show a right
frontoparietal AVM
There was agreement that this AVM was a simple fistula of Spetzler-Martin
grade II, lacking many angioarchitectural features. However, there was
disagreement about whether there were one or two feeders (dashed arrow)
and whether there was a nidal aneurysm or venous varix (solid arrow)
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Figure 37 Anteroposterior (top) and lateral (below) projections of a right
carotid intra-arterial digital subtraction angiogram which show a right
frontal AVM (arrow)
There was disagreement about whether the nidus was greater or less than
30mm in all dimensions, number of feeders, type of feeding artery
angiopathy, presence of angiogenesis, existence of collaterals, nidus border,
discernible fistula in the nidus, number of draining veins, Spetzler-Martin
grade, venous ectasia and existence of nidal aneurysms
f
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Section 4: The frequency and clinical presentation of arteriovenous
malformations of the brain in Scotland
Chapter 11 The point prevalence of arteriovenous malformations of
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Chapter 12 The Scottish Intracranial Vascular Malformation Study
(SIVMS) — incidence of arteriovenous malformations of
the brain
Chapter 13 The Scottish Intracranial Vascular Malformation Study
(SIVMS) - clinical presentation of arteriovenous
malformations of the brain
Chapter 14 The Scottish Intracranial Vascular Malformation Study
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malformations of the brain
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Chapter 11. The point prevalence of arteriovenous malformations of
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From my systematic review of the literature (Chapter 2), I knew there were no
community- or population-based studies specifically investigating brain AVM prevalence
[Berman et al. 2000; Al-Shahi and Warlow 2001]. Hospital-based post mortem series
have reported brain AVM prevalence up to —600 per 100,000, but these estimates must
have been considerably biased by the method of cohort selection and the thoroughness
of lesion ascertainment [Sarwar and McCormick 1978; Courville 1950; Jellinger 1986]. A
community-based study found the point prevalence of the whole spectrum of IVMs to
be 19 (95%CI 10 to 27) per 100,000 on 1 January, 1990 [Brown, Jr. et al. 1996b], from
which an upper limit for brain AVM prevalence of ~10 per 100,000 had been inferred
[Berman et al. 2000],
The size of the study population and the methods of case ascertainment affect
prevalence estimates. Although larger studies produce more precise estimates they are
likely to miss cases (unless incredibly well resourced), whereas thorough ascertainment is
more feasible in smaller studies which inevitably produce less precise estimates. Whilst
common diseases such as stroke are amenable to extensive surveys of population
samples for the disease [O'Mahony et al. 1999], rarer disorders such as brain AVMs
require targeted surveillance of the parts of the healthcare system actively involved in
their management and/or passive inspection of secondary data sources.
Therefore, I sought to estimate the prevalence of brain AVMs in a sizeable adult
population of a geographically and demographically well-defined community in
Scotland, using active surveillance of clinicians involved in the care of such people, as
well as passive case ascertainment from routinely-collected data. It would have been an
overwhelming effort to undertake a Scotland-wide prevalence study as part of SIVMS.
Instead, I chose the Lothian healthboard as the study area, because the population
would be a manageable size for such a study, and being based at the regional





I included adults who were aged 16 years or over and permanendy resident in the
Lothian health board area of Scodand on 30 June 1998, and who had been diagnosed
with a brain AVM prior to this prevalence date. The brain AVM definition I used was
the same as SIVMS, not requiring IADSA for a definite diagnosis (3.2.3, page 98).
I excluded people who did not fully meet the inclusion criteria above, and those with
pure vein of Galen malformations, dural AVMs or any other type of IVM occasionally
confused with a brain AVM [Chaloupka and Huddle 1998].
The Lothian health board covers 700 square miles in South East Scodand, ranging from
the Pendand Hills to the shores of the Firth of Forth and the North Sea, including the
capital city, Edinburgh. The health board area is geographically defined by postcodes,
enabling clear criteria for residency within the community. Although the most recent
decennial census in Scodand was conducted in 2001, the results were not available at the
time of analysis. Between censuses, the GRO estimates the size and age structure of the
Scottish population annually using registration of births and deaths as well as
immigration and emigration data. The estimated population of the Lothian health board
on 30 June 1998 was 773,700, of whom 628,788 were >16 years of age. The stability of
the whole population is reflected by a flux of only 0.2% over the year leading up to 30
June 1998, mostiy attributable to 8,892 births, 8,157 deaths and 665 estimated net
civilian migration.
The study was based at the regional neuroscience centre (Western General Hospital) in





provides the only specialist brain AVM clinic for the South East of Scodand. Few
residents receive health care in England - except on a quaternary referral basis — and
there is litde cross boundary flow of the population for health care, which minimises
missing diagnoses made outside Scodand. Almost every patient is registered with a GP.
Virtually all healthcare is accessed via the National Health Service (NHS), and patients
diagnosed in private practice are usually referred to the NHS specialist brain AVM clinic
(sic). Apart from the usual facilities for rehabilitation, there are no particular services
that would lead to the Lothian healthboard harbouring an excess of disabled people.
ISD in Scodand has centrally registered every person discharged from a NHS hospital
since 1980, collated the GRO's death certificate records, and coded main and subsidiary
diagnoses using versions ICD-9 and ICD-10. These databases are available to research
studies with ethics committee approval. Several mechanisms for ensuring data quality
are in place at ISD, including validation, accreditation, quality assurance and monitoring,
and national coding advice and training programmes [Harley and Jones 1996].
11.2.4 Study design
I used multiple overlapping sources of case ascertainment to identify adults meeting the
inclusion criteria.
11.2.4.1 Collaborative neuroscience network
I approached all consultant neurologists, neurosurgeons and stroke physicians covering
the study area, who were also part of SIVMS's collaborative network in order to obtain
lists of their patients meeting the inclusion criteria. I also searched the diaries from 1995
until 2000 of the specialist brain AVM clinic operating at the regional neuroscience
centre.
11.2.4.2 General practitioners
I wrote to all 557 GPs at the 101 general practices in the study area in 1999, requesting
details of adults registered at the practices who met the inclusion criteria. I pre-supposed
that GPs would find such people memorable, as each GP was unlikely to look after
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more than one person with a brain AVM. I was unable to search GPs' patient databases
due to the inadequate coding of brain AVMs in their 'Read' coding system and because
of changes in UK data protection legislation and confidentiality guidance at the time of
this study (Chapter 17).
11.2.4.3 Routine coding of hospital discharge data
In early 2000, colleagues at ISD searched the national database of hospital admissions
and discharges (SMR01). They identified every adult who was alive on the prevalence
date, and who had been discharged from a Scottish hospital to an address in the Lothian
health board at any time since 1980 with an ICD code for a brain AVM (ICD-10 codes
160.8 and Q28.2; ICD-9 codes 430 and 747.8).
11.2.4.4 Data collection and validation
All available case notes, brain imaging and pathology reports were reviewed to validate
each person's brain AVM diagnosis, and ensure they were alive, at least 16 years of age
and resident in the geographical area of the study on the prevalence date of 30 June
1998. Brain/vascular imaging and/or pathology reports were available in every case.
Residence was determined by comparing an adult's home postcode on the prevalence
date with a database of all the postcodes defining the Lothian health board. I had no
difficulty in matching duplicate notifications of adults between the sources, using first
name, surname and date of birth, in the absence of any other unique identifier.
11.2.5 Statistical analysis
I calculated crude prevalence as the proportion of the adult (aged >16 years) mid-year
population estimate for the Lothian health board that was known to fulfil the inclusion
criteria on the prevalence date. Age-standardised prevalence estimates were directly age-
adjusted to the last census in the UK in 1991 (http: / Avww.census.ac.uk) and the last
census in the USA in 2000 (http: / /factfmder.census.gov). 95% confidence intervals
around prevalence estimates were based on the Poisson distribution, and were calculated
using Confidence Interval Analysis software [Airman et al. 2000]. Tests for statistical
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significance were performed in Statistical Product for the Social Sciences (SPSS) version
10.0.5. Statistical Analysis Software (SAS) version 8 was used for capture-recapture
analysis (11.3.4, page 232).
11.3 Results
11.3.1 Recruitment
In total, 148 people were identified by the three sources of case ascertainment as
potentially meeting the study inclusion criteria. Of these people, medical records were
missing in four, 51 were excluded, mainly because they were resident outside the
Lothian health board, leaving 93 adults included in the study (Figure 38, page 240).
11.3.2 Baseline characteristics
Of those included, 53 were men and 40 were women. Men were significantly younger
on the prevalence date than women (median age 39 years versus 51 years, p=0.003), for
no apparent reason (Table 19, page 237). The majority (77%) had been investigated with
IADSA, usually in combination with axial brain imaging (Figure 39, page 241). Nine
adults (10%) had co-existing aneurysms, and this proportion might have been greater
had all adults had IADSA. 58 (62%) of 93 brain AVMs were located in so-called
eloquent areas (Table 20, page 238), according to the Spetzler-Martin grading scheme's
determination of eloquence (hypothalamus, thalamus, brain stem, cerebellar peduncles,
and sensorimotor, language and visual cortex) [Spetxler and Martin 1986]. Every brain
AVM was solitary, and did not occur in combination with any other IVM. There was
radiological evidence of therapeutic obliteration of the AVM in 25 (27%) adults.
11.3.3 Prevalence
93 adults had been diagnosed with a brain AVM at some time during their life and were
living in the Lothian health board on 30 June 1998, giving a crude prevalence of 14.8
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(95%CI 11.9 to 18.1) per 100,000 adults. Age- and sex-specific prevalences are shown in
Figure 40, page 242; males were more prevalent in younger age groups, accounting for
their lower median age at diagnosis, although the 95% confidence intervals of the sex-
specific prevalence estimates overlapped in each mid-decade age band. Prevalences
direcdy age-adjusted to the GB 1991 census population and the USA 2000 census
population were 14.6 and 14.7 per 100,000 adults respectively.
11.3.4 Adjustment for incomplete case ascertainment
Figure 41 (page 243) demonstrates the degree of overlap between the study's three
major sources of case ascertainment. Routine coding of hospital discharge data was the
most productive source, identifying 70 (75%) cases, followed by hospital consultants
and AVM clinic diaries (52%) and GPs (39%). There was a sizeable overlap between
sources, with 47 (51%) adults identified by at least two sources. I have used capture-
recapture analysis to estimate the number of people potentially missed, based on the
observed overlap between the three sources of case ascertainment [Hook and Regal
1995]. I presupposed that the sources would be dependent but to varying degrees, and
that there was most likely to be dependence between hospital consultants/diaries and
routine coding, because of the derivation of the latter from the former.
There are eight possible log-linear models, each with a different configuration of
dependencies between three sources of ascertainment (Table 21, page 239). The residual
deviance is a measure of the 'goodness of fit' of each model, when compared to the
model in which all sources are assumed to be dependent; the better the fit, the lower the
residual deviance. The model I chose had the lowest residual deviance, and estimated
that 20 (95%CI 7 to 55) prevalent adults were missed by the study. The coverage (or
completeness) of the study — calculated from the number of cases observed (93) as a
proportion of the cases expected on the basis of capture-recapture analysis (100 to 148)
— was 63% to 93%. By including this estimate of 20 missed cases, the ascertainment-




In this first community-based study of brain AVM prevalence, I found a
crude prevalence of 15 (95%CI 12 to 18) per 100,000 adults
The prevalence may be as high as 18 (95%CI 16 to 24) per 100,000
adults if capture-recapture analysis is used to estimate the number of
cases missed by my ascertainment process
Therefore, in the year 2000, adults with a brain AVM numbered between
650-1,000 in Scodand, 7,600-11,400 in the United Kingdom and 35,400-
53,000 in the USA
11.5 Discussion
This study illustrates the burden on the public health of a condition which has potential
long-term risks of recurrent ICrH and epilepsy, as well as other disability, and which
attracts expensive interventional treatments. These estimates have implications for the
planning, purchasing and provision of health services for people with a brain AVM.
Brain AVMs themselves pose several challenges for epidemiological studies. The people
who are diagnosed are probably an inherently biased group, as the suspicion of an
underlying brain AVM and the use of investigations to identify it depends on aspects of
the patient and their presentation. Younger people with recurrent ICrH, recurrent
and/or focal epilepsy and atypical headache are more likely to be investigated. Regional
investigation practices amongst neurologists, neurosurgeons and neuroradiologists will
further influence these biases, as will the availability of non-invasive brain imaging and
IADSA. Moreover, any prevalence estimate will also be affected by historical patterns of
investigation — the paucity of elderly people in the sample is undoubtedly affected by the
reliance on IADSA for diagnosis before the 1970s, when CT was introduced.
These same factors will influence the detection of asymptomatic brain AVMs. The
number of asymptomatic brain AVMs at any one time remains in some senses
11.5.1 The nature of brain AVMs
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imponderable, because the development of brain AVMs is likely to be dynamic — they
are not necessarily congenital [Lasjaunias 1997]. Although published studies of
asymptomatic volunteers undergoing MRI have not detected asymptomatic brain AVMs
[Yue et al. 1997; Katzman et al. 1999], a 'brain check-up' system in Japan has found,
using MRA, 3 (0.1%) of 3085 apparendy healthy people (mean age 55 ± 11 years, male:
female ratio 2:1) to harbour a brain AVM (Yukito Shinohara, Tokai University School of
Medicine, personal communication). The asymptomatic brain AVM prevalence in Japan
is an order of magnitude greater than brain AVM (symptomatic and asymptomatic)
prevalence in Lothian, but comparison of the two studies is difficult because the
Japanese study was clearly not population-based.
11.5.2 Methodological biases
This study is best regarded as providing a minimum estimate of brain AVM prevalence.
Whilst complete ascertainment and overlap between sources would be desirable, it is
virtually impossible in any study of a large population. My estimate of 63-93%
completeness (based on capture-recapture analysis) appears reasonable. The extent of
intersection of my sources of ascertainment will have been affected by: the number of
adults admitted to hospital and so included in routine coding; the accuracy of hospital
discharge data and ICD coding; the thoroughness of GP, consultant and AVM clinic
records; and the extent of clinicians' memories. The absence of any other feasible, local
sources of case ascertainment make this study difficult to improve upon. Perhaps a
future cross-sectional analysis of the SIVMS cohort would be more precise, and so have
good statistical power to detect any future change from this contemporary prevalence
estimate.
11.5.3 Capture-recapture analysis
Capture-recapture methods were originally developed by ecologists for censuses of
wildlife. Animals are captured, tagged, released back into the wild, and the process
repeated (re-captured). The total size of the animal population is estimated from the
proportion of animals that were tagged by the first capture and 'recaptured' by the
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second. The parallels with epidemiological studies using several sources have resulted in
widespread, albeit controversial, use of the technique [Hook and Regal 1995; Papoz et al.
1996]. Capture-recapture analysis has been particularly useful for estimating the
frequency of neurological conditions, because it minimises the cost of exhaustive
methods of case ascertainment and prevents under-estimation of disease frequency
[Taub et al. 1996; Martyn 1998], However, the results of capture-recapture analysis must
be interpreted and presented with caution [Hook and Regal 1999], because the
assumptions inherent in the technique do not always hold in human populations [Papoz
et al. 1996; Martyn 1998; Tilling 2001].
The technique requires that the population size is constant (i.e. there are no changes due
to birth, death or migration), that members of the population under study can be
recognised and are equally 'catchable', and that the sources of ascertainment are
independent to enable the use of asymptotic statistical theory. Although study of a fixed
population is impossible, stable populations — such as the Lothian health board — are an
adequate approximation. In the healthcare setting, sources of ascertainment are usually
dependent to varying degrees; for example, inclusion in one source (hospital consultant
and AVM clinic records) confers inclusion in another source (routine coding of hospital
discharge data). Such positive dependency between two sources could underestimate the
number of people missed. Certain aspects of individuals may make them more likely to
be ascertained by one source than another (for example, people investigated as
outpatients who are not thought to require treatment are more likely to be identified by
GPs than by AVM clinic diaries). Such negative dependency between sources could
overestimate the number of people missed. The assumption of equal 'catchability' rarely
holds, because severely affected individuals are more likely to be captured [Taub et al.
1996]. Therefore, the estimate of the total population of adults with brain AVMs may be
biased by assuming that the missing cases resemble the ascertained ones.
Whilst capture-recapture analysis is most straightforward using two sources, the above
complexities of human populations have attracted methods using more than two
sources and log-linear modelling of source dependencies [Hook and Regal 1995]. It is
generally held that three sources are ideal in epidemiological studies. Clearly the number
of missing people is sensitive to the choice of model (Table 21, page 239). I chose the
most parsimonious model that did not assume dependence between all three sources,
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but modelled dependence between GPs and the hospital source, as well as the
dependence I had presupposed to exist between the hospital source and routine coding.
This latter dependence was expected in practice, because routine coding is derived from
records of hospital admissions. In the chosen model, the other dependence (between
GPs and hospital-based sources) is unsurprising, given the reliance on hospital-based
investigations for brain AVM diagnosis.
A recent approach to address the influence of patient characteristics which may affect
the probability of capture by different sources (for example, demographics and disease
severity), has been to stratify patients by these characteristics or use a multinomial logit
model to identify and account for them [Taub et al. 1996; Tilling and Sterne 1999]. This
is an approach I would have used, were it not for the unavailability of the complete
medical record in every case.
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Males (%) 53 (57)
Median age on the prevalence date (25% and 75% quartiles) in years
Male 39 (30 - 53) *
Female 51 (44 - 65) *
Co-existing aneurysms
Nidal 2
Feeding artery 6 ► 9(10%)
Remote 1
Radiological evidence of AVM obliteration following treatment (%) 25 (27)
* p=0.003 (Mann-Whitney U test)
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Table 20 Principal locations of the 93 brain arteriovenous
malformations, their laterality and so-called eloquence (asterisked)






Frontal 6* 1 6
Fronto-temporal - - 2
Fronto-parietal 3* - 2*
Temporal 7(4*) - 9
Temporo-parietal 4* - 4
Parietal 10* - 15*
Parieto-occipital 5 - 4
Occipital 4* -
Thalamus 1* - 2*
Medulla - 1* -
Cerebellum 2* 1 4*
Total (%) 42 (45%) 3 (3%) 48 (52%)
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Table 21 Eight different log-linear models for 3-source capture-
recapture analysis, accompanied by the residual deviance and
estimated number of missing cases (with 95% confidence interval) for
each model. The chosen model is marked with an asterisk.
Model (source dependence illustrated by-) Residual
deviance
Cases missed (95%CI)
Independent 2.4 13 (7 to 23)
GP - Hospital 1.0 15 (8 to 29)
Hospital - Coding 2.4 14 (6 to 33)
GP - Coding 2.4 13 (6 to 28)
GP - Hospital & GP - Coding 0.9 17 (7 to 39)
GP - Hospital & Hospital - Coding * 0.7 20 (7 to 55)
Hospital - Coding & GP - Coding 2.3 15 (4 to 56)
Hospital - Coding & GP - Coding & GP - Hospital 0 34 (7 to 172)
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Figure 38 Flow diagram of people notified to the study
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Figure 39 Venn diagram illustrating the radiological investigations that









Figure 40 Age- and sex-specific crude point prevalences for adults with
brain arteriovenous malformations, with lower 95%Cls (women, closed




Figure 41 Venn diagram of overlap between the sources of case
















Chapter 12. The Scottish Intracranial Vascular Malformation Study







12.3.2 Definite brain AVMs
12.3.3 Crude incidence




12.5.1 Incidence versus detection
12.5.2 Comparison with other studies




Ideally, accurate estimates of incidence should be based on complete, prospective
ascertainment from a large, well defined, stable population, or a representative sample of
one (2.2.2.1, page 58). These studies should have external validity by sharing standard
definitions, methods and data presentation to make them comparable [Sudlow and
Warlow 1996; Joint Writing Group 2001; Al-Shahi and Warlow 2001]. In this way, they
will not only describe the incidence and clinical and radiological characteristics of
AVMs, but also provide population-based estimates of prognosis with prospective
follow-up, leading to derivation and testing of prognostic models, and potentially
provide a cohort for case-control studies and recruitment into randomised controlled
trials [Al-Shahi and Warlow 2003].
Hospital-based studies will not suffice. Until recently (Chapter 11), prevalence estimates
have been derived from hospital-based autopsy series, but these are subject to each
institution's frequency of post mortem examination and various referral/selection
biases, as well as the special interests — and so meticulousness — of the pathologists
[Berman et al. 2000]. Hospital-based studies — especially those from tertiary referral
centres — are also unrepresentative of the population because they tend to miss both
sudden deaths in the community and people who are not thought to warrant hospital
admission (be they asymptomatic or unsuitable for treatment). Moreover, there is a
growing appreciation of the long-suspected differences between these hospital-based
series, likely to reflect regional investigation and referral patterns, specialists' access to
and interest in particular interventional treatments, and varying classifications used by
research groups [Hofmeister et al. 2000; Halim el al. 2002; Al-Shahi et al. 2002b].
Until SIVMS started, there had been only one truly population-based study of brain
AVM incidence (2.3.1.1, page 61). I hypothesised that the incidence of brain AVMs in
SIVMS might be higher because of both the increasing availability and uptake of brain
imaging since the older study and because of the thoroughness of case ascertainment in




The first two complete years (1999-2000) of SIVMS have been used to calculate the
incidence of brain AVMs amongst adults meeting the SIVMS inclusion criteria (3.2.1,
page 97).
The crude incidence was calculated cumulatively for 1999 and 2000 as the proportion of
the adult (aged >16 years) mid-year population estimate for Scotland that was detected
as having a brain AVM during that year.
Ideally, the incidence calculation should remove prevalent people from the
denominator. I did not do this, because the number of prevalent people was likely to
have been so small, based on my prevalence study (Chapter 11), as to make a negligible
impact on the incidence.
95% confidence intervals around incidence estimates were calculated according to the
Poisson distribution [Altman et al. 2000]. Age-standardised incidence estimates were
directly age-adjusted to the 1991 census in Great Britain (http: / /www.census.ac.uk) and
the last census in the United States of America in 2000 (http:/ / factfinder.census.gov).
Figure 42 (page 252) illustrates the recruitment of adults with definite and uncertain
(probable or possible) brain AVMs to SIVMS from 1st January 1999 to 31st December
2000 inclusive. The collaborative nation-wide network notified the largest number of
people to SIVMS, followed by routine coding of hospital discharge data and death
certificates. Scotland's GPs contributed so few eligible people in 1999 who were as yet
unknown to the study, that I abandoned this source in the second and subsequent years
of the study. Of 418 notifications, 190 (45%) were eligible and included in SIVMS, 96 of




12.3.2 Definite brain AVMs
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Following review of diagnostic brain imaging, reports of pathological examinations and
case notes, 92 (96%) of the 96 included adults were deemed to harbour a definite brain
AVM (Figure 42, page 252). There was an increase in the number of definite cases
detected from 44 to 48 between 1999 and 2000, which was not statistically significant,
with a concomitant rise in the mid-year adult population estimate for Scodand from
4,110,956 to 4,114,052.
12.3.3 Crude incidence
The crude incidence of definite brain AVMs in Scottish adults in 1999 and 2000 was
1.12 (95%CI 0.90 to 1.37) per 100,000 adults per year (Figure 43, page 253). The
incidence of symptomatic definite brain AVMs was 0.89 (95%CI 0.70 to 1.12) per
100,000 adults per year and the incidence of asymptomatic (incidentally discovered)
brain AVMs was 0.23 (95%CI 0.14 to 0.36) per 100,000 adults per year. A detailed
description of the modes of presentation is provided in Chapter 13.
12.3.4 Age- and sex-specific incidence
There does not appear to be a significant difference in incidence between sexes and
mid-decade age bands (Figure 44, page 254). There appears to be a tendency towards a
peak incidence in the 46-55 year age group, although the detection of only 92 adults has
meant that precision is inevitably low and 95%CIs overlap.
12.3.5 Standardised incidence
Age-standardised incidences directly age-adjusted to the last decennial censuses in Great
Britain and the USA were essentially the same as the crude estimate of incidence. The
age-standardised brain AVM incidence, direcfiy age-adjusted to the 1991 census
population of Great Britain (England, Wales and Scodand, but not Northern Ireland)
was 1.10 per 100,000 adults per year. The age-standardised brain AVM incidence,
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directly age-adjusted to the 2000 census population of the United States of America was
1.12 per 100,000 adults per year.
12.4 Summary
• In the years 1999 and 2000, SIVMS received 418 notifications from all
sources of case ascertainment, of which 96 adults were included, and 92
had a definite brain AVM diagnosis
• The crude incidence of definite brain AVMs in Scottish adults was 1.12
(95%CI 0.90 to 1.37) per 100,000 adults per year
• The incidence of symptomatic definite brain AVMs was 0.89 (95%CI
0.70 to 1.12) per 100,000 adults per year
• The incidence of asymptomatic (incidentally discovered) brain AVMs
was 0.23 (95%CI 0.14 to 0.36) per 100,000 adults per year
12.5 Discussion
It is clear from crude incidences that SIVMS has detected brain AVMs at comparable
rates to other studies (Figure 43, page 253), notwithstanding SIVMS's focus on the adult
(rather than the whole) population. Furthermore, the age-standardised incidences barely
change when adjusted to the populations of the UK or USA (probably due the similarity
of the Scottish population to their demographic structures). Therefore, the incidence of
brain AVMs in SIVMS appears generaliseable; it is safe to conclude that in the areas of
the USA, Europe and the Caribbean studied, brain AVM incidence is 1-1.5 per 100,000
per year.
It was interesting that brain AVM incidence did not differ significantly with age. I pre¬
supposed that brain AVMs would be detected at younger ages because of their tendency
to present symptomatically in the fourth and fifth decades and the enthusiasm for
investigating underlying causes of ICrH in the young. Equally, I would expect relative
under-detection in the elderly, because symptomatic lesions would have been detected
already and underlying causes of ICrH tend to be investigated less in the elderly on the
grounds of their diminished life expectancy. Any inconsistency of the age-specific
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incidence rates is, of course, masked by the imprecision of SIVMS. But part of the
explanation for the comparability in incidence between age groups probably lies in
SIVMS's population-based design finding incidental brain AVM diagnoses in the elderly,
often missed by purely hospital-based studies. This is borne out by the tendency for
incidental brain AVMs to present ~10 years later than symptomatic brain AVMs, as I
shall describe in the next chapter.
12.5.1 Incidence versus detection
Stricdy, incidence refers to the development of disease in a population initially free of it
[Sackett et al. 1991; Berman et al. 2000; Al-Shahi and Warlow 2001]. SIVMS will
undoubtedly have missed as-yet-undiagnosed asymptomatic brain AVMs, which could
be considered 'prevalent', and which may declare themselves — so becoming 'incident' —
at a later date, or remain asymptomatic until death. Therefore, my quantification of
incidence is a reflection of the rate of detection of brain AVMs. However, this is also
true of many other diseases — for which the term incidence is used (such as the
detection of asymptomatic cerebral infarction/haemorrhage on CT/MRI). I prefer the
widely understood term 'incidence' to the more semantically correct 'detection rate'.
In this study there were 3 incidental brain AVMs identified amongst 14,630 post
mortems conducted in Scotland between 1999-2000 (0.02%), although these will have
been underascertained. In any case, the number of asymptomatic brain AVMs at any
one time remains imponderable, because of their likely dynamic development and the de
novo appearance of some types [Lasjaunias 1997; Friedman et al. 2000].
Because the extent of detection of asymptomatic brain AVMs is undoubtedly affected
by regional autopsy rates, the availability and resolution of brain imaging and the
propensity of clinicians to use it, some prefer to adapt epidemiological terminology and
describe detection rates, given that the number of truly 'incident' brain AVMs is
immeasurable [Berman et al. 2000; Stapf et al. 2003]. The most meaningful comparison
between studies is the detection rate of symptomatic brain AVMs, because they are the
most clinically relevant. However, because of the tendency of some interventionists to
treat brain AVMs regardless of their mode of presentation, a quantification of
asymptomatic detection rate is also important.
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I suspected that SIVMS might find a higher brain AVM incidence than other studies
because of the increasing use and availability of brain imaging over recent decades.
However, rates were comparable and not significantly different, regardless of the year or
design of the studies (Figure 43, page 253). I have found the proportion of symptomatic
brain AVMs in SIVMS to be very similar to the Mayo Clinic study [Brown, Jr. et al.
1996b], and the detection rate of first-ever haemorrhage from a brain AVM to be very
similar to the rate in the North Manhattan Stroke Study [Stapf et al. 2002]. The New
York Islands Arteriovenous Malformations Study (NYIAVMS)
(http://cpmcnet.columbia.edu/dept/avm) is an ongoing study — similar to SIVMS —
which began in 2000, focuses on brain AVMs only, and is based on a population more
mobile than Scotland with a >4% annual flux at state and/or county level
(http://factfinder.census.gov) [Stapf et al. 2003]. The overall brain AVM incidence
described by NYIAVMS was also similar to SIVMS.
The similarity might be an artefact of under-ascertainment by SIVMS, although this
would also have to apply to NYIAVMS, which is possible. All that remains for the
further exploration of incidence is to monitor it in Scotland and elsewhere in the world,
and to continue to try and improve methods of case ascertainment to see they impact
upon incidence.
12.5.3 Potential biases and limitations
Design, regional biases and challenges posed by brain AVMs themselves will inevitably
affect estimates of incidence.
Truly population-based studies may detect people missed by studies based at tertiary
referral centres because their brain AVMs were not thought to warrant specialist
attention or because their AVMs caused sudden death in the community from
devastating ICrH. Regional variations in autopsy rates, the availability of neurologists,
neurosurgeons and stroke physicians, and the availability of brain imaging will govern
how headache, epilepsy and ICrH are investigated (3.2.4, page 101). SIVMS did not seek
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every ICrH in Scotland, precluding an estimate of how many underlying brain AVMs
might have been missed due to lack of investigation.
Brain AVMs themselves can be difficult to diagnose accurately given their occasional
morphological overlap, the existence of AOVMs, and the perceived inappropriateness
of definitive investigation of certain people, particularly the elderly. Moreover, the
presence of an AVM underlying an ICrH can sometimes only be inferred because of the
obliteration of a brain AVM nidus by the haemorrhage itself, leaving only clues to its
cause, such as an early draining vein on IADSA. Furthermore, there will be an inevitable
bias towards the detection of brain AVMs with a more aggressive prognosis, because
people with recurrent haemorrhage or epilepsy following prior events (perhaps in the
distant past) are more likely to have further or repeated investigation.
SIVMS has provided contemporary estimates of the incidence of brain AVMs in adults,
which helps assess their public health importance. The study is also the foundation for
future studies of the comparative epidemiology of all IVMs and their clinical course and
prognosis. It remains to be seen whether recruitment and patterns of identification and
presentation in SIVMS will remain the same; as larger numbers are recruited, the
precision of my estimates will increase and significant dissimilarities could emerge. I
plan to assess the cumulative incidence of brain AVMs with continued recruitment to
the cohort (which will span a total of at least 5 years), paying particular attention to any
trends in the detection of asymptomatic brain AVMs. Given the poor quality of existing
studies of brain AVM prognosis, other population-based studies are essential for future
evaluations of the clinical course of brain AVMs and the effects of their treatment, as
are randomised controlled trials [Al-Shahi and Warlow 2003].
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Figure 42 Recruitment of adults with brain AVMs to SIVMS, from
notification to inclusion and determination of certainty of diagnosis
252
Chapter 12
Figure 43 Crude incidence of brain AVMs amongst adults in Scotland
(SIVMS), and other population-based studies, with 95% confidence
intervals
The area of each point estimate box is proportional to the number of cases
identified (enumerated above each box)
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Figure 44 Age-specific incidence for brain AVMs with 95%Cls (above);
age- and sex-specific incidence for brain AVMs with either upper or
lower limit of each 95%CI shown for clarity
16-25 26-35 36-45 46-55 56-65 66-75 276
16-25 26-35 36-45 46-55 56-65 66-75 276
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Chapter 13. The Scottish Intracranial Vascular Malformation Study
(SIVMS) - clinical presentation of arteriovenous
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Having established the incidence of adults with brain AVMs, and segregated the
incidence of symptomatic brain AVMs from the detection rate of incidental brain
AVMs, in this chapter I will describe and explore how these adults came to medical
attention. From my systematic review, I knew that a population-based study detected
many more apparently incidental brain AVMs than hospital-based series (Figure 9, page
93), and others have described clear differences in the mode of presentation between
separate tertiary/quaternary referral centres [Hofmeister et al. 2000]. These comparisons
were not helped by the dearth of definitions of modes of clinical presentation in the
literature, nor research groups' variation in allocating one, or more than one, mode of
presentation. A painstaking description of presentation is likely to be relevant in both
research and clinical practice, if the mode of presentation truly influences subsequent
prognosis [Mast et al. 1997].
This chapter uses the definitions of presentation type and timing I set out in Chapter 3
and Chapter 5, relying on both clinical and radiological information, with only a single
mode of presentation allocated to each adult. In the following chapter I will go beyond
the radiological features of the mode of presentation, to elaborate upon the
angioarchitecture of the underlying brain AVMs subsequently detected on IADSA.
13.2 Methods
The allocation of mode of presentation was made purely on the basis of case note and
imaging review. Where typed discharge summaries did not provide sufficient
information, I occasionally needed to copy the hand-written case record. However, no
correspondence was entered into with clinicians to clarify further, often because so
much time had elapsed between the initial presentation and the time I had received and
reviewed the case notes. Whilst classification of haemorrhage type was made largely on
the basis of axial brain imaging, classification of seizure type was often difficult because
of the lack of an eyewitness account and a clear description of the symptoms. If seizure





13.3.1 Certainty of diagnosis
In the years 1999-2000, 96 adults were included in SIVMS with a
definite/probable/possible brain AVM. Of the 96, 92 had a definite brain AVM.
The four adults who could not be deemed definite possessed a possible or probable
brain AVM, on the basis of their clinical presentation, imaging features and the lack of
any other likely explanation for their state:
A 50 year-old man presented with a gradually progressive hemiparesis
and was found to have a possible pontine brain AVM on MRI (Figure
45A-B, page 270). He had had a brainstem ICeH at the age of 42. No
further imaging is planned (study number 143).
A 38 year-old man presented with complex partial seizures with
secondary generalisation, and was found to have a possible brain
AVM in the left callosal area on MRI and IADSA (Figure 45C-D,
page 270), but follow-up IADSA was normal. No further
investigation is planned (study number 347).
A 68 year-old man presented with persistent dizziness and diplopia,
having suffered a brainstem haemorrhage two years beforehand. Re-
evaluation with MRI revealed a probable AVM deep in the right pons
(Figure 46A-B, page 271), but further imaging is not planned due to
his level of disability (study number 376).
A 22 year-old woman presented with a left temporal ICeH. IADSA
performed one and ten days later were normal, as was MRI two
months after the haemorrhage. Diffuse capillary blush on follow-up
IADSA 6 months after the ICeH was thought to suggest a brain
AVM (Figure 46C-D, page 271), and she was referred for stereotactic
radiosurgery. She was not treated because a further IADSA failed to
demonstrate a brain AVM (study number 391).
Although all adults with definite, probable or possible brain AVMs are included in




Of the 92 adults with definite brain AVMs, 49 (53%) were male. The median age at
presentation was 45 (inter-quartile range 22), range 16 to 81 (see Figure 44, page 254 for
distribution). By early 2004, SIVMS had only succeeded in obtaining consent (and with
it details about ethnicity) from 64 (70%) of the cohort: of these 64 adults, 1 (2%) was
Chinese from Taiwan (but resident in Scotland), and 63 (98%) classified themselves as
white, approximating to the ethnicity of the Scottish population (3.2.4.1, page 101).
13.3.3 Clinical features
I will describe the mode of presentation for the whole cohort (13.3.3.1 below),
commenting separately on the subgroup that was dead at presentation and subsequently
diagnosed at post mortem (13.3.3.2 below), and then elaborate on details of each mode
of presentation.
13.3.3.1 Overall pattern of presenting symptoms
Of the incident brain AVMs, one fifth were incidental discoveries and four fifths were
symptomatic (Table 22, page 267). Of the symptomatic cases, 43 (59%) were
attributable to ICrH, 25 (34%) due to one or more seizure(s), and FNDs affected 5
(7%). Adults with brain AVMs that were detected incidentally were older (mean age
60±15 years) than adults who presented with haemorrhage (mean age 42±13 years),
seizure(s) (mean age 40+14 years), or FND (mean age 48±16 years); these differences
were significant (ANOVAdf=3 p=0.00001).
13.3.3.2 Deaths at presentation
At the time of presentation, 4 (4%) of the 92 adults were dead. Of these, 3 were
incidental discoveries at post mortem:
A 70 year-old man died from metastatic squamous cell carcinoma. He
had an ischaemic stroke 7 years beforehand, but no prior symptoms
from his right cerebellar brain AVM (patient 293).
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A 77 year-old man died from cardiac failure and bronchopneumonia
as a consequence of Wegener's granulomatosis. Nineteen years
beforehand, he had an ICeH, followed 5 years before his death by a
seizure disorder. Both the bleed and the epilepsy are likely to have
been attributable to his left superficial temporal AVM, which was
found at post mortem but never diagnosed in life (patient 329).
A 47 year-old woman died from an acute myocardial infarction. Five
months prior to her death, she had presented with an ICeH, followed
by generalised epilepsy. IADSA had been normal. At post mortem,
apart from myocardial infarction, there was an organising haematoma
in the posterior third of the right cerebral hemisphere, with an
underlying right superficial temporo-occipital AVM (patient 360).
However, one death was deemed to be symptomatic. A 19 year-old woman died
suddenly from a devastating ICeH, following general anaesthesia for excision of a
pilonidal sinus. At post mortem the haemorrhage was found to be due to an AVM in
the right basal ganglia, which hitherto had been asymptomatic.
13.3.3.3 Haemorrhage
Almost half of the 43 adults presented with a purely ICeH (Table 23, page 268). The
next most common type was intraparenchymal with intraventricular extension and one
eighth of adults with a bleed had a pure SAH.
The study neuroradiologists attributed all 5 cases of pure SAH to aneurysms associated
with AVMs, rather than the AVM nidus itself. A presentation with pure SAH would
guarantee subsequent IADSA, on which the morphology of one of the associated
aneurysms and/or its proximity to the greatest accumulation of subarachnoid blood
suggested to the study neuroradiologists that it had ruptured. However, in one of these
5 cases, the aneurysm thought to have bled was clipped, but at operation it did not
appear to have ruptured. In these 5 cases of aneurysmal SAH associated with a brain
AVM, the AVM itself could be regarded as asymptomatic, although I have regarded the
nidus and its feeding and nidal aneurysms as an integral unit.
One woman presented with a haemorrhage, having had no prior symptoms, at the age
of 34 years, when 32 weeks pregnant.
However, the allocation of a haemorrhagic mode of presentation was not always easy.
Interestingly, in one adult who presented with what turned out to be an ICeH, CT of
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the brain on the day of presentation did not reveal the bleed, but MRI 2 days later did.
The more common scenario that left the occurrence of haemorrhage in doubt was when
an adult would present with a run of seizures, and CT brain >10 days later left some
doubt about haemorrhage. Usually the amount of oedema and density of the AVM
nidus led us to diagnose a bleed when MRI was never performed.
13.3.3.4 Epilepsy
Of all adults presenting with seizure(s), in 11 (44%) they were generalised, in 8 (32%)
they were simple partial ± secondary generalisation, in 5 (20%) they were complex
partial ± secondary generalisation, and in one person the notes did not contain enough
information to characterise the seizures. Confusingly, one adult with complex partial
seizures ± secondary generalisation had an ipsilateral superficial temporal lobe AVM,
leading to me declare the AVM incidental (the notes left no doubt as to which side of
the body was affected by the seizures).
13.3.3.5 Focal neurological deficits
Five adults presented with FNDs, in which symptoms and/or signs were attributable to
the anatomic location of the AVM nidus, but there was no radiological evidence of
haemorrhage.
Only one FND was persistent:
A 58 year-old woman presented with a sudden left temporal
headache, nausea, difficulty reading and word-finding difficulty. On
examination, she had a right upper homonymous quadrantonopia and
right-sided hyperreflexia. She recovered gradually over several weeks,
during which time she made spelling errors, she had many occipital
headaches, and right-sided photopsia. CT brain two months after
presentation and MRI brain after three months did not demonstrate
blood products, although the MRI detected a left occipital
corticoventricular AVM nidus and a small left frontal meningioma
(patient 239).
Only one FND was progressive:
A 71 year-old man presented with progressive difficulty walking and
impaired balance. CT brain one month later revealed right parietal
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infarction in the vicinity of a right parieto-occipital AVM nidus, and
MRI brain three months later confirmed this infarction with
associated gliosis. The stroke physicians managing this case felt the
AVM accounted for his symptoms, signs and the infarction (patient
221).
Three patients presented with transient FNDs:
A 39 year-old woman presented with sudden dizziness, slurred speech
and falling to the right. Examination revealed nystagmus on left lateral
gaze, but no other abnormalities. Her symptoms resolved within 24
hours. MRI brain one month after presentation revealed a small right
frontal AVM with surrounding gliosis, but no evidence of
haemorrhage or infarction (patient 265).
A 44 year-old man presented with sudden hemisensory symptoms
affecting the left arm and leg, accompanied by a fluctuating headache,
lasting less than 24 hours. Two months later, his sensory symptoms
returned and became persistent, at which time MRI brain revealed a
right thalamic AVM. Four months after presentation, he was treated
with gamma knife radiotherapy; after another 18 months, his sensory
symptoms became progressive, which were attributed to perinidal
oedema following radiotherapy, and treated with oral dexamethasone
(patient 282).
A 29 year-old woman presented with sudden slurred speech and
dizziness lasting for less than a day. CT and MRI brain performed 6
and 7 months after presentation respectively revealed a right
cerebellar AVM, without evidence of infarction or haemorrhage.
Over the following two years, she underwent 3 embolisations which
partially occluded the AVM nidus, and two weeks after the last one
she developed increasing clumsiness, dysarthria, and right hand
weakness, which was attributed to peri-nidal oedema by MRI brain
(patient 363).
13.3.3.6 Incidental
Of the brain AVMs discovered incidentally, 3 were found at post mortem (13.3.3.2,
page 258), and 16 were found on brain imaging. In 6 cases, the relationship of the
presenting event to the AVM was unknown, and in the rest there was another clear
explanation for it. The conditions that led to incidental detection were: ICeH (due to
anticoagulation, not the AVM remote from the bleed), acute confusional states, epilepsy
ipsilateral to the AVM, FNDs either anatomically remote from the AVM or not vascular
in character, migraine, and a host of other symptoms (e.g. variable combinations of
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sensorineural hearing loss, dizziness, tinnitus and unsteadiness leading to imaging 'to
rule out an acoustic neuroma').
13.3.3.7 Disability at presentation
When adults with the above types of presentation are subdivided according to their
disability rating on the modified Rankin scale (rated by the research fellow from the case
notes), there are clear differences (Figure 47, page 272). Those who presented with
epilepsy, focal neurological deficits or symptoms unrelated to the brain AVM were not
dependent. However, of those presenting with haemorrhage, three-quarters were either
dead or dependent at the time, with the level of dependency being fairly evenly spread
across Rankin grades 3-5. Although there was a. tendency towards a less disabling
presentation amongst those with SAH, in comparison with other modes of
haemorrhage, numbers were insufficient to discern any statistically significant
differences.
13.3.3.8 Retrospective events
Of the whole cohort, 23 (25%) had had one or more event(s) prior to presentation that
could have led to earlier brain AVM diagnosis (Table 24, page 269).
Half of the adults with seizure(s) at presentation had had a prior event, and most of
these were one or more seizure(s). But 8% of them had had a haemorrhage for which
investigations had not revealed a cause, and 8% had had a FND that — in retrospect —
was very likely to have been caused by the AVM (e.g. a rapidly-improving hemiparesis
that was not investigated and labelled as functional).
One quarter of adults whose brain AVM was an incidental discovery had had prior
events. These were mostly haemorrhages (21%), but a fan: number had had seizure(s)
(16%). Two of the three patients detected incidentally at autopsy had had retrospective
events attributable to the AVM.





• The 92 adults with definite brain AVMs in the 1999-2000 SIVMS brain
AVM cohort, of whom 53% were male, had a median age of 45 (range
16 to 81) years at presentation
• 19 (21%) of the cohort had their brain AVM discovered incidentally (3 at
post mortem and 16 on brain/vascular imaging), one quarter of these
adults had prior symptoms that were probably attributable to the brain
AVM, and they were significantly older than those with symptomatic
brain AVMs
• Of the symptomatic adults, 59% suffered ICrH, 34% had one or more
seizures and 7% presented with a FND
• Of the adults presenting with ICrH, half of the bleeds were pure ICeH,
pure SAH was always deemed to be due to associated an aneurysm
rather than the brain AVM, and three quarters of all adults presenting
with ICrH were dead or disabled (Rankin >3)
• 44% of the seizures at presentation appeared to be generalised without
focal onset, from their description in case notes
13.5 Discussion
13.5.1 Characteristics ofpresentation
In this population-based study I have found that 21% (95%CI 14% to 30%) of brain
AVMs are incidental discoveries, confirming my hypothesis that SIVMS would detect a
larger proportion than in most hospital-based studies. Adults detected incidentally are
significantly older than people presenting in other ways. This may, in part, be explained
by 26% (95%CI 12% to 49%) of them having symptoms prior to presentation that
might have led to earlier detection (Table 24, page 269).
These missed opportunities to detect brain AVMs earlier have several explanations. In
part, they reflect the availability and uptake of brain imaging in the 2-3 decades prior to
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the start of SIVMS. They also reflect the tendency to investigate seizures only if they
have a focal onset, or if they become recurrent. Furthermore, the four adults that
SIVMS could not classify as definite, but were likely to have an underlying AVM (13.3.1,
page 257), illustrate how brain AVMs may not be pursued in some clinical contexts, and
how they may defy detection despite best investigation. When and if these cases become
definite, because clinical progression dictates further investigation, their presenting
events may in some ways be 'retrospective events'.
Those incidental discoveries without prior symptoms reflect current investigation
practice. For example, the vogue for imaging patients with an asymmetrical
sensorineural hearing loss must surely result in more incidental discoveries (of any type,
bit just AVMs) than the acoustic neuromas sought?
It is also possible that these older, asymptomatic patients harbour brain AVMs with an
unusually benign clinical course; they tend not to have IADSA or interventional
treatment, complicating exploration of whether their angioarchitecture is in some way
unique, yet providing an ideal opportunity to observe their untreated clinical course.
It was unsurprising to find that the vast majority of haemorrhages were
intraparenchymal with or without extension into neighbouring ventricles or the
subarachnoid space (Table 23, page 268), nor was it surprising to find that haemorrhage
was the most disabling mode of presentation (Figure 47, page 272). It was interesting
that seizures due to the brain AVM were apparently generalised without focal onset in
44% and in the rest had a focal onset with or without secondary generalisation.
13.5.2 Comparison with other studies
The Mayo clinic study offers the main opportunity for comparison with another
population-based cohort [Brown, Jr. et al. 1996b], whilst a synthesis of data from three
tertiary/quaternary referral centre databases (Toronto, New York and Paris) is perhaps
the best hospital-based comparator [Hofmeister et al. 2000].
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13.5.2.1 Other population-based studies
Compared to the Mayo clinic population-based study [Brown, Jr. et al. 1996b], in SIVMS
presentation was more frequently incidental (21% versus 15%), less frequently
haemorrhagic (47% versus 65%), and more adults presented with epilepsy (27% versus
19%). Precision in both studies is insufficient to regard these differences as significant.
Furthermore, the Mayo clinic study did not separately identify presentations with FNDs
making comparison difficult. If the differences between the studies are real however,
they may reflect modern investigation practices, tending towards more incidental
discoveries, and to identify more lesions responsible for seizure disorders, perhaps
leading to AVM detection prior to haemorrhage.
13.5.2.2 Hospital-based studies
Because the synthesis of three hospital-based studies was not restricted to adults
[Hofmeister et al 2000], it is not surprising that at presentation their overall mean age
(31 years) was lower than SIVMS median age (45 years). Women were slightly under-
represented in both SIVMS (47%) and the hospital-based studies (45%), for no apparent
reason. Unfortunately, it is difficult to compare mode of presentation with SIVMS,
because the authors quantified total symptom burden, not a single allocated mode of
presentation in each case. However, haemorrhage occurred in a similar proportion of
cases (47% in SIVMS versus 53% in the hospital-based studies).
The only hospital-based study to have assessed disability of haemorrhage was an analysis
of 115 incident haemorrhages, a small proportion of the Columbia AVM database
cohort [Hartmann et al. 1998]. Interestingly, they found the distribution of these
haemorrhages to be somewhat different from SIVMS (Table 23, page 268): there were
more subarachnoid bleeds (30% versus 12%), fewer intraparenchymal bleeds (23%
versus 46%), many more pure intraventricular bleeds (16% versus none), and fewer
bleeds in combined locations (31% versus 42%). However, the Columbia paper had
concluded that haemorrhage from AVMs was rarely disabling, but SIVMS provides a
dramatic contrast. At presentation, 47% of the Columbia cohort had no neurological
deficit (allocated Rankin grade=0), but no person with haemorrhage in SIVMS was
without symptoms (which is the correct interpretation of Rankin grade 0). SIVMS found
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fewer patients to be Rankin grade 1 (9% versus 37%), more patients to be Rankin grade
2-3 (39% versus 13%), and vastly more to be Rankin grade 4-6 (51% versus 3%).
There are likely to be significant differences in mode of presentation between
population-based and hospital-based studies, if an individual patient data analysis were
to be conducted, as there were between hospital based studies for age, sex, and
proportion with haemorrhage [Hofmeister et al. 2000]. These differences are likely to be
attributable, primarily, to the selection bias of tertiary/quaternary referral centre studies;
as I have shown for presentation with haemorrhage, the most disabled patients will not
be referred on for specialist management. Undoubtedly referral patterns, the particular
treatment interests and availabilities of certain centres, and the definitions they use for
clinical events and radiological features (Chapter 10) all contribute to the heterogeneity
observed, and further reinforce the importance of complete, population-based studies.
13.5.3 Limitations of this study
Although SIVMS can congratulate itself for achieving population-based, unbiased
ascertainment, it has failings. The availability of only two years of data at the time of
writing this thesis has meant that precision is poor, with uncomfortably large 95%CIs
(for example, Table 22, page 267). This will improve once the study radiologists have
reviewed all the diagnostic imaging. There are clear limitations of case note review
determining mode and disability of presentation. Whilst I would have liked to assess
these patients myself (92 would have been feasible over 2 years), the inevitable delay
from presentation to notification made this an impossibility, as did the geographical
remoteness of some areas of Scotland. Relying on case note review and what happens in
everyday clinical practice (often outside neuroscience centres) meant that brain imaging
which was of the wrong type or conducted at the wrong time complicated allocation of
presentation type, and blurred the distinction between haemorrhage and FNDs.
However, my experience of reviewing case notes has reinforced my belief (perhaps a
pre-existing prejudice and competing interest!) that a neurological opinion is needed for
correctly identifying asymptomatic cases, seizure types, and classifying FNDs as a
unique entity (rather than a repository for poorly understood presentations).
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Table 22 Mode of presentation of 92 incident adults with a definite brain
AVM








Incidental 19 (21%) 19 (21%, 14% to 30%) -
Symptomatic 73 (79%) - -
Haemorrhage - 43 (47%, 37% to 57%) 43 (59%, 47% to 70%)
Epilepsy - 25 (27%, 19% to 37%) 25 (34%, 24% to 46%)
FND - 5 (5%, 2% to 12%) 5 (7%, 3% to 15%)
Total 92 (100%) 92 (100%) 73 (100%)
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Table 23 Characteristics of the 43 adults presenting with haemorrhage
from a brain AVM
Type of presenting haemorrhage n (%)
n (%) n (%)
due to aneurysm with aneurysm(s)
Intraparenchymal 20 (46) 0 2 (20)
Intraparenchymal & intraventricular 11 (26) 0 1 (10)






Intraparenchymal & subarachnoid 2 (5) 0 0
Intraventricular & subarachnoid 1 (2) 0 0
Intraventricular 0 0 0
Subdural 0 - -
Unknown 0 - -
Total (%) 43 (100) 5 (100) 10 (100)
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Table 24 Haemorrhage, epilepsy and focal neurological deficits
recorded in the case notes prior to presentation in the 1999-2000 brain
AVM cohort
FND = focal neurological deficit
Type of presentation
Retrospective event
Incidental Haemorrhage Seizure(s) FND
(n=19) (n=43) (n=25) (n=5)
Haemorrhage 4 (21%) 0 2 (8%) 0
FND 1 (5%) 1 (2%) 2 (8%) 0
Seizure(s) 3(16%) 4 (9%) 9 (36%) 0
Any type of event 5 (26%) 5(12%) 13 (52%) 0
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Figure 45 Illustrations of imaging of included, but not definite, brain
AVMs
A and B: Axial (A) and coronal (B) MRI of a possible AVM in the left pons
(arrows)
C and D: Sagittal T2-weighted MRI (C) reveals high signal in the cingulate
gyrus and corpus callosum (arrow), but the callosal abnormality (arrow) on
left carotid angiography (D) can only be declared a possible AVM
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Figure 46 Illustrations of imaging of included, but not definite, brain
AVMs
A and B: Axial T2-weighted MRI (A) and T1-weighted MRI with contrast (B)
reveal a possible right pontine AVM with evidence of prior infarction
C and D: Axiai CT (C) demonstrates a left temporal intracerebral haematoma
(arrow), but catheter angiography 6 months later (D) revealed a difuse
capillary blush only (arrow)
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Figure 47 Distribution of the modified Rankin scale immediately
following presentation, according to presentation type
Modified Rankin scale: 0 = no symptoms; 1 = minor symptoms, which do not
interfere with lifestyle; 2 = some restrictions to lifestyle, but look after
themselves; 3 = significant restriction to lifestyle, preventing total
independence; 4 = severe handicap preventing independent existence, but
not requiring constant attention; 5 = severe handicap, totally dependent,
requiring attention night and day; 6 = the patient is dead.
□ 0 □ 1 D2 D3 14 15 16
w
I
Incidental Haemorrhage Epilepsy FND
Rankin grade Presentation type
Incidental Haemorrhage Epilepsy FND
0 6 0 0 0
1 5 4 20 5
2 3 7 5 0
3 0 10 0 0
4 2 9 0 0
5 0 12 0 0
6 3 1 0 0
<3 * 14 (74%) 11 (26%) 25 (100%) 5 (100%)
>3 * 5 (26%) 32 (74%) 0 0
* p<0.05 (Fisher's exact test)
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Chapter 14. The Scottish Intracranial Vascular Malformation Study
(SIVMS) - radiological features of arteriovenous














From my systematic review (Chapter 2), I was aware of the interest shown in
angioarchitecture as a means of understanding AVM haemodynamics as well as
predicting AVMs' haemorrhagic tendency (although these latter studies were based on a
flawed retrospective association of angioarchitecture with prior haemorrhagic
presentation). When designing SIVMS I therefore sought to collect these various
attributes, with a view to exploring whether they really are predictors of subsequent
prognosis. After starting data collection, I soon realised how these attributes were
dependent on viewing the entire angiographic run and how observers were not
consistent in their assessment, which led me to develop SIVMS definitions (Chapter 6)
and quantify observer agreement (Chapter 10). Despite the time-consuming exercise of
collecting these variables, they were inevitably incomplete because only three-quarters of
the cohort ever had IADSA, and furthermore the quality of these data was poor
(Chapter 7). This chapter briefly summarises the characteristics of the brain AVMs in
the cohort.
14.2 Methods
Data were collected on paper forms, using standard definitions. Rudimentary
morphological data were obtained from pathology reports if no imaging was performed;
these data comprised location at least, and details about aneurysms and size if provided.
If CT, MRI and IADSA were performed prior to treatment, I collected data from them
all. If patients had more than one CT, MRI or IADSA, the data summarised below are




14.3.1 General morphological attributes
Table 25 (page 279) summarises the attributes of the 92 adults with definite brain
AVMs. There were no multiple AVMs, but one co-existed with a remote calcified lesion,
thought probably to be a cavernous malformation (MRI was never performed). There
was a tendency towards more AVMs on the right side of the brain, but 95%CIs were
wide. The vast majority of AVMs were lobar in the cerebral hemispheres, and almost
two-thirds of them were in 'eloquent' locations.
14.3.2 Nidus size
Nidus size measurements were available for 81 (88%) of adults from at least one
imaging modality, or pathological examination. Pure arteriovenous fistulae were
allocated a nidus size of Omm in all directions. Maximum nidus dimension was 60mm,
and the median dimension was <20mm in all planes (Table 25, page 279). Comparing
imaging modalities, there were no overall differences in average nidus size in any plane
(Figure 48, page 280). Comparing measurements of the same nidus made by any two
modalities, there appeared to be greater agreement between axial imaging (Figure 49,
page 281) than there was when comparing IADSA with CT (Figure 50, page 282), or
MRI (Figure 51, page 283).
14.3.3 Angiographic features
Although almost three quarters of the cohort had IADSA, the proportion investigated
with IADSA varied according to the mode of presentation. The numbers investigated
with IADSA, by mode of presentation, were: 8 of 19 incidental (42%, 95%CI 26% to
61%), 37 of 43 haemorrhagic (86%, 95%CI 75% to 93%), 24 of 25 seizure(s) (96%,
95%CI 84% to 99%), and 2 of 5 FND (40%, 95%CI 14% to 73%).
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Aneurysms co-existed with the AVM in 20 (22%) of the cohort overall. Aneurysms were
nidal in 6 (30%), remote in 4 (20%), and distal feeding artery in 3 (15%); the only
aneurysms that were multiple were located on proximal feeding arteries, and these
affected 11 (55%) of those with aneurysms.
Arterial feeders were most commonly multiple, as were draining veins. Arterial
tortuosity, angiopathy, collateral supply and angiogenesis affected few patients. The
nidus border was compact in the majority of cases. Venous varices and ectasia were not
uncommon, although venous stenosis was poorly documented and rarely present.
14.3.4 Spetzler-Martin grade
The number of brain AVMs with a Spetzler-Martin grade simply reflects the number
who had IADSA in order to define the pattern of venous drainage. The distribution of
grades reflects the characteristics of those AVMs that in clinical practice were deemed
suitable for IADSA (often with the intention to intervene): largely small AVMs with
superficial venous drainage.
14.4 Summary
• Overall there was no preponderance for brain AVMs to be on one side
of the brain
• 75% of AVM nidi were lobar in location, 53% were superficial, and 59%
were located in surgically 'eloquent' brain areas
• Median nidus diameter was <20mm in all dimensions
• The completeness of SIVMS's description of brain AVM morphological
characteristics depends on the extent of their investigation, with
angioarchitecture only available in 68 (74%) cases
• 22% of AVMs had associated aneurysms, 9% ofAVMs were pure AVFs,
venous drainage was purely superficial in 75%, and the majority had >2
feeding arteries and >2 draining veins
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• Many angioarchitectural features (e.g. arterial angiopathy, angiogenesis,
collaterals, and venous stenosis) were only present in a minority of brain
AVMs
14.5 Discussion
I have found that it is possible to describe basic morphological data for a population-
based cohort of adults with brain AVMs in every case, but that angioarchitecture can
only be described in ~75% and even then data quality is poor (because collection of
some of these variables was incomplete). This will bias any future prognosis analyses by
using a subgroup of the cohort, and one that is likely to reflect a more benign clinical
course, because they have survived to undergo IADSA and — often — subsequent
treatment. Deep venous drainage is emerging as an independent risk factor for future
haemorrhage occurrence in recent hospital-based cohort studies [Mast et al. 1997;
Stefani et al 2002], so this prognostic factor can only be tested in three-quarters of the
SIVMS cohort.
Furthermore, I have found that in routine clinical practice (without the use of
angiographic sizing markers and magnification correction factors), agreement between
CT and MRI tends to be a little better than that between IADSA and one of the axial
imaging modalities. This reinforces the superiority of axial studies for measuring nidus
size.
From a comparison of three tertiary/quaternary referral centre AVM databases, there
were clear differences between centres in AVM size and eloquence of its brain location
[Hofmeister et al. 2000]. In SIVMS, 45 of 81 (56%, 95%CI 45% to 66%) cases in which
nidus size was known had an overall AVM maximum diameter <3 cm in every plane,
but this was only the case for 38% (95%CI 35% to 41%) in the hospital-based studies.
In SIVMS, 17 of 67 (25%, 95%CI 17% to 37%) AVMs had deep venous drainage,
clearly a smaller proportion than the 55% (95%CI 52% to 59%) with such drainage in
hospital-based studies. Furthermore, in SIVMS AVMs were situated in eloquent regions
of the brain in 59% (95%CI 49% to 68%), again a lower proportion than the 71%
(95%CI 69% to 74%) in hospital-based studies. Notwithstanding the incomplete
angiographic characterisation of the whole SIVMS cohort, these comparisons suggest
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that the hospital-based studies were attracting larger, more complex brain AVMs,
probably because of their specialist treatment capabilities, often in the 'multi-modality'
treatment of larger AVMs.
These differences further emphasise the importance of studying a more representative
patient group in a population-based design. Clearly, radiological evaluation that is both
appropriate and comprehensive better describes the angioarchitecture of a more
representative sample of adults with brain AVMs, just as a more comprehensive
neurological evaluation could better characterise their mode of clinical presentation.
278
Chapter 14
Table 25 Morphological features of brain AVMs on diagnostic






Side of the brain
Brain area
Location within brain area
Eloquent brain area?
Associated aneurysms?
Spetzler Martin grade (n=68)











Discernible fistula in nidus (n=67)
Number of draining veins (n=67)
Venous drainage pattern (n=67)






Left 43%, midline 4%, right 53%
Deep 12%, brainstem 1%, cerebellar 10%,
ventricular 2%, lobar 75%
Superficial 53%, corticoventicular 21%,
periventricular 1%, deep 25%
54 (59%)
20 (22%)




1 (32%), 2 (17%), 3 (8%), 4 (6%), 5 (1%), 6 (6%), 7
(1%), >8 (29%)
None (63%), mild (28%), moderate (7%), severe
(2%)
None (72%), dilated (27%), dilated & stenosed (1%)
Absent (92%), present (8%)
Absent (85%), present (15%) of which 40% were
dural and 60% were leptomeningeal
Compact (85%), diffuse (15%)
7 (10%)
1 (45%), 2 (25%), 3 (6%), 4 (9%), 6 (9%), >8 (6%)




7 (20%), of which 5 were at a dural sinus and 2
were elsewhere
remote, probable cavernous malformation
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Figure 48 Comparison of the distribution of measurements of nidus size
in three directions, for brain AVMs that were visualised on CT, MRI and
IADSA (n=20)
Dark lines = median dimension in mm, grey boxes = limits of 95%CI of mean,
error bars = range of values, with outliers and extremes represented by



































































Figure 49 Bland and Altman plots comparing CT with MRI in all three
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Figure 50 Bland and Altman plots comparing CT with IADSA in all three
planes, for brain AVMs that were visualised on both modalities (n=20)
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Figure 51 Bland and Altman plots comparing MRI with IADSA in all
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15.1 Main findings of this thesis — a summary of summaries
15.2 Implications for routine practice






15.3.6 Randomised controlled trials
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15.1 Main findings of this thesis - a summary of summaries
15.1.1 Systematic review of studies of the frequency, clinical
presentation and prognosis of brain arteriovenous
malformations
• There is a serious shortage of high quality studies of the frequency,
presentation, clinical course and prognosis of brain AVMs
• Whilst very litde can be reliably concluded about the likely prevalence of
brain AVMs, their incidence in unselected populations is of the order of
1 per 100,000 per year
• Long-term crude annual case fatality due to a brain AVM is 1-1.5%
• The crude annual risk for the first occurrence of a haemorrhage from an
unruptured brain AVM is approximately 2%, and this may be increased
by co-existent aneurysm(s)
• The risk of haemorrhage recurrence may be as high as 18% in the first
year, although consistent risk factors for haemorrhage recurrence have
not yet been observed
• Brain AVMs seem to carry an annual risk of developing de novo seizures
of 1%, with a good prospect of control on anti-epileptic drugs
• The risk of rupture during pregnancy and for patients with HHT has not
been accurately established
15.1.2 Methods of a population-based disease register for adults with
intracranial vascular malformations
• SIVMS aspires to meet the standards of an ideal study of prognosis, as
defined in Chapter 2 (Table 4, page 85)
• SIVMS includes adults who were aged >16 years at the time of a first-in-




• This thesis, however, only pertains to the adults with brain AVMs,
diagnosed between 1 January 1999 and 31 December 2000
• The SIVMS neuroradiologists divide brain AVM diagnoses into definite,
probable and possible on the basis of diagnostic criteria
• Whilst the point of inception is the presentation that led to the brain
AVM diagnosis being made, the incidence date is the year in which the
definite diagnosis was first made
• Cases are recruited using multiple overlapping sources of case
ascertainment (a collaborative neuroscience network, central coding of
hospital discharge data and death certificates, and a mailshot to every GP
in Scotland, used in the first year of SIVMS only)
• Recruitment and data collection are controlled by a Microsoft Access
database, with in-built audit processes
15.1.3 Database design for a population-based disease register for
adults with intracranial vascularmalformations
• SIVMS stores paper records of study materials and identifiable data
collected for every individual in the study, the fundamentals of which are
stored in an electronic relational database
• A customised database application has been created using Microsoft
Access, which effectively runs the study, imports data (e.g. information
from secondary data sources) and exports data (e.g. for Mail Merge using
MicrosoftWord)
• The database is password-protected, resides on a secure network, allows
multiple users to update it simultaneously, and it is regularly backed up
15.1.4 Variables relating to patients with brain arteriovenous
malformations and their clinical features
• Data about clinical events that affect study participants are derived from
their hospital and GP case notes, follow-up GP questionnaires, hospital
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case notes surveillance, as well as questionnaires completed by the
participants
All clinical events that could possibly be related to a brain AVM are
stored, whether they occurred at presentation (inception), prior to it
(retrospective events), or during follow-up
Clinical events are attributed to the brain AVM, an associated aneurysm,
a procedure complication, another cause altogether, or unknown (when
the brain AVM might have been responsible)
The definitions used by SIVMS have external validity in the light of
recent definitions proposed by the Joint Writing Group
Morphological variables relating to brain arteriovenous
malformations
SIVMS has a minimum morphological dataset for brain AVMs,
specifying the location and side of the bram the nidus resides in, as well
as the presence of any associated aneurysms (identified by radiological or
pathological examination)
Other attributes of the arterial feeders, nidus and draining veins are only
described if brain/vascular imaging is adequate to characterise them
Composite variables, such as the Spetzler-Martin surgical grade, may be
derived if adequate data are available from pathological and/or
radiological investigation
The definitions used by SIVMS have reasonable external validity in the
light of recent definitions proposed by the Joint Writing Group, the
latter being more specific
The retention of hard copies of every participant's imaging in the SIVMS




15.1.6 The Scottish Intracranial Vascular Malformation Study (SIVMS)
- data quality
• Baseline data quality in SIVMS is a reflection of study definitions,
process and database procedures
• SIVMS maximises data quality by using clear definitions of clinical and
radiographic variables, automatically checking minimum data provision
and consistency at data entry, deliberately analysing for errors, and
spotting outliers
• 89% of patients were alive at the time of recruitment, of whom 86%
were approached to join the study, of whom 69 (95%) returned their
forms and consented to join SIVMS (72% of the whole cohort)
• 96% of GPs granted access to case notes, but only 91% of them have
been received; 99% of consultants granted access to case notes, and 99%
of these notes have been received; 98% of diagnostic scans performed at
these hospitals have been received
• Basic demographic data were present for every patient, and more
detailed information were available if they consented
• Complete data were available for the location of each brain AVM, but
size in three dimensions was available for only 83% of the cohort
15.1.7 The Scottish Intracranial Vascular Malformation Study (SIVMS)
- evaluation ofpopulation-based design
• The optimal sources of case ascertainment were notifications from a
multidisciplinary network of collaborators in the clinical neurosciences,
supplemented by routine coding of hospital discharge and death
certificate data
• There was ~50% overlap between these two sources




Age-standardised incidence ratios did not suggest significant differences
in ascertainment between health board areas
15.1.8 The Scottish Intracranial Vascular Malformation Study (SIVMS)
- evaluation of ICD-10 coding and potential sources of bias
• Coding missed 37% of adults with brain AVMs, although it benefited
SIVMS by being the sole source of 4% of the whole cohort of brain
AVMs
• The sensitivity of ICD-10 coding of brain AVMs was 72% (95%CI 61%
to 80%); false negatives were mainly due to incorrect coding, brain AVM
diagnoses not appearing on the discharge summary or death certificate,
or missing records in the coding dataset
• The positive predictive value of an apparently incident ICD-10 code for
a brain AVM was 46% (95%CI 38% to 55%); false positives were mainly
due to intracranial aneurysms and perimesencephalic subarachnoid
haemorrhage (160.8) and other IVM types (Q28.2)
• Even with as small a cohort as 92 adults, I have also been able to
demonstrate that both simplified methods of case ascertainment and
reliance on IADSA for diagnosis all would have biased the cohort,
sometimes very seriously
15.1.9 Observer variation in the interpretation of catheter angiograms
of brain A VMs
• This study of 5 neuroradiologists' interpretations of 40 IADSA studies
was a pragmatic effort to understand both intra- and inter-observer
agreement in day-to-day assessment ofAVM angioarchitecture
• The IADSAs were of adequate quality, although it will always be difficult
to reflect the dynamic nature of angiography in hard copy format




• Inter-observer agreement was greatest for characteristics such as nidus
size (although there was a tendency for variation to increase as nidus size
increases), moderate for Spetzler-Martin grade and the presence of
aneurysms, and worst for the presence of venous stenosis and type of
nidus border
15.1.10 The point prevalence of arteriovenous malformations of the
brain in the Lothian healthboard region of Scotland
• In this first community-based study of brain AVM prevalence, I found a
crude prevalence of 15 (95%CI 12 to 18) per 100,000 adults
• The prevalence may be as high as 18 (95%CI 16 to 24) per 100,000
adults if capture-recapture analysis is used to estimate the number of
cases missed by my ascertainment process
• Therefore, in the year 2000, adults with a brain AVM numbered between
650-1,000 in Scodand, 7,600-11,400 in the United Kingdom and 35,400-
53,000 in the USA
15.1.11 The Scottish Intracranial VascularMalformation Study (SIVMS)
- incidence of arteriovenous malformations of the brain
• In the years 1999 and 2000, SIVMS received 418 notifications from all
sources of case ascertainment, of which 96 adults were included, and 92
had a definite brain AVM diagnosis
• The crude incidence of definite brain AVMs in Scottish adults was 1.12
(95%CI 0.90 to 1.37) per 100,000 adults per year
• The incidence of symptomatic definite brain AVMs was 0.89 (95%CI
0.70 to 1.12) per 100,000 adults per year
• The incidence of asymptomatic (incidentally discovered) brain AVMs
was 0.23 (95%CI 0.14 to 0.36) per 100,000 adults per year
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15.1.12 The Scottish Intracranial Vascular Malformation Study (SIVMS)
- clinical presentation of arteriovenous malformations of the
brain
• The 92 adults with definite brain AVMs in the 1999-2000 SIVMS brain
AVM cohort, of whom 53% were male, had a median age of 45 (range
16 to 81) years at presentation
• 19 (21%) of the cohort had their brain AVM discovered incidentally (3 at
post mortem and 16 on brain/vascular imaging), one quarter of these
adults had prior symptoms that were probably attributable to the brain
AVM, and they were significantly older than those with symptomatic
brain AVMs
• Of the symptomatic adults, 59% suffered ICrH, 34% had one or more
secures and 7% presented with a FND
• Of the adults presenting with ICrH, half of the bleeds were pure ICeH,
pure SAH was always deemed to be due to associated an aneurysm
rather than the brain AVM, and three quarters of all adults presenting
with ICrH were dead or disabled (Rankin >3)
• 44% of the seizures at presentation appeared to be generalised without
focal onset, from their description in case notes
15.1.13 The Scottish Intracranial VascularMalformation Study (SIVMS)
- radiological features of arteriovenous malformations of the
brain
• Overall there was no preponderance for brain AVMs to be on one side
of the brain
• 75% of AVM nidi were lobar in location, 53% were superficial, and 59%
were located in surgically 'eloquent' brain areas
• Median nidus diameter was <20mm in all dimensions
292
Chapter 15
• The completeness of SIVMS's description of brain AVM morphological
characteristics depends on the extent of their investigation, with
angioarchitecture only available in 68 (74%) cases
• 22% ofAVMs had associated aneurysms, 9% of AVMs were pure AVFs,
venous drainage was purely superficial in 75%, and the majority had >2
feeding arteries and >2 draining veins
• Many angioarchitectural features (e.g. arterial angiopathy, angiogenesis,
collaterals, and venous stenosis) were only present in a minority of brain
AVMs
15.2 Implications for routine practice
My first-ever estimates of retrospective, community-based prevalence and prospective,
population-based incidence provide information for health planners about the frequency
of brain AVMs, to inform the adequate provision of healthcare and resources. The
dissimilarities I have observed between the composition of existing hospital-based
studies and population-based studies (SIVMS and the Mayo Clinic study) urges caution
in the interpretation of some of the literature. Sudden death from brain AVMs and early
case fatality from AVM haemorrhage at presentation are likely to have been
underestimated by hospital-based studies, as is the disability conferred by AVM
haemorrhage at presentation.
The findings from the systematic review and the observer variability study also
discourage reliance on most features of angioarchitecture for prognostic risk-
stratification. Many of the studies suggesting that certain angioarchitectural features
confer a high risk of haemorrhage are simply a retrospective correlation with prior mode
of presentation, and inter-observer variation is so high in assessing most of these
characteristics that the studies are unlikely to be generaliseable. Although inter- and
intra-observer agreement was good for nidus size, the use of size markers during
IADSA is likely to improve observer agreement still further.
Whilst most of these implications are dismissive, SIVMS will ultimately make a positive
contribution to clinical practice — given time — by portraying the clinical course of a
representative cohort with more external validity than hospital-based studies.
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The existence of SIVMS, its early findings, and its likely ability to describe at least the
early clinical course of its cohort has implications for the future direction of SIVMS and
other research projects.
15.3.1 Epidemiology
In the interest of describing the global epidemiology of brain AVMs, other population-
based studies — such as NYIAVMS — will provide interesting comparisons.
Furthermore, continuing to monitor AVM incidence in Scotland will provide insights
into whether detection rates change with increasing availability and use of brain imaging,
and whether the asymptomatic detection rate declines (with better detection of earlier
symptomatic events) or rises (with use of brain imaging).
15.3.2 Clinical presentation
It will be important to confirm the morbidity of presenting and recurrent AVM
haemorrhage, which I have found to be greater than the New York group. A case-
control study would help establish the role of brain AVMs in causing headache,
although the knowledge of AVM diagnosis will confer a, perhaps insurmountable, recall
bias. The further study of FNDs will help to establish whether AVMs do cause cerebral
infarction, whether these events are simply missed bleeds, and whether they are due to
steal/venous hypertension. This calls for better assessment of patients at presentation
and when they experience further consequences of their brain AVM or its treatment, by
neurologists with access to appropriate imaging protocols.
15.3.3 Prognosis
The ultimate aim for SIVMS is to establish the rates of the following primary outcomes
at 5 years: survival, death or dependence (Rankin scale > 3), first occurrence, and
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recurrence of brain haemorrhage, development of de novo epilepsy, and median time to
one year remission of seizures.
The extent to which I can analyse prognosis will be dependent on the frequency of
outcome events. They may range from 2% to 20% per annum for the outcomes above.
To increase the precision around the estimated rates of important outcomes, and
increase the power of any prognostic model, SIVMS will need to recruit more patients
and follow-up the whole cohort for longer to observe an adequate number of outcomes.
This process would be made easier by amalgamation of the SIVMS dataset with a
comparable study. However, the other groups interested in IVMs in Toronto, New
York, Paris and Berlin have described considerable heterogeneity between their own
hospital-based cohorts, which make them unsuitable for combination with this
prospective, population-based cohort. I can only hope that the similarity I have found
between SIVMS and the population-based cohort from the Mayo clinic can be
reproduced if other population-based studies are set up. Amalgamation of several,
similar datasets could well enhance the precision and power of prognostic data.
All outcome data in SIVMS are amenable to actuarial analysis. The critical factor in
producing a reliable prognostic model using multiple regression analysis is the number
of outcome events per prognostic variable. Generally a ratio of no more than 10:1 is
required. Using follow-up data up to July 2004, I have observed 9 brain haemorrhages
during follow-up, which would total ~25 after six years of follow-up, enabling me to
design a simple prognostic model with two or three variables. More powerful models
will be created for outcomes such as epilepsy and composite outcomes such as death or
dependency on the Rankin scale. The prognosis for different subgroups will also be of
interest (e.g. presentation with haemorrhage, pregnancy, and associated aneurysms). I
will attempt to describe the first minimum spontaneous regression rate based on
SIVMS.
Given that there are no randomised-controlled trials (RCTs) of the interventions for
IVMs (endovascular techniques, neurosurgery and stereotactic radiotherapy), and that
the current evidence base for their use rests on case series alone, observation of
outcome stratified by differences in treatment in this prospective, population-based
study could provide better evidence of their effectiveness. Accumulation of further data
will enable independent validation of surgical grading schemes. Observation of practice
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will determine whether there is geographical variation in access to and uptake of
different treatment modalities.
15.3.4 Imaging
The most important imaging question to be addressed is what the optimal investigation
for ICeH should be. An RCT could compare different modalities and timings of
imaging to establish this in a large sample. The diagnostic sensitivities and specificities of
the available imaging studies for identifying AVMs also need to be established in various
clinical situations. Serial scanning to establish whether untreated AVMs change in size
over time (and to more accurately establish the spontaneous obliteration rate) would be
interesting, but it would create perhaps inappropriately high anxiety amongst
participants and consequent high drop-out rates. Studying the haemodynamics ofAVMs
at the time of FNDs using functional imaging techniques and SPECT might help
understand how these deficits come about.
15.3.5 Aetiology
Extremely litde is known about the aetiology of AVMs, although it is likely to be
multifactorial. A case-control study could address whether vascular risk factors play a
part in AVM aetiology, and whether anticoagulants/antiplatelet agents play a role in
AVM haemorrhage. A starting point for establishing whether there is a genetic
component to apparendy sporadic AVMs will be to study the family histories of a
representative sample of patients (e.g. reflecting the distribution of age and modes of
presentation in population-based studies).
15.3.6 Randomised controlled trials
All of diese endeavours, especially observation and identification of particular
prognostic subgroups, will create a necessary platform from which to launch RCTs. The
most meaningful are likely to be comparisons of different techniques — when there is
clinical equipoise about which would be best — for ruptured brain AVMs, and a policy
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of no treatment against one of treatment for unruptured brain AVMs. It is heartening
that, at the time of submission of this thesis, plans are afoot to apply for funding for the
latter trial based in the USA and Europe.
I found setting up SIVMS far more burdensome than I had anticipated, and the final
section of this thesis will be a reflection on that. As if co-ordinating multicentre,
multidisciplinary collaboration and data collection was not onerous enough, simply
negotiating LREC approval of an MREC-approved study was unnecessarily difficult (see
next section, Chapter 16). Let alone understanding, assimilating, and debating
sometimes contradictory and incompatible privacy legislation and confidentiality
guidance (see next section, Chapter 17)! Although these pressures questioned my resolve
at regular intervals, I rationalised my way through dark months, understanding that
changes in society, a spate of public medical 'scandals', and Britain's harmonisation with
European directives created a unique, changing regulatory context for my observational
research project. Undoubtedly, by successfully defending the ideal of unbiased research
against these pressures, my bond with SIVMS became even stronger.
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The foregoing original research projects would not have been possible (or funded)
without the approval of the relevant ethical bodies in Scotland. This section of the thesis
is a reflection on the burden that this important activity imposed on the SIVMS team. In
this chapter I describe the process and outcome of ethics committee review, as it was in
1998. In the following chapter I discuss Britain's unclear and sometimes contradictory
position on patients' privacy, data protection legislation, and confidentiality guidance at
the time of SIVMS.
In 1991 the Department of Health delegated responsibility for ethical review of research
in the NHS to Local Research Ethics Committees (LRECs) of the health authorities
[Department of Health 1991]. A rapidly expanding workload [Cookson 1992], and few
further guidelines, led to LRECs developing varying levels of autonomy and a diversity
of working practices [Harries et al 1994; Hotopf et al 1995; Garfield 1995; While 1995;
Redshaw et al. 1996; Busby and Dolk 1998]. This system posed particular problems for
multicentre research at that time, which required approval from many different ethics
committees [Meade 1994],
In 1997 — the year before SIVMS was set up — a long-awaited [Warnock 1988; Alberti
1995], standardised method for the review of multicentre research began with the
creation of several multicentre research ethics committees (MRECs) across Britain
[NHS Executive 1997]. Under this new system, multicentre research was defined as
taking place over five or more LREC geographical boundaries. A multicentre
application had to be submitted by its principal investigator to a single MREC
somewhere in the geographical region of the study for an independent opinion on all
the ethical and scientific aspects of the research proposal. Once the MREC approved
the application, it must then be distributed to every LREC in the geographical location
of the study. Each LREC's Executive Sub-Committee has to approve the suitability of
the local site, researcher(s) and facilities before the research can start in their area.
This system was designed to minimise the burden of ethical review for LRECs and
reduce the unsatisfactory delays that LRECs had caused for researchers in the past
[Foster and Holley 1998]. The procedure was intended to be expedited by centralising
the process of ethical review with MRECs and by providing clear guidelines to LREC
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Executive Sub-Committees on what aspects of an MREC-approved multicentre
application they might review and how long this should take [Palmer 1998].
The first year of the new MREC procedure was evaluated by the Research Ethics
Committee Project at the Centre of Medical Law and Ethics, King's College, London
[Chief Medical Officers for Scotland England and Wales 1998]; the main focus of that
evaluation, however, was on the MRECs themselves. At the time of setting up SIVMS,
there were no published data on the working practices of LRECs in the new era of
MRECs. Therefore, following MREC approval of SIVMS in July 1998, I took the
opportunity to collect data on LREC endorsement of this MREC-approved, multicentre
study in the autumn of 1998 [Al-Shahi and Warlow 1999].
16.2 Methods
I had to apply to 15 LRECs for local review and endorsement of the application for
SIVMS and the Lothian AVM prevalence study that had been approved by the MREC
for Scotland. Each LREC application required a variable number of copies of:
• the MREC application form (23 pages)
• the supplementary form covering local investigator experience plus his or her
curriculum vitae (8 pages)
• all correspondence with the MREC (6 pages)
• the research protocol, consent form and patient information leaflet (7 pages).
Recommendations for the expected timescale of LREC Executive Sub-Committee
review ofMREC-approved applications had been published and circulated to all LREC
Chairmen and Administrators in Scotland, providing a 'reference standard' with which
to compare this study's experience [Palmer 1998]. These recommendations stated that a
meeting should be called within two weeks of receipt of an application and a decision
should be communicated to the applicant within five working days of an LREC Sub-





In my analysis, the date of receipt of an application by an LREC was assumed to be the
next working day after its postage by first class mail; all other dates were taken from
LREC correspondence. LREC identities have been anonymised.
Figure 52 (page 306) shows the delay experienced at the outset, from assumed receipt of
an application to calling an LREC meeting (only eight of the 15 LRECs had established
Executive Sub-Committees). The median delay to review of an application at an LREC
meeting was 28 (range 14 to 97) days, twice the recommendation of two weeks.
Of particular relevance to researchers is the delay from application to final LREC
approval, shown in Figure 53 (page 307); the difference between the two bars indicates
the length of time taken to resolve any amendments with each LREC. The median delay
from application to the time of LREC final approval was 39 (range 21 to 109) days. In
fact, only three LRECs raised objections, all of which were on different grounds. One
LREC disputed elements of study design (which is strictly in the jurisdiction of the
MREC); the second requested additional study materials, and the third requested
changes to the content of the patient information sheet.
The process of LREC application was time-consuming and labour-intensive, although I
did not have to attend any LREC meetings in person and no application forms specific
to any of the LRECs were requested. There was considerable variation between LRECs
in the number of copies of each application they required (Figure 54, page 308). The
median number of copies was 10 (range 1 to 18), amounting to a total of 5789 A4 pages,
weighing 26.9kg. Photocopying and printing the applications cost £231.56 and the price
of postage by Royal Mail was £77.15. The total of £308.71 does not include the cost of
the salaried person-hours invested by the SIVMS secretary, a research projects' co¬
ordinator and myself.
16.4 Discussion
The original Department of Health directive to LRECs encouraged them to promote
good research [Department of Health 1991]. It has been suggested that unnecessarily
delaying research of potential benefit to the public is itself unethical [Stacey 1998;
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Nicholl 2000]. Applicants for ethical approval of multicentre research were previously
frustrated by the delays incurred by the LREC system, the costs of application, and
unnecessary duplication of effort [Garfield 1995; Black et al. 1995; Middle et al. 1995;
Busby and Dolk 1998; Foster and Holley 1998]. My experiences suggest that — in 1998 —
Scottish LRECs were not practising uniformly, that they did not all comply with set
guidelines, and although SIVMS was not delayed (because I applied in good time to
accommodate potential delays), it could have been.
The creation ofMRECs in 1997 was an attempt to expedite and standardise the process
of gaining ethical approval for multicentre research, thereby making the process more
transparent and quantifiable. In my case, delays of up to 16 weeks in gaining LREC
approval, using 5789 pages of A4 paper at a cost of over £300 for materials alone have
been a large price to pay for just three different LREC amendments. Comparing the
26.9kg of paperwork with an average person weighing 70kg, gaining ethical approval for
multicentre research in Scotland had cost SIVMS, "more than an arm and a leg."
By observing the practises of LRECs in Scotland, I have demonstrated that many of the
old impediments still delayed multicentre research, and elimination of unnecessary
variation in LREC operating procedures was still necessary to encourage timely medical
research. LRECs were certainly over-burdened by a large volume of lengthy applications
for approval of multicentre projects. I did not seek to address the demands imposed
upon LRECs, but they were undoubtedly great.
A wealth of similar accounts from other multicentre studies in the same time period
rapidly followed the submission of SIVMS's experiences for publication [Al-Shahi and
Warlow 1999]. Their findings were similar to mine: not all LRECs had executive sub¬
committees and LRECs did not comply with their guidelines either uniformly of
adequately. One involved 51 LRECs (both before and after the introduction of MRECs)
in a study using cancer registry data in England, which concluded, "is it ethical for
LRECs to create a bureaucratic quagmire in cases where the MREC has already given
ethical approval?" [Larcombe and Mott 1999]. Another studied 125 LRECs in England
after MREC introduction, found only 40% of LRECs to comply with the
recommendations for handling such applications, and concluded that the system, "...at
times presents an unethical barrier to potentially beneficial research" [Tully et al. 2000].
Another study, of 99 LRECs in England, found only 33% complied with guidance on
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decision time and concluded that, "...the two tier system of ethical review retains the
inefficiencies of the former system" [Lux et al. 2000].
This unsatisfactory situation for researchers and ethics committees alike called for
further improvement to the process of ethical committee review of multicentre research.
I had some constructive solutions at the time [Al-Shahi and Warlow 1999]. Greater use
of electronic communication via the internet could have reduced the cost and time delay
of postage and the cost of reproduction of paper forms. LRECs required only a small
proportion of the bulky MREC application form for their review; the form could have
been redesigned to further minimise the amount of paperwork relayed to the LRECs.
Further guidance was also needed on the extent to which observational, epidemiological
research involving minimal contact with patients needed to be subject to the same
process of rigorous ethical review as clinical trials of novel treatments [Royal College of
Physicians 1996].
In a BMJ editorial following the publication of the above observational data, the
president of the Royal College of Physicians of London recommended a common
application form for MRECs and a shorter form for LRECs, the formation of a national
advisory body, and better information and financial support for LRECs [Alberti 2000].
To the credit of those responsible for the conduct of RECs, despite researchers'
protests and the recommendations of this BMJ editorial, plans for reform had already
been laid. Their national survey of the first year of the MREC system had found there to
be problems with what constituted ethical review, policy (e.g. the resolution of issues of
procedure or ethics between MRECs and LRECs), and the operational system (e.g. poor
dissemination to LRECs of their reviewing responsibilities and inconsistency in the
amount of paperwork requested). Furthermore, the MREC central office established a
working party to report on the ethical review of epidemiological and health services
research, which identified 4 categories of such research (each with a different pathway
of review) and recommended corresponding changes to MREC standard operating
procedures.
The main reform has been the creation of the Central Office for Research Ethics
Committees (COREC), responsible for policy advice, co-ordinating operational systems,
training and support for RECs and researchers in the entire UK (www.corec.org.uk).
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One of its first actions was to produce an operational modification for the system of
ethical review of research protocols where there is no need for a local researcher,
thereby minimising time and financial expenditure for both researchers conducting
multicentre epidemiological research, and RECs themselves. This became effective on 1
November 2000 and will hopefully mean that, along with the other activities of
COREC, my experiences with ethical approval of SIVMS will be a relic of the past. I
doubt, however, that this will be the end of the story; the new operational arrangements
have already been challenged as having, "an underlying emphasis on facilitating research
to the extent that there is potential for it to adversely affect the interests of individual
research participants" [Cave and Holm 2002], and users are bemoaning the new
COREC application form [Greenhalgh 2004]!
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Figure 54 Number of A4 pages required for application to each LREC
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Having negotiated approval of the research projects in this thesis with the MREC for
Scodand and the relevant LRECs (Chapter 16), a GP who was a Medical Adviser to the
local Primary Care Trust, challenged the methods of my prevalence study in late 1999
(11.2, page 228). This GP objected to my method of ascertainment, which involved
asking GPs to release patient-identifiable data about adults with a brain AVM, without
their explicit consent. He stated that this was 'inviting' GPs to breach the Data
Protection Act. Similar concerns had been, and occasionally continue to be, expressed
by GPs about adults in the SIVMS incident cohort study.
The data protection and confidentiality climate changed during the set-up and conduct
of this thesis. In British society, the main preoccupation of the media was with a
number of public inquiries into failures of care and consent in the NHS (e.g. Bristol
cardiac surgery, Alder Hey retention of organs). New legislation and guidance produced
in the late 1990s did not complement each other. Therefore, the wealth of new
publications from different bodies landing on doctors' doormats caused confusion.
Each new piece of legislation or guidance often attracted scare-mongering publicity in
the medical and national press. This compounded doctors' anxiety, resulting in
defensive attitudes towards research studies.
The challenge of defending meaningful research, yet aspiring to best confidentiality and
data protection practice, diverted my attention — for months — to a detailed examination
of legislation and confidentiality guidance at the time. These efforts culminated in a
published letter and editorial [Warlow and Al-Shahi 2000; Al-Shahi and Warlow 2000],
and further endorsement of both the incidence and prevalence study methods after
negotiation — over the period of a year — with the MREC.
17.2 Background
At the dawn of the new millennium, there was still an almost unique opportunity in
Britain for high quality observational epidemiology and health services research. The use
of unselected and representative samples of routinely collected data from hospital and
GP databases has been possible in only a few countries outside the UK. The Mayo
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Clinic Foundation in Rochester, Minnesota has been a notable example of this since the
early 1900s, but they were hit by privacy legislation jeopardising such research in 1997
[Melton, III 1997],
Fundamental advances in the understanding of aetiology, risk factors, and prognosis
have been made through the use of population surveillance, longitudinal cohorts and
case-control studies, often using disease registers [Weddell 1973; Donaldson 1992;
Newton and Garner 2002]. These studies have inevitably involved using data about large
numbers of people, sometimes without their explicit consent. To my knowledge, there
have been no published or publicised cases where researchers or auditors conducting or
contributing to such studies have been judged to breach confidentiality.
Ideally, of course, patients in any research study or audit should have given either
explicit or implicit consent to the use of data that preferably should not identify them
directly. Although consent is essential for most trials of any intervention, it is a
somewhat Utopian requirement of purely observational research and audit, particularly if
it relies on huge quantities of previously collected data. But there are specific
circumstances that preclude explicit consent for certain groups of patients: some
individuals might be dead or untraceable, 4-14% of those with cancer deny their
diagnosis [Gavin et al. 2002], and those with neurological diseases might well be
cognitively impaired or suffer comorbid mood disorders [Carson et al. 2000].
Paternalism aside, approaches by researchers or auditors could cause considerable
distress to such individuals. Furthermore, if a patient is approached for their consent
and they do not respond, they have neither opted-in nor opted-out, leaving ambiguity
about whether they should be included or not.
Systematic 'authorisation bias' invalidates the findings of observational studies if people
are excluded for lack of their consent. For example, adults in Rochester, Minnesota were
less likely to consent if they were female, younger than 60, living close to the Mayo
Clinic and had a more sensitive diagnosis (e.g. mood disorder) [Jacobsen et al. 1999].
More recently, the organisers of the Registry of the Canadian Stroke Network have
found that the in-hospital mortality rate was much lower for patients who gave written
informed consent than for those who had not [Tu et al. 2004]. This is an unsurprising
finding, and I have found exactly the same result with the adults in this thesis, when
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comparing the all-cause mortality during follow-up of adults who gave consent to join
SIVMS with those who did not (Figure 55, page 323).
If anonymised information were to be used, in an effort to protect confidentiality when
using data without explicit consent, this often will not suffice. Anonymised or pseudo-
anonymised identifiers can be used when searching secondary data sources for hard
outcomes (e.g. death). But patient-identifiable data are clearly required to follow up
patients indirectly (e.g. via GPs) for information about morbidity, and to communicate
with the GP about future attempts to gain a patient's consent when it had previously
not been possible to obtain it.
So, identifiable data about large numbers of people, occasionally without their consent -
where it would be impossible or impractical to obtain it — is sometimes required to
conduct unbiased research.
Prior to the year 2000, accessing identifiable data without patients' consent had not been
highly contentious (Table 26, page 322). However, at the turn of the new millennium,
rapid changes in technology, the law and society were re-shaping the way identifiable
information about individuals could and should be handled. Of course, the rest of the
world struggled with the same dilemmas that affected the UK. For example, in the USA,
national privacy standards formed part of the Health Insurance Portability and
Accountability Act (HIPAA) 1996; but an additional Privacy Rule came into effect,
which permitted disclosure of information without the patient's authorisation for public
health use, records research etc. [Anonymous 2001].
In Britain, there was unease. Even the disclosure of anonymised data — without consent
from every individual — had been judged in a legal ruling to constitute a breach of the
duty of confidence owed to patients. This might have had detrimental implications for
observational research and audit [Walton et al. 1999], had it not been overturned by a
judgement in the Court of Appeal. Lord Justice Simon Brown, in his summing up, did
give a favourable opinion on the conduct of studies such as SIVMS:
"...It is clear on the information before us that for certain limited
purposes patient information is used in identifiable rather than
anonymised form... For present purposes, I say no more than that,
provided, as I understand to be the case, the use of such identifiable
data is very strictly controlled, there appears no reason to doubt that
it is acceptable — whether because it falls within the public interest
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defence or, as is perhaps the preferable view, because the scope of the
duty of confidentiality is circumscribed to accommodate it..
The first of the changes that destabilised doctors' long-standing Common Law duty of
confidentiality to their patients were the restrictions on processing not only electronic
but also paper-based records in the Data Protection Act (DPA) 1998, which came into
force on 1 March 2000.
17.3 Changes in UK data protection legislation 1999-2000
The DPA 1998, applicable throughout the UK, established a schedule of eight
admirable principles, accompanied by supplementary schedules of conditions. These
applied to living individuals; the deceased are not covered by DPA 1998. The second
schedule requires either informed patient consent for the use of their data, or that their
processing is necessary for 'functions of a public nature exercised in the public interest'
(paragraph 5d), or 'legitimate interests pursued by the data controller' (paragraph 6). I
believed that my research interest was legitimate, and the research was in the public
interest, thereby excusing the requirement for informed consent from the patients
whose GP or hospital consultant believe that direct contact with them will do them
more harm than good.
Furthermore, any use of identifiable data relating to the 'physical or mental health or
condition' of a living individual requires either their informed consent, or that the
'processing is necessary for medical purposes' (schedule 3, paragraph 8). Whilst these
'medical purposes' subsume 'medical research', audit is not specifically mentioned and
no further definition of medical research, nor exceptions to the need for consent, are
given (section 33). This is where the (deliberate, perhaps) ambiguity lies, and even more
unsatisfactorily for researchers, some uses of data that would be legal under the DPA
1998 remained a breach of confidentiality under common law [Strobl et al. 2000], A
dilemma, perhaps, for resolution in a court of law.
However, the Data Protection (Processing of Sensitive Personal Data) Order 2000
sanctioned the processing of identifiable data so long as it was in the substantial public
interest, was necessary for research purposes, did not influence decisions made about
individuals, and did not damage them (paragraph 9). This too, whilst seeming supportive
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of research endeavours, could be interpreted conversely; researchers were especially
worried about the re-use of existing data collections because the DPA 1998 seemed to
prohibit the use of information on individuals for purposes other than that originally
intended [Silman and Macfarlane 2001], Another dilemma, perhaps, for resolution in a
court of law.
In the Human Rights Act (HRA) 1998 [Thomson et al. 2001], which came into force in
October 2000, it stated, "everyone has the right to respect for his/her private life and
family life, home and correspondence (article 8)... there shall be no interference by a
public authority with the exercise of this right except such as is in accordance with the
law and is necessary in a democratic society... for the protection of health or morals..."
It is anticipated, again, that eventually judges will have to weigh the balance between the
interests of the individual and those of the community [Hewson 2000].
So the law appeared sympathetic to uses of data for medical research, but left the public
interest still a matter for the common law.
17.4 Changes in UK confidentiality guidance 1999-2000
In late 1999 and throughout 2000, several professional organisations responded to these
legal developments by updating their guidance on confidentiality and the use of personal
information (Table 26, page 322) [World Medical Association 1964; British Medical
Association 1999; General Medical Council 2000; Medical Research Council 2000].
There was a real risk that strict and selective application of some directives could
seriously jeopardise audit, clinical governance, and observational epidemiological
research, thereby compromising patient care and the public interest.
The General Medical Council's (GMC) guidance Confidentiality was perhaps the greatest
cause of anxiety amongst doctors [Leslie and Webb 2001]. I think that it, like the DPA
1998, condoned a wide variety of research methods, including using patient-identifiable
data without consent in certain situations. The GMC guidance did seem to lend support
to the conduct of research such as SIVMS in which it is notpracticable to obtain consent
from everyone, there is no direct effect of the research on patients' health or care, and
where the benefit to future patients is far in excess of any potential harm.
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Firstly, the GMC acknowledged the need for identifiable data:
Disclosure of information about patients for purposes such as
epidemiology, public health safety, or the administration of health
services, or for use in education or training, clinical or medical audit,
or research is unlikely to have personal consequences for the patient.
In these circumstances you should still obtain patients' express
consent to the use of identifiable data or arrange for members of the
health care team to anonymise records (see also paragraphs 16 and
18). (Paragraph 15)
However, the two paragraphs referred to above supported continued study of an
unbiased cohort where it is not practicable to obtain consent from everyone, and where
the interests of society are served by the results of research:
However, where information is needed for the purposes of the kind
set out in paragraph 15, and you are satisfied that it is not practicable
either to obtain express consent to disclosure, nor for a member of
the health care team to anonymise records, data may be disclosed
without express consent... (Paragraph 16)
In cases where you have considered all the available means of
obtaining consent, but you are satisfied that it is not practicable to do
so, or that patients are not competent to give consent, or
exceptionally, in cases where patients withhold consent, personal
information may be disclosed in the public interest where the benefits
to an individual or to society of the disclosure outweigh the public
and the patient's interest in keeping the information confidential.
(Paragraph 18)
Lasdy, the GMC's guidance invited researchers to do exactly what I did when the GP
protested about the prevalence study, and request the MREC's opinion:
Where research projects depend on using identifiable information or
samples, and it is not practicable to contact patients to seek their
consent, this fact should be drawn to the attention of a research ethics
committee so that it can consider whether the likely benefits of the
research outweigh the loss of confidentiality. Disclosures may
otherwise be improper, even if the recipients of the information are
registered medical practitioners. The decision of a research ethics
committee would be taken into account by a court if a claim for
breach of confidentiality were made, but the court's judgement would
be based on its own assessment of whether the public interest was
served. More detailed guidance is issued by the medical royal colleges
and other bodies. (Paragraph 31)
But the lack of explicit supportive statements and the ability to read the guidance two
ways meant it did not compare well with the DPA 1998 [Fills 2001]. Moreover,
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researchers were left to anticipate where the public interest might be judged to lie. So
the GMC's guidance Confidentiality led to misinterpretation, confusion and
scaremongering publicity, mainly about the threat to cancer registries [Ballantyne 2000;
Paterson 2001; Brewster et al. 2001], Keen that cancer registries were not perceived to
be the only activity jeopardised, others raised awareness about neurology research and
medical research in general [Warlow 2001], health services research in general [Cassell
and Young 2002], public health surveillance [Verity and Nicoll 2002], medical screening
research [Wald and Law 2001], and investigating doctors' performance [Capek and
Roland 2002].
17.5 Suggestions for resolving the contradictions in the UK in
2000
It seemed that selective adherence to the stricter statements in British statutory
regulations and guidance could jeopardise the methodological integrity of research and
audit by a blanket requirement for anonymisation of data as well as informed consent
from every individual to use identifiable data about them, for each separate study. This
would not just hinder the progress of medical knowledge, but might well lead to
completely incorrect conclusions and make the process of clinical governance
impossible, so damaging the public interest. My supervisor and I posed three solutions
[Al-Shahi and Warlow 2000].
Firstly, the law needed to be clarified. The 'medical purposes' mentioned in section 33
of the DPA 1998 subsume 'medical research', but audit is not specifically mentioned
and no further definition of medical research, nor exceptions to the need for consent,
are given. Despite these ambiguities, a British statutory instrument (released in the same
year as the DPA 1998 came into force) seemed to sanction the processing of patient-
identifiable data (without mentioning informed consent) [Anonymous 2000], Not only
did these statutes need clarification, but so did the additional implications of common
law and recent case law on the scope of the duty of confidentiality, and to what extent it




Secondly, some consistent guidance offered by professional organisations would have
helped. Informed consent was required for the use of identifiable information from
every individual in any medical research study by the British Medical Association [British
Medical Association 1999], although it was not emphatically required by other
organisations [World Medical Association 1964; Royal College of Physicians 1990;
Department of Health 1996; United Kingdom Central Council for Nursing 1996;
General Medical Council 2000]. The requirements of audit and observational research
for informed consent sometimes differed [British Medical Association 1999; General
Medical Council 2000], inviting yet another unacceptable double standard in
distinguishing the two [Warlow and Al-Shahi 2000],
Thirdly, unbiased public consultation is essential to determine the ideal balance between
individual confidentiality and data protection on the one hand, and on the other the
legitimate use — in the public interest - of patient-identifiable data without consent.
Some patients may not regard their contact with the NHS as constituting implied
consent to the use of identifiable data about themselves for purposes other than their
own medical care. But surely there is an overriding public interest in unbiased
observational research into diseases about which scant data are available, and accurate
audit of medical services which may not be optimal or could be improved [General
Medical Council 2000]? Hindering this progress would be unethical [Royal College of
Physicians 1996].
17.6 Changes in privacy opinion, guidance and law in the UK
since 2000
These three suggestions for resolution have been addressed, to varying degrees, since
2000. In Scodand and Northern Ireland, where health is a devolved matter, the
evolution of the privacy struggle has differed from England and Wales.
Important new legislation in England and Wales has been incorporated into section 60
of the Health and Social Care Act (HSCA) 2001. This is intended to be an interim
measure, pending improved public awareness about the uses of their data and
satisfactory means of handling (preferably anonymising) data flows. Section 60 allows
the Secretary of State to make regulations covering the processing of patient
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information for medical purposes, where this might otherwise be subject to legal
challenge under common law. Whilst the HSCA 2001 cannot be more permissive than
the DPA 1998 allows, through a bureaucratic process involving a Patient Information
Advisory Group (PIAG), applications for legal approval of specific projects and certain
classes of research can be made, with renewal required on an annual basis.
The Confidentiality and Security Advisory Group for Scotland (CSAGS) was given the
task of addressing the legal, ethical and professional requirements on confidentiality in
NHS Scotland. It was set up in September 2000, as an independent committee,
supported by the Scottish Executive Health Department (SEHD), "to provide advice on
the confidentiality and security of health related information to the Scottish Executive,
the public and health care professionals." Approximately 150 responses to its
consultative paper of July 2001 came from the health service, including the SIVMS
Steering Committee. The CSAGS final report, published in April 2002, stopped short of
recommending a legislative solution in Scotland. CSAGS preferred consensus, informed
debate and widespread acceptance of its proposed arrangements [Fraser 2003]. It set
minimum standards, including the provision of better information to patients and the
universal adoption of a working practice of always questioning the need for any data
collected or shared to be patient-identifiable. Although requiring a public interest
defence of the use of identifiable information without explicit consent, their document
states:
'Our initial view was that explicit consent would be the requirement,
based on the ethical premise that patients have a right to know about
the use of their personal health data outwith their treatment needs
and a right to withhold consent for such uses. That ideal remains best
practice and our expectation is that it should become normal practice
as better-informed patients share in future decisions about uses of
their data. However, we have found the arguments in favour of
permitting implied consent for [disease registers] persuasive, i.e. to
safeguard valuable data for the future of services and the
improvement of the health of the population.' (paragraph 7.17)
There have been public consultation exercises about health privacy since the year 2000.
A MORI poll in 2001, asking the question, " who should see my health information?"
found the public favoured their GP (95%) over hospital care staff (87%) over medical
research staff (63%) over other GP surgery staff (44%). Another survey, conducted by
the Consumers' Association and the NHS Information Authority (NHSIA) in 2002
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{Caringfor Information, a Modelfor the Future), found the public felt that who accessed their
data was most important, not how the data were used, but that access should be limited
to 'need-to-know' uses. This latter survey was repeated in 2003 (2,300 respondents out
of 4,000 recipients i.e. 57.5% response rate); from this exercise, there evolved a 'sealed
envelope' approach to patients' health data, in which patients would permit varying
degrees of access to different portions of their data. I have reservations about whether
these studies have made a clear enough distinction between surveying the healthy public
versus patients, whether they have been representative given poor response rates, and
how practical their conclusions have been.
17.7 Discussion
Ambiguous statutory regulations, contradictory guidance and a vocal minority of
objecting patients or those representing them, might eventually thwart not only
observational research relying on patient-identifiable data, but also audit and so clinical
governance. Of course, investigators must design studies appropriately and have their
use of existing, valuable data sets sanctioned. Ethics committees must adjudicate
proposals consistently and should not have to endure the threat of court action to
determine where the public interest lies. Patients need to be better aware of the bonafide
purposes to which data about them may be put [Department of Health 1996].
At the moment, there are three means of secondary use of data in research. Firstly, data
should be anonymised wherever possible. Of course, there are various reasons why
identifiable data are needed [Black 2003]: linkage within a database, linkage between
databases, adjustment for confounding factors, ensure completeness of recruitment,
avoid double counting, investigate social factors, assess applicability of research findings,
and directly identify individuals during follow-up. Secondly, identifiable data can be used
with consent/assent. Thirdly, where neither of these approaches is possible or
practicable, patient-identifiable data have to be used without explicit consent, under a
public interest mandate.
What remains unclear is how the public interest impinges on the privacy interests of the
individual. I believe strongly in the right to confidentiality, given the good intentions of
bona fide researchers and their scrupulous attention to data security and safeguards to
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minimise disclosure [Fienberg 2001]. I believe the public interest lies in continuing
research and audit that may occasionally need to use patient-identifiable data without
explicit consent. I also believe that where every citizen has a right to state-funded
healthcare, they also have responsibilities to current and future patients by participation
in research and audit [Doll and Peto 2001]. Final clarification may be required in case
law, and some thought no doctor would be likely to seek this solution given the delay,
adverse publicity and cost involved [Smith 2001]. If a researcher were to do this, "he or
she would become a minor icon of 21st century medical research, for many lives and a
great deal of public money would be saved" [Peto et al 2004]. Sir Richard Doll has
already stepped forward [Fazackerley 2004]! The alternative to a judgement in case law is
further primary legislation. There are so many grey areas for medical research in the law,
that a 'Medical Research Bill' is called for to reassure doctors, patients and the public.
Others in the research community have also favoured a legislative solution [Brewster et
al 2001]. Although they now have one in the HSCA 2001, it is undoubtedly bureaucratic
and only intended to be temporary.
Looking back, it was the GMC guidance that caused the most confusion, and others
agree [Ellis 2001]. Interestingly, the GMC blamed the law; a GMC spokesman was
quoted in an article as saying, "it is generally accepted now that it was not the GMC's
guidance that was at fault, it was the contradictory nature of the Data Protection Act"
[Pritchard 2001], At the time of completing this thesis, the GMC released new updated
guidance (intended to be a core statement of principles, accompanied by a continually
updated booklet of 'frequently-asked questions'), but sadly their dissimilar approach to
research and audit is accentuated, not diminished. This will undoubtedly make canny
researchers recognise the similarity between their own endeavours and audit, doubtless
culminating in a re-branding of their projects. There is already anecdotal evidence that
numbers of applications to MRECs and to the ISD Privacy Advisory Committee in
Scotland are dwindling. It is unclear whether this is due to research being discouraged
by the regulatory environment, or research going by another name.
Thankfully SIVMS has survived — but not without a time-consuming, but worthwhile,
debate with the MREC, and stopping the recruitment of venous malformations because
of the difficulties this patient group caused with lack of explicit consent. Whilst SIVMS
will be exempted from authorisation bias, it will also enable me to further simulate it
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(Figure 55, page 323) to explore how much bias would have been introduced had
consent been required in every case. Resolution of the dilemma would have been much
easier if SIVMS investigators had been directly involved in the clinical care of every
patient, facilitating patient consent or assent via a relative.
In the future, SIVMS will continue to use patient-identifiable data without informed
consent (where impossible or impractical to obtain it) until challenged, using the public
interest argument. Although SEHD suggested to CSAGS that it would fund a
widespread public consultation and information campaign about the use of current and
prior data, it remains to be seen if this will happen. If it does, it will need to be large,
unbiased, and well-informed [Lawlor and Stone 2001], Alternative forms of informed
and 'community' consent [Cassell and Young 2002] may be necessary, where the public
are assumed to be informed of uses of their data at any point of contact with the health
service. What is certain is that, until the law is explicit, researchers will practice in a
climate of uncertainty and fear [Peto et al. 2004].
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Table 26 Statutory regulations and guidance on the use of patient-
identifiable data, pertinent to medical research and audit in Britain, in
reverse chronological order
Date in effect Statutory regulations
Pending European Convention on Human Rights and Biomedicine (1997)
2001 May Health and Social Care Act (2001)
2000 October United Kingdom Human Rights Act (1998)
2000 March United Kingdom Data Protection Act (1998)
1987 August European Convention for the Protection of Individuals with regard
to Automatic Processing of Personal Data (1981)
Date in effect Guidance
2004 April General Medical Council
Confidentiality: protecting and providing information
+ frequently asked questions
2002 April Confidentiality & Security Advisory Group for Scotland (CSAGS)
Protecting patient confidentiality
2000 October Medical Research Council
Personal information in medical research
2000 October World Medical Association
Declaration of Helsinki
2000 June General Medical Council
Confidentiality
1999 October British Medical Association
Confidentiality and disclosure of health information
1997 December Department of Health
Report on the review ofpatient-identifiable information (Caldicott
report)
1996 June United Kingdom Central Council for Nursing, Midwifery and
Health Visiting
Guidelines for professional practice
1996 March Department of Health
The protection and use of patient information




Figure 55 Kaplan Meier curve for all 92 adults with brain AVMs in SIVMS
1999-2000, illustrating survival free of death (all causes)
Participants are subdivided according to whether SIVMS was able to gain
their consent (upper curve, n=64), or could not obtain consent (lower curve,
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Notification
1. Collaborator notification form
2. GP mailshot
3. Notification thank you (collaborator)
4. Notification thank you (GP)
Exclusion
5. Patient excluded (GP)
6. Patient excluded (collaborator)
7. Patient excluded (collaborator notifier)
8. Patient excluded (GP notifier)
Recruitment
9. Consultant enrolment
10. Consultant (notifier) enrolment
11. Consultant enrolment (dead)
12. Consultant (notifier) enrolment (dead)
13. Consultant (not neuroscience) enrolment
14. Consultant (not neuroscience) enrolment (dead)
15. Consultant (another hospital) enrolment
16. Consultant enrolment (ISD notification)
17. GP enrolment
18. GP (notifier) enrolment
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Recruitment (continued)
19. GP enrolment (dead)
20. Change of GP
21. Patient enrolment
22. Patient enrolment (delayed)
23. Patient enrolled
24. Patient enrolled (dead)
25. Patient enrolled (details changed)
Collection of case notes
26. GP notes request
27. GP notes request (dead)
28. Hospital notes request
29. Hospital notes request (dead)
Follow-up
30. GP annual follow-up (no patient questionnaire)
31. GP annual follow-up (patient questionnaire)
32. Annual GP case notes request
33. Annual hospital case notes request
34. Patient annual questionnaire
35. Patient annual epilepsy questionnaire
36. Patient annual headache questionnaire
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flfo iv indicate the type
of fVM the patient is
diagnosed wth and
when ihe diagnosis
was fist made (by
imaging or biopsy).




Please teH us which
consultant and GP
look aflerthis paSent.
Type ft) of fWW indicate tfie quantity
AVM Brain arteriovenous malformation
CM Cavernous malformation
VM Venous malformation
DAVM Dura I arteriovenous malformation
IHT Inter med iate type
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Patients newly-diagnosed with any type of Intracranial Vascular Malformation in
1999
We would be very grateful for your help with the Scottish Intracranial Vascular
Malformation Study (SIVMS) to establish the incidence of all people affected by any type
of intracranial vascular malformation (IVM) in the Scottish population. As you know, IVMs
are an important cause of intracranial haemorrhage, epilepsy, headache, and progressive
neurological deficit in otherwise healthy young adults.
You are not likely to have many, or even any, patients on your list with this diagnosis.
However, we would be very grateful to you for taking a minute or two to list on the attached
three-stage questionnaire any patients, about whom we have not already contacted you,
who you know fulfil the following criteria:
+ 1st diagnosed AFTER 1st JANUARY 1999




Dural arteriovenous fistula (DAVF)
^ Age 16 years or over
SIVMS is a prospective, observational study of all
patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1S| January
1999. The study is based in the departments of
Neuroradiology, Neurology, Neurosurgery and
Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network encompasses all the
other Radiology Departments in the country. We aim to
register all patients with an IVM in Scotland to better
define the epidemiology of these rare, but important
conditions. Data will be collected from individuals'
medical records. Copies of their imaging will be stored
for further analysis. Patient confidentiality will be
respected at all times. We have the approval of the
Scottish Multicentre Research Ethics Committee and
your Local Research Ethics Committee. The protocol
is available on request, or from our website.
Please do not bother to return the form if you do not have any suitable patients. If you
would like to obtain any patient's permission for the release of this information, we enclose
a letter that you could send to them for this purpose. Please let us know if you require
administrative or financial assistance in approaching any of your patients who meet these
inclusion criteria. Thank you very much for your help.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Trainina Fellow Professor of Medical Neuroloav
Steering Committee
Aberdeen: Mr DG Currie, Dundee: Dr RC Roberts, Edinburgh: Dr R Al-Shahi, Dr RJ Sellar, Professor CP Warlow, Glasgow: Dr JJ Bhattacharya, Mr V Papanastassiou
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February 2000
Dear
Re. The Scottish Intracranial Vascular Malformation Study
I wonder if you would be prepared to help Professor CP Warlow and his team of
researchers at all the other Neuroscience Departments across Scotland with a study they
are conducting? They are trying to find out how many people in Scotland are affected by a
type of tangle of blood vessels in the head, called an intracranial vascular malformation, or
'IVM' for short. I am writing to you because I believe you have one of these IVMs, or have
been affected by one in the past.
Their study has full approval from the relevant ethics committees. It involves examining
your case notes to extract a few details of your medical history, and sending you a
questionnaire once each year. They will ensure that any information collected about you
will be confidential and used only for their study.
Could you please return the tear-off slip to me, indicating whether you are happy for me to




Please / appropriate box
Yes No
I am happy for Professor Warlow, or a member of
his team, to examine my case notes ' '
Signature Date
Print your name
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Department of Clinical Neurosciences \*
Bramwell Dott Building
Western General Hospital » - I j
Crewe Road £ tiPPPPPVt *
Edinburgh EH4 2XU















«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname»'s recent
diagnosis of an intracranial vascular malformation (IVM). We will now wait four weeks
before sending any study enrollment forms to his GP and hospital consultant. We enclose
a blank notification form to replace the completed form you have just sent us, for the next
patient you see with a new diagnosis of an IVM!
Yours Sincerely,
Dr Rustam Al-Shahi
MRC Clinical Training Fellow
Sivms No.«PatlD»
Prof. Charles P. Warlow
Professor of Medical Neurology
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«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname»'s recent
diagnosis of an intracranial vascular malformation (IVM). We will now start our process of
carefully validating the diagnosis, and approaching the patient for his consent to
participate in this observational study if you and their hospital consultant deem them
suitable for postal consent.
Many Thanks,
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
SIVMS No.«PatlD»
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VPSC.I,,
Department of Clinical Neurosciences ■>
Bramwell Dott Building 4* J -'■» '
Western General Hospital £ 1 I * « j
1 IIP!Crewe Road
Edinburgh EH4 2XU
tel/fax: 0131 537 2944
e-mail: sivms@skull-dcn.ed ac.uk t











«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
Your patient, «PatTitle» «PatSurname», was considered for inclusion in the Scottish
Intracranial Vascular Malformation Study. Because you may have spoken or written to her
about the study, we wanted to let you know that she has, in fact, been excluded because
she does not have one of the diagnoses we are looking for. Feel free to contact us should
you have any questions.
Yours Sincerely.
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
SIVMS No.«PatlD»
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Department of Clinical Neurosciences
Bramwell Dott Building <}
Western General Hospital p
Crewe Road J
Edinburgh EH4 2XU







Re. «PatTitle» «PatForename» «PatSurname»,
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
Your patient, «PatTitle» «PatSurname», was considered for inclusion in the Scottish
Intracranial Vascular Malformation Study. Because you may have spoken or written to her
about the study, we wanted to let you know that she has, in fact, been excluded because
she does not have one of the diagnoses we are looking for. Feel free to contact us should
you have any questions.
Many Thanks,
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
SIVMS No.«PatlD»
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Department of Clinical Neurosciences
Bramwell Dott Building
Western General Hospital p
Crewe Road J
Edinburgh EH4 2XU
tel/fax: 0131 537 2944 ^






Re. «PatTitle» «PatForename» «PatSurname», DOB «PatDOB»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname» for the purposes
of our study. Since you may have spoken or written to «PatTitle» «PatSurname» about the
study, we wanted to let you know that she has, in fact, been excluded because she does





MRC Clinical Training Fellow
SIVMS No.«PatlD»
Prof. Charles P. Warlow
Professor of Medical Neurology
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VP"»"nj. .
Department of Clinical Neurosciences
Bramwell Dott Building A "
Western General Hospital j! fe o 1 %
Crewe Road » »
Edinburgh EH4 2XU
tel/fax: 0131 537 2944
■11









Re. «PatTitle» «PatForename» «PatSurname»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname» for the purposes
of our study. Since you may have spoken or written to «PatTitle» «PatSurname» about the
study, we wanted to let you know that he has, in fact, been excluded because he does not




Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
SIVMS No.«PatlD»
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«PatAddress1» «PatAddress2» «PatAddress3», «PatCity» «PatPostCode»
«PatTitle» «PatSurname» under your care has been put forward for the Register of the
Scottish Intracranial Vascular Malformation Study (SIVMS). We are writing to ask you to
check the accuracy of the information we have been supplied with, and ensure that
«PatTitle» «PatSurname» is still alive and aware of her diagnosis. Please could you also
indicate whether it is appropriate to approach her by post and whether you are happy for
us to have access to her hospital records for the purpose of this research project?
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1sl January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their angiograms will be stored for further analysis. As of January 2001, of the patients we approach,
11% do not reply to our enrolment letter, only 2% decline to complete an annual questionnaire, and
87% agree to participate and complete annual questionnaires. We will be sending the patient's GP a
very brief annual questionnaire to determine if the patient is still alive and, if so, whether they have been
admitted to hospital in the preceding year. If they are still alive and appropriate for continued follow-up,
the patient will receive an annual quality of life questionnaire if they have already agreed to receive it.
There will be no additional therapeutic interventions over and above the care they are already receiving.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
Would you please complete the enclosed five-step form and return it to us at your earliest
convenience in the freepost envelope supplied. Do not hesitate to contact us if you have
any further questions.
Yours Sincerely,
Department of Clinical Neurosciences ■»,
Bramwell Dott Building j* , '
Western General Hospital # [" ' %
Crewe Road
Edinburgh EH4 2XU






Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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Date of first diagnosis 07/06/00
«patientName» is still alive
She is aware of her diagnosis of an IVM (as above)












It is appropriate to send her a postal consent form, if her
consultant also approves










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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tel/fax: 0131 537 2944
e-mail: sivms@skull.dcn.ed.ac.uk
web: http://www.dcn.ed.ac.uk/ivm/









«PatAddress1» «PatAddress2» «PatAddress3», «PatCity» «PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname»'s recent
diagnosis of an intracranial vascular malformation (IVM). We are writing to ask you to
check the accuracy of the information we have, and ensure that «PatTitle» «PatSurname»
is still alive and aware of her diagnosis. Please could you also indicate whether it is
appropriate to approach her by post and whether you are happy for us to have access to
her hospital records for the purpose of this research project?
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their angiograms will be stored for further analysis. As of January 2001, of the patients we approach,
11% do not reply to our enrolment letter, only 2% decline to complete an annual questionnaire, and
87% agree to participate and complete annual questionnaires. We will be sending the patient's GP a
very bn'efannual questionnaire to determine if the patient is still alive and, if so, whether they have been
admitted to hospital in the preceding year. If they are still alive and appropriate for continued follow-up,
the patient will receive an annual quality of life questionnaire if they have already agreed to receive it.
There will be no additional therapeutic interventions over and above the care they are already receiving.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
Would you please complete the enclosed five-step form and return it to us at your earliest
convenience in the freepost envelope supplied. Do not hesitate to contact us if you have
any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollment\consultant reg letter notif.doc SIVMS No. «PatlD»
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«PatTitle» «PatSurname» is still alive
She is aware of her diagnosis of an IVM (as above)
I agree to grant access to her hospital records for the



















Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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vVt.SI«I0,
Department of Clinical Neurosciences ^
Bramwell Dott Building ^
Western General Hospital » HHI
Crewe Road y JPVPPVWk ft
Edinburgh EH4 2XU
















«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
«PatTitle» «PatSurname», who has been under your care and died on «PatDeathDate»,
has been put forward for the Register of the Scottish Intracranial Vascular Malformation
Study (SIVMS). We are writing to ask you to check the accuracy of the information we
have been supplied with, and to ask for access to his hospital records for the purpose of
this research project.
• SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments of
Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience centres.
Our collaborative network also encompasses all the other Radiology Departments in the country. We aim
to register all patients with an IVM in Scotland to better define the epidemiology of these rare, but
important conditions. Data will be collected from individuals' medical records. Copies of their imaging will
be stored for further analysis. Patient confidentiality will be respected at all times. We have the
approval of the Multicentre Research Ethics Committee for Scotland and your Local Research
Ethics Committee.
Would you please complete the enclosed three-step form and return it to us at your
earliest convenience in the freepost envelope supplied. Do not hesitate to contact us if you
have any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollment\consultant reg letter (dead)2.doc. SIVMS No.«PatlD»
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| I agree to grant access to her hospital records for the O
'
purpose of this research project









Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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tel/fax: 0131 537 2944
e-mail: sivrns@skull.dcn.ed.ac.uk
web: http://www.dcn.ed.ac.uk/ivm/










«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
Thank you very much for letting us know about «PatTitle» «PatSurname»'s recent
diagnosis of an intracranial vascular malformation (IVM) for the purposes of the Scottish
Intracranial Vascular Malformation Study (SIVMS). Because they were under your care
and died on «PatDeathDate», we are writing to ask you to check the accuracy of the
information we have been supplied with, and to ask for access to «PatTitle»
«PatSurname»'s hospital records for the purpose of this research project.
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their imaging will be stored for further analysis. Patient confidentiality will be respected at all times.
We have the approval of the Multicentre Research Ethics Committee for Scotland and your
Local Research Ethics Committee.
Would you please complete the enclosed three-step form and return it to us at your
earliest convenience in the freepost envelope supplied. Do not hesitate to contact us if you
have any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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| I agree to grant access to her hospital records for the LH
purpose of this research project









Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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Department of Clinical Neurosciences
Bramwell Dott Building tf
Western General Hospital £
Crewe Road J
Edinburgh EH4 2XU





«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
«PatTitle» «PatSurname», who has been under your care, has been put forward for the
Register of the Scottish Intracranial Vascular Malformation Study (SIVMS). We are writing
to ask you to check the accuracy of the information we have been supplied with, and
ensure that «PatTitle» «PatSurname» is still alive and aware of his diagnosis. Please
could you also indicate whether it is appropriate to approach him by post and whether you
are happy for us to have access to his hospital records for the purpose of this research
project?
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their angiograms will be stored for further analysis. As of January 2001, of the patients we approach,
11% do not reply to our enrolment letter, only 2% decline to complete an annual questionnaire, and
87% agree to participate and complete annual questionnaires. We will be sending the patient's GP a
very brief annual questionnaire to determine if the patient is still alive and, if so, whether they have been
admitted to hospital in the preceding year. If they are still alive and appropriate for continued follow-up,
the patient will receive an annual quality of life questionnaire if they have already agreed to receive it.
There will be no additional therapeutic interventions over and above the care they are already receiving.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
If you have referred «PatTitle» «PatSurname» to a Neurologist or Neurosurgeon, please
let us know who they are so that we can seek their consent for this patient's enrolment in
our study. If not, would you please complete the enclosed five-step form and return it to us
at your earliest convenience in the freepost envelope supplied.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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«PatTitle» «PatSurname» is still alive □ □
She is aware of her diagnosis of an IVM (as above)
I agree to grant access to her hospital records for the





It is appropriate to send her a postal consent form, if her
GP also approves










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
«PatTitle» «PatSurname», who has been under your care and died on «PatDeathDate»,
has been put forward for the Register of the Scottish Intracranial Vascular Malformation
Study (SIVMS). We are writing to ask you to check the accuracy of the information we
have been supplied with, and to ask for access to «PatTitle» «PatSurname»'s hospital
records for the purpose of this research project.
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1sl January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their imaging will be stored for further analysis. Patient confidentiality will be respected at all times.
We have the approval of the Multicentre Research Ethics Committee for Scotland and your
Local Research Ethics Committee.
If a Neurologist or Neurosurgeon looked after «PatTitle» «PatSurname» prior to his death,
please let us know who they are so that we can seek their consent for this patient's
enrolment in our study. If not, would you please complete the enclosed three-step form
and return it to us at your earliest convenience in the freepost envelope supplied. Do not
hesitate to contact us if you have any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\rnaterials\enrollment\consultant reg letter not neuro (dead).doc. SIVMS No.«PatlD»
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Edinburgh EH4 2XU
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I agree to grant access to his hospital records for the O
purpose of this research project










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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«PatAddress1» «PatAddress2» «PatAddress3» , «PatCity» «PatPostCode»
«PatTitle» «PatSurname», who has been under your care, has been put forward for the
Register of the Scottish Intracranial Vascular Malformation (IVM) Study. Although
«PatTitle» «PatSurname» is also under the care of «mainCons» at the «MainCentre» for
his IVM(s), we are writing to ask for access to his medical records at your hospital for the
purpose of this research project.
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their angiograms will be stored for further analysis. As of January 2001, of the patients we approach,
11% do not reply to our enrolment letter, only 2% decline to complete an annual questionnaire, and
87% agree to participate and complete annual questionnaires. We will be sending the patient's GP a
very brief annual questionnaire to determine if the patient is still alive and, if so, whether they have been
admitted to hospital in the preceding year. If they are still alive and appropriate for continued follow-up,
the patient will receive an annual quality of life questionnaire if they have already agreed to receive it.
There will be no additional therapeutic interventions over and above the care they are already receiving.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
Could you please complete the enclosed two-step form and return it to us at your earliest
convenience in the freepost envelope supplied. Do not hesitate to contact us if you have
any further questions.
Yours Sincerely,
Department of Clinical Neurosciences tic
Bramwell Dott Building ^ Mny ^
Western General Hospital f J, s \
Crewe Road J VW •
Edinburgh EH4 2XU - L'Sl •
tel/fax: 0131 537 2944 % flLLlL *
e-mail: sivms@skull.dcn.ed.ac.uk t £
web: http://www.dcn.ed.ac.uk/ivm/ y%
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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Patient name «patientName»












I agree to grant access «PatTitle» «PatSurname»'s EH EH
hospital records for the purpose of this research project









Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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We would be very grateful for your help with the Scottish Intracranial Vascular
Malformation Study (SIVMS) to establish the incidence of all people affected by any type
of intracranial vascular malformation (IVM) in the Scottish population. We have the full
approval of the relevant ethics committees. We may have been in touch with you before,
in which case we are sorry if any information has been duplicated.
We believe that «Field10» «Field9» was diagnosed with
a/an «IVM» whilst under your care between
«DateAdmission» and «DateDischarge». We are writing to
ask if you would kindly check the accuracy of the
information we have been supplied with. We have
acquired this information from routine coding of hospital
discharge data, which can occasionally be inaccurate. We
would be very grateful if you could complete the enclosed
form and return it to us at your earliest convenience in the
freepost envelope supplied. If the diagnostic information is
inaccurate, we are sorry to have bothered you
unnecessarily, but please return the form anyway. Do not
hesitate to contact us if you have any questions. Thank
you in advance for your help.
Inclusion criteria
1st diagnosed AFTER 1 JANUARY 99




Dural arteriovenous fistula (DAVF)
Resident in Scotland
Age 16 years or over at diagnosis
Exclusion criteria
An aneurysm ON ITS OWN
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
\\dcn-skull\vol1\trialdev\sivms\i.s.d\consultant isd inquiry.doc Link number «Field1»
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Patient Name «Field10» «Field9»




Resident in Scotland at «Field14» □ □
IVM type . «ivm» EH EH
Date of FIRST EVER diagnosis between «Admission» and «Discharge» 1
«Field10» «Field9» is still alive □ □
If any of the answers to questions 1 -4 were 'No', please comment here...
She is aware of her diagnosis of an IVM (as above) EH EH
I am willing to grant access to her hospital records just for the !
purpose of this research project
Is it appropriate to approach her with a postal consent form
and information leaflet, if her GP also approves?
If 'No', please comment:
If you are no longer looking after «Field10» «Field9», please let










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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tel/fax: 0131 537 2944
e-mail: sivms@skull.dcn.ed.ac.uk
web: http://www.dcn.ed.ac.uk/ivm/









«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
We would like to contact «PatTitle» «PatSurname», who has been put forward for the
Register of the Scottish Intracranial Vascular Malformation Study (SIVMS). We are often
told about new cases by Radiologists, so you may receive this letter before seeing the
imaging report or hospital correspondence. We are writing to ask if you would kindly check
the accuracy of the information we have been supplied with and that «PatTitle»
«PatSurname» is still alive and aware of her diagnosis. Please could you also indicate
whether it is appropriate to approach her by post and whether you are happy for us to have
access to her GP records for the purpose of this research project only (we are happy to
discuss remuneration)?
SIVMS is a prospective, observational study of all patients in Scotland with any type of intracranial
vascular malformation (IVM). The study is based in all four Scottish Neuroscience centres and our
collaborative network also encompasses all the other Radiology Departments in the country. We aim
to register all patients with an IVM in Scotland to better define the epidemiology of these rare, but
important conditions. Data will be collected from individuals' medical records. As of January 2001, of
the patients we approach, 11% do not reply to our enrolment letter, only 2% decline to complete an
annual questionnaire, and 87% agree to participate and complete annual questionnaires. We would
like to send you a very brief annual questionnaire to collect vital follow-up information about
«patientName» that may only be known to you. If the patient is still alive and appropriate for continued
follow-up, they will receive an annual quality of life questionnaire if they have already agreed to
receive it. There will be no additional therapeutic interventions over and above the care they are
already receiving. For your interest, the protocol is enclosed.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
We would be very grateful if you could complete the enclosed five-step form and return it to
us in the freepost envelope supplied. Do contact us if you have any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollrnent\gp reg Ietter2.doc SIVMS No.«PatlD»
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«patientName» is still alive
She is aware of her diagnosis of an IVM (as above)











It is appropriate to send her a postal consent form, if her Q Q
consultant also approves










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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Re. «patientName». DoB «PatDOB»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
We are about to contact «PatTitle» «PatSurname», whom you kindly put forward for the
Register of the Scottish Intracranial Vascular Malformation Study (SIVMS). We are writing to
ask you to check the accuracy of the information we have, and ensure that «PatTitle»
«PatSurname» is still alive and aware of her diagnosis. Please could you also indicate
whether it is appropriate to approach her by post and whether you are happy for us to have
access to her GP records for the purpose of this research project only?
SIVMS is a prospective, observational study of all patients in Scotland diagnosed with any type of
intracranial vascular malformation (IVM) after 1st January 1999. The study is based in the departments
of Neuroradiology, Neurology, Neurosurgery and Neuropathology in all four Scottish Neuroscience
centres. Our collaborative network also encompasses all the other Radiology Departments in the
country. We aim to register all patients with an IVM in Scotland to better define the epidemiology of
these rare, but important conditions. Data will be collected from individuals' medical records. Copies of
their angiograms will be stored for further analysis. As of January 2001, of the patients we approach,
11 % do not reply to our enrolment letter, only 2% decline to complete an annual questionnaire, and 87%
agree to participate and complete annual questionnaires. We will be sending the patient's GP a very
brief annual questionnaire to determine if the patient is still alive and, if so, whether they have been
admitted to hospital in the preceding year. If they are still alive and appropriate for continued foliow-up,
the patient will receive an annual quality of life questionnaire if they have already agreed to receive it.
There will be no additional therapeutic interventions over and above the care they are already receiving.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
Would you please complete the enclosed five-step form and return it to us at your earliest
convenience in the freepost envelope supplied. We enclose a copy of the study protocol. Do
not hesitate to contact us at the number above if you have any further questions.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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Date of first diagnosis Unknown
«patientName» is still alive
She is aware of her diagnosis of an IVM (as above)











It is appropriate to send her a postal consent form, if her Q Q
consultant also approves










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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«PatAddress1» «PatAddress2» «PatAddress3», «PatCity» «PatPostCode»
«PatTitle» «PatSurname» has been put forward for the Register of the Scottish Intracranial
Vascular Malformation Study (SIVMS). We are occasionally told about new cases by
Pathologists, so you may receive this letter before seeing the post mortem report or
hospital correspondence. We are writing to ask if you would kindly check the accuracy of
the information we have been supplied with and, in particular, to ask for access to her GP
medical records for the purpose of this research project only.
SIVMS is a prospective, observational study of all patients in Scotland with any type of intracranial
vascular malformation (IVM). The study is based in all four Scottish Neuroscience centres and our
collaborative network also encompasses all the other Radiology Departments in the country. We aim
to register all patients with an IVM in Scotland to better define the epidemiology of these rare, but
important conditions. Data will be collected from individuals' medical records. For your interest, we
enclose a copy of the study protocol.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
We would be very grateful if you could complete the enclosed four-step form and return it
to us in the freepost envelope supplied. Do contact us if you have any further questions.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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«PatTitle» «PatSurname» is dead □ □
I agree to grant access to her GP records for the purpose
of this research project only
If 'No', please comment:
□ □
| Please tell us where the GP notes are located (e.g.









Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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Re. «patientName» Date of birth «PatDOB»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
We believe «patientName» has recently become your patient. He is already registered with
the Scottish Intracranial Vascular Malformation Study (SIVMS), because we have been told
that he had a diagnosis of «IVMType» on 12/10/99. We would like to inform you about his
inclusion in our study, and ask you to kindly return the attached sheet to us in the freepost
envelope provided.
SIVMS is a prospective, observational study of all patients in Scotland with any type of intracranial
vascular malformation (IVM). The study is based in all four Scottish Neuroscience centres and our
collaborative network also encompasses all the other Radiology Departments in the country. We aim
to register all patients with an IVM in Scotland to better define the prognosis and treatment of these
rare, but important conditions. Data will be collected from individuals' medical records.
We would like to send you a very brief annual questionnaire to determine if «patientName» is still alive
and if so, whether he has been admitted to hospital in the preceding year. If he is still alive and
appropriate for continued follow-up, he will receive an annual quality of life questionnaire. There will
be no additional therapeutic interventions over and above the care he is already receiving. For your
interest, the protocol is enclosed.
Patient confidentiality will be respected at all times. We have the approval of the Multicentre
Research Ethics Committee for Scotland and your Local Research Ethics Committee.
We would be very grateful to you for completing the enclosed form and returning it to us in
the freepost envelope supplied. Do contact us if you have any further questions.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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«patientName»'s last GP, «oldGP» at «oldPrac», «oldAdd1» «oldAdd2», «oldCity» gave us
the following answers on «PatGPLetterResponse» - please amend or complete the
answers if applicable:
Can we have access to «patientName»'s GP notes? Yes
Did «oldGP» think «patientName» is aware of his yeg
diagnosis?
Overall decision (taking into account «CollTitle»
«CollForename» «CollSurname»'s opinion) about whether Yes
«patientName» is aware of his diagnosis
Did «oldGP» think it appropriate to send «patientName» a
consent form (and annual quality of life questionnaire, if Yes
he agrees)?
Overall decision (taking into account «CollTitle»
«CollForename» «CollSurname»'s opinion) to approach No
«patientName» by post
Has «patientName» consented to join the study yet? Yes
Please sign below and return this form to us in the freepost envelope provided, to indicate










Please return this form in the freepost envelope provided to: SIVMS, Department of
Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU
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13 March 2003














Re. «name», «PatAddress1», «PatAddress2», «PatAddress3»
«PatCity» «PatPostCode» Date of birth «PatDOB»
Thank you for replying to our last letter about «PatTitle» «PatSurname» on
«PatGPLetterResponse».
We are sorry to have to bother you about our study again, but we would be grateful for
your help to avoid "cold-calling" «PatTitle» «PatSurname» ourselves, yet obtain her
consent to join our study to gain important information about the prognosis and treatment
of her condition.
All we are asking you to do is to sign the enclosed letter from yourself to «PatTitle»
«PatSurname», unless you wish to re-draft it, and post it with the enclosed package to her
in the pre-paid envelope provided. The forms and pre-paid envelope are designed to make
the task as easy and inexpensive for you as possible.
We are sorry to bother you with what we hope will be a small task. We have been
instructed to approach patients in this way by the Multicentre Research Ethics Committee
for Scotland. Do contact us if you have any questions or comments.
Thank you in advance for your support.
Yours Sincerely
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
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I am writing to you on behalf of Professor Charles Warlow and colleagues in the
Department of Clinical Neurosciences at the Western General Hospital in Edinburgh. They
are running the Scottish Intracranial Vascular Malformation Study (SIVMS). SIVMS is a
medical research study that gathers information about people with any type of intracranial
vascular malformation, known as 'IVMs' for short. As a result of your recent tests at the
«CentreName», they understand you may be affected by this medical condition.
Please could you read the enclosed information leaflet, which gives further information
about the study? If you are willing to take part, I would be very grateful if you would
complete the consent form and SIVMS Questionnaire, and return them in the enclosed
freepost envelope to the study team in Edinburgh as soon as you can. They would be very
pleased if you took part so that we can all find out more about IVMs and how to manage
them better.
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1. Have you read the information leaflet? □ □
2. Has the leaflet given you enough information about the study? □ □
3. Have you been offered an opportunity to ask questions and
discuss this study (see leaflet)? □ □
4. If so, have you received satisfactory answers to your questions? □ □
5. Do you understand that participation is entirely voluntary? □ □
6. Do you understand that you are free to withdraw from the
study:
at any time? □ □
without having to give a reason for withdrawing? □ □
without this affecting your future medical care? □ □
Are you happy to receive a short questionnaire once a year? □ □
Can we have access to your medical records, for the











Now return this to us in the freepost envelope. Thank you!
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Your title «PatTitle»
Your first name «PatForename»
Your middle initials «Patlnitials»
Your surname «PatSurname»





Telephone number «PatTelephone» please supply if missing







Who is your next of kin?
What is their telephone number?
What is your marital status?
Are you? male go to 8 female go to
6
Maiden name (if applicable)
How many children have you had?
8 Which hand do you write with? Right [□ Left ] Both □
9 What is your ethnic origin?
□ □(please tick one) White Pakistani
Black-Caribbean u Bangladeshi u
Black-African 11 Chinese I
Black-other □ Indian □
Other □
Please go to page 2...
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We have been told you have «IVMType»
It was first diagnosed on «PatDiagnosisDate»
You are looked after by «collName»
at the following hospital «CentreName»




14 Please list any other medical problems you may have
15 Please list any pills, tablets or other treatments you are taking
15 Has anyone in your family had a brain haemorrhage, epilepsy or
an abnormal tangle of blood vessels in their brain like yours?
Please tick one box
yesn
n°d
17 Is there anything else that you think we should know, or that you
would like to add?
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13 March 2003














Re. «name», «PatAddress1», «PatAddress2», «PatAddress3»
«PatCity» «PatPostCode» Date of birth «PatDOB»
Thank you for replying to our annual questionnaire about «PatTitle» «PatSurname» on
«LastOfAGReplyDate», in which you indicated that it is now appropriate for us to approach
him for his consent to join the study, when it had not been in the past.
We are sorry to have to bother you about our study again, but we need your help to avoid
"cold-calling" «PatTitle» «PatSurname» ourselves, yet obtain his consent to join our study
to gain important information about the prognosis and treatment of his condition.
All we are asking you to do is to sign the enclosed letter from yourself to «PatTitle»
«PatSurname», unless you wish to re-draft it, and post it with the enclosed package to her
in the pre-paid envelope provided. The forms and pre-paid envelope are designed to make
the task as easy and inexpensive for you as possible.
We are sorry to bother you with what we hope will be a small task. We have been
instructed to approach patients in this way by the Multicentre Research Ethics Committee
for Scotland. Do contact us if you have any questions or comments.
Thank you in advance for your support.
Yours Sincerely
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\eriroliment\patient recruitment letter in the future.doc SIVMS No.«PatlD»
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I am writing to you on behalf of Professor Charles Warlow and colleagues in the
Department of Clinical Neurosciences at the Western General Hospital in Edinburgh. They
are running the Scottish Intracranial Vascular Malformation Study (SIVMS). SIVMS is a
medical research study that gathers information about people with any type of intracranial
vascular malformation, known as 'IVMs' for short. As a result of your recent tests at the
«CentreName», they understand you may be affected by this medical condition.
Please could you read the enclosed information leaflet, which gives further information
about the study? If you are willing to take part, I would be very grateful if you would
complete the consent form and SIVMS Questionnaire, and return them in the enclosed
freepost envelope to the study team in Edinburgh as soon as you can. They would be very
pleased if you took part so that we can all find out more about IVMs and how to manage
them better.
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ti* 4f
«name» Ifebk*''
«PatAddress1» / H \ S I V M S








1. Have you read the information leaflet? □ □
2. Has the leaflet given you enough information about the study? □ □
3. Have you been offered an opportunity to ask questions and
discuss this study (see leaflet)?
□ □
4. If so, have you received satisfactory answers to your questions? □ □
5. Do you understand that participation is entirely voluntary? □ □
6. Do you understand that you are free to withdraw from the
study:
at any time? □ □
without having to give a reason for withdrawing? □ □
without this affecting your future medical care? □ □
Are you happy to receive a short questionnaire once a year? □ □
Can we have access to your medical records, for the
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Your title «PatTitle»
Your first name «PatForename»
Your middle initials «Patlnitials»
Your surname «PatSurname»





Telephone number «PatTelephone» please supply if missing
email address please supply if missing
2 Who is your next of kin?
3 What is their telephone number?
4 What is your marital status?
5 Are you?
6 Maiden name (if applicable)
7 How many children have you had?
male go to 8 female go to
6
Which hand do you write with? Right □ Left [ ] Both
What is your ethnic origin?









Please go to page 2...
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We have been told you have «IVMType»
It was first diagnosed on «PatDiagnosisDate»
You are looked after by «collName»
at the following hospital «CentreName»




14 Please list any other medical problems you may have
15 Please list any pills, tablets or other treatments you are taking
15 Has anyone in your family had a brain haemorrhage, epilepsy or
an abnormal tangle of blood vessels in their brain like yours?
Please tick one box
YesD
NoQ
17 Is there anything else that you think we should know, or that you
would like to add?
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Re. «name», «PatAddress1» «PatAddress2» «PatAddress3» «PatCity»
«PatPostCode»
Enrolment of your patient, «name», with SIVMS is now complete and her status in the
study is as follows:
Type of intracranial vascular malformation «IVMType»
Date of first diagnosis «PatDiagnosisDate»
Access to GP records No
Access to hospital records No
Will «PatTitle» «PatSurname» receive
questionnaires?
No
Thank you for your collaboration. Feel free to contact us if you have any questions or
comments about the study.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollment\gpconsultant patient enrolled.doc SIVMS «PatlD»
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Re. «name», «PatAddress1» «PatAddress2» «PatAddress3», «PatCity»
«PatPostCode»
Although we are aware that «PatTitle» «PatSurname» died on «PatDeathDate», and we
will not be attempting to contact any members of her family, we want to let you know that
SIVMS holds data about her, and that her status in the study is as follows:
Type of intracranial vascular malformation «IVMType»
Date of first diagnosis «PatDiagnosisDate»
Date of death «PatDeathDate»
Access to GP records? No
Access to hospital records? No
Will «PatTitle» «PatSurname» receive
questionnaires?
No
Thank you for your collaboration. Feel free to contact us if you have any questions or
comments about the study.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollment\gpconsultant patient enrolled (dead).docSIVMS «PatlD»
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Department of Clinical Neurosciences
Bramwell Dott Building
Western General Hospital ,
Crewe Road J
Edinburgh EH4 2XU "







«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatDistrict»
«PatPostCode»
Enrolment of your patient, «PatTitle» «PatSurname», with SIVMS is now complete and her
status in the study is as follows:
Type of intracranial vascular malformation IVM type
IVM type
Date of first diagnosis Date
Access to GP records «PatGPRecordsConsent»
Access to hospital records «RegNotesAccess »
Will «PatTitle» «PatSurname» receive questionnaires? «PatQConsent»
Thank you for your collaboration. Feel free to contact us if you have any questions or
comments about the study.
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\enrollment\gpconsultant patient enrolled changed.doc SIVMS 267
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«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
We are writing to request copies of «patientName»'s case-notes. She is enrolled with the
Scottish Intracranial Vascular Malformation Study, and you previously indicated that you
would be happy for us to have access to her GP notes.
We would be very grateful if you could now send us copies of the following:
a) your referral letter(s) and hospital clinic letters relevant to «patientName»'s IVM
b) discharge summaries relevant to «patientName»'s IVM
c) reports of brain imaging
d) a computerised diagnostic summary sheet, if your practice produces them
We do not require copies of our own letters or forms that we have sent to you.
If your practice staff cannot provide these copies or there is a charge for providing them,
we would be very happy to discuss with them how best to arrange for copies to be made,
perhaps by sending the notes to us. Would you please attach the enclosed label to the
front of «PatTitle» «PatSurname»'s practice notes to ensure they are not destroyed, as
SIVMS is a long-term study and we hope to follow-up the patients for many years, possibly
decades. We enclose a freepost envelope for your reply.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\medical recordstgpcasenotesrequestletter (alive).doc SIVMS No.«PatlD»
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Dear «Practitioner Services Manager»
Re: «Patient_Name», nee Maiden Name
«PatAddress1» «PatAddress2» «PatAddress3», «PatCity» «PatPostCode»
Date of birth «PatDOB», Date of death «PatDeathDate»
under the care of «GPTitle» «GPForename» «GPInitials» «GPSurname»
at «GPPracticeName»
We are writing to request copies of «PatTitle» «PatSurname»'s notes, because she is
registered with the Scottish Intracranial Vascular Malformation Study. Although she is
dead, it is important that we collect information from her notes. Please could we have
copies of any clinic letters, discharge summaries and reports of brain imaging that have
been produced since we last requested them on «PatGPDateNotesRequested». Please
attach the enclosed label to the front of her case-notes to prevent them from being
destroyed, as SIVMS is a long-term study.
We enclose a copy of approval given by her GP, allowing us to gain access to her case-
notes. We also enclose a copy of the study protocol and copies of approval for our study's




Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\medical recordslgpcasenotesrequestletter (deceased).doc SIVMS No. «PatlD»
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13 March, 2003
















Re: «patientName», «PatAddress1» «PatAddress2» «PatAddress3» «PatCity»
«PatDistrict» «PatPostCode»
Date of birth «PatDOB»
Hospital No. «RegHospitalNo»
under the care of «collname»
We are writing to request copies of the case-notes for «PatTitle» «PatSurname», who is
enrolled with the Scottish Intracranial Vascular Malformation Study. Please could we have
copies of:
• clinic letters and discharge summaries from the correspondence section
• neuroradiology and neuropathology reports from the investigation section
Please attach the enclosed label to the front of the patient's case-notes to prevent them
from being destroyed, as SIVMS is a long-term study.
We enclose a copy of the approval from the patient's consultant, allowing us to gain
access to the case-notes. If you wish, we would be happy to send you a copy of the study
protocol and copies of approval for our study's methods from the Multi-Centre Research
Committee for Scotland and your Local Research Ethics Committee.
Many Thanks,
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\medical recordsMiospitalcasenotesrequestletter (dead or alive).doc SIVMS No.«PatlD»
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13 March, 2003
















Re: «patientName», «PatAddress1» «PatAddress2» «PatAddress3» «PatCity»
«PatDistrict» «PatPostCode»
Date of birth «PatDOB», Date of death «PatDeathDate»
Hospital No. Unknown«RegHospitalNo»
under the care of «collname»
We are writing to request copies of the case-notes for «PatTitle» «PatSurname», who is
enrolled with the Scottish Intracranial Vascular Malformation Study. Please could we have
copies, , of:
• clinic letters and discharge summaries from the correspondence section
• neuroradiology and neuropathology reports from the investigation section
We enclose a copy of the approval from the patient's consultant, allowing us to gain
access to the case-notes. Please attach the enclosed label to the front of the patient's
case-notes to prevent them from being destroyed, as SIVMS is a long-term study. If you
wish, we would be happy to send you a copy of the study protocol and copies of approval
for our study's methods from the Multi-Centre Research Committee for Scotland and your
Local Research Ethics Committee.
Many Thanks,
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivrns\medica! records\hospitalcasenotesrequestletter (dead).doc SIVMS No.«Pat!D»
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Department of Clinical Neurosciences ^9 V
Bramwell Dott Building j? ■.■■■*■■ \
Western General Hospital » V.'
Crewe Road J rtP^
Edinburgh EH4 2XU fj?* i r i i h ■ 3
tel/fax: 0131 537 2944 - %• ■' „
e-mail: sivms@skull.dcn.ed.ac.uk j
web: http://www.dcn.ed.ac.uk/ivm/ ggp y<
13 March, 2003






Re. «PatTitle» «PatForename» «Patlnitials» «PatSurname»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
It is now approximately one year since we last checked «PatTitle» «PatSurname»'s
participation in the Scottish Intracranial Vascular Malformation Study (SIVMS). Although we
do follow-up «PatTitle» «PatSurname» through her hospital notes, there is vital follow-up
information that only you will be able to help us with.
For this reason, we have also enclosed a letter asking for copies of recent records held in
her GP notes relating to this follow-up information.
We would therefore be very grateful if you could please check the details on the attached
sheet and return the seven-step form with the relevant copies of her GP notes, if
appropriate, to us in the freepost envelope provided.
We enclose a pad of post-its and a yearly GP newsletter, as a small token of our gratitude
to you for helping with the study.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\followup\gp annual letter noq.doc SIVMS No.«PatlD»
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Patient name «PatTitle» «PatForename» «Patlnitials» «PatSurname»
Date of birth «PatDOB»









Is «PatTitle» «PatSurname» still alive?
If you answered 'No', please tell us her date of death:
Is her address the same (as above)?
If you answered 'No', please amend the address.
Recently, it has not been appropriate to contact «PatTitle» «PatSurname»
by post. Should we now send her Another consent pack (we did so before)
If you answered 'No', please comment:
Has «PatTitle» «PatSurname» been seen about her intracranial
vascular malformation in hospital in the last year?
If you answered 'Yes', please fill in this section:
Approximate
date of hospital Which hospital? Consultant Reason for appointment /
visit/stay (if known) admission
please continue overleaf if necessary
If not already mentioned in has «PatTitle» «PatSurname» suffered
from the following in the last year (giving date(s) where applicable)?
Brain haemorrhage(s) Yes / No
day/month/year
Epilepsy Yes / No
day/month/year
Which of these best describes «PatTitle» «PatSurname»'s current state?
No symptoms □
Minor symptoms, which do not interfere with her lifestyle □
Some restrictions to her lifestyle, but she looks after herself □
Significant restriction to lifestyle, preventing total independence □
Severe handicap preventing independent existence, but not requiring constant attention □
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Department of Clinical Neurosciences V
Bramwell Dott Building j? ? (
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e-mail: sivmsiSiskull.dcn.ed.ac.uk \ \
web: http://www.dcn.ed.ac.uk/ivm/ If ^
13 March, 2003






Re. «PatTitle» «PatForename» «Patlnitials» «PatSurname»
«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
It is now approximately one year since «PatTitle» «PatSurname» was last contacted about
the Scottish Intracranial Vascular Malformation Study (SIVMS).
Because we are about to send him a follow-up questionnaire, we would be very grateful to
you for checking the details on the attached sheet. Although we do follow-up «PatTitle»
«PatSurname» through his hospital notes, there is vital follow-up information that only you
will be able to help us with.
For this reason, we have also enclosed a letter asking for copies of recent records held in
his GP notes relating to this follow-up information.
We would therefore be very grateful if you could please check the details on the attached
sheet and return the seven-step form with the relevant copies of his GP notes, if
appropriate, to us in the freepost envelope provided.
We enclose a pad of post-its and a yearly GP newsletter, as a small token of our gratitude
to you for helping with the study.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\followup\gp annual letter q.doc SIVMS No.«PatlD»
414
Appendix of study materials - 31 - GP annual follow-up (patient questionnaire) Chapter 19







| Is «PatTitle» «PatSurname» still alive?I If you answered 'No', please tell us his date of death:
t Is his address the same (as above)?
I If you answered 'No', please amend the address.
, «PatTitle» «PatSurname» agreed to complete an annual questionnaire.
| Is it still appropriate to send him a questionnaire?
If you answered 'No', please comment:
(Has «PatTitle» «PatSurname» been seen about his intracranialvascular malformation in hospital in th l st year?
If you answered 'Yes', please fill in this section:
Approximate
date of hospital Which hospital? Consultant Reason for appointment /








please continue overleaf if necessary
If not already mentioned in has «PatTitle» «PatSurname» suffered
from the following in the last year (giving date(s) where applicable)?
Brain haemorrhage(s) Yes / No
day/month/year
Epilepsy Yes / No
day/month/year
Which of these best describes «PatTitle» «PatSurname»'s current state?
No symptoms □
Minor symptoms, which do not interfere with his lifestyle □
Some restrictions to his lifestyle, but he looks after himself □
Significant restriction to lifestyle, preventing total independence □
Severe handicap preventing independent existence, but not requiring constant attention □
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«PatAddress1» «PatAddress2» «PatAddress3» «PatCity» «PatPostCode»
We last wrote to request copies of «PatTitle» «PatSurname»'s case-notes on
«PatGPDateNotesRequested». He is enrolled with the Scottish Intracranial Vascular
Malformation Study, and you previously indicated that you would be happy for us to copy
his GP notes.
We would be very grateful if you could now send us copies of correspondence since
«DateofLastCorrespondence», especially relating to clinically significant events that you
mentioned on the enclosed follow-up questionnaire. We would like copies of the following
that have been produced since «DateofLastCorrespondence»:
a) your referral letter(s) and hospital clinic letters relevant to «PatTitle» «PatSurname»'s
IVM
b) discharge summaries relevant to «PatTitle» «PatSurname»'s IVM
c) reports of brain imaging
d) a diagnostic summary sheet, if your practice produces them
We do not require copies of our own letters that we have sent to you. Please let us know if
there is not a sticker on the front of the notes indicating that «PatTitle» «PatSurname» is
included in this study, and we will send you one.
If your practice staff cannot provide these copies or there is a charge for providing them,
we would be very happy to discuss with them how best to arrange for copies to be made
and/or charged for, perhaps by sending the notes to us. We enclose a freepost envelope
for your reply.
Yours Sincerely
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
d:\data\s.i.v.m,s\wrlting\thesis\sivms !etters\annualgpcasenotesreqiiesttetter{alive).docSIVMS No.«PatlD»
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Re: «patientName», «PatAddress1» «PatAddress2» «PatAddress3» «PatCity»
«PatDistrict» «PatPostCode»
Date of birth «PatDOB»
Hospital No. «RegHospitalNo»
under the care of «collname»
«PatForename» «PatSurname» is enrolled with the Scottish Intracranial Vascular
Malformation Study, and it is now one year since we last requested copies of his case-
notes. Please could we have copies, that have been produced since
«RegDateOfLastCorrespondance», of:
• clinic letters and discharge summaries from the correspondence section
• neuroradiology and neuropathology reports from the investigation section
If there is not a sticker on the front of the notes indicating his enrolment with our study,
please let us know and we will send you one.
Many Thanks,
Yours Sincerely,
Dr Rustam Al-Shahi Prof Charles P Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
d:\data\s.i.v.m.s\writing\thesis\sivms Ietters\annualhospitalcasenot0srequestletier.doc SIVMS No.«PatlD»
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Thank you very much indeed for agreeing to participate in the Scottish Intracranial
Vascular Malformation Study (SIVMS). We are grateful for your response to the short
enrollment questionnaire we sent you on «PatEnrDateSent».
We would like you to tell us how you are getting on by completing the enclosed yearly
questionnaire that asks some questions about your daily activities and your health. Your
answers are extremely valuable to us, so please take some time to complete the
questionnaire carefully. We anticipate it will take between 20 and 30 minutes to complete.
Do ask a relative or friend to help you if you cannot complete the questionnaire. As we
mentioned in the information leaflet, your confidentiality is respected at all times.
When you have completed the questionnaire, please return it in the enclosed freepost
envelope as soon as you can. Do not hesitate to contact us if you require any information
about the questionnaire, help with its completion or further information. To keep you up-to-
date with the study, we have enclosed a yearly participant newsletter.
Thank you in advance for your support.
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\followup\patient questionnaire letter.doc SIVMS No.«PatlD»
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Your First Name «PatForename»








Please correct your details, ifnecessary
Instructions for completing the questionnaire
1. Please answer every question.
2. Some questions may look a bit like others, but each one is different.
3. Please take time to read each question carefully, and tick the box next to
the answer that is closest to the way you feel.
4. Ask a friend or relative for help ifyou need it.
5. Return your completed questionnaire in the freepost envelope provided.
6. Please turn the page and begin answering the questions now.
419
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1. Please read the following descriptions from people who have had
similar medical problems to you and choose one which best
describes your present state:
Tick one bo;
I have no problems at all and cope well with life.
I have a few symptoms but these do not interfere with my everyday life.
I have symptoms which have caused some changes in my life, but I am still
able to look after myself.
I have symptoms which have significantly changed my life and prevent me
from coping fully, and I need some help with looking after myself.
I have quite severe symptoms which mean I need to have help from other
people, but I am not so bad as to need attention day and night.
I have major symptoms which severely handicap me and I need constant
attention day and night.







3. Compared to one year ago, how would you rate your health in
general now?
Tick one bo;
Much better than one year ago
Somewhat better than one year ago
About the same
Somewhat worse now than one year ago
Much worse now than one year ago T
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4. The following questions are about activities you might do during a







Tick one box on each line
a) Vigorous activities, such as
running, lifting heavy objects,
participating in strenuous sports
b) Moderate activities, such
as moving a table, pushing a
vacuum cleaner, bowling or
playinggolf
c) Lifting or carrying groceries
d) Climbing several flights of
stairs
e) Climbing one flight of
stairs
f) Bending, kneeling or
stooping
g) Walking more than a mile
h) Walking half a mile
j) Walking 100 yards
j) Bathing and dressing
yourself
5. During the past 4 weeks, have you had any of the following
problems with your work or other regular daily activities as a result
ofyour physical health?
Tick one box on each line
Yes Nc
Cut down on the amount of time you spent on work or other activities Q j
Accomplished less than you would like ^ 1
Were limited in the kind of work or other activities Q
Had difficulty performing the work or other activities j
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6. During the past 4 weeks, have you had any of the following
problems with your work or other regular daily activities as a result
of any emotional problems (such as feeling depressed or anxious)?
Tick one box on each line
Yes No
Cut down on the amount of time you spent on work or other activities Q j i
Accomplished less than you would like Q j j
Didn't do work or other activities as carefully as usual Q j j
7. During the past 4 weeks, to what extent has your physical health or
emotional problems interfered with your normal social activities















9. During the past 4 weeks, how much did pain interfere with your
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10. These questions are about how you feel and how things have been
with you during the past 4 weeks. For each question please
indicate the one answer that comes closest to the way you have
been feeling. How much during the past 4 weeks:
Tick one box on each line
a) Did you feel full of life?
b) Have you been a very
nervous person?
C) Have you felt so down in
the dumps that nothing
could cheer you up?
d) Have you felt calm and
peaceful?
e) Did you have a lot of
energy?
f) Have you felt downhearted
and low?
g) Did you feel worn out?
h) Have you been a happy
person?
j) Did you feel tired?
11. During the past 4 weeks, how much of the time has your physical
health or emotional problems interfered with your social activities
(like visiting friends or close relatives)?
Tick one bo:
All of the time
Most of the time
A good bit of the time
Some of the time
A litde of die time
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□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
Tick one box on each line
I seem to get ill more easily
than other people
I am as healthy as anybody
I know
I expect my health to get
worse
My health is excellent




No, I have occasional accidents (once a week) ^
No, I am incontinent or need help with an enema




No, I have occasional accidents (less than once a day) ^
No, I am incontinent (or use a catheter)
15. In the last two days did you manage to clean your teeth, brush your
hair or shave without help?
Tick one bo:
Yes [
No, I need help
16. In the past two weeks could you use the toilet (or commode)
without help from another person?
Tick one bo:
Yes, I am independent
No, I need minor assistance £
No, I need quite a lot of help
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17. In the last two weeks did you need help from another person to eat
meals?
Tick one bo:
No, I am independent
Yes, I need some help
Yes, I need quite a lot of help £
18. In the past two weeks did you need help from another person to get
out of bed or up from a chair?
Tick one bo:
No, I am totally independent
Yes, I need minimal help ^
Yes, I can sit unaided, but I need help to transfer
Yes, I am unable to transfer
19. In the past two weeks did you need help from another person with
walking?
Tick one bo;
No, I am independent for at least 50 yards
Yes, I can walk 50 yards with help [j
I am independent in a wheelchair for 50 yards
Yes, I am immobile ^
20. In the last two weeks did you need help from another person to
dress and undress?
Tick one bo:
No, I am independent
Yes, I need help with some things
Yes, I need help with ?nost things
21. In the past two weeks did you need help from another person to
climb stairs?
Tick one bo>
No, I am independent
Yes, I need physical help or verbal support
I am unable ^
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22. In the last two weeks did you manage to have a bath, shower or
wash all over without help?
Tick one bo:
Yes
No, I need help
23. I feel tense or 'wound up':
Tick one bo:
Most of the time
A lot of the time
From time to time, occasionally
Not at all
24. I still enjoy the things I used to enjoy:
Tick one bo:
Definitely as much
Not quite so much
Only a little
Hardly at all
25. I get a sort of frightened feeling as if something awful is about to
happen:
Tick one bo:
Very definitely and quite badly
Yes, but not too badly ^
A little, but it doesn't worry me
Not at all
26. I can laugh and see the funny side of things:
Tick one bo:
As much as I always could
Not quite so much now
Definitely not so much now ^
Not at all
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27. Worrying thoughts go through my mind:
Tick one bo;
A great deal of the time
A lot of the time
From time to time, but not too often
Only occasionally





Most of the time






30. I feel as if I am slowed down:
Tick one bo;
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32. I have lost interest in my appearance:
Tick one bo:
Definitely
I don't take as much care as I should
I may not take quite as much care
I take just as much care as ever






34. I look forward with enjoyment to things:
Tick one bo:
As much as I ever did
Rather less than I used to
Definitely less than I used to
Hardly at all
35. I get sudden feelings of panic:
Tick one bo:
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37. Do you have nose bleeds?
Yes n If 'Yes' go to question 38
No If 'No' go to question 40
38. At what age did they start? |







40. Do you have any red spots on your lips, tongue or fingers?
Yes Q] If 'Yes' go to question 41
No Q If 'No' go to question 43
41. How many red spots do you have? |
42. Where are these red spots?





44. Do you have epilepsy ('seizures'or 'fits')?
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45. Who completed this questionnaire?
] You
Someone else... Please state name and relationship to the person
named on the front of this form:
46. Signature of the person Date of completion:
completing this questionnaire:
47. Please add any comments below:
48. Please return this questionnaire to us in the freepost envelope.
THANK YOU FOR YOUR HELP!
I-IADS © RP Snaith and AS Zigmond, 1983,1992, 1994, Adapted and reproduced by permission of the Publishers, NFER-NEISON, 2
Oxford Road East, Windsor, Berkshire SL4 1DF, UK. All rights reserved. Record form items originally published in Acta Psychiatrics
Scandinavica, 67, 361-70, © Munksgaard International Publishers Ltd. Copenhagen, 1983.
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13 March, 2003















Thank you very much indeed for completing your yearly SIVMS questionnaire on
«QCompletionDate».
In the questionnaire you mentioned that you had suffered from epilepsy, seizures or fits.
Could you kindly complete the enclosed additional, small questionnaire to give us a little
more information about them? We will not be bothering you with any other questionnaires
until next year!
When you have completed the questionnaire, please return it in the enclosed freepost
envelope as soon as you can. Do not hesitate to contact us if you require any information
about the questionnaire, help with its completion or further information.
Thank you in advance for your support.
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\followup\patient epilepsy questionnaire letter.doc SIVMS No.«PatlD»
431




Your First Name «PatForename»








Please correct your details, if necessary
Instructions for completing the questionnaire
1. Please answer every question.
2. Some questions may look a bit like others, but each one is different.
3. Please take time to read each question carefully, and tick the box next to
the answer that is closest to the way you feel.
4. Ask a friend or relative for help ifyou need it.
5. Return your completed questionnaire in the freepost envelope provided.
6. Please turn the page and begin answering the questions now.
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1. Below are some descriptions of different kinds of epileptic attacks.
Which of these descriptions matches the attacks you have?
Please tick all the boxes that apply to yoi
'Grand mal' attacks. Unconsciousness with the body becoming stiff with jerking
of all the limbs, and frothing at the mouth, possibly with difficulty breathing. Followed by a
period of sleepiness and confusion lasting for at least 5 minutes before a full recovery.
'Petit mal' attacks. A brief episode of no more than a few seconds with blankness
without falling and possibly flickering of the eyelids.
Attacks with a trance-like state, sometimes with hp-smacking, swallowing,
gesturing or fidgeting, followed by confusion, usually with at least a minute before full
recovery.
Attacks of falling with a brief loss of consciousness preceded by a feeling of
lightheadedness which comes on gradually, but which may be followed by sweating and
clamminess, shakiness and sickness
Brief jerks of the arms and body (sometimes the legs) occurring usually within
an hour or two ofwaking without any blackout
Some other kind of attack
please describe below
2. Do your attacks happen:
Please tick one box
Only while you are asleep
Only while you are awake
At any time of day or night
3. How old were you when you had your first epileptic attack?
years
4. When did you have your last attack?
Please give the date
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5. How many epileptic attacks have you had in the past year?
Please tick one box
None
Less than one per month
One or more per month
6. Who completed this questionnaire?
You
^ Someone else... Please state name and relationship to the person
named on the front of this form:
7. Signature of the person Date of completion:
completing this questionnaire:
8. Please return this questionnaire to us in the freepost envelope.
THANK YOU FOR YOUR HELP!
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Department of Clinical Neurosciences V1 i^_ ■»
Bramwell Dott Building 4? |H^ 't
Western General Hospital f \
Crewe Road y IM *
Edinburgh EH4 2XU ~ ■ «J 4 !












Thank you very much indeed for completing your yearly SIVMS questionnaire on
«QCompletionDate».
In the questionnaire you mentioned that you had suffered from headaches. Could you
kindly complete the enclosed additional, small questionnaire to give us a little more
information about them? We will not be bothering you with any other questionnaires until
next year!
When you have completed the questionnaire, please return it in the enclosed freepost
envelope as soon as you can. Do not hesitate to contact us if you require any information
about the questionnaire, help with its completion or further information.
Thank you in advance for your support.
Yours Sincerely,
Dr Rustam Al-Shahi Prof. Charles P. Warlow
MRC Clinical Training Fellow Professor of Medical Neurology
g:\trialdev\sivms\materials\followup\patient headache questionnaire letter.doc SiVMS No.«PatlD»
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Your First Name «PatForename»








Please correct your details, ifnecessary
Instructions for completing the questionnaire
1. Please answer every question.
2. Some questions may look a bit like others, but each one is different.
3. Please take time to read each question carefully, and tick the box next to
the answer that is closest to the way you feel.
4. Ask a friend or relative for help ifyou need it.
5. Return your completed questionnaire in the freepost envelope provided.
6. Please turn the page and begin answering the questions now.
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1. How often have you had headaches in the past year?
Please tick one box
Never
Less than once per month
Once or more per month
2. Have you had at least 5 separate attacks of headache severe
enough to require that you stop or decrease your activities or take




If 'No' stop here





4. Do your headache attacks usually last more than four hours and




If 'No' stop here.
5. Are your most bothersome headaches:
Tick one box on each lint
Yes Nc
Often pulsating ('throbbing')? Q j
Often on one side of the head, for at least a portion of the headache attack? ^ j
Severe enough to make you stop or decrease your activities? j
Made worse by physical activity? j
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6. Are your headache attacks accompanied by:
Chapter 19
Tick one box on each lira
Yes Nc
Nausea or vomiting? Q
Sensitivity to tight? j
Sensitivity to noise? |
7. With at least 2 of your headache attacks have you had temporary
visual disturbance (for example, shimmering lights, zigzags, blind





If 'No' go to question 13




Light objects appearing excessively bright Q
All objects appearing grey or yellow Q
Distortion of all linear objects Q
Dancing or moving cobwebs ^
Moving black veils Q
Scintillating picket fences Q
Silver stars Q
Heat waves
Flashing gold tights [[
Sparklers




None of the above (describe your own
9. Does the visual disturbance go away completely within 60
minutes?
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11. Does the visual disturbance change (for example, get worse or




12. Is the visual disturbance associated with headache, nausea, and/or




13. With at least 2 of your headache attacks have you had temporary
numbness, tingling, or both involving the lips, tongue, fingers or









15. Who completed this questionnaire?
1 You
Someone else... Please state name and relationship to the person
named on the front of this form:
16. Signature of the person Date of completion:
completing this questionnaire:
17. Please return this questionnaire to us in the freepost envelope.
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Patient-related variables (continued)
Study notifications about the patient
Unique identifier for each notification NotificationID davesPatientNotification
Patient's unique identifier NotifPatID davesPatientNotification
Identifier for collaborator/ISD notifying the patient (from the
table davesCoIlaborators)
NotifCollabID davesPatientNotification
Centre the collaborator notified from (from the table
davesCentres)
NotifCentrelD davesPatientNotification
GP notifying the patient (from the table davesGPs) NotifGPID davesPatientNotification
Date of notification NotificationDate davesPatientNotification
Date of first IVM diagnosis provided at notification NotiflstDiagDate davesPatientNotifi cation
IVM type IVMnotifSetType tbIIVMnotifSet
IVM quantity IVMnotifSetQuantity tbIIVMnotifSet
Study recruitment details
Patient's GP's idenitifer (from the table davesGPs) PatGPID davesPatientDetails
Patient's main consultant's identifier (from the table PatConsultantCollaboratorlD davesPatientDetails
davesCoIlaborators)
Main consultant's place of work (from the table PatConsultantCentrelD davesPatientDetails
davesCentres)
Does the GP think the patient is aware of their diagnosis? PatGPAware davesPatientDetails
Does the consultant think the patient is aware of their PatConsAware davesPatientDetails
diagnosis?
Overall decision about patient's awareness of diagnosis
(moderated)
PatDiagAware davesPatientDetails
Does the GP grant access to the patient's notes? PatGPRecordsConsent davesPatientDetails
Does the GP think SIVMS can contact the patient by post? PatQAppropGP davesPatientDetails
Does the consultant think SIVMS can contact the patient
by post?
PatQAppropConsult davesPatientDetails
Date of patient's completion of consent form PatQConsentDate davesPatientDetails
Does the patient consent to us copying their notes? PatParticipation davesPatientDetails
Does the patient consent to receive questionnaires? PatQConsent davesPatientDetails
Overall decision about postal contact with the patient PatQOverallDecision davesPatientDetails
Exclusion date PatExclusionDate davesPatientDetails
Exclusion reason PatExcludeReason davesPatientDetails
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Patient-related variables (continued)
Hospitals visited
Hospital's identifier (from the table davesCentres) RegCentrelD davesPatientRegistration
Consultant's collaborator identifier (from the table
davesCollaborators)
RegConsultantID davesPatientRegistration
Does the consultant grant access to the patient's notes? RegNotesAccess davesPatientRegistration
Hospital's notes identification number for this patient RegHospitaINo davesPatientRegistration
Date of last copy letter held by SIVMS at this hospital RegDateofLastCorrespondance davesPatientRegistration
Hospital's imaging identification number for this patient RegXRayNo davesPatientRegistration
Patient's medical history
Neurological comorbidities PatPresComorbBrain davesPatientDetails
Systemic comorbidities PatPresComorbSystemic davesPatientDetails
Is there a family history of IVMs (moderated)? PatPreslVMFamHist daveSPatientDetails
Family history details PatlVMFamHistDetails davesPatientDetails
Name of each drug the patient takes DrugName davesPatientDrug
Start date of each drug DrugStartDate davesPatientDrug
End date of each drug DrugStartDate davesPatientDrug
Patient's obstetric history
Number of children at the time of recruitment PatChildren davesPatientDetails
Start date of each pregnancy PregStartDate davesPatientPregnancy
End date of each pregnancy PregEndDate davesPatientPregnancy
Mode of first IVM presentation (inception)
First presentation date PatPresentationDate davesPatientDetails
First presentation type PatPresentationType davesPatientDetails
IVM outcome events extracted from case notes
Length of follow-up
Date of last correspondence we have from the GP notes PatGPDateofLastCorrespondence davesPatientDetails
Date of most recent follow-up from all sources (moderated) PatMostRecentCommunication davesPatientDetails
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Patient-related variables (continued)
IVM outcome events extracted from case notes (continued)
Death
Date of death PatDeathDate davesPatientDetails
Place of death PatDeathPlace davesPatientDetails
Cause of death PatDeathCause davesPatientDetails
Source of information about cause of death PatDeathCauseSource davesPatientDetails
Post mortem or neuropathology examination performed? PathPMorBiopsy tbIPathology
Where the examination was performed PathCentrelD tbIPathology
Date of examination PathDate tbIPathology
Details about each outcome event
Date of each event ClinEvDate davesClinEvent
Type of event ClinEvType davesClinEvent
Caused by IVM/aneurysm/other ClinEvCause davesClinEvent
IVM causing event ClinEvlVM davesClinEvent
Aneurysm causing event ClinEvAneurysm davesClinEvent
Source of clinical event information ClinEvSource davesClinEvent
Type of epilepsy EpilepsyType tblEpilepsy
Activity of epilepsy EpilepsyActivity tblEpilepsy
On anticonvulsants? EpilepsyTreatment tbIEpilepsy
Time of epilepsy? EpilepsyTime tbIEpilepsy
Type of haemorrhage HaemlnfHaemType tbIHaemorrhageslnfarctions
Type of infarction HaemlnflnfarctionType tbIHaemorrhageslnfarctions
Radiological and/or clinical support for stroke? HaemlnfProof tbIHaemorrhageslnfarctions
Type of headache HeadType tbIHeadaches
Headache frequency HeadFrequency tbIHeadaches
GP-rated outcomes
Unique identifier for GP annual questionnaire AnnualGPID tbIAnnualGPConfirmations
Date of GP questionnaire completion AGReplyDate tbIAnnualGPConfirmations
Modified Rankin score for each patient each year AGModifiedRankin tbIAnnualGPConfirmations
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Patient-related variables (continued)
Patient-rated outcomes
Unique identifier for GP (and patient) questionnaire QAnnuaiGPiD




Has the patient had headaches this year?
Have you had at least 5 separate attacks?
Do you have headache-free intervals of days to weeks
between severe headache attacks?
Do your headache attacks usually last more than 4 hours
and less than 3 days
Often pulsating
Often on the side of the head
Severe enough to make you stop







Light objects appearing excessively bright
All objects appearing grey or yellow
Distortion of all linear objects
























































Herringbone pattern Head8n tbl Headaches
Double vision Head8o tbl Headaches
Blind spot Head8p tbIHeadaches
None of the above Head80ther tbIHeadaches
Does the visual disturbance go away completely within 60
minutes?
Head9 tbIHeadaches
How long does the visual disturbance last? Head10 tbIHeadaches
Does the visual disturbance change (for example, get
worse or change in character) within 4 minutes?
Head11 tbIHeadaches
Is the visual disturbance associated with headache,
nausea, and/or light sensitivity immediately or within 60
minutes?
Head12 tbIHeadaches
With at least 2 of your headache attacks have you had
temporary numbness, tingling, or both involving the lips,
tongue, fingers or legs, occurring just before or during the
headache?
Head13 tbIHeadaches
Have you had headaches accompanied by both visual
disturbance and temporary numbness/tingling?
Head14 tbIHeadaches
Epilepsy
Has the patient had epilepsy this year? QEpilepsy davesAnnualQuest
Grand mal attacks EpilepsyQIa tblEpilepsy
Petit mal attacks EpilepsyQIb tblEpilepsy
Attacks with a trance-like state EpilepsyQIc tbIEpilepsy
Attacks of falling EpilepsyQId tbIEpilepsy
Brief jerks of the arms and body EpilepsyQIe tbIEpilepsy
Some other kind of attack EpilepsyQIf tbIEpilepsy
Description of other kind of attack EpilepsyQIfDescription tbIEpilepsy
Do your attacks happen... EpilepsyQ2 tbIEpilepsy
How old were you when you had your first epileptic attack? EpilepsyQ3 tbIEpilepsy
When did you have your last attack? EpilepsyQ4 tbIEpilepsy
How many epileptic attacks have you had in the past year? EpilepsyQ5 tbIEpilepsy
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Barthel Index (patient questionnaire identifier) BarthelQID davesBarthel
Bowel control BarthelQI davesBarthel
Bladder control BarthelQ2 davesBarthel
Clean teeth/brush hair/shave in last 2 days BarthelQ3 davesBarthel
Use of toilet in past 2 weeks BarthelQ4 davesBarthel
Eating meals in past 2 weeks BarthelQ5 davesBarthel
Getting up in past 2 weeks BarthelQ6 davesBarthel
Walking in past 2 weeks BarthelQ7 davesBarthel
Dressing/undressing in past 2 weeks BarthelQ8 davesBarthel
Climbing stairs in past 2 weeks BarthelQ9 davesBarthel
Washing/bathing/showering in past 2 weeks BarthelQIO davesBarthel
Hospital Anxiety and Depression Scale (HADS)
HADS patient questionnaire identifier HADSQID davesHADS
Tense/wound up HADSQ1 davesHADS
Still enjoy things as formerly HADSQ2 davesHADS
Frightened feeling (impending doom) HADSQ3 davesHADS
Laugh/see funny side HADSQ4 davesHADS
Worrying thoughts HADSQ5 davesHADS
Cheerful HADSQ6 davesHADS
Sit at ease/relax HADSQ7 davesHADS
Feel slowed down HADSQ8 davesHADS
Frightened feeling (butterflies) HADSQ9 davesHADS
Interest in appearance HADSQ10 davesHADS
Feel restless HADSQ11 davesHADS
Look forward with enjoyment HADSQ12 davesHADS
Sudden panic HADSQ13 davesHADS
Enjoy book/radio/TV HADSQ14 davesHADS
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SF-36 patient questionnaire identifier
General health now
Change in health
Vigorous activities limited by health
Moderate activities limited by health
Lifting/carrying groceries limited by health
Climbing several flights of stairs limited by health
Climbing 1 flight of stairs limited by health
Bending/kneeling/stooping limited by health
Walking > 1 mile limited by health
Walking several blocks limited by health
Walking 1 block limited by health
Bathing/dressing self limited by health
Cut time on work/other activities due to health in past 4
weeks
Accomplished less work/other activities due to health in
past 4 weeks
Limited type of work/other activities due to health in past 4
weeks
Had difficulty with work/other activities due to health in
past 4 weeks
Cut time on work/other activities due to emotional
problems in past 4 weeks
Accomplished less than would wish due to emotional
problems in past 4 weeks
Less care over work/other activities due to emotional
problems in past 4 weeks
Social activities impacted by health/emotional problems in









































Bodily pain during past 4 weeks SF36Q7 davesSF36
Normal work impacted by pain in past 4 weeks SF36Q8 davesSF36
Full of pep in past 4 weeks SF36Q9a davesSF36
Very nervous in past 4 weeks SF36Q9b davesSF36
Down in dumps in past 4 weeks SF36Q9C davesSF36
Calm and peaceful in past 4 weeks SF36Q9d davesSF36
Lots of energy in past 4 weeks SF36Q9e davesSF36
Downhearted and blue in past 4 weeks SF36Q9f davesSF36
Worn out in past 4 weeks SF36Q9g davesSF36
Happy in past 4 weeks SF36Q9h davesSF36
Tired in past 4 weeks SF36Q9i davesSF36
Social activities impacted by health/emotional problems in
past 4 weeks (duration)
SF36Q9J davesSF36
Get sick easier than other people SF36Q10a davesSF36
Healthy as anyone SF36Q10b davesSF36
Expect health to worsen SF36Q10C davesSF36
Health is excellent SF36Q10d davesSF36
Hereditary haemorrhagic telangiectasia (HHT) annual screening questions
Epistaxis HHTNoseBleed davesHHT
Age epistaxis started HHTNBIdStartAge davesHHT
Frequency of epistaxis HHTNBIdFreq davesHHT
Telangiectasia HHTRedSpots davesHHT
Number of telangiectasia HHTRedSpotNo davesHHT
Location of telangiectasia HHTRedSpotLoc davesHHT
IVM-related variables
Patient details
Date of patient's first-ever IVM diagnosis (moderated) PatDiagnosisDate davesPatientDetails
IVM multiplicity for this patient PatlVMCode davesPatientDetails
448
Appendix of variables Chapter 19
IVM-related variables (continued)
General characteristics of each IVM
Type of IVM IVMType daveslVM
Date of earliest definite diagnosis of this IVM IVMIstDiagDate daveslVM
Side of brain IVMSide daveslVM
Brain area IVMBrainArea daveslVM
Location in brain area IVMLocation daveslVM
Eloquence of brain area IVMEIoquence daveslVM
Spetzler Martin grade (brain AVMs only) IVMSpetzlerMartin daveslVM
Borden grade (dural AVMs only) DAVFBordenGrade tbIDAVF
Cognard grade (dural AVMs only) DAVFCognard Grade tbIDAVF
Additional general characteristics of each IVM from every type of brain imaging






















Are there any associated aneurysms on the scan? ScanAneurysms davesScan
Catheter angiogram data
Is the angiogram normal? ScanAngioNormal davesScan
Did superselective angiography reveal further information? ScanSSAExtralnfo davesScan
Avascular mass on angiography? RadAvascularMass davesRadAng
Degree of arterial tortuosity RadArterialTortuosity davesRadAng
Arterial angiopathy RadArterialAngiopathy davesRadAng
Angiogenesis RadAngiogenesis davesRadAng
Collateral vessels RadAngioCollaterals davesRadAng
Origin of collateral supply RadAngioCollatSupply davesRadAng
Related to a dural sinus? RadAngioSinusRelatedTo davesRadAng
Side of the sinus RadAngioSide davesRadAng
State of the sinus RadAngioSinusState davesRadAng
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IVM-related variables (continued)
Catheter angiogram data (continued)
Unique identifier for each arterial feeder ArtFeederlD davesArtFeeders
Scan the feeder was identified on ArtFeedScanID davesArtFeeders
IVM the feeder is associated with ArtFeedlVMID davesArtFeeders
Type of feeder ArtFeedType davesArtFeeders
Side of the feeder ArtFeedSide davesArtFeeders
Type of feeding branch ArtFeedBranch davesArtFeeders
Quantity of feeders from each branch ArtFeedQuantity davesArtFeeders
Number of draining veins AVMNidusCompts tbIAVM
Dominant venous trunk AVMDominantTrunk tbIAVM
Destination of each draining vein DWein tbIDrainingVeins
Side of each draining vein DVSide tbIDrainingVeins
Direction of flow (dural AVMs only) DVFIowDirection tbIDrainingVeins







Venous stenosis AVMVenousStenosis tbIAVM
Location of venous stenosis AVMVenousStenosisLoc tbIAVM
Type of brain AVM nidus border AVMNidusBorder tbIAVM
Discernible fistula in brain AVM nidus AVMNidusFistula tbIAVM
CT/MRI data
Mass effect on the scan RadMassEffect davesRadCTMR
Hydrocephalus on the scan RadHydrocephalus davesRadCTMR
Oedema related to IVM RadOedema davesRadCTMR
Vessel calcification on CT RadCTVesselCalcification davesRadCTMR
Calcification from old haemorrhage on CT RadCTOIdHaemCalc davesRadCTMR
Gliosis on MRI RadMRIGIiosis davesRadCTMR
Evidence of prior haemorrhage on MRI RadMRIOIdHaemEvidence davesRadCTMR
Acute haemorrhage RadAcuteHaem DavesRadCTMR
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IVM-related variables (continued)
CT/MRI data (continued)
Type of haemorrhage RadNewHaemType davesRadCTMR
Brain area of haemorrhage RadNewHaemArea davesRadCTMR
Side of haemorrhage RadAcuteHaemSide davesRadCTMR
Low density without mass effect (CT) RadLowDensity davesRadCTMR
Cerebral infarction (MRI) RadCerebral Infarction davesRadCTMR
Cerebral infarction location (MRI) RadCerebrallnfarctionLoc davesRadCTMR
Cerebral infarction side (MRI) RadCerebral InfarctionLocSide davesRadCTMR
Dilation of adjacent dural sinus RadDilation davesRadCTMR
Thrombosis of adjacent dural sinus RadThrombosis davesRadCTMR
Perinidal contrast enhancement on MRI RadMRIPerinidalEnhance davesRadCTMR
Signal characteristics on MRI (CMs only) RadSignalCharsCM davesRadCTMR
Variables related to associated aneurysm(s)
Aneurysm unique identifier (identified on brain imaging)








Aneurysm / IVM identifier
Type of intervention
Date of intervention
Did they receive the intervention?
AneurlD
PA_AneurysmlD
AneurPatID
AneurLocation
AneurArtery
AneurSide
RadAneurMorph
RadAneurLuminDiam
davesAneurysm
tblPathologyAneurysms
davesAneurysm
davesAneurysm
davesAneurysm
davesAneurysm
davesRanAneur
davesRanAneur
IntervlVMID
IntervAneurysmlD
tbl Interventions
IntervType tbl Interventions
IntervDate tbl Interventions
IntervTreated tbl Interventions
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